<SEC-DOCUMENT>0001493152-22-031433.txt : 20221110
<SEC-HEADER>0001493152-22-031433.hdr.sgml : 20221110
<ACCEPTANCE-DATETIME>20221110172054
ACCESSION NUMBER:		0001493152-22-031433
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		50
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221110
DATE AS OF CHANGE:		20221110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celcuity Inc.
		CENTRAL INDEX KEY:			0001603454
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38207
		FILM NUMBER:		221378658

	BUSINESS ADDRESS:	
		STREET 1:		16305 36TH AVENUE N
		STREET 2:		SUITE 100
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55446
		BUSINESS PHONE:		763-392-0767

	MAIL ADDRESS:	
		STREET 1:		16305 36TH AVENUE N
		STREET 2:		SUITE 100
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Celcuity LLC
		DATE OF NAME CHANGE:	20140324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-gaap-supplement="http://fasb.org/us-gaap-sup/2022q3" xmlns:srt-supplement="http://fasb.org/srt-sup/2022q3" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:CELC="http://celcuity.com/20220930">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_CELC_celcuity.com_20220930 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20220101_20220930 -->
<!-- Field: Set; Name: xdx; ID: xdx_056_edei%2D%2DEntityCentralIndexKey_0001603454 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityCentralIndexKey">0001603454</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0030" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0031" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2022-09-30" id="xdx2ixbrl0093" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2022-09-30" id="xdx2ixbrl0105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-12-31" id="xdx2ixbrl0106" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-09-30" id="xdx2ixbrl0111" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl0112" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0201" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0202" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0203" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-07-012022-09-30" id="xdx2ixbrl0216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-07-012021-09-30" id="xdx2ixbrl0217" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0219" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0245" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0247" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0251" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0257" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0270" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0289" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0336" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0341" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0367" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0369" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0373" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0386" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0448" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0449" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:IssuanceOfCommonStockLicensingAgreement" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0475" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0487" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0514" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0535" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0541" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:GrossProceedsFromAnAtmOffering" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0543" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:PropertyAndEquipmentIncludedInAccountsPayable" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0577" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses" contextRef="From2021-01-012021-09-30" id="xdx2ixbrl0583" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0585" unitRef="USD" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="celc-20220930.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-01-01to2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-03">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-03</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-04-012022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-04-01</xbrli:startDate>
        <xbrli:endDate>2022-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-09-132022-09-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-09-13</xbrli:startDate>
        <xbrli:endDate>2022-09-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-07-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-13_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-13_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-01_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-01_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-152022-05-15_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-15</xbrli:startDate>
        <xbrli:endDate>2022-05-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-15_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-15_custom_PurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:PurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-02-042022-02-04_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-02-04</xbrli:startDate>
        <xbrli:endDate>2022-02-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-02-04_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-02-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-122022-10-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-12</xbrli:startDate>
        <xbrli:endDate>2022-10-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-07-02_custom_FollowOnOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-07-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-07-01_custom_FollowOnOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-07-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-07-01_custom_FollowOnOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-07-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-262021-02-26_custom_FollowOnOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-26</xbrli:startDate>
        <xbrli:endDate>2021-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-262021-02-26_custom_FollowOnOfferingMember_custom_UnderwriterMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELC:UnderwriterMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-26</xbrli:startDate>
        <xbrli:endDate>2021-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-26_custom_FollowOnOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-252021-02-26_custom_FollowOnOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-25</xbrli:startDate>
        <xbrli:endDate>2021-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-052020-06-05_custom_AtmAgreementMember_custom_PlacementSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">CELC:AtmAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">CELC:PlacementSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-05</xbrli:startDate>
        <xbrli:endDate>2020-06-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-05_custom_AtmAgreementMember_custom_PlacementSharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">CELC:AtmAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">CELC:PlacementSharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_AtmAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">CELC:AtmAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_custom_AtmAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">CELC:AtmAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_AtmAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">CELC:AtmAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_custom_AtmAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">CELC:AtmAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-05-31_custom_InMayTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_InMayTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_InMayTwoThousandTwentyTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_custom_InDecemberTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InDecemberTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_InDecemberTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InDecemberTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_InDecemberTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InDecemberTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_InDecemberTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InDecemberTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_custom_InDecemberTwoThousandTwentyOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InDecemberTwoThousandTwentyOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-31_custom_InMayTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_InMayTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_InMayTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_InMayTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_custom_InMayTwoThousandTwentyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_RestrictedStockMember17143015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember17143015">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_RestrictedStockMember17143031">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember17143031">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-10-25_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-10-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-01_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-01_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-01_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-242017-10-25_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-24</xbrli:startDate>
        <xbrli:endDate>2017-10-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-05-112021-05-12_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-05-11</xbrli:startDate>
        <xbrli:endDate>2021-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-05-12_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-05-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_TwoThousandSeventeenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-10_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-01-01_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-01-01_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-01-01_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_EmployeeStockPurchasePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-07-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-07-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-072021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-07</xbrli:startDate>
        <xbrli:endDate>2021-04-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember17144187">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:LoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermBLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermBLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-162022-05-16_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-16</xbrli:startDate>
        <xbrli:endDate>2022-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermCLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermCLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermDLoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermELoanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-05-162022-05-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-05-16</xbrli:startDate>
        <xbrli:endDate>2022-05-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-072022-08-09_custom_AmendedLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-07</xbrli:startDate>
        <xbrli:endDate>2022-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-082022-08-09_custom_AmendedLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-08</xbrli:startDate>
        <xbrli:endDate>2022-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-08-082022-08-09">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-08-08</xbrli:startDate>
        <xbrli:endDate>2022-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-30_custom_OriginalAndAmendedLoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OriginalAndAmendedLoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-04-08_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-04-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-072021-04-08_custom_LicenseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:LicenseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-07</xbrli:startDate>
        <xbrli:endDate>2021-04-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-072021-04-08_custom_PfizerIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001603454</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELC:PfizerIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-07</xbrli:startDate>
        <xbrli:endDate>2021-04-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 50%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_907_edei--DocumentType_c20220101__20220930_z41w5XPtM0X"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 50%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Mark
One)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 24.5pt; text-align: justify; text-indent: -24.5pt; background-color: white"><b><span id="xdx_90D_edei--DocumentQuarterlyReport_c20220101__20220930_znEMT6cmohf8"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 24.5pt; text-align: justify; text-indent: -24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the quarterly period ended <span id="xdx_909_edei--DocumentPeriodEndDate_c20220101__20220930_zLKtKkdI1KMa"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 30, <span id="xdx_906_edei--DocumentFiscalYearFocus_c20220101__20220930_zd47egbU6EP1"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 24.5pt; text-align: justify; text-indent: -24.5pt; background-color: white"><b><span id="xdx_905_edei--DocumentTransitionReport_c20220101__20220930_zc7aPzBqBySe"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commission
File No. <span id="xdx_90E_edei--EntityFileNumber_c20220101__20220930_zFpboAdixqnl"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityFileNumber">001-38207</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 50%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90C_edei--EntityRegistrantName_c20220101__20220930_zaVxEleQEPDb"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityRegistrantName">CELCUITY INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 50%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20220101__20220930_zFMAMqFlHqjc"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.
    <span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20220101__20220930_zNcLbWfSZUla"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityTaxIdentificationNumber">82-2863566</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
    of incorporation)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
    Employer Identification No.)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20220101__20220930_zpEBkIVAwYTk"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityAddressAddressLine1">16305
36th Avenue North; Suite 100</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityAddressCityOrTown_c20220101__20220930_znj9R2ggBpbd"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityAddressCityOrTown">Minneapolis</ix:nonNumeric></span>,
<span id="xdx_906_edei--EntityAddressStateOrProvince_c20220101__20220930_zU8oSMG8Ykd4"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Minnesota</ix:nonNumeric></span> <span id="xdx_90C_edei--EntityAddressPostalZipCode_c20220101__20220930_zJfcOVToBLr6"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:EntityAddressPostalZipCode">55446</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of principal executive offices, including zip code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_906_edei--CityAreaCode_c20220101__20220930_z6rhhKaUQWJ8"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:CityAreaCode">(763)</ix:nonNumeric></span> <span id="xdx_90C_edei--LocalPhoneNumber_c20220101__20220930_zbMCgCQpTCYd"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:LocalPhoneNumber">392-0767</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 50%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--Security12bTitle_c20220101__20220930_zacuoTfS8cLk"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--TradingSymbol_c20220101__20220930_zKa9Pm9ts3f2"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" name="dei:TradingSymbol">CELC</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    <span id="xdx_902_edei--SecurityExchangeName_c20220101__20220930_z991ip6HIjOh"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_90C_edei--EntityCurrentReportingStatus_c20220101__20220930_zROnT1lPMkd6"><span style="-sec-ix-hidden: xdx2ixbrl0030">YES</span></span> &#9746;  NO &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_900_edei--EntityInteractiveDataCurrent_c20220101__20220930_z5tkGwsIS1Fa"><span style="-sec-ix-hidden: xdx2ixbrl0031">YES</span></span> &#9746; NO &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 23%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityFilerCategory_c20220101__20220930_zkiZSSElyyX3"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--EntitySmallBusiness_c20220101__20220930_z5vPyNkRIbf7"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--EntityEmergingGrowthCompany_c20220101__20220930_zQk1L6zvJHre"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_907_edei--EntityExTransitionPeriod_c20220101__20220930_z2j7Zhspbmzd"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES &#9744; <span id="xdx_909_edei--EntityShellCompany_c20220101__20220930_zL7TArgfk2Yb"><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">NO</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 3, 2022 there were <span id="xdx_907_edei--EntityCommonStockSharesOutstanding_iI_pid_c20221103_zOeq9Aysae98"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2022-11-03" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,459,739</ix:nonFraction></span> shares of the registrant&#8217;s common stock, $0.001 par value per share, outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Celcuity
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Table
of Contents</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; padding-left: 3pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PAGE</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; text-align: center"><a href="#ak_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART I. FINANCIAL INFORMATION</b></span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0"><a href="#ak_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1.</b> Financial Statements (unaudited)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#ak_003">Condensed Balance Sheets as of September 30, 2022 and December 31, 2021</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; padding-left: 9pt"><a href="#ak_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Statements of Operations for the three months and nine months ended September 30, 2022 and 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; padding-left: 9pt"><a href="#ak_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Statements of Stockholders&#8217; Equity for the three months and nine months ended September 30, 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; padding-left: 9pt"><a href="#ak_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Statements of Stockholders&#8217; Equity for the three months and nine months ended September 30, 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; padding-left: 9pt"><a href="#ak_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed Statements of Cash Flows for the nine months ended September 30, 2022 and 2021</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; padding-left: 0pt"><a href="#ak_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Unaudited Condensed Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><a href="#ak_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 2.</b> Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><a href="#ak_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 3.</b> Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><a href="#ak_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4.</b> Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; text-align: center"><a href="#ak_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART II. OTHER INFORMATION</b></span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-left: 3pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><a href="#ak_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1.</b> Legal Proceedings</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><a href="#ak_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 1A.</b> Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><a href="#ed_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 2.</b> Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><a href="#ed_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 3.</b> Defaults Upon Senior Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><a href="#ed_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 4</b>. Mine Safety Disclosures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">46<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><a href="#ed_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 5</b>. Other Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">46</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><a href="#ed_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM 6.</b> Exhibits</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 0pt"><a href="#ed_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signatures</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this report, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Celcuity,&#8221; and the &#8220;Company&#8221;
mean Celcuity Inc., unless the context indicates another meaning.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_001"></span>PART
I. FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_002"></span>ITEM
1. Financial Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_003"></span>Celcuity
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Balance Sheets </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_111_zMX6pstJso72" summary="xdx: Statement - Condensed Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: -10pt; font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20220930_zrFlOsaz4sTa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_491_20211231_zFrFhNGUIYj8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center; padding-left: 0pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited) </b></span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AssetsAbstract_iB_zxXdS1tkchc3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-left: -10pt">Assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrentAbstract_i01B_zTYHi94ZDoGb" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: -10pt">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzyOV_ziwJXZi4PFnh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; text-indent: 10pt; padding-left: -10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,483,776</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,286,381</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DepositsAssetsCurrent_i02I_maACzyOV_z1JT7NwNsRja" style="vertical-align: bottom; background-color: White">
    <td style="text-indent: 10pt; padding-left: 0pt">Deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,009</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepositsAssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,009</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DeferredCostsCurrent_i02I_maACzyOV_zOwKJD462vEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Deferred transaction costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredCostsCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,147</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredCostsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,144</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--PayrollTaxReceivable_i02I_maACzyOV_z9iblmIHXMt6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Payroll tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:PayrollTaxReceivable" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,926</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:PayrollTaxReceivable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">298,764</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PrepaidExpenseCurrent_i02I_maACzyOV_zu6DKCpMaCn1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt">Prepaid assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,578,252</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">722,677</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrent_i02TI_mtACzyOV_maAz2af_zbZZCf2bXYU8" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,694,110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,351,975</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maAz2af_zm8sGotpb3Wg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">302,005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">312,444</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maAz2af_ziZL8bSZiJ3h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Operating lease right-of-use assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">295,535</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">241,901</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Assets_i01TI_mtAz2af_zdjiACkHOuu1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total Assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,291,650</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,906,320</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Liabilities and Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrentAbstract_i01B_z4fKLE8l3oJ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i02I_maLCzjhd_zqwMjT3lBW" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,168,198</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,507,099</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--FinanceLeaseLiabilityCurrent_i02I_maLCzjhd_zxkqEPpCffJ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Finance lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,916</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,850</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCzjhd_zAstBXe1JWyd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,643</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">189,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCzjhd_z8YqGASQemOb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt">Accrued expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,278,315</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">802,893</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i02TI_mtLCzjhd_maLztoB_zTDaH7IGyUYc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-left: 0pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,645,072</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,505,700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityNoncurrent_i02I_maLztoB_zCPwMcsqTN22" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Finance lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0093">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,449</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLztoB_zLmDGZGqreN3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,771</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermNotesPayable_i01I_maLztoB_zRyrDSDe2IV4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Note payable, non-current</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,013,407</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,625,923</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Liabilities_i01TI_mtLztoB_maLASEzpKd_zn4ko5at5UPi" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total Liabilities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,766,309</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,195,843</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CommitmentsAndContingencies_i01I_maLASEzpKd_z8miz6KYKNHl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: justify; padding-left: 0pt">Commitments and Contingencies (Note 4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0105">-</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0106">-</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-left: 0pt">Stockholders&#8217; Equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PreferredStockValue_i02I_maSEzSob_zYo0Ti0vPEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">Preferred stock, $<span id="xdx_906_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220930_zktQ6fLD8Tnb" title="Preferred stock, par or stated value per share"><span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20211231_zKp3MFcmldK2" title="Preferred stock, par or stated value per share"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value: <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20220930_z38Wld09KVr7" title="Preferred stock, shares authorized"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20211231_z4k6FnkQuo16" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,500,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90E_eus-gaap--PreferredStockSharesIssued_iI_c20220930_zuCsXnDyY2ac" title="Preferred stock, shares issued"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_c20220930_zN2r4jvWA2T" title="Preferred stock, shares outstanding"><span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_c20211231_zseDypygxNv8" title="Preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231_zxObPwUl1QTc" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of September 30, 2022 and December 31, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0111">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0112">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommonStockValue_i02I_maSEzSob_znUJBGB3tEKa" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">Common stock, $<span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220930_zz3DLK1EBZxi" title="Common stock, par or stated value per share"><span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20211231_z4OMkrknrWmd" title="Common stock, par or stated value per share"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value: <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_c20220930_z3C2OcFOkeV5" title="Common stock, shares authorized"><span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_c20211231_z9vssrz4Jnc" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,000,000</ix:nonFraction></ix:nonFraction></span></span> and 25,000,000 shares authorized as of September 30, 2022 and December 31, 2021, respectively; <span id="xdx_908_eus-gaap--CommonStockSharesIssued_iI_c20220930_z9AVHfuC5gN9" title="Common stock, shares issued"><span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_iI_c20220930_zqeqioznmNP5" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,942,958</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20211231_zUiF80qeKP53" title="Common stock, shares issued"><span id="xdx_905_eus-gaap--CommonStockSharesOutstanding_iI_c20211231_z2CAq5m5Sctk" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,918,887</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,919</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AdditionalPaidInCapital_i02I_maSEzSob_zKM2qH57dbW6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,225,939</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">124,622,405</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzSob_zMz05wS0ysrc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Accumulated deficit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,715,541</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,926,847</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquity_i02TI_maLASEzpKd_mtSEzSob_z9rJssECAhp5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total Stockholders&#8217; Equity</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,525,341</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,710,477</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEzpKd_zY3AxhYno9H4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">65,291,650</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,906,320</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: italic 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See accompanying notes to the financial statements</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_014"></span>Celcuity
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Statements of Operations </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_113_zglD5pOTW1K8" summary="xdx: Statement - Condensed Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_498_20220701__20220930_zQaS8KPJ0Cfc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20210701__20210930_zyHpJR6Ydswc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_494_20220101__20220930_ziaFT5HlQdce" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20210101__20210930_zCZhy64M7WK" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingExpensesAbstract_iB_zXYOt6cO7F52" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt"><b>Operating expenses:</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_i01_maOEzVPb_zmuYOUYNc8T2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; text-indent: 10pt; padding-left: 0pt">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,621,505</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,960,515</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,685,505</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,266,965</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--GeneralAndAdministrativeExpense_i01_maOEzVPb_zgB9MDdlwiRj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,022,050</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">639,271</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,066,382</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,768,058</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpenses_i01T_mtOEzVPb_msOILzsbR_ziQ7ITnDcOAg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,643,555</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,599,786</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,751,887</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,035,023</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingIncomeLoss_iT_mtOILzsbR_maILFCOzYIH_zuWEpAprsJMb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,643,555</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,599,786</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,751,887</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,035,023</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zr65K98Cb2Ac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InterestExpense_i01N_di_msNIEzdBS_zGLXLQNgwhtl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">537,661</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">433,072</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,428,108</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">824,283</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--InvestmentIncomeInterest_i01_maNIEzdBS_z1bfM92sQaHc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">287,495</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,612</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">391,301</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,803</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GainLossOnDispositionOfAssets1_i01_maNIEzdBS_zcGQYCVp3Xmh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt">Loss on sale of fixed assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0201">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0202">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0203">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">263</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzdBS_maILFCOzYIH_zUUWz0hz8RRj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Other income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">250,166</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">427,460</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,036,807</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">816,743</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtILFCOzYIH_maNILzP05_zAfU8zyuCWE7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"><b>Net loss before income taxes</b></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,893,721</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,027,246</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,788,694</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,851,766</ix:nonFraction></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--IncomeTaxExpenseBenefit_msNILzP05_zaMgTh8DzKfd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Income tax benefits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0216">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0217">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0218">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0219">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NetIncomeLoss_iT_mtNILzP05_z0LvSGs9FmZc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"><b>Net loss</b></td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,893,721</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,027,246</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,788,694</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,851,766</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasic_zsMxhIrOM6fg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Net loss per share, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.75</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.41</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.95</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">1.78</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_zfs3JlmOxHD6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Weighted average common shares outstanding, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,938,224</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,877,619</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,928,727</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,867,484</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the financial statements </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_004"></span>Celcuity
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Statements of Changes in Stockholders&#8217; Equity </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
and Nine Months Ended September 30, 2022 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_114_zrlGvjujhXK5" summary="xdx: Statement - Condensed Statements of Changes in Stockholders&apos; Equity (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zzR7VJY5Rnp3" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td id="xdx_4B4_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zTViEABY2M8i" style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zyBw3EJ67iMf" style="border-bottom: Black 1pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td id="xdx_4B7_z01jfZ0qyXPf" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">Additional Paid-In </td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">Accumulated </td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">Capital</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: center">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_438_c20220101__20220331_eus-gaap--StockholdersEquity_iS_zUBdNQcsc6a9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-weight: bold">Balance at December 31, 2021</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHh5RHfgDXO8" title="Beginning balance, shares" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,918,887</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,919</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">124,622,405</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,926,847</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,710,477</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_zYyYV6KJazk7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zySljFyiJ0i1" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0247">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0243">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">756,271</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0245">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">756,271</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_z8rMsc8imXab" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of common stock options, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziniW0eGfBfi" title="Exercise of common stock options, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,415</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,413</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0251">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,414</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_zGgAzk2rS318" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0257">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,934,447</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,934,447</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43F_c20220401__20220630_eus-gaap--StockholdersEquity_iS_zC4ld7rICzLb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at March 31, 2022 </b><i>(unaudited)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zadn1ww9rIB4" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,920,302</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,920</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">125,386,089</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">63,861,294</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">61,539,715</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_zHisDkQLJw5e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN0EGldTpvec" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,519,456</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0270">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,519,459</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_zHTNqEmdD9fi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Employee stock purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7WWIdi5BYOe" title="Employee stock purchases, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,888</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,525</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,541</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_znJxEVVI1ZZ5" style="vertical-align: bottom; background-color: White">
    <td>Exercise of common stock options, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220401__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zcCj2MaQ02a2" title="Exercise of common stock options, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,871</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,540</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,542</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zz8TkwCA7Ktd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0289">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,960,526</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-04-012022-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,960,526</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_438_c20220701__20220930_eus-gaap--StockholdersEquity_iS_z2tgt91GT63e" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at June 30, 2022
    <i>(unaudited)</i></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKyIIKVoh3N6" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,941,334</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,941</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">126,995,610</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">73,821,820</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,188,731</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_zmewdWEcs5D8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN8pIPBWr3Q3" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0301">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,223,054</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0303">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,223,054</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zNPs8s3iLbVf" style="vertical-align: bottom; background-color: White">
    <td>Exercise of common stock options, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zL5E1XqzziI6" title="Exercise of common stock options, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,374</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,275</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0310">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,277</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_zshi7OaJINib" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0315">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,893,721</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,893,721</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_439_c20220701__20220930_eus-gaap--StockholdersEquity_iE_zbFMuHClFjo1" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at September 30, 2022 </b><i>(unaudited)</i></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20220701__20220930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9e3zj5Dldbk" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,942,958</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,943</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,225,939</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">84,715,541</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">43,525,341</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the financial statements </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_005"></span>Celcuity
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Statements of Changes in Stockholders&#8217; Equity </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three
and Nine Months Ended September 30, 2021 </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">Common Stock</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Additional Paid-In</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">Accumulated</td><td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Shares</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Amount</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"> Capital</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Deficit</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt; text-align: center">&#160;</td></tr>
  <tr id="xdx_43F_c20210101__20210331_eus-gaap--StockholdersEquity_iS_zhLHmYsnkkC6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; font-weight: bold">Balance at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znLxEke612w4" title="Beginning balance, shares" style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,299,822</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,013,551</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,321,581</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,702,270</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_zm5R0xWxo4i4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,098</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0336">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">449,098</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--StockIssuedDuringPeriodValueStockWarrantsExercised_zjaZD71D3o9h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise of common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodSharesStockWarrantsExercised_pid_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdld1S4FNYek" title="Exercise of common stock warrants, shares" style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesStockWarrantsExercised" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,185</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,256</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0341">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueStockWarrantsExercised" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,257</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zyFhO4beMLxe" style="vertical-align: bottom; background-color: White">
    <td>Exercise of common stock options, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zocgWEYxmDN2" title="Exercise of common stock options, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,707</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0348">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueOther_z3GTb2iJkjOf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFgvgdz4Msmf" title="Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,971,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,971</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,766,522</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,768,493</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockIssuedDuringPeriodValueNewIssues_z5toFVba2Wk8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock in an at-the-market (&#8220;ATM&#8221;) offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVvMbxVkDgT3" title="Issuance of common stock in an at-the-market (&quot;ATM&quot;) offering, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,082</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,959</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0362">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,962</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_iN_di_zxG52VHGUTre" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance costs associated with ATM offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0367">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,868</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0369">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,868</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_z0fgz8rbQE78" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0373">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,791,668</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,791,668</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43A_c20210401__20210630_eus-gaap--StockholdersEquity_iS_zSdXQ2BFNZjb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at March 31, 2021 </b><i>(unaudited)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_pid_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmbgdrJYYR68" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,287,896</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,288</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,275,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,113,249</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,174,544</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_z9jfj79J5YA5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXVeeSz2Xexb" title="Stock-based compensation, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,964</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">540,314</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0386">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">540,317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_zzxnjIvJ6sbb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Employee stock purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztOMzh6G7lGf" title="Employee stock purchases, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,496</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,811</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,817</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_z4D2NwRMb3Hh" style="vertical-align: bottom; background-color: White">
    <td>Exercise of common stock options, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzWIVUuCLME" title="Exercise of common stock options, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,136</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,859</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zFFxSJ0P0Fnh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock warrants, note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,839</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0407">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,839</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement_zbsNgvFu6bk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock, licensing agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares_pid_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zuo6jBkjJlDj" title="Issuance of common stock, licensing agreement, shares" style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">349,406</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,999,651</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0418">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,032,852</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,032,852</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20210701__20210930_eus-gaap--StockholdersEquity_iS_zpPpv650oZ7" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at June 30, 2021 </b><i>(unaudited)</i></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_pid_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjLPbmKQCahk" title="Beginning balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,654,898</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,655</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,167,970</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,146,101</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,034,524</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensationGross_z1PFzNQfsVae" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">699,916</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">699,916</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zr4URe8eiz3a" style="vertical-align: bottom; background-color: White">
    <td>Exercise of common stock options, net of shares withheld for exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOZFsko2ZF37" title="Exercise of common stock options, net of shares withheld for exercise price, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,099</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0436">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueOther_zwOM2fmgQH07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesOther_pid_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zChS7GmqhSd6" title="Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,250,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,250</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,759,842</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0443">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,762,092</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_zngB4mIJBp6l" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0448">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0449">-</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,027,246</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,027,246</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_43A_c20210701__20210930_eus-gaap--StockholdersEquity_iE_zpeiXlkBfbMi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance at September 30, 2021 </b><i>(unaudited)</i></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pid_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUmt9A68XWE" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,905,898</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,906</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">123,632,827</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">49,173,347</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,474,386</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the financial statements </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_006"></span>Celcuity
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Condensed
Statements of Cash Flows </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_112_z4Gcb94P5aU7" summary="xdx: Statement - Condensed Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20220930_z9uIrxJIoLgc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_499_20210101__20210930_zSYbhHvJZE0k" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended September 30,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zR3RD948v6S6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><b>Cash flows from operating activities:</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_i01_maNCPBUzcpX_zkwrZ5VBGysj" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">28,788,694</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,851,766</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_z5tLowrT6kVj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used for operations:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--Depreciation_i02_maNCPBUzcpX_zMqYEGygm7Ie" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">161,981</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,206</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_i02_maNCPBUzcpX_z7GV3CBew2J7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,498,784</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,689,331</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfCommonStockLicensingAgreement_i02_maNCPBUzcpX_zQPEbsHMfG9f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Issuance of common stock, licensing agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0475">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:IssuanceOfCommonStockLicensingAgreement" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_maNCPBUzcpX_zseFwZTixYW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization of debt issuance costs and discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">284,184</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,361</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PaidInKindInterest_i02_maNCPBUzcpX_zhl9Ayiszu3l" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payment-in-Kind interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">311,764</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PaidInKindInterest" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">196,348</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IncreaseDecreaseInNonCashOperatingLeaseExpense_i02_maNCPBUzcpX_zztkak1tqFb9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash operating lease, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:IncreaseDecreaseInNonCashOperatingLeaseExpense" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,791</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:IncreaseDecreaseInNonCashOperatingLeaseExpense" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,681</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--GainLossOnDispositionOfAssets1_i02N_di_msNCPBUzcpX_zX2OjdwJVXh9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Loss on sale of fixed assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0487">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">263</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_z6lGTbVHTbwe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IncreaseDecreaseInPayrollTaxReceivable_i03N_di_msNCPBUzcpX_z3nNmZwPiYn3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Payroll tax receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:IncreaseDecreaseInPayrollTaxReceivable" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">37,838</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:IncreaseDecreaseInPayrollTaxReceivable" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">166,309</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i03N_di_msNCPBUzcpX_z5gVTgpVeuv8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Prepaid assets and deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,855,575</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,311</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maNCPBUzcpX_zMss94BtUUFb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,553,176</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,553,381</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i03_maNCPBUzcpX_zn0qtX64X3P9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,270,422</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">105,239</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtNCPBUzcpX_maCCERCzEEB_zgJ3QimpPx0d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Net cash used for operating activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,528,911</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,187,938</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zu5i3QiOWHDk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><b>Cash flows from investing activities:</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUzSKk_zztwQLMY2K5f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,724</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,959</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromSaleOfPropertyPlantAndEquipment_i01_maNCPBUzSKk_zsQw7yCQjcwh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from sale of property and equipment</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0514">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzSKk_maCCERCzEEB_zqtcXvosIsa5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Net cash used for investing activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,724</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">71,459</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zvoSmP081Sba" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><b>Cash flows from financing activities:</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromWarrantExercises_i01_maNCPBUzVJA_zuc1azeQ3Atf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from exercise of common stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,257</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUzVJA_zT2HXkoJO8Jc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from exercise of employee stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,233</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,959</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--ProceedsFromEmployeeStockPurchases_i01_maNCPBUzVJA_zGCebyUE1lJj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from employee stock purchases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:ProceedsFromEmployeeStockPurchases" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,541</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:ProceedsFromEmployeeStockPurchases" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,817</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts_i01_maNCPBUzVJA_zeVJHXmFtFe1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Proceeds from follow-on offering, net of underwriting discounts and offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,530,585</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProceedsFromDebtNetOfIssuanceCosts_i01_maNCPBUzVJA_zD8vONhnWTUh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Proceeds from note payable, net of debt issuance costs and discount of $<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20220930_z83TESfVRZEd" title="Debt issuance costs and discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">652,061</ix:nonFraction></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0535">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,347,939</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PaymentsOfDebtIssuanceCosts_i01N_di_msNCPBUzVJA_zz3V20lLltYa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payments for debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,463</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0541">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--GrossProceedsFromAnAtmOffering_i01_maNCPBUzVJA_zFsm2pKwq727" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Gross proceeds from an ATM offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0543">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:GrossProceedsFromAnAtmOffering" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,962</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PaymentsForRegistrationStatementCosts_i01N_di_msNCPBUzVJA_zLIUxIrXKFb3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Payments for secondary registration statement costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:PaymentsForRegistrationStatementCosts" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,897</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="CELC:PaymentsForRegistrationStatementCosts" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,868</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_ecustom--PaymentsForFinanceLeases_i01N_di_msNCPBUzVJA_zznOUy95NEwi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Payments for finance leases</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="CELC:PaymentsForFinanceLeases" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,384</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="CELC:PaymentsForFinanceLeases" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,353</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzVJA_maCCERCzEEB_zYDiA5HROtnk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Net cash (used for) provided by financing activities</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">226,970</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,988,298</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCCERCzEEB_zlx4TN8MyDCd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,802,605</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,728,901</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashAndCashEquivalentsAbstract_iB_zRANmPe9cuac" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><b>Cash and cash equivalents:</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01S_zNqziq2ExQ0a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Beginning of period</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,286,381</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,637,911</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_i01E_z7Jsne2FLaL4" style="vertical-align: bottom; background-color: White">
    <td>End of period</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,483,776</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,366,812</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zMi94Mu2gLx9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><b>Supplemental disclosure of cash flow information:</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--InterestPaidNet_i01_zmTiESMR9Tcf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">832,161</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">454,573</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zFS1bRLaZ1Cf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><b>Supplemental disclosures of non-cash investing and financing activities:</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PropertyAndEquipmentIncludedInAccountsPayable_i01_zxDDfaoTfad6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment included in accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="CELC:PropertyAndEquipmentIncludedInAccountsPayable" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">104,818</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0577">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--OfferingAndRegistrationStatementCostsIncludedInAccountsPayable_i01_zPeoT7IOLug" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Offering and registration statement costs included in accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,230</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0580">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses_i01_zmkx4Bcc7Gv5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred financing costs and offering and registration statement costs included in accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">205,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0583">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockIssued1_i01_zhzxvEyoyZzg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Issuance of common stock warrants and final fee recognized as discount to note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0585">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">964,839</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>See
accompanying notes to the financial statements</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 5.4pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_007"></span>CELCUITY
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES
TO CONDENSED FINANCIAL STATEMENTS (unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(For
the Three and Nine Months Ended September 30, 2022 and 2021)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zw7MUWbS5I81" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_829_zhBT55h4gk46">Organization</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Nature
of Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
Inc., a Delaware corporation (the &#8220;Company&#8221;), is a clinical-stage biotechnology company focused on development of targeted
therapies for multiple solid tumor indications. The Company&#8217;s lead therapeutic candidate is gedatolisib, a potent, reversible dual
inhibitor that selectively targets all Class I PI3K isoforms and mTOR. Its mechanism of action and pharmacokinetic properties are highly
differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The Company initiated a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its CELsignia companion
diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit
from already approved targeted therapies. The Company was co-founded in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based
in Minnesota. The Company has not generated any revenues to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zxQ7AMVz0DJk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_825_zGGnkadNp5Xl">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfrANUBxlxji" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86C_zxtv3naAxj1b">Basis
of Presentation</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited financial statements include the accounts of the Company and have been prepared in accordance with Article 10
of Regulation S-X promulgated by the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, as permitted by Article 10,
the unaudited financial statements do not include all of the information required by accounting principles generally accepted in the
United States (&#8220;U.S. GAAP&#8221;). The balance sheet at December 31, 2021 was derived from the audited financial statements at
that date and does not include all the disclosures required by U.S. GAAP. In the opinion of management, all adjustments which are of
a normal recurring nature and necessary for a fair presentation have been reflected in the financial statements. These unaudited condensed
financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021
and the related footnotes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021. Operating
results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected during the
remainder of the current year or for any future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_84A_eus-gaap--UseOfEstimates_zjVRsRnV9Mwk" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_z89nW2pJ8Wxe">Accounting
Estimates</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject
to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zqUToOfwFlx4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_860_zvmYCTBzhKP9">Risks
and Uncertainties</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the development stage including, but not limited to, dependency on, the clinical and
commercial success of its initial drug product, gedatolisib, the clinical and commercial success of its diagnostic tests, ability to
obtain regulatory approval of its drug product, gedatolisib, ability to obtain regulatory approval of its diagnostic tests, the need
for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians
and consumers, and significant competition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbMsd4XJPq63" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zCrGxj1rJxwg">Clinical
Trial Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers,
which includes the conduct of preclinical studies and clinical trials. These costs can be a significant component of the Company&#8217;s
research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in
accordance with service agreements with its third-party service providers. The Company makes significant judgments and estimates in determining
the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its prepaid assets or accrued
expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status
and timing of actual services performed, number of patients enrolled, and the rate of patient enrollments may vary from the Company&#8217;s
estimates, resulting in an adjustment to expense in future periods. Changes in these estimates that result in material changes to the
Company&#8217;s prepaid assets or accrued expenses could materially affect the Company&#8217;s results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="CELC:ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock"><p id="xdx_849_ecustom--ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_zhvoTjzrn2cl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zehZ66s6Orgh">Application
of New or Revised Accounting Standards</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), a company constituting an &#8220;emerging growth company&#8221;
is, among other things, entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company but has
irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or
revised accounting standards. As a result, the Company will comply with new or revised accounting standards on the relevant dates on
which adoption of such standards is required for public companies that are not emerging growth companies. The Company&#8217;s emerging
growth company filer status will cease on its Form 10-K filing for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zRIm0r2XZaQf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_863_zDXFXap8NjRa">Recently
Adopted Accounting Pronouncements</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU No. 2021-04, Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options, which provides guidance on how an issuer should account for modifications made to equity-classified written call
options. The guidance in the ASU requires the issuer to treat the modification of an equity-classified warrant that does not cause the
warrant to become liability-classified as an exchange of the original warrant for a new warrant. The issuer should measure the effect
of a modification as the difference between the fair value of the modified warrant and the fair value of that warrant immediately before
modification. The standard is effective for all entities for all fiscal years beginning after December 15, 2021. The Company adopted
this accounting standard effective January 1, 2022, and based on the standard, determined that the Representative&#8217;s Warrant amendment
was equity-classified, treated as a deemed dividend within Additional Paid-in Capital, and the estimated incremental fair value of the
modification for the Representative&#8217;s Warrant at the date of amendment was $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220913__20220913_zIluUtMtiSDa" title="Incremental fair value of warrant"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-09-132022-09-13" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,988</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zqU8sxSQtQDc" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <span id="xdx_820_z8yipxpIIx7h">Net Loss Per Common Share</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">Basic
and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average
common shares outstanding during the period. For all periods presented, the common shares underlying the options and warrants have been
excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to
calculate both basic and diluted loss per common share is the same.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three and nine months ended September 30, 2022 and 2021, potentially dilutive securities excluded from the computations of diluted
weighted-average shares outstanding were options to purchase <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8EYhiPqkb98" title="Antidilutive securities excluded from computation of earnings per share"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z800QFPx29Aj" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,919,114</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zifTRwaVUf79" title="Antidilutive securities excluded from computation of earnings per share"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zdDUSCTGb9r5" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,184,721</ix:nonFraction></ix:nonFraction></span></span> shares of common stock, respectively, warrants to
purchase <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z1LPZsAjwyn8" title="Antidilutive securities excluded from computation of earnings per share"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z28vQTFPfbYh" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012022-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">309,652</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zz3gT6KkhOUe" title="Antidilutive securities excluded from computation of earnings per share"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2RqLufUauRi" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-07-012021-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">378,442</ix:nonFraction></ix:nonFraction></span> </span>shares of common stock, respectively, and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zkW2K0hdlhsg" title="Antidilutive securities excluded from computation of earnings per share"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zng2qg55EAXh" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012022-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,273</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z6JfWqN4bBr3" title="Antidilutive securities excluded from computation of earnings per share"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z1HjuW97fuG2" title="Antidilutive securities excluded from computation of earnings per share"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,964</ix:nonFraction></ix:nonFraction></span></span> shares of restricted common stock, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASU 2021-04, for purposes of calculating basic and diluted net loss per share for the three- and nine-month periods ended
September 30, 2022, the reported net loss was increased by approximately $<span id="xdx_90E_ecustom--DeemedDividend_c20220101__20220930_zaYurw4ObVp4" title="Deemed dividend"><span id="xdx_90B_ecustom--DeemedDividend_c20220701__20220930_z6Ii1JRpd0Rb" title="Deemed dividend"><ix:nonFraction name="CELC:DeemedDividend" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="CELC:DeemedDividend" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,000</ix:nonFraction></ix:nonFraction></span></span> related to the deemed dividend resulting from the amendment
to the warrant agreement as further discussed in Note 5. This adjustment increased the basic and diluted net loss per share by $<span id="xdx_907_ecustom--IncreasedNetLossPerShareBasicAndDiluted_c20220701__20220930_zDMk0jkSunKh" title="Increased net loss per share basic and diluted"><span id="xdx_903_ecustom--IncreasedNetLossPerShareBasicAndDiluted_c20220101__20220930_zOyE3fq1wkpc" title="Increased net loss per share basic and diluted"><ix:nonFraction name="CELC:IncreasedNetLossPerShareBasicAndDiluted" contextRef="From2022-07-012022-09-30" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="CELC:IncreasedNetLossPerShareBasicAndDiluted" contextRef="From2022-01-01to2022-09-30" decimals="INF" unitRef="USDPShares">.02</ix:nonFraction></ix:nonFraction></span></span> for
the three- and nine-month periods ended September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_803_eus-gaap--CommitmentsDisclosureTextBlock_zWXa0xCTHHvf" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <span id="xdx_821_z7EBdCFi3EGf">Commitments</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 19.8pt; text-align: justify; text-indent: -19.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Operating
and Finance Leases</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 19.8pt; text-align: justify; text-indent: -19.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases its corporate space in Minneapolis, Minnesota. In September 2017, the Company entered into a non-cancelable operating
lease agreement for building space. The lease commenced, and the Company moved to the facility in May 2018, in conjunction with the termination
of its then existing lease. Rent expense is recorded on a straight-line basis over the lease term. In July 2020, the Company signed an
amendment to extend this lease through April 30, 2022. The lease amendment provides for monthly rent, real estate taxes and operating
expenses. As a result of the lease amendment, the Company recorded an incremental $<span id="xdx_90E_eus-gaap--IncreaseDecreaseInOperatingCapital_c20200701__20200731_zCRxHo4R7KO2" title="Increase in operating ROU asset and lease liability"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="From2020-07-012020-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">197,211</ix:nonFraction></span> in the operating right-of-use (&#8220;ROU&#8221;)
asset and lease liability. In July 2021, the Company signed the second amendment to extend this lease through April 30, 2023. The lease
amendment provides for monthly rent, real estate taxes and operating expenses. As a result of the lease amendment, the Company recorded
an incremental $<span id="xdx_90F_eus-gaap--IncreaseDecreaseInOperatingCapital_c20210701__20210731_zPScVKEnpaI8" title="Increase in operating ROU asset and lease liability"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="From2021-07-012021-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">193,571</ix:nonFraction></span> in the operating right-of-use (&#8220;ROU&#8221;) asset and lease liability. In July 2022, the Company signed
the third amendment to extend this lease through April 30, 2024. This amendment provides for monthly rent, real estate taxes and operating
expenses. The Company recorded an incremental $<span id="xdx_905_eus-gaap--IncreaseDecreaseInOperatingCapital_c20220701__20220731_zzVaBArDB4mh" title="Increase in operating ROU asset and lease liability"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingCapital" contextRef="From2022-07-012022-07-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">195,437</ix:nonFraction></span> in the operating right-of-use (&#8220;ROU&#8221;) asset and lease liability pertaining
to this amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2018, the Company entered into a non-cancelable finance lease agreement for office equipment with a five-year term. The underlying
assets are included in furniture and equipment. The lease contains a bargain purchase option at the end of the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
an implicit rate is not provided, the Company uses its incremental borrowing rate based on the information available at the lease commencement
date in determining the present value of the lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Clinical
Research Studies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company enters into contracts in the normal course of business to conduct research and development programs internally and through third
parties that include, among others, arrangements with vendors, consultants, CMO&#8217;s, and CRO&#8217;s. The Company currently has five
Phase 2 clinical trial agreements in place to evaluate targeted therapies selected with one of our CELsignia tests. Timing of milestone
payments related to the Phase 2 clinical trials are uncertain and the contracts generally provide for termination following a certain
period after notice, therefore the Company believes that non-cancelable obligations under the agreements are not material. The Company
also has a license agreement in place with Pfizer to research, develop, manufacture and commercialize gedatolisib. In conjunction with
the license agreement, the Company continued a Phase 1b study &#8211; B2151009 related to gedatolisib. These patients subsequently transitioned
to an Expanded Access study &#8211; CELC-G-001. Contracts related to the Phase 1B study and the Expanded Access study, are generally
based on time and material. In addition, contracts related to the Company&#8217;s Phase 3 clinical study (VIKTORIA-1) are
generally cancelable with reasonable notice within 120 days and the Company&#8217;s obligations under these contracts are primarily based
on services performed through termination dates plus certain cancelation charges, if any, as defined in each of the respective agreements.
In addition, these agreements may, from time to time, be subjected to amendments as a result of any change orders executed by the parties.
As of September 30, 2022, the Company had only one material non-cancelable contractual commitment with respect to these arrangements,
which totaled approximately $<span id="xdx_90E_eus-gaap--ContractualObligation_iI_pn5n6_c20220930_zPrR7hpV2JLf" title="Non-cancelable contractual commitment"><ix:nonFraction name="us-gaap:ContractualObligation" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1LClExyCUUh" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. <span id="xdx_82E_zoGrFvfP3ini">Stockholders&#8217;
Equity</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 13, 2022, the Company entered into a First Amendment to Representative&#8217;s Warrant (the &#8220;Warrant Amendment&#8221;)
with Craig-Hallum Capital Group LLC (&#8220;Craig-Hallum&#8221;), amending the terms of that certain Representative&#8217;s Warrant,
dated September 22, 2017 (the &#8220;Representative&#8217;s Warrant&#8221;) issued by the Company to Craig-Hallum in connection with
the Company&#8217;s initial public offering. Under the terms of the Warrant Amendment, (i) the number of shares of the Company&#8217;s
common stock issuable upon exercise of the Representative&#8217;s Warrant was reduced from <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220913__srt--RangeAxis__srt--MaximumMember_zF1CFQc9Aag6" title="Common stock issuable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-09-13_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">138,000</ix:nonFraction></span> shares to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220913__srt--RangeAxis__srt--MinimumMember_zEoE6FgYnjt2" title="Common stock issuable"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2022-09-13_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,000</ix:nonFraction></span> shares, and (ii)
the exercise period of the Representative&#8217;s Warrant was extended three years to <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220913_zeK3xhnjZmT1" title="Warrants maturity date"><ix:nonNumeric contextRef="AsOf2022-09-13" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">September 19, 2025</ix:nonNumeric></span>. There were no other material
amendments or modifications to the Representative&#8217;s Warrant. The estimated incremental fair value of the Representative&#8217;s
Warrant at the date of amendment was $<span id="xdx_901_ecustom--EstimatedIncrementalFairValueOfWarrants_c20220913__20220913_zOJPltQKlmA5" title="Estimated incremental fair value of the warrants"><ix:nonFraction name="CELC:EstimatedIncrementalFairValueOfWarrants" contextRef="From2022-09-132022-09-13" format="ixt:numdotdecimal" decimals="0" unitRef="USD">271,988</ix:nonFraction></span>. As the Company has an accumulated deficit balance in Retained Earnings, the incremental
impact will be recorded as a deemed dividend, classified within Additional Paid-in Capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2022, the Company held a Special Meeting of Stockholders, at which the Company&#8217;s stockholders approved a proposal
to amend the Company&#8217;s Certificate of Incorporation to increase the authorized number of the Company&#8217;s Common Stock from
<span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220901__srt--RangeAxis__srt--MinimumMember_zsS6t1PSH463" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-09-01_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">30,000,000</ix:nonFraction></span> shares to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220901__srt--RangeAxis__srt--MaximumMember_zVhPwLaDeMS5" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-09-01_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,000,000</ix:nonFraction></span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2022, the Company entered into a securities purchase agreement with certain institutional and other accredited investors for
the sale of Company common stock, preferred stock that may be convertible into common stock and warrants initially exercisable for preferred
stock for $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20220515__20220515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zi8b80b3LzRa" title="Sale of stock, value"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" contextRef="From2022-05-152022-05-15_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">100</ix:nonFraction></span> million in the aggregate, before deducting placement agent fees and other offering expenses. Pursuant to the securities
purchase agreement, investors will purchase shares of common stock and preferred stock at a price per share of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_c20220515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zeUaOPo6FYHk" title="Sale of stock price per share"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-05-15_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.75</ix:nonFraction></span> (on an as converted
to common stock basis). For each share of common stock and each 1/10 of a share of preferred stock purchased, investors will receive
a warrant exercisable for<span id="xdx_90B_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20220515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBD2r5QMIc09" title="Conversion price per share"> <ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="AsOf2022-05-15_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.40</ix:nonFraction></span> shares of common stock. The exercise price of the warrants will be at a <span id="xdx_90D_ecustom--PercentageOfWarrantExercisePrice_iI_pid_dp_uPure_c20220515__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zwvJjZLxptyi" title="Percentage of warrant exercise price"><ix:nonFraction name="CELC:PercentageOfWarrantExercisePrice" contextRef="AsOf2022-05-15_custom_PurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">40</ix:nonFraction>%</span> premium to the price paid
by investors for the initial shares of common stock purchased in the private placement. The preferred stock will be convertible into
common stock at the holder&#8217;s election, subject to certain limitations such as beneficial ownership. The closing of the private
placement is conditioned on, among other customary items, the first patient enrolled in the Company&#8217;s Phase 3 clinical
study (VIKTORIA-1) having received their first dose of treatment at a clinical site located in the United States, provided that if such
date does not occur on or before December 31, 2022, each investor will have the right to terminate its obligation to purchase securities
under the securities purchase agreement. The Company also entered into a customary registration rights agreement with the investors pursuant
to which it agreed to file a registration statement with the SEC registering the resale of (i) the shares of common stock to be issued
and sold in the private placement, (ii) the shares of common stock issuable upon conversion of the preferred stock purchased in the private
placement and (iii) the shares of common stock issuable upon conversion of the shares of preferred stock that may be issued upon exercise
of warrants purchased in the private placement. As of September 30, 2022, the Company has incurred $<span id="xdx_902_ecustom--SaleOfStockTransactionFee_iI_c20220930_zW12ZCCoNdia" title="Incurred transaction fee"><ix:nonFraction name="CELC:SaleOfStockTransactionFee" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">142,241</ix:nonFraction></span> in fees related to the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 4, 2022, the Company entered into an Open Market Sale Agreement<sup>SM</sup> with Jefferies LLC, as agent (&#8220;Jefferies&#8221;),
pursuant to which we may offer and sell, from time to time, through Jefferies, shares of our common stock having an aggregate offering
price of up to $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220204__20220204__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_z5NN1CxPvd53" title="Aggregate offering price, common stock shares"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2022-02-042022-02-04_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>. The Company will pay Jefferies a commission equal to <span id="xdx_900_ecustom--CommissionPercentage_iI_pid_dp_uPure_c20220204__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zsAJDimyeWh4" title="Aggregate offering price, commission percentage"><ix:nonFraction name="CELC:CommissionPercentage" contextRef="AsOf2022-02-04_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction>%</span> of the aggregate gross proceeds from each sale
of such shares. On October 12, 2022, pursuant to the above agreement, the Company sold <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20221012__20221012__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zV16oqAstL53" title="Sale of stock number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-10-122022-10-12_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> shares of common stock in a single transaction
at a price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20221012__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIMOBa3O3Hz7" title="Sale of stock price per shares"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2022-10-12_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.35</ix:nonFraction></span> per share, generating gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20221012__20221012__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9gbieHF9Q2g" title="Gross proceeds from public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-10-122022-10-12_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.2</ix:nonFraction></span> million ($<span id="xdx_901_ecustom--GrossProceedsNetOfCommissionsAndOfferingExpenses_pn5n6_c20221012__20221012__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBXhydOGzIK1" title="Gross proceeds net of commissions and offering expenses"><ix:nonFraction name="CELC:GrossProceedsNetOfCommissionsAndOfferingExpenses" contextRef="From2022-10-122022-10-12_us-gaap_SubsequentEventMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction></span> million net of commissions and offering expenses).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">On
July 1, 2021, the Company completed a follow-on offering whereby it sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210701__20210702__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zvOB5HpzNaF4" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-07-012021-07-02_custom_FollowOnOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,250,000</ix:nonFraction></span> shares of common stock at a public offering price
of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20210701__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_z0c7UKs8cB76" title="Issuance of public offering price per shares"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2021-07-01_custom_FollowOnOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">25.00</ix:nonFraction></span> per share. The offering generated approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210701__20210701__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zMte52NkxjO4" title="Gross proceeds from public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-07-012021-07-01_custom_FollowOnOfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">56.3</ix:nonFraction></span> million before deducting underwriting discounts of approximately $<span id="xdx_909_eus-gaap--PaymentsForUnderwritingExpense_pn5n6_c20210701__20210701__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_z7INJy2BOfxl" title="Underwriting discounts"><ix:nonFraction name="us-gaap:PaymentsForUnderwritingExpense" contextRef="From2021-07-012021-07-01_custom_FollowOnOfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.4</ix:nonFraction></span>
million and offering expenses of approximately $<span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20210701__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zCTS9rMaUrp4" title="Offering expenses"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2021-07-01_custom_FollowOnOfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span> million.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, the Company completed a follow-on offering whereby it sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210226__20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zTFbfEDHBS9f" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-02-262021-02-26_custom_FollowOnOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,971,100</ix:nonFraction></span> shares of common stock (including <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210226__20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zcfTPmt4T8Pc" title="Sale of stock number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-02-262021-02-26_custom_FollowOnOfferingMember_custom_UnderwriterMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">257,100</ix:nonFraction></span> shares
of common stock in connection with the full exercise of the underwriters&#8217; option to purchase additional shares) at a public offering
price of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zJkjNdPBEZDg" title="Issuance of public offering price per shares"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2021-02-26_custom_FollowOnOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.00</ix:nonFraction></span> per share. The aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares
pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, was approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210226__20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zSq8xcrBdnwb" title="Gross proceeds from public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-02-262021-02-26_custom_FollowOnOfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">27.6</ix:nonFraction></span> million before
deducting underwriting discounts of approximately $<span id="xdx_90A_eus-gaap--PaymentsForUnderwritingExpense_pn5n6_c20210225__20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zhVPFwh0iJTa" title="Deducting underwriting discounts"><ix:nonFraction name="us-gaap:PaymentsForUnderwritingExpense" contextRef="From2021-02-252021-02-26_custom_FollowOnOfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.6</ix:nonFraction></span> million and offering expenses of approximately $<span id="xdx_905_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zzjxQRvudk3j" title="Offering expenses"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2021-02-26_custom_FollowOnOfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.2</ix:nonFraction></span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">On
June 5, 2020, the Company entered into an At Market Issuance Sales Agreement (the &#8220;ATM Agreement&#8221;) with B. Riley FBR, Inc.
(the &#8220;Agent&#8221;). Pursuant to the ATM Agreement, the Company was able to offer and sell from time to time, at its option, shares
of common stock having an aggregate offering price of up to $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20200605__20200605__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember__srt--RestatementAxis__custom--PlacementSharesMember_zBZ06rhN0sca" title="Aggregate offering price, common stock shares"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2020-06-052020-06-05_custom_AtmAgreementMember_custom_PlacementSharesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000,000</ix:nonFraction></span>, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20200605__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember__srt--RestatementAxis__custom--PlacementSharesMember_zQ4cFnQUnlq8" title="Common stock par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-06-05_custom_AtmAgreementMember_custom_PlacementSharesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (the &#8220;Placement Shares&#8221;),
through the Agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2022 and 2021, the Company sold<span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220101__20220930__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember_z2pnYh62TvCa" title="Sale of stock number of shares issued in transaction"> <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2022-01-012022-09-30_custom_AtmAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> and <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210101__20210930__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember_zCARXh8zCj74" title="Sale of stock number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2021-01-012021-09-30_custom_AtmAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,082</ix:nonFraction></span> shares, respectively, of common stock pursuant to the
ATM Agreement, at an average selling price of $<span id="xdx_900_ecustom--AverageSellingPricePerShare_iI_pid_c20220930__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember_zhaCWxjn6Mw3" title="Average selling price per share"><span id="xdx_901_ecustom--AverageSellingPricePerShare_iI_pid_c20210930__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember_z3K6shU1BAT8" title="Average selling price per share"><ix:nonFraction name="CELC:AverageSellingPricePerShare" contextRef="AsOf2022-09-30_custom_AtmAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="CELC:AverageSellingPricePerShare" contextRef="AsOf2021-09-30_custom_AtmAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">12.64</ix:nonFraction></ix:nonFraction></span> </span>per share. On February 23, 2021, in conjunction with the Company&#8217;s follow-on
offering, the ATM Agreement was terminated through the Agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z6UB62rPNOBe" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. <span id="xdx_82F_zOIXLcdCIUZ5">Stock-Based Compensation</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXKRuVCbhS02" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity for all stock options outstanding for the nine months ended September 30:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zdSt5uUNIXZ9" style="display: none">Schedule
of Stock Options Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; padding-left: 0pt">Options outstanding at beginning of year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrSCzwii4Kzb" title="Options outstanding beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,315,321</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmG3tyVwNtA9" title="Weighted Average Exercise Price, beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.97</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWx4nS4S9Woi" title="Options outstanding beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">849,949</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7kTOrfTJbX5" title="Weighted Average Exercise Price, beginning balance" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.33</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z24bDTEAooDb" title="Options outstanding shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">720,047</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoylRQYZJfY9" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.19</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEP0ol8c0Ztl" title="Options outstanding shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">402,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB4wUqGVw9Ia" title="Weighted Average Exercise Price, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">23.04</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1OruBtbAq8g" title="Options outstanding shares, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,660</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHD4IcmxjWWh" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgmXMz0byNYh" title="Options outstanding shares, Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,620</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsJqcpimauh5" title="Weighted Average Exercise Price, Exercised" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.26</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaY9De5qD7Mi" title="Options outstanding shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">111,594</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWKU3C96ypi" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.86</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxtm3Yyu4rJj" title="Options outstanding shares, Forfeited" style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,158</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm09d9yhCHfc" title="Weighted Average Exercise Price, Forfeited" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">19.07</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt">Balance at September 30</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGne0HUh0gpi" title="Options outstanding ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,919,114</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziwFvkBcgfff" title="Weighted Average Exercise Price, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.08</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx6aSSNQFs51" title="Options outstanding ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,184,721</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgGaml9ho3j9" title="Weighted Average Exercise Price, ending balance" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.84</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Options exercisable at September 30:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUhW99Mu70Tb" title="Options exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">882,215</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zI25OtkO4F1b" title="Weighted Average Exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.92</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmdmu8OU9Rj1" title="Options exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">560,915</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za9XuG27QAMh" title="Weighted Average Exercisable, ending balance" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.45</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Weighted Average Grant Date Fair Value for options granted during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjfrX6Ysl6ie" title="Weighted Average Grant Date Fair Value for options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.87</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Weighted Average Grant Date Fair Value for options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">15.28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z2AOOaCgIouk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"><p id="xdx_898_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zoQy3AYiKgE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
following table summarizes additional information about stock options outstanding and exercisable at September 30, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BB_znZyJLodyZig" style="display: none">Schedule
of Stock Options Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOL8fsPOb8yg" title="Options outstanding" style="width: 13%; text-align: center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,919,114</ix:nonFraction></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEv8n7Gm0i4l" title="Options outstanding, weighted average remaining contractual life"><ix:nonNumeric contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.98</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLxtS2Xgalb6" title="Options outstanding, weighted average exercise price" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.08</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlyBlU1AP091" title="Options outstanding, aggregate intrinsic value" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,791,703</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjQeS3QHL4w4" title="Options exercisable" style="width: 12%; text-align: center"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">882,215</ix:nonFraction></td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEh8N1UvUQZe" title="Options exercisable, weighted average exercise price" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.92</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zImAuNvoARlj" title="Options exercisable, aggregate intrinsic value" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,779,591</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_z4CfFqdHaSrf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized stock-based compensation expense for stock options of $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAK0dPfSBFz2" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,162,751</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSFCafLS0qDf" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">673,022</ix:nonFraction></span> for the three months ended September
30, 2022 and 2021, respectively and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZe47tGM0jrf" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,329,969</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-09-30_us-gaap_StockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,611,575</ix:nonFraction></span> for the nine months ended September 30, 2022 and 2021, respectively. In
May 2022, the Company modified the exercise price on <span id="xdx_903_ecustom--StockOptionAwardsSharesModified_c20220531__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_pdd" title="Stock option awards shares modified"><ix:nonFraction name="CELC:StockOptionAwardsSharesModified" contextRef="AsOf2022-05-31_custom_InMayTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">776,324</ix:nonFraction></span> stock option awards to $<span id="xdx_908_ecustom--ModifiedStockOptionExercisePrice_c20220531__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_pdd" title="Stock option exercise price per share"><ix:nonFraction name="CELC:ModifiedStockOptionExercisePrice" contextRef="AsOf2022-05-31_custom_InMayTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.50</ix:nonFraction></span>, the closing market price on the Nasdaq Capital
Market on May 17, 2022. The effect of this modification on stock-based compensation was $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20220701__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_zf3ht9msEeXf" title="Modification on stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2022-07-012022-09-30_custom_InMayTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,088</ix:nonFraction></span> for the three months ending September
30, 2022 and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20220101__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_zkmb53GlDmAi" title="Modification on stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2022-01-012022-09-30_custom_InMayTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">477,431</ix:nonFraction></span> for the nine months ending September 30, 2022. The effect of this modification on stock-based compensation over
the remaining service period will be approximately $<span id="xdx_90E_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_pdp0_c20220101__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_zJw3K86iQogk" title="Remaining stock based compensation expense related to modification"><ix:nonFraction name="CELC:RemainingStockBasedCompensationExpenseRelatedToModification" contextRef="From2022-01-012022-09-30_custom_InMayTwoThousandTwentyTwoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">389,000</ix:nonFraction></span>. In December 2021, the Company modified the exercise price on <span id="xdx_908_ecustom--StockOptionAwardsSharesModified_c20211231__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_pdd" title="Stock option awards shares modified"><ix:nonFraction name="CELC:StockOptionAwardsSharesModified" contextRef="AsOf2021-12-31_custom_InDecemberTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">311,000</ix:nonFraction></span> stock
option awards to $<span id="xdx_901_ecustom--ModifiedStockOptionExercisePrice_c20211231__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_pdd" title="Stock option exercise price per share"><ix:nonFraction name="CELC:ModifiedStockOptionExercisePrice" contextRef="AsOf2021-12-31_custom_InDecemberTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.44</ix:nonFraction></span>, the closing market price on the Nasdaq Capital Market on December 15, 2021. No director or officer awards were
modified. The effect of this modification on stock-based compensation was $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20220701__20220930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_zG37NdoIA3S9" title="Modification on stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2022-07-012022-09-30_custom_InDecemberTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,778</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20210701__20210930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_zwpaitmJbdq2" title="Modification on stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2021-07-012021-09-30_custom_InDecemberTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> for the three months ended September 30, 2022
and 2021, respectively and $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20220101__20220930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_zBjO7YAWKebf" title="Modification on stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2022-01-012022-09-30_custom_InDecemberTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,562</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20210101__20210930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_zg2Fq2Rbyai4" title="Modification on stock-based compensation"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2021-01-012021-09-30_custom_InDecemberTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> for the nine months ended September 30, 2022 and 2021, respectively. The effect of this modification
on stock-based compensation over the remaining service period will be approximately $<span id="xdx_90B_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_pdp0_c20220101__20220930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_z2scb6adw252" title="Remaining stock based compensation expense related to modification"><ix:nonFraction name="CELC:RemainingStockBasedCompensationExpenseRelatedToModification" contextRef="From2022-01-012022-09-30_custom_InDecemberTwoThousandTwentyOneMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">219,000</ix:nonFraction></span>. In May 2020, the Company modified the exercise
price on <span id="xdx_902_ecustom--StockOptionAwardsSharesModified_c20200531__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_pdd" title="Stock option awards shares modified"><ix:nonFraction name="CELC:StockOptionAwardsSharesModified" contextRef="AsOf2020-05-31_custom_InMayTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">203,750</ix:nonFraction></span> stock option awards to $<span id="xdx_909_ecustom--ModifiedStockOptionExercisePrice_c20200531__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_pdd" title="Stock option exercise price per share"><ix:nonFraction name="CELC:ModifiedStockOptionExercisePrice" contextRef="AsOf2020-05-31_custom_InMayTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.10</ix:nonFraction></span>, the closing market price on the Nasdaq Capital Market on May 14, 2020. No director or
officer awards were modified. The effect of this modification on stock-based compensation was $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20220701__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_zmm1nhLhElac" title="Stock based compensation expense related to modification"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2022-07-012022-09-30_custom_InMayTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,681</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20210701__20210930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_zvg30821IeBf" title="Stock based compensation expense related to modification"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2021-07-012021-09-30_custom_InMayTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,602</ix:nonFraction></span> for the three months
ended September 30, 2022 and 2021, respectively and $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20220101__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_zk4Je60sKHtl" title="Stock based compensation expense related to modification"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2022-01-012022-09-30_custom_InMayTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,897</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20210101__20210930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_zAHjbcXvfNof" title="Stock based compensation expense related to modification"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" contextRef="From2021-01-012021-09-30_custom_InMayTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,396</ix:nonFraction></span> for the nine months ended September 30, 2022 and 2021. The effect
of this modification on stock-based compensation over the remaining service period will be approximately $<span id="xdx_90D_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_c20220101__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_pp0p0" title="Remaining stock based compensation expense related to modification"><ix:nonFraction name="CELC:RemainingStockBasedCompensationExpenseRelatedToModification" contextRef="From2022-01-012022-09-30_custom_InMayTwoThousandTwentyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,000</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z9UDxxKJQwg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Black-Scholes option-pricing model was used to estimate the grant date fair value of equity-based awards with the following weighted-average
assumptions for the nine months ended September 30:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zRtXAuSVZuD9" style="display: none">Schedule
of Assumptions for Fair Value of Equity-based Awards</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_ztDYIhGZ9d81" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.68</ix:nonFraction></span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zhlccm75GFb3" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-01-012022-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.93</ix:nonFraction></span></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_zrhyCssAWLvc" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.63</ix:nonFraction></span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_z0XOL4D44oul" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.16</ix:nonFraction>%</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zhz9fIEUQC82" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">76.2</ix:nonFraction></span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zM0sHkmKRRn" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-01-012022-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">79.6</ix:nonFraction>%</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_z5TZleI7sOqa" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">76.6</ix:nonFraction></span>% - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_ztYCAenRGsV1" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">76.9</ix:nonFraction>%</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zvsIlC59A2ig" title="Expected life (years)"><ix:nonNumeric contextRef="From2022-01-012022-09-30_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.29</ix:nonNumeric></span> to <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_z0Lf6IOqg6N9" title="Expected life (years)"><ix:nonNumeric contextRef="From2022-01-012022-09-30_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_z6iXcr5GsyLk" title="Expected life (years)"><ix:nonNumeric contextRef="From2021-01-012021-09-30_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonNumeric></span> to <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_z0hnYf9aWiyi" title="Expected life (years)"><ix:nonNumeric contextRef="From2021-01-012021-09-30_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.08</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt">Expected dividend yield</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930_zLtew7ruHLdi" title="Expected dividend yield" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction>%</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210930_zMXjb4JBSQSi" title="Expected dividend yield" style="border-bottom: Black 1pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction>%</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zvggBn5mqZX9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
inputs for the Black-Scholes valuation model require management&#8217;s significant assumptions. Prior to the Company&#8217;s initial
public offering, the price per share of common stock was determined by the Company&#8217;s board based on recent prices of common stock
sold in private offerings. Subsequent to the initial public offering, the price per share of common stock is determined by using the
closing market price on the Nasdaq Capital Market on the grant date. The risk-free interest rates are based on the rate for U.S. Treasury
securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life is
based on the simplified method in accordance with the SEC Staff Accounting Bulletin Nos. 107 and 110. The expected volatility is estimated
based on historical volatility information of peer companies that are publicly available in combination with the Company&#8217;s calculated
volatility since being publicly traded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumptions used for
options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options issued in connection
with the agreements would also be cancelled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWcVavv2naSk" title="Restricted stock awards outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,273</ix:nonFraction></span> and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXuzyC9VjK53" title="Restricted stock awards outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,964</ix:nonFraction></span> shares of restricted stock outstanding as of September 30, 2022 and 2021, respectively, and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWiSqwz30QA3" title="Restricted stock awards vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2022-07-012022-09-30_us-gaap_RestrictedStockMember17143015" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">250</ix:nonFraction></span> and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zms9SGSqxkXg" title="Restricted stock awards vested"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember17143015" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></span> shares
of restricted stock vested during the three months ended September 30, 2022 and 2021. The Company recognized stock-based compensation
expense for restricted stock of $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pp0p0" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30_us-gaap_RestrictedStockMember17143015" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,245</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zc6dzIGeXS9j" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember17143015" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,792</ix:nonFraction></span> for the three months ended September 30, 2022 and 2021, respectively and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pp0p0" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockMember17143031" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,686</ix:nonFraction></span> and
$<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pp0p0" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember17143031" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">59,359</ix:nonFraction></span> for the nine months ended September 30, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company initially reserved a maximum of <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20171025__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zetR1SO8ohM7" title="Common stock, shares reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2017-10-25_custom_TwoThousandSeventeenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">750,000</ix:nonFraction></span> shares of common stock for issuance under the 2017 Amended and Restated Stock Incentive
Plan (the &#8220;2017 Plan&#8221;). The number of shares reserved for issuance was automatically increased by <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20200101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zkAsYA1wbPFj" title="Increase in number of shares reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-01-01_custom_TwoThousandSeventeenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">102,540</ix:nonFraction></span>, <span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_ztT5DeoIX6Ol" title="Increase in number of shares reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-01-01_custom_TwoThousandSeventeenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">102,998</ix:nonFraction></span> and <span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zj6XN6vz8t4" title="Increase in number of shares reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-01-01_custom_TwoThousandSeventeenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">149,189</ix:nonFraction></span>
shares on January 1, 2020, 2021 and 2022, respectively, and will<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20171024__20171025__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_ztmUDAshJJB2" title="Stock option description"> <ix:nonNumeric contextRef="From2017-10-242017-10-25_custom_TwoThousandSeventeenPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">increase automatically on January 1 each year from 2023 through 2027
by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding
December 31</ix:nonNumeric></span>. At the Annual Meeting held on May 12, 2021 and May 12, 2022, the stockholders approved a one-time, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20210511__20210512__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zGjxZJ02LvK4" title="Additional shares authorized under plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2021-05-112021-05-12_custom_TwoThousandSeventeenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span> increase each
year for a total increase of <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210512__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zCovsXtxhoNk" title="Number of shares reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-05-12_custom_TwoThousandSeventeenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> to the number of shares reserved for issuance under the 2017 Plan. However, the Company&#8217;s
board may reduce the amount of the increase in any particular year. The total remaining shares available for grant under the Company&#8217;s
2017 Plan as of September 30, 2022 was <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zf9avpulotPh" title="Shares available for grant under the 2017 Plan"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-09-30_custom_TwoThousandSeventeenPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">325,094</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_zs2M9xn82wi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
unrecognized compensation cost related to stock options and restricted stock is estimated to be recognized as follows for the year ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z5Anm6SF7JPa" style="display: none">Schedule
of Unrecognized Compensation Cost</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20220930_zS9IIv1QzhC3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_iI_pp0p0_maESSBCz4AO_z19kAJ5fFKx4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,116,837</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear_iI_pp0p0_maESSBCz4AO_z0vwGnH7SMxd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,277,254</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_iI_pp0p0_maESSBCz4AO_zqm7R22ELJB5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,130,739</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_iI_pp0p0_maESSBCz4AO_zAn3k5whQCfe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,333,749</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_iI_pp0p0_maESSBCz4AO_z7t9Gflps688" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">176,866</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iTI_pp0p0_mtESSBCz4AO_zR07yCLDDgHh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total estimated compensation cost to be recognized</b></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,035,445</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A5_zOXLhAEw9Hk5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized stock-based compensation expense related to its employee stock purchase plan of $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_pp0p0" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-07-012022-09-30_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,058</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20210930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_pp0p0" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-07-012021-09-30_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,102</ix:nonFraction></span> for the three months
ended September 30, 2022 and 2021, respectively and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zQqNkw4Tpe8e" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-09-30_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">132,129</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zbKMndYp0QRj" title="Recognized stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-09-30_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,397</ix:nonFraction></span> for the nine months ended September 30, 2022 and 2021, respectively.
The Company initially reserved a total of <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20180510__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_pdd" title="Common stock, shares reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2018-05-10_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000</ix:nonFraction></span> shares for issuance under the employee stock purchase plan. The number of shares reserved
for issuance was automatically increased by <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20200101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zJtgFytBFeS9" title="Common stock, shares reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-01-01_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,270</ix:nonFraction></span>, <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zmaYiPQLkmNg" title="Common stock, shares reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2021-01-01_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,499</ix:nonFraction></span> and <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zILi5CZUiaK7" title="Common stock, shares reserved for issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2022-01-01_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">74,594</ix:nonFraction></span> shares on January 1, 2020, 2021 and 2022, respectively, and will
increase automatically on each subsequent January 1 by <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zZw14CMUmRwe" title="Stock option description"><ix:nonNumeric contextRef="From2022-01-012022-09-30_custom_EmployeeStockPurchasePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">the number of shares equal to 0.5% of the total outstanding number of shares</ix:nonNumeric></span> of
Company common stock as of the immediately preceding December 31. However, the Company&#8217;s board may reduce the amount of the increase
in any particular year. The total remaining shares available for issuance under the employee stock purchase plan as of September 30,
2022 was <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_z8eBTO69ADXf" title="Shares available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2022-09-30_custom_EmployeeStockPurchasePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">208,929</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_znTevyzLbkY4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized total stock-based compensation expense as follows for the three and nine months ended September 30:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zyqj1H369I9j" style="display: none">Schedule of Stock-based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220701__20220930_z6aPTmK7hdK" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210701__20210930_zlkjrihu6ZO7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20220930_zPjxEGuS9ZVg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20210930_z58qM5soSdba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense in operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrpIe4TThLch" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">676,524</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">434,597</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,937,707</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,017,855</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQtyiiTlTWO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">546,530</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,319</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,561,077</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">671,476</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_z5ThuDlj7Iei" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,223,054</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-07-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">699,916</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-01to2022-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,498,784</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,689,331</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zqqrnSF5MODg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zVMkAPbuDKu7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. <span id="xdx_82C_zAZeOe7h8Sce">Debt</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 8, 2021, the Company entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Innovatus Life Sciences
Lending Fund I, LP, a Delaware limited partnership (&#8220;Innovatus&#8221;) in its capacity as Collateral Agent and sole Lender. The
Lender agreed to loan up to $<span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zzfwTxSNil7b" title="Line of credit faciltiy, maximum borrowing capacity"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">25</ix:nonFraction></span> million in three tranches consisting of (i) a $<span id="xdx_90D_ecustom--NonContingentTermALoanFunded_iI_pn6n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zGu5jhyeGrsg" title="Non contingent term A loan, funded"><ix:nonFraction name="CELC:NonContingentTermALoanFunded" contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">15.0</ix:nonFraction></span> million non-contingent term A loan that was funded
on April 8, 2021, (ii) a $<span id="xdx_909_ecustom--TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo_iI_pn6n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zRwe3BKO65h2" title="Term B loan to be funded before March 31, 2022"><ix:nonFraction name="CELC:TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo" contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million term B loan to be funded upon request of the Company no later than March 31, 2022, and (iii) a $<span id="xdx_90B_ecustom--TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree_iI_pn6n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zM6bq93rvq6f" title="Term C loan to be funded before March 31, 2023"><ix:nonFraction name="CELC:TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree" contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span>
million term C loan to be funded upon request of the Company no later than March 31, 2023 (collectively the &#8220;Term Loans&#8221;).
The Company is no longer eligible to draw on the term B loan. Funding of the term C is subject to the Company&#8217;s ability to achieve
certain milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210407__20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zK9qT0Nlql62" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2021-04-072021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">The
Loan Agreement also contains certain events of default, warranties and covenants of the Company. In connection with each funding of
the Term Loans, the Company is required to issue Innovatus a warrant (the &#8220;Warrants&#8221;) to purchase a number of shares of
the Company&#8217;s stock equal to 2.5% of the principal amount of the relevant Term Loan funded by the exercise price, which will
be based on the lower of (i) $14.40 per share or (ii) the volume weighted price per share of the Company&#8217;s stock for the
five-trading day period ending on the last trading day immediately preceding the funding date of the Term C loan</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The warrants may be exercised on a cashless basis and are immediately exercisable through the tenth anniversary of the applicable
funding date. In connection with the first tranche of the Term Loans, the Company issued a warrant to Innovatus to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z6698ZyWczUi"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,042</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of the Company&#8217;s common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zaeppbZ3P0ng"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.40</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. The company evaluated the warrant under ASC 470, debt, and recognized an additional debt discount of approximately $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn5n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zKJmPnIXIP5b"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.3</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
based on the relative fair value of the base instruments and warrants. The company calculated the fair value of the warrant using
the Black-Scholes model. In connection with the funding of the first tranche of the Term Loans, a final fee of approximately $<span id="xdx_90F_ecustom--FinalFeePayableToLenderAmount_iI_pn5n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zZfurxJObuR1" title="Final fee payable to lender, amount"><ix:nonFraction name="CELC:FinalFeePayableToLenderAmount" contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span>
million was recorded as additional principal as a debt discount, and a facility fee of approximately $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zL9IvyET5Mj4" title="Debt discount, amount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.1</ix:nonFraction></span>
million was recorded as additional debt discount. The Company is also required to maintain a minimum cash balance in agreement with
the term loans&#8217; default terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2022, the Company amended the Loan Agreement. Under the amended Loan Agreement, Innovatus, as Lender, has agreed to loan up
to $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20220809__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zaZYsiKv85n6" title="Face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">75</ix:nonFraction></span> million, a $<span id="xdx_90E_ecustom--IncreaseFromOriginalLoanAmount_iI_pn6n6_c20220809__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zSA1ywUATHIe" title="Increase from original loan amount"><ix:nonFraction name="CELC:IncreaseFromOriginalLoanAmount" contextRef="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">50</ix:nonFraction></span> million increase from the original Loan Amount, in five tranches consisting of: (i) a $<span id="xdx_90B_ecustom--NonContingentTermALoanFunded_iI_pn6n6_c20210408__us-gaap--PlanNameAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z19Sd4urRey7" title="Non contigent term A loan, funded"><ix:nonFraction name="CELC:NonContingentTermALoanFunded" contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember17144187" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">15</ix:nonFraction></span> million term A loan that
was funded on April 8, 2021 upon entering into the original Loan Agreement, (ii) a $<span id="xdx_90E_ecustom--UnfundedContingentLoanAmount_iI_pn6n6_c20220809__us-gaap--PlanNameAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermBLoanMember_z7H4tT48xq89" title="Unfunded contingent loan, amount"><ix:nonFraction name="CELC:UnfundedContingentLoanAmount" contextRef="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermBLoanMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million term B loan to be funded upon request
of the Company no later than December 31, 2022, with such funding conditioned upon the closing of the Company&#8217;s $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20220516__20220516__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zty9UH6Qm9Fh" title="Private placement value"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2022-05-162022-05-16_us-gaap_PrivatePlacementMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">100</ix:nonFraction></span> million private
placement announced on May 16, 2022, (iii) a $<span id="xdx_908_ecustom--UnfundedContingentLoanAmount_iI_pn6n6_c20220809__us-gaap--PlanNameAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermCLoanMember_zUq4gZmdjvbf" title="Unfunded contingent loan, amount"><ix:nonFraction name="CELC:UnfundedContingentLoanAmount" contextRef="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermCLoanMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span> million term C loan to be funded upon request of the Company no later than April 1,
2024, (iv) a $<span id="xdx_903_ecustom--UnfundedContingentLoanAmount_iI_pn6n6_c20220809__us-gaap--PlanNameAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_z48AqmjDMT2k" title="Unfunded contingent loan, amount"><ix:nonFraction name="CELC:UnfundedContingentLoanAmount" contextRef="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">20</ix:nonFraction></span> million term D loan to be funded upon request of the Company no later than November 1, 2024, and (v) a $<span id="xdx_905_ecustom--UnfundedContingentLoanAmount_iI_pn6n6_c20220809__us-gaap--PlanNameAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_zg55QHBusuwc" title="Unfunded contingent loan, amount"><ix:nonFraction name="CELC:UnfundedContingentLoanAmount" contextRef="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">10</ix:nonFraction></span> million term
E loan to be funded upon request of the Company no later than February 28, 2025. Funding of the term B loan is conditioned upon the closing
of the Company&#8217;s $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20220516__20220516_zAA7L8Vj8RVa" title="Private placement"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2022-05-162022-05-16" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">100</ix:nonFraction></span> million private placement announced on May 16, 2022, and funding of the term C, D, and E loans are conditioned
upon satisfaction of certain clinical trial milestones and certain financial covenants determined on a pro forma as-funded basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the amended Loan Agreement, Innovatus has the right, at its election and until August 9, 2025, the third anniversary of the loan amendment
date, to convert into Common Stock up to <span id="xdx_907_ecustom--LoanConvertibleToStockPercentageDescription_c20220807__20220809__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zC86WYImKVRd" title="Loan convertible to stock percentage, description"><ix:nonNumeric contextRef="From2022-08-072022-08-09_custom_AmendedLoanAgreementMember" name="CELC:LoanConvertibleToStockPercentageDescription">(1) 20% of the outstanding principal amount of term A loan, and (ii) an additional 7% of the
amount by which the aggregate principal amount of the funded term B, C, D, and E loans exceed $35 million, provided that the aggregate
outstanding principal amount of all term loans is at least $35 million, which such conversion based upon a price per share equal to $10.00</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateTerms_pid_dp_c20220808__20220809__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zQA0BzkYi9qi" title="Debt instrument interest rate description"><ix:nonNumeric contextRef="From2022-08-082022-08-09_custom_AmendedLoanAgreementMember" name="us-gaap:DebtInstrumentInterestRateTerms">The
Company is entitled to make interest-only payments for forty-eight months, or up to sixty months from the original Loan Agreement date
if certain conditions are met. The Term Loans will mature on April 8, 2027, the sixth anniversary of the initial funding date, and will
bear interest at a rate equal to the sum of (a) the greater of (i) Prime Rate (as defined in the amended Loan Agreement) or (ii) 3.25%,
plus 5.7%. Additionally, the Company elected to make 4.95% of the interest rate as payable in-kind, which shall accrue as principal monthly.
The Amended Loan Agreement includes certain other fees, such as a final fee of 4.5% of the funded loan amounts not converted into equity
by the lender, which apply if prepayment, an event of default, or change of control occurs prior to August 9, 2025, the third anniversary
of the Amendment date</ix:nonNumeric></span>. Subject to certain other conditions, no final fee will be payable after August 9, 2025. The Company has the option
to prepay the loan at any time following the first anniversary of the amended loan agreement date, with tiered prepayment fees ranging
from 0 to 1% based on when the prepayment occurs. Upon a change in control or event of default, mandatory prepayment will be required,
and if such an event occurs prior to the first anniversary of the Amendment date, an additional prepayment fee of <span id="xdx_909_ecustom--PrepaymentFeePercentage_pid_dp_uPure_c20220808__20220809_z0ZjeKbhgKPi" title="Prepayment fee, percentage"><ix:nonFraction name="CELC:PrepaymentFeePercentage" contextRef="From2022-08-082022-08-09" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% applies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amended Loan Agreement remains secured by all assets of the Company. Proceeds will be used for working capital purposes and to fund the
Company&#8217;s general business requirements. The amended Loan Agreement contains customary representations and warranties and covenants,
subject to customary carve outs, and includes financial covenants related to or based upon liquidity, trailing twelve months revenue
and the funded loan amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the original and amended Loan Agreement and the funding of the first tranche of the Term Loans, the Company incurred
debt issuance costs of approximately $<span id="xdx_90F_eus-gaap--DeferredFinanceCostsNet_iI_pn5n6_c20220930__us-gaap--TypeOfArrangementAxis__custom--OriginalAndAmendedLoanAgreementMember_zCkwEM33pdq" title="Debt issuance costs"><ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2022-09-30_custom_OriginalAndAmendedLoanAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.7</ix:nonFraction></span> million. The debt issuance costs, and the debt discount are amortized to interest expense using
the effective interest method over the life of the Term Loans. The carrying value of the debt approximates fair value as of September
30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_z3hywg2T9Sxg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
debt consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zwQdiXEVN5H2" style="display: none">Schedule of Long-term Debt</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220930_zSdtxMAoWKBf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_zybcH2Zrfoa3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left; padding-left: 0pt">Note payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,000,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PaymentInKindInterestDebt_iI_pp0p0_z4m5s1Q3Ftvg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Add: Payment-in-Kind interest (added to principal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:PaymentInKindInterestDebt" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">611,765</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--NotesPayableFinalFee_iI_pp0p0_zipceAQgQnM1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Add: final fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="CELC:NotesPayableFinalFee" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">675,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_zUNaJdvNygJk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Less: unamortized debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">481,304</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_zezllae4Aubl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt">Less: unamortized debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">792,054</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermNotesPayable_iI_pp0p0_zUheqJ7AMeol" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total long-term debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,013,407</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AC_zMk3ZtldIhae" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zhnlFTHiOxbd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
principal payments, including the final fee, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zHuPh91ALB1h" style="display: none">Schedule
of Long Term Debt Future Principal Payments</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220930_z09LQuF2GXyf" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ending</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDz4sG_zto0sL3raXBh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,854,412</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDz4sG_zt7yblrzK9Gk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,805,882</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDz4sG_z17m7x6XjMDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,626,471</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDz4sG_zuDbGb81iiil" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2022-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,286,765</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zgK8pDPU1rt1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2022-01-01to2022-09-30" escape="true" name="CELC:LicenseAgreementDisclosureTextBlock"><p id="xdx_809_ecustom--LicenseAgreementDisclosureTextBlock_z2okYjVSxaMc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span id="xdx_823_z7fGJVbc0gOa">License
Agreement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 8, 2021, the Company entered into a license agreement with Pfizer to research, develop, manufacture and commercialize gedatolisib,
a potent, well-tolerated, reversible dual inhibitor that selectively targets all Class I PI3K isoforms and mTOR. The Company paid Pfizer
$<span id="xdx_90C_ecustom--UpfrontFees_iI_pn5n6_c20210408__us-gaap--PlanNameAxis__custom--LicenseAgreementMember_zpzhxhNPT9Ph" title="Upfront fees"><ix:nonFraction name="CELC:UpfrontFees" contextRef="AsOf2021-04-08_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million in upfront fees and issued to Pfizer $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueNewIssuesForEquityGrant_pn5n6_c20210407__20210408__us-gaap--PlanNameAxis__custom--LicenseAgreementMember_zLHu5w4JkEXk" title="Value of shares issued for equity grant"><ix:nonFraction name="CELC:StockIssuedDuringPeriodValueNewIssuesForEquityGrant" contextRef="From2021-04-072021-04-08_custom_LicenseAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million of shares of the Company&#8217;s common stock pursuant to an Equity Grant
Agreement. The upfront payment and the issuance of shares were expensed to research &amp; development in full for the three months ending
June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events,
up to an aggregate of $<span id="xdx_900_ecustom--MilestonePayable_pn5n6_c20210407__20210408__us-gaap--RelatedPartyTransactionAxis__custom--PfizerIncMember_zcH3aGBA11k9" title="Milestone payments"><ix:nonFraction name="CELC:MilestonePayable" contextRef="From2021-04-072021-04-08_custom_PfizerIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">335.0</ix:nonFraction></span> million. Additionally, the Company will pay Pfizer tiered royalties on sales of gedatolisib at percentages
ranging from the low to mid-teens, which may be subject to deductions for expiration of valid claims, amounts due under third-party licenses
and generic competition. Unless earlier terminated, the license agreement will expire upon the expiration of all royalty obligations.
The royalty period will expire on a country-by-country basis upon the later of (a) 12 years following the date of first commercial sale
of such product in such country, (b) the expiration of all regulatory or data exclusivity in such country for such product or (c) the
date upon which the manufacture, use, sale, offer for sale or importation of such product in such country would no longer infringe, but
for the license granted in the license agreement, a valid claim of a licensed patent right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to terminate the license agreement for convenience upon 90 days&#8217; prior written notice. Pfizer may not terminate
the agreement for convenience. Either the Company or Pfizer may terminate the license agreement if the other party is in material breach
and such breach is not cured within the specified cure period. In addition, either the Company or Pfizer may terminate the license agreement
in the event of specified insolvency events involving the other party.</span></p>

</ix:nonNumeric><p id="xdx_81D_zbWDMi0QIKV6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_008"></span>ITEM
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed
financial statements and the related notes appearing under Item 1 of Part I of this Quarterly Report on Form 10-Q (this &#8220;Quarterly
Report&#8221;). Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including
information with respect to our plans and strategy for our business and expected financial results, includes forward-looking statements
that involve risks and uncertainties. You should review the &#8220;Risk Factors&#8221; discussed in Item 1A of Part II in this Quarterly
Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied
by the forward-looking statements contained in the following discussion and analysis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications.
The Company&#8217;s lead therapeutic candidate is gedatolisib, a pan-PI3K/mTOR inhibitor. Its mechanism of action and pharmacokinetic
properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together.
The Company initiated VIKTORIA-1, a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its
CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients
likely to benefit from already approved targeted therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
is a potent, well-tolerated, small molecule reversible dual inhibitor, administered intravenously, that selectively targets all class
I isoforms of PI3K and mammalian target of rapamycin (mTOR). In April 2021, we obtained exclusive global development and commercialization
rights to gedatolisib under a license agreement with Pfizer, Inc. We believe gedatolisib&#8217;s unique mechanism of action, differentiated
chemical structure, favorable pharmacokinetic properties, and intravenous formulation offer distinct advantages over currently approved
and investigational therapies that target PI3K or mTOR alone or together.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overcomes
                                            limitations of therapies that only inhibit a single class I PI3K isoform or only one mTOR
                                            kinase complex</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
is a pan-class I isoform PI3K and mTOR inhibitor with low nanomolar potency for the p110&#945;, p110&#946;, p110&#947;, and
p110&#948; isoforms and mTORC1 and mTORC2 complexes. Each PI3K isoform and mTOR complex is known to preferentially affect different
signal transduction events that involve tumor cell survival, depending upon the aberrations associated with the linked pathway. When
a therapy only inhibits a single class I isoform (e.g., alpelisib, a PI3K-&#945; inhibitor) or only one mTOR kinase complex (e.g.,
everolimus, an mTORC1 inhibitor), numerous feedforward and feedback loops between the PI3K isoforms and mTOR complexes
cross-activates the uninhibited sub-units. This, in turn, induces compensatory resistance that reduces the efficacy of isoform
specific PI3K or single mTOR kinase complex inhibitors. Inhibiting all four PI3K isoforms and both mTOR complexes, as gedatolisib
does, thus prevents the confounding effect of isoform interaction that may occur with isoform-specific PI3K inhibitors and the
confounding interaction between PI3K isoforms and mTOR.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Better
                                            tolerated by patients than oral PI3K and mTOR drugs</b></span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
is administered intravenously (IV) on a four-week cycle of three weeks-on, one week-off, in contrast to the orally administered pan-PI3K
or dual PI3K/mTOR inhibitors that are no longer being clinically developed. Oral pan-PI3K or PI3K/mTOR inhibitors have repeatably been
found to induce significant side effects that were not well tolerated by patients. This typically leads to a high proportion of patients
requiring dose reductions or treatment discontinuation. The challenging toxicity profile of these drug candidates ultimately played a
significant role in the decisions to halt their development, despite showing promising efficacy. By contrast, gedatolisib stabilizes
at lower concentration levels in plasma compared to orally administered PI3K inhibitors, resulting in less toxicity, while maintaining
concentrations sufficient to inhibit PI3K/mTOR signaling.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Isoform-specific
PI3K inhibitors administered orally were developed to reduce toxicities in patients. While the range of toxicities associated with isoform-specific
inhibitors is narrower than oral pan-PI3K or PI3K/mTOR inhibitors, administering them orally on a continuous basis still leads to challenging
toxicities. The experience with an FDA approved oral p110-&#945; specific inhibitor, Piqray, illustrates the challenge. In its Phase
3 pivotal trial Piqray was found to induce a Grade 3 or 4 adverse event (AE) related to hyperglycemia in 39% of patients evaluated. In
addition, 26% of patients discontinued alpelisib due to treatment related adverse events. By contrast, in the 103-patient dose expansion
portion of the Phase 1b clinical trial with gedatolisib, only 7% of patients experienced Grade 3 or 4 hyperglycemia and less than 10%
discontinued treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, 492 patients with solid tumors have received gedatolisib in eight clinical trials sponsored by Pfizer. Of the
492 patients, 129 were treated with gedatolisib as a single agent in three clinical trials. The remaining 363 patients received gedatolisib
in combination with other anti-cancer agents in five clinical trials. Additional patients received gedatolisib in combination with other
anti-cancer agents in nine investigator sponsored clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
Phase 1b trial (B2151009) evaluating patients with HR+/HER2- metastatic breast cancer was initiated in 2016 and subsequently enrolled
138 patients. Nine patients from this study continue to receive study treatment, as of September 30, 2022, each of whom have received
study treatment for more than three years. The B2151009 clinical trial was an open label, multiple arm Phase 1b study that evaluated
gedatolisib in combination with palbociclib (CDK4/6 inhibitor) and fulvestrant or letrozole in patients with HR+/HER2- advanced breast
cancer. Thirty-five patients were enrolled in two dose escalation arms to evaluate the safety and tolerability and to determine the maximum
tolerated dose (MTD) of gedatolisib when used in combination with the standard doses of palbociclib and endocrine therapy (letrozole
or fulvestrant). The MTD was determined to be 180 mg administered intravenously once weekly. A total of 103 patients were subsequently
enrolled in one of four expansion arms (A, B, C, D).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">High
objective overall response rates (ORR) were observed in all four expansion arms and were comparable in each arm for PIK3CA WT and PIK3CA
MT patients. In treatment-na&#239;ve patients (Arm A), ORR was 85%. In patients who received prior hormonal therapy alone or in combination
with a CDK4/6 inhibitor (Arms B, C, and D), ORR ranged from 32% to 77%. Each arm achieved its primary endpoint target, which was reporting
higher ORR in the study arm than ORR from either the PALOMA-2 (ORR=55%) study that evaluated palbociclib plus letrozole for Arm A or
the PALOMA-3 study (ORR=25%) that evaluated palbociclib plus fulvestrant for Arms B, C, and D. For all enrolled patients, a clinical
benefit rate (CBR) of &#8805;79% was observed. Median progression-free survival (PFS) was 31.1 months for patients receiving first-line
treatment (Arm A) and 12.9 months for patients who received a prior CDK4/6 inhibitor and were treated in the study with the Phase 3 dosing
schedule (Arm D).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gedatolisib
combined with palbociclib and endocrine therapy demonstrated a favorable safety profile with manageable toxicity. The majority of treatment
emergent adverse events were Grade 1 and 2. The most frequently observed adverse events included stomatitis/mucosal inflammation, the
majority of which were Grade 1 and 2. The most common Grade 4 AEs were neutropenia and neutrophil count decrease, which were assessed
as related to treatment with palbociclib. No grade 5 events were reported in this study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
activated VIKTORIA-1, a Phase 3, open-label, randomized clinical trial to evaluate the efficacy and safety of two regimens in adults
with HR+/HER2- advanced breast cancer whose disease has progressed after prior CDK4/6 therapy in combination with an aromatase
inhibitor: 1) gedatolisib in combination with palbociclib and fulvestrant; and 2) gedatolisib in combination with fulvestrant. Two
hundred clinical sites in North America, Europe, South America, Asia, and Australia have been selected to participate in the study.
The first clinical site was activated in the third quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial will enable separate evaluation of subjects according to their PIK3CA status. Subjects who meet eligibility criteria and
are PIK3CA WT will be randomly assigned (1:1:1) to receive a regimen of either gedatolisib, palbociclib, and fulvestrant (Arm A), gedatolisib
and fulvestrant (Arm B), or fulvestrant (Arm C). Subjects who meet eligibility criteria and are PIK3CA MT will be randomly assigned (3:3:1)
to receive a regimen of either gedatolisib, palbociclib, and fulvestrant (Arm D), alpelisib and fulvestrant (Arm E), or gedatolisib and
fulvestrant (Arm F).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
proprietary CELsignia diagnostic platform is the only commercially ready technology we are aware of that uses a patient&#8217;s living
tumor cells to identify the specific abnormal cellular process driving a patient&#8217;s cancer and the targeted therapy that best treats
it. This enables us to identify patients whose tumors may respond to a targeted therapy, even though they lack a previously associated
molecular mutation. By identifying cancer patients whose tumors lack an associated genetic mutation but have abnormal cellular activity
a matching targeted therapeutic is designed to inhibit, CELsignia CDx can expand the markets for a number of already approved targeted
therapies. Our current CDx identifies breast and ovarian cancer patients whose tumors have cancer drivers potentially responsive to treatment
with human epidermal growth factor receptor 2-negative (HER2), mesenchymal-epithelial transition factor (c-MET), or phosphatidylinositol
3-kinases (PI3K) targeted therapeutics. While U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval or clearance is not currently
required for CELsignia tests offered as a stand-alone laboratory developed test, if we are partnered with a drug company to launch a
CELsignia test as a companion diagnostic for a new drug indication, we would be required to obtain premarket approval, or PMA, in conjunction
with the pharmaceutical company seeking a new drug approval for the matching therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are supporting the advancement of new potential indications for four different targeted therapies, controlled by other pharmaceutical
companies, that would rely on a CELsignia CDx to select patients. Five Phase 2 trials are underway to evaluate the efficacy and safety
of these therapies in CELsignia selected patients. These patients are not currently eligible to receive these drugs and are not identifiable
with a molecular test.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supporting
the development of a potential first-in-class targeted therapy for breast cancer, like gedatolisib, with our CELsignia platform is a
natural extension of our strategy to use our CELsignia CDx to enable new indications for other companies&#8217; targeted therapies. By
combining companion diagnostics designed to enable proprietary new drug indications with targeted therapies that treat signaling dysregulation
our CDx identifies, we believe we are uniquely positioned to improve the standard-of-care for many early and late-stage breast cancer
patients. Our goal is to play a key role in the multiple treatment approaches required to treat breast cancer patients at various stages
of their disease. With each program, we are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leveraging the proprietary insights CELsignia provides
    into live patient tumor cell function</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Using a CELsignia CDx to identify new patients likely
    to respond to the paired targeted therapy</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing a new targeted therapeutic option for breast
    cancer patients</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maximizing the probability of getting regulatory approval
    to market the targeted therapy indication</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2022, Celcuity amended its existing debt financing agreement with an affiliate of Innovatus Capital Partners, LLC (&#8220;Innovatus&#8221;)
to provide Celcuity with up to $75 million in term loans, a $50 million increase from the original debt financing agreement dated April
8, 2021. Celcuity received $15 million at the closing of the original agreement in April 2021. Celcuity will be able to draw an additional
$20 million tranche following closing the of the $100 million private placement. Celcuity will be able to draw on two additional tranches
of $10 million each and one additional tranche of $20 million upon achievement of certain clinical trial milestones and satisfaction
of certain financial covenants determined on a pro forma as-funded basis. Funding of these additional tranches is also subject to other
customary conditions and limits on when the Company can request funding for such tranches. Celcuity is entitled to make interest only
payments for the 48-month period from the original agreement date or for the 60-month period from the original agreement date if certain
conditions are met. The loans will mature on April 8, 2027, the sixth anniversary of the initial funding date. Innovatus has the right
to convert outstanding principal into shares of Celcuity common stock until the third anniversary of the loan amendment date, with such
amount limited to an aggregate of up to $6.5 million assuming all tranches are funded. The loan is secured by all of Celcuity&#8217;s
assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
completed selection of clinical trial sites for the Phase 3 VIKTORIA-1 clinical trial. The 200-sites selected exceeded the number of
sites initially targeted. Operational activities are focused now on facilitating activation of these sites
and to dose the first patient. The clinical trial protocol was updated to include an additional study arm
(Arm F) to evaluate gedatolisib plus fulvestrant in 50 patients who have PIK3CA mutations. This update was made in response to a
recommendation from the European Medicines Agency (EMA) that the study arms for PIK3CA mutated patients mirror the same study arms
for PIK3CA non-mutated patients. No changes were made to the primary endpoints. VIKTORIA-1 will evaluate the safety and efficacy of
gedatolisib in combination with fulvestrant with or without palbociclib in adults with HR+/HER2- advanced breast cancer whose
disease progressed while receiving prior CDK4/6 therapy. Further details about the study are available at <span style="text-decoration: underline">ClinicalTrials.gov.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 18, 2022, gedatolisib was granted Breakthrough Therapy Designation for HR+/HER2- metastatic breast cancer after progression on CDK4/6
therapy. Breakthrough Therapy designation is granted by the FDA to expedite the development and regulatory review of an investigational
medicine that is intended to treat a serious or life-threatening condition. The criteria for Breakthrough Therapy designation require
preliminary clinical evidence that demonstrates the drug may have substantial improvement on one or more clinically significant endpoints
over available therapy. The benefits of Breakthrough Therapy Designation include more intensive guidance from the FDA on an efficient
development program, access to a scientific liaison to help accelerate review time, and potential eligibility for priority review if
relevant criteria are met. Celcuity&#8217;s breakthrough application was supported by data from a Phase 1b study that assessed the safety,
tolerability and clinical activity of gedatolisib in combination with palbociclib and fulvestrant in patients with HR+/HER2- metastatic
breast cancer whose disease progressed during treatment with a CDK4/6 therapy and an aromatase inhibitor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2022, the Company entered into a securities purchase agreement with certain institutional and other accredited investors for
the sale of Company common stock, preferred stock that may be convertible into common stock and warrants initially exercisable for preferred
stock for $100 million in the aggregate, before deducting placement agent fees and other offering expenses. Pursuant to the securities
purchase agreement, investors will purchase shares of common stock and preferred stock at a price per share of $5.75 (on an as converted
to common stock basis). For each share of common stock and each 1/10 of a share of preferred stock purchased, investors will receive
a warrant exercisable for 0.40 shares of common stock. The exercise price of the warrants will be at a 40% premium to the price paid
by investors for the initial shares of common stock purchased in the private placement. The preferred stock will be convertible into
common stock at the holder&#8217;s election, subject to certain limitations such as beneficial ownership. The closing of the private
placement is conditioned on, among other customary items, the first patient enrolled in the Company&#8217;s Phase 3 clinical
study (VIKTORIA-1) having received their first dose of treatment at a clinical site located in the United States, provided that if such
date does not occur on or before December 31, 2022, each investor will have the right to terminate its obligation to purchase securities
under the securities purchase agreement. The Company also entered into a customary registration rights agreement with the investors pursuant
to which it agreed to file a registration statement with the SEC registering the resale of (i) the shares of common stock to be issued
and sold in the private placement, (ii) the shares of common stock issuable upon conversion of the preferred stock purchased in the private
placement and (iii) the shares of common stock issuable upon conversion of the shares of preferred stock that may be issued upon exercise
of warrants purchased in the private placement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impact
of COVID-19 on our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we have largely returned to normal operations in our facility, the COVID-19 pandemic continues and its effect on our operations and financial
condition will depend in large part on future developments which cannot be reasonably estimated at this time. Future developments include
the duration, scope and severity of the pandemic, the emergence of new virus variants that are more contagious or harmful than prior
variants, actions taken by governmental authorities, suppliers, clinical trial sites, and other business partners to contain or mitigate
the pandemic&#8217;s impact, and the potential adverse effects on the suppliers, labor market and general economic activity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we continue to advance our clinical trial collaborations, we remain in close contact with our current clinical sponsors, and principal
investigators, as well as prospective pharmaceutical company and clinical collaborators, to monitor the impact of COVID-19 on our trial
enrollment timelines and collaboration discussions. We experienced delays in the enrollment of patients in our ongoing clinical trials
and now expect interim results from two of our CELsignia Phase 2 clinical trials, FACT-1 and FACT-2 to be delayed until mid-2023 and
final results approximately nine months later. We could experience further delays in clinical trials and collaborations with pharmaceutical
companies and sponsors if new variants emerge or if the spread of COVID-19 once again accelerates. Due to the inherent uncertainty associated
with the COVID-19 pandemic, we are unable to predict the impact the pandemic may have on our clinical trial work and overall financial
condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not generated any revenue from sales to date, and we continue to incur significant research and development and other expenses related
to our ongoing operations. As a result, we are not and have never been profitable and have incurred losses in each period since our inception
in 2012. For the three months ended September 30, 2022 and 2021, we reported a net loss of approximately $10.9 million and $6.0 million,
respectively and for the nine months ended September 30, 2022 and 2021, we reported a net loss of approximately $28.8 million and $22.9
million, respectively. As of September 30, 2022, we had an accumulated deficit of&#8201;approximately $84.7 million. As of September
30, 2022, we had cash and cash equivalents of approximately&#8201;$57.5 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Components
of Operating Results</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenue. With the execution of the Pfizer license agreement in April 2021, whereby we acquired exclusive
world-wide licensing rights to develop and commercialize gedatolisib, we expect to conduct clinical trials to support potential regulatory
approval to market gedatolisib. If we obtain regulatory approvals to market gedatolisib, we expect to generate revenue from sales of
the drug for the treatment of breast cancer patients. Additionally, we will seek to generate revenue from partnership agreements with
pharmaceutical companies to provide companion diagnostics for such pharmaceutical partners&#8217; existing or investigational targeted
therapies. If a new drug indication is received that requires use of our companion diagnostic to identify eligible patients, we expect
to generate revenues from sales of tests to treating physicians.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have primarily focused on research and development of our CELsignia platform, development and validation of our CELsignia
tests, and research related to the discovery of new cancer sub-types. Beginning in April 2021, we are also focusing on development of
gedatolisib, a PI3K/mTOR targeted therapy. Research and development expenses primarily include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">employee-related
                                            expenses related to our research and development activities, including salaries, benefits,
                                            recruiting, travel and stock-based compensation expenses;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">laboratory
                                            supplies;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">consulting
                                            fees paid to third parties;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            trial costs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">validation
                                            costs for gedatolisib;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">facilities
                                            expenses; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">legal
                                            costs associated with patent applications.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.75in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal
and external research and development costs are expensed as they are incurred. As we continue development of gedatolisib, manage the
VIKTORIA-1 Phase 3 trial and other clinical trials to evaluate the efficacy of targeted therapies in cancer patients selected with one
of our CELsignia tests, the proportion of research and development expenses allocated to external spending will grow at a faster rate
than expenses allocated to internal expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of salaries, benefits and stock-based compensation related to our executive, finance and
support functions. Other general and administrative expenses include professional fees for auditing, tax, and legal services associated
with being a public company, director and officer insurance, investor relations and travel expenses for our general and administrative
personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sales
and Marketing</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
and marketing expenses consist primarily of professional and consulting fees related to these functions. To date, we have incurred immaterial
sales and marketing expenses as we continue to focus primarily on the development of our first drug, gedatolisib, CELsignia platform
and corresponding CELsignia tests. We would expect to begin to incur increased sales and marketing expenses in anticipation of the commercialization
of our first drug, gedatolisib, and CELsignia tests. These increased expenses are expected to include payroll-related costs as we add
employees in the commercial departments, costs related to the initiation and operation of our sales and distribution network and marketing
related costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense is primarily due to a Loan Agreement and finance lease obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income consists of interest income earned on our cash and cash equivalent balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Results
of Operations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the Three Months Ended September 30, 2022 and 2021</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase (Decrease)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><b>Statements of Operations Data:</b></td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left; text-indent: 10pt; padding-left: 0pt">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">9,621,505</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,960,515</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,660,990</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">94</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,022,050</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">639,271</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">382,779</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">60</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">10,643,555</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,599,786</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,043,769</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">90</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(10,643,555</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,599,786</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,043,769</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">90</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left"></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(537,661</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(433,072</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(104,589</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt">Interest income</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">287,495</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,612</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">281,883</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,023</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Other income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(250,166</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(427,460</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">177,294</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(41</td><td style="padding-bottom: 1pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"><b>Net loss before income taxes</b></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(10,893,721</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(6,027,246</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(4,866,475</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">81</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Income tax benefits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"><b>Net loss</b></td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(10,893,721</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(6,027,246</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(4,866,475</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">81</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Comparison
of the Nine Months Ended September 30, 2022 and 2021</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase (Decrease)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">$</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent Change</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><b>Statements of Operations Data:</b></td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 44%; text-align: left; text-indent: 10pt; padding-left: 0pt">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">24,685,505</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">20,266,965</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">4,418,540</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">22</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,066,382</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,768,058</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,298,324</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">73</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27,751,887</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">22,035,023</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,716,864</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">26</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Loss from operations</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(27,751,887</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(22,035,023</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(5,716,864</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">26</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,428,108</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(824,283</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(603,825</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">73</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">391,301</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,803</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">383,498</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,915</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt">Loss on sale of fixed assets</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(263</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">263</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n/a</span></td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Other income (expense), net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,036,807</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(816,743</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(220,064</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">27</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt"><b>Net loss before income taxes</b></td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(28,788,694</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(22,851,766</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">(5,936,928</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">26</td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Income tax benefits</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"><b>Net loss</b></td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(28,788,694</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(22,851,766</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(5,936,928</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">26</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses for the three months ended September 30, 2022 were approximately $9.6 million, representing an increase
of approximately $4.7 million, or 94%, compared to the same period in 2021. Of the $4.7 million increase in research and development
expenses, $1.2 million was related to increased employee and consulting expenses, of which $0.2 million was in the form of non-cash stock-based
compensation. The remaining $3.5 million increase of research and development expenses is primarily related to costs for existing clinical
trials and for activities supporting the initiation of the VIKTORIA-1 pivotal trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development expenses for the nine months ended September 30, 2022 were approximately $24.7 million, representing an increase
of approximately $4.4 million, or 22%, compared to the same period in 2021. Included in the $4.4 million increase is a $10 million reduction
in gedatolisib licensing related expenses offset by increases of $14.4 million in other research and development expenses. In the 2021
period, research and development expenses included a $10.0 million upfront license fee related to the execution of the Pfizer license
agreement while there were no licensing agreement expenses for gedatolisib in 2022. Of the $14.4 million increase in research and development
expense, $4.2 million was related to increased employee and consulting expenses, of which $0.9 million was in the form of non-cash stock-based
compensation. The remaining $10.2 million increase of research and development expenses is related to costs for existing clinical trials
and for activities supporting the initiation of the VIKTORIA-1 pivotal trial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
a significant amount of research and development is central to our business model. We plan to increase our research and development expenses
for the foreseeable future as we seek to develop gedatolisib, discover new cancer sub-types, and develop and validate additional CELsignia
tests to diagnose such sub-types. We also expect to incur increased expenses to support companion diagnostic business development activities
with pharmaceutical companies as we develop additional CELsignia tests and initiate a clinical trial for gedatolisib.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses for the three months ended September 30, 2022 were approximately $1.0 million, representing an increase
of approximately $0.4 million, or 60%, compared to the same period in 2021. Employee related expenses accounted for $0.3 million of the
$0.4 million increase, including approximately $0.3 million in non-cash stock-based compensation. The remaining $0.1 million increase
of general and administrative expenses resulted from director and officer insurance and other professional fees associated with being
a public company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
general and administrative expenses for the nine months ended September 30, 2022 were approximately $3.1 million, representing an increase
of approximately $1.3 million, or 73%, compared to the same period in 2021. Employee related expenses accounted for $1.1 million of the
$1.3 million increase, including approximately $0.9 million in non-cash stock-based compensation. The remaining $0.2 million of the increase
resulted from director and officer insurance and other professional fees associated with being a public company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate that our general and administrative expenses will increase in future periods, reflecting both increased costs in connection
with the potential future commercialization of gedatolisib and CELsignia tests, an expanding infrastructure, and increased professional
fees associated with being a public company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense for the three months ended September 30, 2022 was $0.5 million and represents an increase of $0.1 million, or 24%, compared to
the same period in 2021. The increase is due to a higher interest rate on the loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
expense for the nine months ended September 30, 2022 was $1.4 million and represents an increase of $0.6 million, or 73%, compared to
the same period in 2021. The increase is due to the loan agreement being in place for the entire nine-month period in 2022 rather than
for only a fraction of the period in 2021 and a higher interest rate on the loan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Interest
Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income for the three months ended September 30, 2022 was $0.3 million higher compared to the same period in 2021. The increase was due
to higher market interest rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
income for the nine months ended September 30, 2022 was $0.4 million higher compared to the same period in 2021. The increase was due
to higher market interest rates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have incurred losses and cumulative negative cash flows from operations. Through September 30, 2022, we have
raised capital of approximately $13.7 million and $7.5 million through private placements of common equity and unsecured convertible
notes, respectively. On September 22, 2017, we closed on the initial public offering of our common stock, which generated
approximately $<span style="background-color: white">23.3 </span>million of additional cash after taking into account underwriting
discounts and commissions and offering expenses. On June 5, 2020, we entered into an At Market Issuance Sales Agreement with B.
Riley, FBR, Inc (the &#8220;ATM Agreement&#8221;). The ATM Agreement allowed us to sell shares of common stock up to an aggregate
offering price of $10.0 million. Through September 30, 2022, we generated approximately $0.1 million of additional cash through
sales pursuant to the ATM Agreement, after taking into account commissions and offering expenses. On February 26, 2021, we completed
a follow-on offering of our common stock, which generated approximately $25.8 million of additional cash after taking into account
underwriting discounts and offering expenses. In conjunction with the follow-on offering, the ATM Agreement was terminated. On April
8, 2021, we entered into a loan agreement with Innovatus Life Sciences Lending Fund I, LP (&#8220;Innovatus&#8221;), whereby
Innovatus agreed to loan up to $25 million in three tranches consisting of (i) a $15.0 million non-contingent term A loan that was
funded on April 8, 2021, (ii) a $5 million term B loan with a deadline of March 31, 2022 and we are no longer eligible to draw on,
and (iii) a $5 million term C loan to be funded upon our request no later than March 31, 2023. Funding of the term C loan is subject
to our ability to achieve certain milestones. On July 1, 2021, we completed a follow-on offering of our common stock, which
generated approximately $52.8 million of additional cash after taking into account underwriting discounts of approximately $3.4
million and offering expenses of approximately $0.1 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 4, 2022, we entered into an Open Market Sale Agreement<sup>SM</sup> with Jefferies LLC, as agent, pursuant to which we may offer
and sell, from time to time, through Jefferies, shares of our common stock having an aggregate offering price of up to $50,000,000. On
October 12, 2022, pursuant to  this agreement, the Company sold 500,000 shares of common stock in a single transaction at a price
of $10.35 per share, generating gross proceeds of $5.2 million ($4.8 million net of commissions and offering expenses).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2022, we entered into a securities purchase agreement with certain institutional and other accredited investors for the sale
of Company common stock, preferred stock that may be convertible into common stock and warrants exercisable for common stock for $100
million in the aggregate, before deducting placement agent fees and other offering expenses. Pursuant to the securities purchase agreement,
investors will purchase shares of common stock and preferred stock at a price per share of $5.75 (on an as converted to common stock
basis), with the closing (funding) of such purchase to occur following the achievement of a milestone in our Phase 3 study
(VIKTORIA-1). The sale of shares of common stock includes forty percent (40%) warrant coverage and customary resale registration rights.
Please see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Recent Developments&#8221;
above for additional details.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2022, the Company amended the loan agreement with Innovatus to provide up to $75 million in term loans. As mentioned above,
the initial term A loan of $15 million was funded on April 8, 2021. Th Company will be able to draw an additional $20 million following
the closing of the $100 million private placement. Additionally, the Company will be able to draw on two additional tranches of $10 million
and one additional tranche of $20 million upon achievement of certain clinical trial milestones and satisfaction of certain financial
covenants determined on a pro forma as-funded basis. Funding of these additional tranches is also subject to other customary conditions
and limits on when the Company can request funding for such tranches.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
from our historical capital raising activities has been our primary source of funds for our operations since inception. As of September
30, 2022, our cash and cash equivalents were approximately $57.5 million, and we had an accumulated deficit of approximately $84.7 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that our research and development and general and administrative expenses will increase as we continue to develop gedatolisib,
conduct research related to the discovery of new cancer sub-types, conduct clinical trials, and pursue other business development activities.
We would also expect to incur sales and marketing expenses as we commercialize gedatolisib and our CELsignia tests. We expect to use
cash on hand, together with the funds to be received under the securities purchase agreement described above, to fund our research and
development expenses, clinical trial costs, capital expenditures, working capital, sales and marketing expenses, and general corporate
expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our current business plan, we believe that our current cash on hand will provide sufficient cash to finance operations and pay obligations
when due for at least the next twelve months.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may seek to raise additional capital to expand our business, pursue strategic investments, and take advantage of financing or other opportunities
that we believe to be in the best interests of the Company and our stockholders. Additional capital may be raised through the sale of
common or preferred equity or convertible debt securities, entry into debt facilities or other third-party funding arrangements. The
sale of equity and convertible debt securities may result in dilution to our stockholders and those securities may have rights senior
to those of our common shares. Agreements entered into in connection with such capital raising activities could contain covenants that
would restrict our operations or require us to relinquish certain rights. Additional capital may not be available on reasonable terms,
or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the primary sources and uses of cash for the nine months ended September 30:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Net cash provided by (used in):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left; text-indent: 10pt; padding-left: 0pt">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(26,528,911</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(14,187,938</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(46,724</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(71,459</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt">Financing activities</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(226,970</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">92,988,298</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Net increase (decrease) in cash and cash equivalents</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(26,802,605</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,728,901</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was approximately $26.5 million for the nine months ended September 30, 2022 and consisted primarily
of a net loss of&#8201;approximately $28.8 million and working capital changes of approximately $2.0 million, offset by non-cash expense
items of approximately $4.3 million. The approximately $2.0 million of working capital changes was primarily due to an increase of approximately
$5.9 million in prepaid assets, partially offset by increases in accounts payable and accrued expenses of approximately $1.6 million
and $2.3 million, respectively. Non-cash expense items of approximately $4.3 million primarily consisted of approximately $3.5 million
of stock-based compensation expense, non-cash interest expense of approximately $0.6 million and depreciation expense of approximately
$0.2 million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities was approximately $14.2 million for the nine months ended September 30, 2021 and consisted primarily
of a net loss of&#8201;approximately $22.9 million, offset by non-cash expense items of approximately $7.3 million and working capital
changes of $1.4 million. Non-cash expense items of approximately $7.3 million primarily consisted of $5.0 million for issuance of common
stock related to a license agreement, stock-based compensation expense of approximately $1.7 million, non-cash interest expense of approximately
$0.4 million and depreciation expense of approximately $0.2 million. The approximately $1.4 million of working capital changes was primarily
due to an increase in accounts payable and accrued expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in investing activities for the nine months ended September 30, 2022 and 2021 were minimal and consisted of purchases of property
and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in financing activities was approximately $0.2 million for the nine months ended September 30, 2022 and consisted of payments
for secondary registration statement costs, offset partially by proceeds from the exercise of employee stock options and proceeds from
employee stock purchases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities for the nine months ended September 30, 2021 was approximately $93.0 million. The $93.0 million
primarily consisted of approximately $78.5 million from net proceeds from the sale of shares of our common stock through two follow-on
offerings and approximately $14.4 million from net proceeds related to the closing of a loan agreement. The remaining $0.1 million was
the result of proceeds from the exercise of common stock warrants and employee stock options and proceeds from employee stock purchases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Accounting Pronouncements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time-to-time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies and
adopted by us as of the specified effective date. Unless otherwise discussed in Note 2 to our unaudited condensed financial statements
included in Item 1 of Part I of this Quarterly Report, we believe that the impact of recently issued standards that are not yet effective
will not have a material impact on our financial position or results of operations upon adoption.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Critical
Accounting Policies and Use of Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management&#8217;s discussion and analysis of financial condition and results of operations is based on our unaudited condensed financial
statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make
estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities
at the date of the financial statements, as well as the reported expenses during the reporting periods. These items are monitored and
analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our
estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; the results of
which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other
sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ
materially from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
significant accounting policies are more fully described in Note 2 to our unaudited condensed financial statements included in Item 1
of Part I of this Quarterly Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Private
Securities Litigation Reform Act</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Private Securities Litigation Reform Act of 1995 provides a &#8220;safe harbor&#8221; for forward-looking statements. Such forward-looking
information is included in this Quarterly Report and in other materials filed or to be filed by us with the SEC (as well as information
included in oral statements or other written statements made or to be made by us). Forward-looking statements include all statements
based on future expectations. This Quarterly Report contains forward-looking statements that involve risks and uncertainties including,
but not limited to, (i) our clinical trial plans and the estimated costs for such trials, including the timing of activating a
Phase 3 clinical trial for gedatolisib and enrolling patients in such trial; (ii) our expectations with respect to costs and timelines
to develop, validate and launch CELsignia tests and to continue to develop gedatolisib; (iii) our beliefs related to the perceived advantages
of our CELsignia tests compared to traditional molecular or other diagnostic tests; (iv) the expected benefits of gedatolisib; (v) our
expectations regarding the timeline of patient enrollment and results from clinical trials, including the existing clinical trial for
gedatolisib; (vi) the future payments that may be owed to Pfizer under the license agreement; (vii) our expectations regarding partnering
with pharmaceutical companies and other third parties; (viii) our expectations regarding revenue from sales of CELsignia tests and revenue
from milestone or other payment sources; (ix) our plans with respect to research and development and related expenses for the foreseeable
future; (x) our expectations regarding business development activities, including companion diagnostic related activities with pharmaceutical
companies, expanding our sales and marketing functions and the costs associated with such activities; (xi) our expectations with respect
to the CELsignia tests and the analytical capabilities and potential impact of such tests; (xii) our beliefs regarding the ability of
our cash on hand to fund our research and development expenses, capital expenditures, working capital, sales and marketing expenses,
and general corporate expenses, as well as the increased costs associated with being a public company; (xiii) our expectations with respect
to closing on our $100 million private placement announced May 16, 2022 and our plans with respect to potentially raising capital; and
(xiv) our expectations regarding the impact that the COVID-19 pandemic and related economic effects will have on our business and results
of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
some cases, you can identify forward-looking statements by the following words: &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221;
&#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221;
&#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221;
or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking
statements are only predictions and are not guarantees of performance. These statements are based on our management&#8217;s beliefs and
assumptions, which in turn are based on their interpretation of currently available information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
statements involve known and unknown risks, uncertainties and other factors that may cause our results or our industry&#8217;s actual
results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these
forward-looking statements. Certain risks, uncertainties and other factors include, but are not limited to, our limited operating history;
the potential impact of the COVID-19 pandemic on our business; our initial success being heavily dependent on the success of our CELsignia
HER2 Pathway Activity Test; our inability to develop and commercialize gedatolisib; our inability to determine whether our CELsignia
tests are currently commercially viable; challenges we may face in developing and maintaining relationships with pharmaceutical company
partners; the complexity and timeline for development of CELsignia tests and gedatolisib; the uncertainty and costs associated with clinical
trials; the uncertainty regarding market acceptance by physicians, patients, third-party payors and others in the medical community,
and with the size of market opportunities available to us; the pricing of molecular and other diagnostic products and services that compete
with us; uncertainty with insurance coverage and reimbursement for our CELsignia tests; <span style="background-color: white">difficulties
we may face in managing growth, such as hiring and retaining a qualified sales force and attracting and retaining key personnel; changes
in government regulations; and obtaining and maintaining intellectual property protection for our technology and time and expense associated
with defending third-party claims of intellectual property infringement, investigations or litigation threatened or initiated against
us. </span>These and additional risks, uncertainties and other factors are described more fully in Item 1A of Part II of this Quarterly
Report . Copies of filings made with the SEC are available through the SEC&#8217;s electronic data gathering analysis and retrieval system
(EDGAR) at www.sec.gov.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read the cautionary statements made in this Quarterly Report as being applicable to all related forward-looking statements wherever
they appear in this Quarterly Report. We cannot assure you that the forward-looking statements in this Quarterly Report will prove to
be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should read this
Quarterly Report completely. Other than as required by law, we undertake no obligation to update these forward-looking statements, even
though our situation may change in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_009"></span>ITEM
3. Quantitative and Qualitative Disclosures about Market Risk</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a smaller reporting company, we are not required to provide disclosure pursuant to this item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_010"></span>ITEM
4. Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Chief Executive Officer and Chief Financial Officer, referred to collectively herein as the Certifying Officers, are responsible for
establishing and maintaining our disclosure controls and procedures. The Certifying Officers have reviewed and evaluated the effectiveness
of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act
of 1934, as amended (the &#8220;Exchange Act&#8221;)) as of September 30, 2022. Based on that review and evaluation, the Certifying Officers
have concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures, as designed
and implemented, are effective and provide reasonable assurance that information required to be disclosed by us in the periodic and current
reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the periods specified by
the SEC&#8217;s rules and forms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)
during the three months ended September 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_011"></span>PART
II. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_012"></span>ITEM
1. Legal Proceedings</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time we may be involved in disputes or litigation relating to claims arising out of our operations. We are not currently a party
to any legal proceedings that could reasonably be expected to have a material adverse effect on our business, financial condition and
results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ak_013"></span>ITEM
1A. Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk
factors that could cause actual results to differ from our expectations and that could negatively impact our financial condition and
results of operations are summarized and discussed in more detail below, in each case including certain updates from those set forth
in our Quarterly Report for the period ended March 31, 2022. Additional risks and uncertainties not presently known to us or that are
currently not believed to be significant to our business may also affect our actual results and could harm our actual business, financial
condition and/or operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            have a limited operating history and we may never generate revenue or profit;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
                                            inability to raise additional capital on acceptable terms in the future may limit our ability
                                            to develop and commercialize our integrated therapeutic (Rx) and companion diagnostic (CDx)
                                            strategy;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            are currently conducting and will continue to conduct clinical trials. Clinical trials are
                                            expensive and complex with uncertain outcomes, which may prevent or delay commercialization
                                            of any drug product candidates or CELsignia tests;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            COVID-19 pandemic may materially and adversely impact our business, including ongoing clinical
                                            trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            future strategy is dependent on the success of our initial drug product, gedatolisib, as
                                            well as other drug products we may develop. If we are unable to successfully complete clinical
                                            development of, obtain regulatory approval for or commercialize our drug products, or if
                                            we experience delays in doing so, our business will be materially and adversely impacted;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            successful development of biopharmaceuticals such as gedatolisib is highly uncertain;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            were not involved in the early development of gedatolisib; therefore, we are dependent on
                                            third parties having accurately generated, collected, interpreted and reported data from
                                            certain preclinical and clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            an organization, we have never successfully completed any registrational clinical trials,
                                            and we may be unable to do so for any drug candidates we may develop;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
                                            a new drug to be approved for marketing, the FDA in the United States and health authorities
                                            in other countries, must determine that the drug is safe and effective. Because all drugs
                                            can have adverse effects, the data from our Phase 3 clinical study must demonstrate to the
                                            satisfaction of the FDA and other health authorities that the benefits of gedatolisib in
                                            combination with palbociclib and fulvestrant, or gedatolisib in combination with fulvestrant,
                                            outweigh its risks. Failure to demonstrate sufficient magnitude of benefit, even if the benefit
                                            is found to be statistically significant, may not support regulatory approval;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we encounter difficulties enrolling patients in any of our clinical trials, our clinical
                                            development activities could be delayed or otherwise adversely affected;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we are unable to obtain and maintain intellectual property protection for our products and
                                            technology, or if the scope of the intellectual property protection obtained is not sufficiently
                                            broad, our competitors could develop and commercialize products or technology similar or
                                            identical to ours, and our ability to successfully commercialize our technology and diagnostic
                                            tests may be impaired;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            depend on intellectual property licensed from third parties, including from Pfizer for our
                                            lead product candidate, gedatolisib, and termination of this license could result in the
                                            loss of significant rights, which would materially and adversely impact our business;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            we fail to comply with our obligations under our patent license with Pfizer, we could lose
                                            certain license rights that are important to our business;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
                                            success with CELsignia is heavily dependent on the success of our first CELsignia trials
                                            and we cannot be certain of the outcomes of such trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            may not be successful in finding pharmaceutical company partners for continuing development
                                            of additional CELsignia tests;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
                                            our CELsignia HER2 Pathway Activity Test and CELsignia Multi-Pathway Activity Test are commercially
                                            ready, we have not attempted to market these to physicians or their patients as stand-alone
                                            tests and have no ability to determine if these tests or any of our other tests will be commercially
                                            viable;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            will be dependent on our ability to attract and retain key personnel; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            face significant competition from other pharmaceutical and diagnostic companies.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 33pt; text-align: justify; text-indent: -16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have a limited operating history and we may never generate revenue or profit.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical-stage biotechnology company that commenced activities in January 2012. We only have a limited operating history and our
business plan has not been tested. Since inception, we have had no revenue and have incurred significant operating losses. We have financed
our operations primarily through equity and debt offerings. To generate revenue and become and remain profitable, we must continue to
pursue our integrated companion diagnostic (CDx) and therapeutic (Rx) strategy that leverages our CELsignia CDx platform. To do so, we
need to successfully complete our five existing clinical trial collaborations, continue to develop other CELsignia tests for other cancer
sub-types, cultivate partnerships with pharmaceutical companies, and develop and commercialize gedatolisib pursuant to our license agreement
with Pfizer. We must also build operational and financial infrastructure to support commercial operations, train and manage employees,
and market and sell our CELsignia tests (as a companion diagnostic and/or as a stand-alone test) and, once fully developed and commercialized,
our anticipated drug products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may never succeed in any of these activities and, even if we do, we may never generate revenue that is sufficient to achieve profitability.
We expect to continue to incur significant expenses and operating losses for the foreseeable future, and the net losses we incur may
fluctuate significantly from quarter to quarter. Our failure to become and remain profitable would decrease our value and could impair
our ability to raise capital, maintain or expand our research and development efforts, expand our business, or continue our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
inability to raise additional capital on acceptable terms in the future may limit our ability to develop and commercialize our integrated
therapeutic (Rx) and companion diagnostic (CDx) strategy.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may require additional capital to finance capital expenditures and operating expenses over the next several years as we launch our integrated
therapeutic and companion diagnostic strategy and expand our infrastructure, commercial operations and research and development activities.
We may seek to raise additional capital through equity offerings, debt financings, collaborations or licensing arrangements. Additional
funding may not be available to us on acceptable terms, or at all. If we raise funds by issuing equity securities, dilution to our stockholders
could result. Any equity securities issued may also provide for rights, preferences or privileges senior to those of holders of our existing
securities. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment
obligations and could also include restrictive covenants, such as limitations on our ability to incur additional debt or issue additional
equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely
affect our ability to conduct our business. In the event that we enter into collaborations or licensing arrangements to raise capital,
we may be required to accept unfavorable terms. If the first dosing of the first patient enrolled in our Phase 3 clinical study (VIKTORIA-1)
does not occur on or before December 31,2022, each investor under the securities purchase agreement we entered into on May 15, 2022,
will have the right to terminate its obligation to purchase our securities under the securities purchase agreement. If we are not able
to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more research and development
programs or selling and marketing initiatives. In addition, we may have to work with a partner on one or more of our products or market
development programs, which could lower the economic value of those programs to our company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will be dependent on our ability to attract and retain key personnel.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations will be materially dependent upon the services of our officers and key employees, including Brian F. Sullivan, our Chief Executive
Officer, and Dr. Lance G. Laing, our Chief Science Officer. Successful implementation of our business plan will also require the services
of other consultants and additional personnel. We cannot assure you that we will be able to attract and retain such persons as employees,
independent contractors, consultants or otherwise. If we are not able to attract individuals with the skills required for our business,
or if we lose the services of either Mr. Sullivan or Dr. Laing, we may be unable to successfully implement our business plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
COVID-19 pandemic may materially and adversely impact our business, including ongoing clinical trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
outbreak of COVID-19 and government measures taken in response have had a significant impact on the global economy, with healthcare systems
particularly affected. In response to the COVID-19 outbreak, public health measures have been implemented across much of the United States,
Europe and Asia, including in the locations of our offices, clinical trial sites, and partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of the COVID-19 pandemic, we have and may in the future experience disruptions that could materially and adversely impact our
clinical trials, business, financial condition and results of operations. Potential disruptions include but are not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            or difficulties in enrolling patients in clinical trials and obtaining the results of completed
                                            clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
                                            rates of patients withdrawing from clinical trials following enrollment as a result of quarantine
                                            or concerns about COVID-19;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
                                            of healthcare resources away from the conduct of clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            in prospective clinical trial collaborations with pharmaceutical companies and sponsors;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
                                            or delays in the operations of the FDA or other regulatory authorities, which may impact
                                            review and approval timelines;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                            on our ability to recruit and hire key personnel due to our inability to meet with candidates
                                            because of travel restrictions; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limitations
                                            on employee resources that would otherwise be focused on the conduct of clinical trials and
                                            research as a result of focus addressing COVID-19 mitigation and loss of productivity from
                                            remote work.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 33pt; text-align: justify; text-indent: -16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beyond
the direct effect of the pandemic, COVID-19 has had broad economic effects. The economic impact of COVID-19 may adversely affect us in
a variety of ways, including without limitation making our stock price more volatile, making it more difficult to raise additional capital
through offerings of equity or debt securities, and reducing the availability of bank loans. As a result, we may face difficulties raising
capital and capital raising efforts may be on terms than are less favorable than would have been previously available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the effects of COVID-19 described herein are expected to apply to any future recurrences of COVID-19 and any other pandemics that
may occur in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Drug Product, Gedatolisib</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
future strategy is dependent on the success of our initial drug product, gedatolisib, as well as other drug products we may develop.
If we are unable to successfully complete clinical development of, obtain regulatory approval for or commercialize our drug products,
or if we experience delays in doing so, our business will be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not yet completed any registrational clinical trials or the development of any drug products. Our future success and ability
to generate revenue from our drug products, which we do not expect will occur for several years, if ever, is dependent on our ability
to successfully develop, obtain regulatory approval for and commercialize one or more drug products. We may not have the financial resources
to continue development of, or to modify existing or enter into new collaborations for, a drug product if we experience any issues that
delay or prevent regulatory approval of, or our ability to commercialize, our drug products, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            inability to demonstrate to the satisfaction of the FDA or comparable foreign regulatory
                                            authorities that our drug products are safe and effective;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">insufficiency
                                            of our financial and other resources to complete the necessary preclinical studies and clinical
                                            trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
                                            or inconclusive results from our preclinical studies, clinical trials or the clinical trials
                                            of others for drug products similar to ours, leading to a decision or requirement to conduct
                                            additional preclinical studies or clinical trials or abandon a program;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product-related
                                            adverse events experienced by subjects in our clinical trials or by individuals using drugs
                                            or therapeutic biologics similar to our drug products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            in submitting applications, or delays or failure in obtaining the necessary approvals from
                                            regulators to commence a clinical trial or a suspension or termination of a clinical trial
                                            once commenced;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
                                            imposed by the FDA or comparable foreign regulatory authorities regarding the scope or design
                                            of our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">poor
                                            effectiveness of our drug products during clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">better
                                            than expected performance of control arms, such as placebo groups, which could lead to negative
                                            or inconclusive results from our clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            in enrolling subjects in clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high
                                            drop-out rates of subjects from clinical trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate
                                            supply or quality of drug products or other materials necessary for the conduct of our clinical
                                            trials;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
                                            than anticipated clinical trial or manufacturing costs;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
                                            FDA or comparable regulatory authority inspection and review of a clinical trial site;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
                                            of our third-party contractors or investigators to comply with regulatory requirements or
                                            otherwise meet their contractual obligations in a timely manner, or at all;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
                                            and changes in regulatory requirements, policy and guidelines, including the imposition of
                                            additional regulatory oversight around clinical testing generally or with respect to our
                                            therapies in particular; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying
                                            interpretations of data by the FDA and comparable foreign regulatory authorities.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 33pt; text-align: justify; text-indent: -16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
preliminary efficacy and safety data reported for the B2151009 Phase 1b clinical trial was provided to us by Pfizer and is subject to
change once data cleansing and data verification activities are completed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preliminary efficacy and safety data reported for the B2151009 Phase 1b clinical trial was provided to us by Pfizer. Pfizer provided
this data as of a data cutoff date of January 11, 2021, before Pfizer had cleaned the data, locked the clinical database, and completed
preparation of a final Clinical Study Report. We have not independently reviewed or verified the data, which includes case report forms
(CRF) for each patient and reconciliation with the data endpoints reported. We may discover, upon performing the study close out activities
for B2151009, which includes reconciliation and adjudication of the endpoint reported data with the CRF, inconsistencies with the data
as originally provided by Pfizer to us. As a result, the data presented as of the date hereof is subject to change once data cleaning
and verification activities have been completed and other study close-out procedures are completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
were not involved in the early development of gedatolisib; therefore, we are dependent on third parties having accurately generated,
collected, interpreted and reported data from certain preclinical and clinical trials gedatolisib.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had no involvement with or control over the initial preclinical and clinical development of gedatolisib. We are dependent on third parties
having conducted their research and development in accordance with the applicable protocols and legal, regulatory and scientific standards;
having accurately reported the results of all preclinical studies and clinical trials conducted with respect to such drug product; and
having correctly collected and interpreted the data from these trials. If these activities were not compliant, accurate or correct, the
clinical development, regulatory approval or commercialization of our drug product will be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
an organization, we have never successfully completed any registrational clinical trials, and we may be unable to do so for any drug
candidates we may develop.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to successfully complete registrational clinical trials in order to obtain the approval of the FDA or comparable foreign regulatory
authorities to market our drug products. Carrying out clinical trials, including later-stage registrational clinical trials, is a complicated
process. As an organization, we have not previously completed any registrational clinical trials. In order to do so, we will need to
build and expand our clinical development and regulatory capabilities, and we may be unable to recruit and train qualified personnel.
We also expect to continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry
out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory
approval of or commercialize any potential product candidates. Consequently, we may be unable to successfully and efficiently execute
and complete necessary clinical trials in a way that leads to submission and approval of our drug products. We may require more time
and incur greater costs than our competitors and may not succeed in obtaining regulatory approval of any drug products that we develop.
Failure to commence or complete, or delays in, our planned clinical trials, could prevent us from or delay us in commercializing our
drug products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we encounter difficulties enrolling patients in any of our clinical trials, our clinical development activities could be delayed or otherwise
adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient
number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical
trials for a variety of reasons, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            patient eligibility and exclusion criteria defined in the protocol;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            size of the patient population required for analysis of the clinical trial&#8217;s primary
                                            endpoints;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            proximity of patients to clinical trial sites;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            design of the clinical trial;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to recruit clinical trial investigators with the appropriate competencies and experience,
                                            and the ability of these investigators to identify and enroll suitable patients;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">perception
                                            of the safety profile of our drug products;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to obtain and maintain patient consents; and</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 33pt; text-align: justify; text-indent: -16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delays
in patient enrollment may result in increased costs or may affect the timing or outcome of our clinical trials, which could prevent completion
of these trials and adversely affect our ability to advance the development of our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in
completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
obtain the requisite regulatory approvals to commercialize any drug products, we must demonstrate through extensive preclinical studies
and clinical trials that such drug product is safe and effective in humans. Clinical testing is expensive and can take many years to
complete, and its outcome is inherently uncertain. We may be unable to establish clinical endpoints that applicable regulatory authorities
would consider clinically meaningful, and a clinical trial can fail at any stage of testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Differences
in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier
clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and
many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain
marketing approval of their products. Additionally, we are conducting and plan to conduct some open-label trials, where both the patient
and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo.
Most typically, open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose
levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in those
trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a &#8220;patient bias&#8221; where patients
perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label
clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the outcomes of the clinical
trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given
this knowledge. Where a randomized, placebo-controlled clinical trial is designed to allow enrolled subjects to cross-over to the treatment
arm, there may be a risk of inadvertent unblinding of subjects prior to cross-over, which may limit the clinical meaningfulness of those
data and may require the conduct of additional clinical trials. As such, the results from an open-label trial may not be predictive of
future clinical trial results with any of our product candidates for which we include an open-label clinical trial when studied in a
controlled environment with a placebo or active control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
completion of clinical trials is a prerequisite to submitting a new drug application, or NDA, to the FDA and similar marketing applications
to comparable foreign regulatory authorities for each drug product and, consequently, the ultimate approval and commercial marketing
of any drug products. We may experience delays in activating our Phase 3 clinical trial due to requests from the FDA for additional information,
including additional nonclinical or clinical data, or for requests to amend the clinical trial protocol. Additional delays may be incurred
once the Phase 3 clinical trial is initiated if it takes longer than expected to activate the targeted number of clinical sites, if the
enrollment of patients is negatively affected by COVID-19, by staffing shortages at clinical sites, or by other unanticipated factors,
or if the FDA and other regulatory authorities require us to pause our Phase 3 clinical trial due to unexpected safety issues. We also
may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct that could delay
or prevent our ability to receive marketing approval or commercialize our current product candidates or any future product candidates.
Our costs will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical
trials will begin as planned, will need to be reassigned or will be completed on schedule, or at all. Significant clinical trial delays
also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our
competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates
and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial
condition and results of operations significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>For
a new drug to be approved for marketing, the FDA and other regulatory authorities, must determine that the drug is safe and effective.
Because all drugs can have adverse effects, the data from our Phase 3 clinical study must demonstrate to the satisfaction of the FDA
and other health authorities that the benefits of gedatolisib in combination with palbociclib and fulvestrant, or gedatolisib in combination
with fulvestrant, outweigh its risks. Failure to demonstrate sufficient magnitude of benefit, even if the benefit is found to be statistically
significant, may not support regulatory approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a drug meets its primary efficacy endpoint objective in a Phase 3 clinical trial, and the drug sponsor has additional nonclinical and
clinical data required by the FDA or other regulatory authorities, the drug sponsor may submit an NDA seeking marketing approval. Upon
submission of an NDA, these health authorities perform a benefit-risk assessment that considers the strength and quality of evidence
available and takes remaining uncertainties into account. These considerations include an assessment of the strengths and limitations
of clinical trials, including design, and potential implications for assessing drug efficacy, the magnitude of benefit and interpretation
of clinical importance, the benefit attributed to the drug when studied in combination with other therapies, and the clinical relevance
of the study endpoints. We have sought feedback from the FDA and other regulatory authorities on the design of our Phase 3 clinical trial
with the goal of addressing these considerations in the clinical trial&#8217;s design. However, due to the complexity of clinical trials,
the uncertainty of outcomes, and the uncertainty of how the FDA and other regulatory authorities may balance benefits and risks in their
review of an NDA, it may not be practical or possible to address all benefit-risk assessment considerations in a Phase 3 clinical trial
so that sufficient evidence is generated to support a marketing approval, even if the primary endpoint objective is achieved. The FDA
or other regulatory authorities may require us to redesign or conduct additional unplanned clinical trials before granting any approval
and we may not get approval at all. If we are required to conduct additional clinical trials or other testing of our drug candidates
beyond those that we currently contemplate, if we are unable to successfully complete clinical trials or other testing of our product
candidates, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns,
we may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            delayed in obtaining marketing approval for our such product candidates or not obtain marketing
                                            approval at all;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                            approval for indications or patient populations that are not as broad as intended or desired;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                            approval with labeling that includes significant use or distribution restrictions or safety
                                            warnings, including boxed warnings;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            subject to changes in the way the product is administered;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            required to perform additional clinical trials to support approval or be subject to additional
                                            post-marketing testing requirements;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">have
                                            regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions
                                            on its distribution in the form of a REMS or through modification to an existing REMS;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be
                                            sued; or</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
                                            damage to our reputation.</span></td></tr>
                                                                                      </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
successful development of biopharmaceuticals is highly uncertain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Successful
development of biopharmaceuticals is highly uncertain and is dependent on numerous factors, many of which are beyond our control. Product
candidates that appear promising in the early phases of development may fail to reach the market for several reasons including, among
other things, that clinical trial results may show the product candidates to be less effective than expected or to have unacceptable
side effects or toxicities; we may fail to receive the necessary regulatory approvals or there may be a delay in receiving such approvals;
or the proprietary rights of others and their competing products and technologies that may prevent our product candidates from being
commercialized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory
authority varies significantly from one drug product to the next and from one country to the next and may be difficult to predict. Even
if we are successful in obtaining marketing approval, commercial success of any approved products will also depend in large part on the
availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid
programs and managed care organizations in the U.S. or country specific governmental organizations in foreign countries, which may be
affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require
us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement,
which could be costly and divert our resources. If government and other healthcare payors were not to provide coverage and adequate reimbursement
for our products once approved, market acceptance and commercial success would be reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if any of our drug products receive marketing approval, we will be subject to significant post-approval regulatory obligations.
In addition, there is always the risk that we, a regulatory authority or a third party might identify previously unknown problems with
a product post-approval, such as adverse events of unanticipated severity or frequency. Compliance with these requirements is costly,
and any failure to comply or other issues with our drug products post-approval could adversely affect our business, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition from other biopharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other
compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical
companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions.
Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development
staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may
also prove to be significant competitors, particularly as they develop novel approaches to treating disease indications that our product
candidates are also focused on treating. Established pharmaceutical companies may also invest heavily to accelerate discovery and development
of novel therapeutics or to in-license novel therapeutics that could make the product candidates that we develop obsolete. Mergers and
acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors.
Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of
capital for investment in these industries. Our competitors, either alone or with collaboration partners, may succeed in developing,
acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or
less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the
development of our technologies and products. We believe the key competitive factors that will affect the development and commercial
success of our product candidates are efficacy, safety, tolerability, reliability, convenience of use, price and reimbursement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain regulatory approval of drug products, the availability and price of our competitors&#8217; products could limit the demand
and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of
our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment
to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates
for use in limited circumstances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if any drug product we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients,
third-party payors and others in the medical community necessary for commercial success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any future drug product we develop receives marketing approval, whether as a single agent or in combination with other therapies, it
may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community.
If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues
and we may not become profitable. The degree of market acceptance of any product candidate, if approved for commercial sale, will depend
on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy
                                            and potential advantages compared to other treatments;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability to offer our products, if approved, for sale at competitive prices;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convenience
                                            and ease of administration compared to other treatments;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            willingness of the target patient population to try new therapies and of physicians to prescribe
                                            these therapies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            strength of marketing and distribution support;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ability to obtain sufficient third-party coverage, market access and adequate reimbursement;
                                            and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            prevalence and severity of any side effects.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Intellectual Property for Gedatolisib</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend on intellectual property licensed from third parties, including from Pfizer for our lead product candidate, and termination of
this license could result in the loss of significant rights, which would harm our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are dependent on patents, know-how and proprietary technology, both our own and licensed from others. All patents covering gedatolisib
and any combination therapies using our product candidates are licensed from third parties. Any termination of a product license could
result in the loss of significant rights and would cause material adverse harm to our ability to commercialize our product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disputes
may also arise between us and our licensors regarding intellectual property subject to a license agreement, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether
                                            and the extent to which our technology and processes infringe on intellectual property of
                                            the licensor that is not subject to the licensing agreement;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            right to sublicense patent and other rights to third parties under collaborative development
                                            relationships;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            diligence obligations with respect to the use of licensed technology in relation to our development
                                            and commercialization of our product candidates and what activities satisfy those diligence
                                            obligations; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            ownership of inventions and know-how resulting from the joint creation or use of intellectual
                                            property by our licensors and us and our partners.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements
on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are generally also subject to all of the same risks with respect to protection of intellectual property that we own, as we are for intellectual
property that we license. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize
products could materially suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to comply with our obligations under our patent license with Pfizer, we could lose license rights that are important to our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a party to a license agreement with Pfizer pursuant to which we in-license key patents for our gedatolisib. This license imposes
various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, Pfizer
may have the right to terminate the license, in which event we would not be able to develop or market the products covered by such licensed
intellectual property. We may have limited control over the maintenance and prosecution of these in-licensed rights, activities or any
other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such
activities by these licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid
and enforceable patents and other intellectual property rights. We have limited control over the manner in which our licensors initiate
an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual
property that is licensed to us. It is possible that the licensors&#8217; infringement proceeding or defense activities may be less vigorous
than had we conducted them ourselves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth
of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. We may be unable to acquire
or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we
identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on
reasonable terms, if at all, which could harm our business. We may need to cease use of the compositions or methods covered by such third-party
intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property
rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be
feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies
licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established,
or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights
that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a
competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.
There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual
property surrounding the additional product candidates that we may seek to acquire.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Government Regulation for Gedatolisib</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not obtain the necessary regulatory approvals to commercialize our product candidate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need FDA approval to commercialize our product candidate in the U.S. In order to obtain FDA approval, we must submit to the FDA
a new drug application, or NDA, demonstrating that the drug product is safe for humans and effective for its intended use. This demonstration
requires significant research and animal tests, which are referred to as pre-clinical studies, as well as human tests, which are referred
to as clinical trials. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depends upon the type, complexity
and novelty of the drug product and requires substantial resources for research, development and testing. We cannot predict whether our
research and clinical approaches will result in a drug that the FDA considers safe for humans and effective for indicated uses. The FDA
has substantial discretion in the drug approval process and may require us to conduct additional pre-clinical and clinical testing or
to perform post-marketing studies. The approval process may also be delayed by changes in government regulation, future legislation or
administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals
may delay commercialization of, and our ability to derive product revenues from, our drug product; impose costly procedures on us; or
diminish any competitive advantages that we may otherwise enjoy. Even if we comply with all FDA requests, the FDA may ultimately reject
our NDA. We cannot be sure that we will ever obtain regulatory clearance for our drug product. Failure to obtain FDA approval of our
drug product will severely undermine our business by reducing our number of salable products and, therefore, corresponding product revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
FDA or comparable foreign regulatory authorities may disagree with our regulatory plan for our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
general approach for FDA approval of a new drug is dispositive data from one or more well-controlled Phase 3 clinical trials of the product
candidate in the relevant patient population. Phase 3 clinical trials typically involve a large number of patients, have significant
costs and take years to complete.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trial results may not support approval of our product candidates. In addition, our product candidates could fail to receive
regulatory approval, or regulatory approval could be delayed, for many reasons, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may disagree with the dosing regimen, design
                                            or implementation of our clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory
                                            authorities that our product candidates are safe and effective for any of their proposed
                                            indications;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may encounter safety or efficacy problems caused by the COVID-19 pandemic;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            results of clinical trials may not meet the level of statistical significance required by
                                            the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
                                            may be unable to demonstrate that our product candidates&#8217; clinical and other benefits
                                            outweigh their safety risks;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may disagree with our interpretation of
                                            data from preclinical studies or clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            data collected from clinical trials of our product candidates may not be sufficient to the
                                            satisfaction of the FDA or comparable foreign regulatory authorities to support the submission
                                            of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory
                                            approval in the U.S. or elsewhere;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes
                                            or facilities of third-party manufacturers with which we contract for clinical and commercial
                                            supplies; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            approval policies or regulations of the FDA or comparable foreign regulatory authorities
                                            may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Breakthrough
Therapy Designation or Fast Track Designation from the FDA may not actually lead to a faster development or regulatory review or approval
process.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a drug is intended for the treatment of a serious or life-threatening condition and the product demonstrates the potential to
address unmet medical needs for this condition, the product sponsor may apply for Fast Track Designation. The designation offers the
opportunity for frequent interactions with the FDA to discuss the drug&#8217;s development plan and to ensure collection of
appropriate data needed to support drug approval, as well as eligibility for submission of a New Drug Application.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a drug may receive Breakthrough Therapy Designation if it is intended, alone or in combination with one or more other
products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product
may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. The benefits of Breakthrough Therapy Designation include more intensive
guidance from the FDA on an efficient development program, access to a scientific liaison to help accelerate review time, and
potential eligibility for priority review if relevant criteria are met. This designation can expedite the development and regulatory
review of an investigational medicine that is intended to treat a serious or life-threatening condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
Fast Track and Breakthrough Therapy Designations are within the discretion of the FDA. While the FDA has granted both designations
to our lead drug candidate, gedatolisib, such designations may not result in a faster development process, review or approval
compared to products considered for approval under conventional FDA procedures, and neither designation assures ultimate approval by
the FDA. In addition, the FDA may later decide that the product no longer meets the qualification conditions and may rescind either
or both such designations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or
maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction
may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a
product candidate, a comparable foreign regulatory authority must also approve the manufacturing, marketing and promotion of the product
candidate in those countries.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval
procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than,
those in the U.S., including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may
not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., a product candidate must be
approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge
for our products is also subject to approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the U.S. have requirements
for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory
approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could
delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international
markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential
of our product candidates will be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory
review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements
or experience unanticipated problems with our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging,
storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other
post-marketing information, including both federal and state requirements in the U.S. and requirements of comparable foreign regulatory
authorities. In addition, we will be subject to continued compliance with requirements for any clinical trials that we conduct post-approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers
and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements.
Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including
manufacturing, production and quality control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which
the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing,
including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. Certain endpoint data
we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or secondary endpoint
data such as patient-reported outcome measures. The FDA may impose consent decrees or withdraw approval if compliance with regulatory
requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously
unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party
manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information, imposition of post-marketing studies or clinical trials to assess new safety risks or imposition
of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
                                            on the marketing or manufacturing of our products, withdrawal of the product from the market
                                            or voluntary or mandatory product recalls;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
                                            warning letters or holds on clinical trials;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
                                            by the FDA to approve pending applications or supplements to approved applications filed
                                            by us or suspension or revocation of license approvals;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
                                            seizure or detention or refusal to permit the import or export of our product candidates;
                                            and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
                                            or the imposition of civil or criminal penalties.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted
only for the approved indications and in accordance with the provisions of the approved label. The policies of the FDA and comparable
foreign regulatory authorities may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory
approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future
legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval
that we may have obtained and we may not achieve or sustain profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our CELsignia Tests</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
success with CELsignia is heavily dependent on the success of our first CELsignia trials.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy is focused on attracting pharmaceutical company partnerships that provide revenue from the sale of CELsignia tests
during clinical trials, from milestone payments during clinical trials, from sales of our CELsignia tests as companion diagnostics or
stand-alone tests thereafter, and, potentially, from royalties on the incremental drug revenues our tests enable. Our ability to obtain
such partnerships and generate such revenue depends in part on the ability of our first CELsignia tests to demonstrate the potential
incremental opportunity available for pharmaceutical companies. We do not expect to receive the first interim results for our prospective
clinical trials for the CELsignia HER2 Pathway Activity Test until mid 2023 and with final results expected approximately
nine months later. Success of the clinical trials using the CELsignia HER2 Pathway Activity Test or CELsignia Multi-Pathway Activity
Test will depend on many factors, such as successfully enrolling patients, meeting trial endpoint goals, and completing the trial in
a timely manner. Our ability to complete the trial could be delayed or prevented for several reasons that are out of our control, such
as the FDA withdrawing its authorization and approval to perform the study, NSABP, West Cancer Center, Massachusetts General Hospital,
MD Anderson Cancer Center, or University of Rochester determining that the human and/or toxicology test results do not support continuing
the trial, or participants having adverse reactions or side-effects to the drugs administered in the study. If we are unable to demonstrate
that the CELsignia HER2 Pathway Activity Test or CELsignia Multi-Pathway Activity Test is suitable as a companion diagnostic for the
targeted therapy, we will likely not be able to generate future revenue from our CELsignia HER2 Pathway Activity Test or CELsignia Multi-Pathway
Activity test and may not be able to attract other pharmaceutical companies to partner with us for the development and commercialization
of other CELsignia tests. Further, potential pharmaceutical company partners may delay negotiating development agreements until results
of the first clinical trial using our CELsignia HER2 Pathway Activity Test trial are available. Even if the ultimate outcome of the first
clinical trial using a CELsignia HER2 Pathway Activity Test trial is positive, any delays could materially and adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in finding pharmaceutical company partners for continuing development of additional CELsignia tests.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to develop strategic partnerships with pharmaceutical companies for developing additional CELsignia tests. Many of the potential
partners are global, multi-billion-dollar pharmaceutical companies with sophisticated research and development organizations and multiple
priorities. We may not be successful in our efforts to establish such a strategic partnership or other alternative arrangements for our
CELsignia tests because, among other things, our research and development pipeline may be insufficient, such tests may be deemed to be
at too early of a stage of development for collaborative effort, or third parties may not view such tests as having the requisite potential
to demonstrate efficacy. In addition, we may be restricted under collaboration agreements from entering into future agreements with other
partners. Even if we are able to find suitable partners, we may not be successful in negotiating development agreements with such partners
that provide revenue from the sale of our CELsignia tests, from milestone payments, and/or from royalties on the incremental drug revenues
that our tests enable. If we are unable to reach agreements with suitable strategic partners on a timely basis, on acceptable terms or
at all, we may have to curtail the development of additional CELsignia tests, our expected revenue opportunities may be significantly
smaller than expected and our business may fail.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>While
our CELsignia HER2 Pathway Activity Test and CELsignia Multi-Pathway Activity Test are commercially ready, we have not attempted to market
these to physicians or their patients as stand-alone tests and have no ability to determine if these tests or any of our other tests
will be commercially viable.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
our CELsignia HER2 Pathway Activity Test and CELsignia Multi-Pathway Activity Test are analytically validated, conducted in our CLIA
certified and CAP accredited laboratory, and currently ready for commercial use as an LDT, we have not attempted to market them to physicians
or their patients. Furthermore, we have commenced only limited communications with KOLs to build awareness and credibility of our CELsignia
diagnostic platform and CELsignia tests. Accordingly, we have no ability to determine whether our CELsignia HER2 Pathway Activity Test,
CELsignia Multi-Pathway Activity Test or any other future CELsignia tests, will be commercially viable as stand-alone tests. We may never
be successful in generating revenue from our CELsignia tests as stand-alone tests, and if we are unable to build pharmaceutical partnerships
that enable us to market the CELsignia HER2 Pathway Activity Test, the CELsignia Multi-Pathway Activity Test, and other tests as companion
diagnostic tests, we may never generate any revenue and our business may fail.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing
our CELsignia tests involves a lengthy and complex process that may not be successful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
CELsignia tests may take several years to develop from the time they are discovered to the time they are available for patient use, if
ever. In order to develop additional CELsignia tests into commercially ready products, we need to successfully complete a variety of
activities, including, among others, conducting substantial research and development, conducting extensive analytical testing, and maintaining
our CLIA certified and CAP accredited laboratory. In addition, our business strategy is focused on our CELsignia tests being sold as
companion diagnostics. This will require obtaining and maintaining partnerships with pharmaceutical companies and successfully completing
clinical studies that demonstrate the suitability of the applicable CELsignia test as a companion diagnostic for their targeted therapies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
activities will require us to expend significant resources. Based on comparable companies in this industry, few research and development
projects result in commercially viable products, and success in early clinical studies often is not replicated in later studies. At any
point, we may abandon development of a product candidate for several reasons, such as a clinical validation study failing to demonstrate
the prospectively defined endpoints of the study. We may also be required to expend considerable resources repeating clinical studies,
which would adversely affect the timing for generating potential revenue from a new product and our ability to invest in other products
in our pipeline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Clinical
trials are expensive and complex with uncertain outcomes, which may prevent or delay commercialization of our CELsignia tests.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
our CELsignia tests to become a companion diagnostic for a matching targeted therapy, we must conduct clinical trials to demonstrate
that patients who have an abnormal signaling pathway, as identified by our CELsignia tests, respond to treatment with a matching targeted
therapy. Clinical testing is expensive, is difficult to design and implement, and can take many years to complete, and its outcome is
inherently uncertain. As a company, we have limited experience in conducting or participating in clinical trials. We cannot be certain
that any future clinical trials will conclusively demonstrate that any CELsignia test is effective as a companion diagnostic. If our
trials do not yield positive results, we may be unable to maintain the pharmaceutical company partnerships we build or find additional
partners, we may not be able to successfully commercialize our CELsignia tests or generate any revenue, our business may fail, and you
may lose part or all of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot be certain that our existing clinical trial or future clinical trials, if any, will begin or be completed on time, if at all.
We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to commercialize
our CELsignia tests, such as:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
                                            or failure in reaching agreement on acceptable clinical trial contracts or clinical trial
                                            protocols with planned trial sites and/or strategic partners;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
                                            or failure in reaching agreement with the FDA or a comparable foreign regulatory authority
                                            on a trial design, in obtaining authorization from such authorities to commence the trial,
                                            and/or in complying with conditions or other requirements imposed by such regulatory authorities
                                            with respect to the trial;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
                                            or failure in recruiting and enrolling suitable subjects to participate in one or more clinical
                                            trials, or in such participants completing a trial or returning for follow-up during or after
                                            the trial;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
                                            sites, investigators or other third-parties deviating from the trial protocol, failing to
                                            conduct the trial in accordance with regulatory and contractual requirements, and/or dropping
                                            out of a trial;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            imposition of a clinical hold for any of our clinical trials, where a clinical hold in a
                                            trial in one indication would result in a clinical hold for clinical trials in other indications;
                                            and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in governmental regulations or administrative actions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
nonclinical or clinical trial delays could prevent us from maintaining and/or developing new pharmaceutical company partnerships. Delays
could also shorten any periods during which we may have the exclusive right to commercialize our CELsignia tests or allow our competitors
to bring products to market before we do. As such, any delays could impair our ability to successfully commercialize our CELsignia tests
and may materially and adversely affect our business, financial condition, results of operations and prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even
if our CELsignia tests achieve positive clinical trial results, they may fail to achieve the degree of market acceptance by physicians,
patients, third-party payors and others in the medical community necessary for commercial success.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our potential CELsignia tests, including our first CELsignia HER2 Pathway Activity Test and CELsignia Multi-Pathway Activity Test,
achieve positive clinical trial results, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party
payors and others in the medical community necessary for commercial success. For example, conventional genomic- or proteomic-based analyses
are commonly used today to diagnose cancer and prescribe cancer medications, and physicians may continue to rely on these diagnostic
tests instead of adopting the use of a CELsignia test. The degree of market acceptance of our CELsignia tests will depend on a number
of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">their
                                            efficacy and other potential advantages compared to alternative diagnostic tests;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to offer them for sale at competitive prices;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">their
                                            convenience and ease of obtaining patient specimens compared to alternative diagnostics;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            willingness of the target patient population to try new diagnostics and of physicians to
                                            initiate such diagnostics;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            strength of marketing and distribution support;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            availability of third-party coverage and adequate reimbursement for our diagnostic tests;
                                            and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            ability to partner with pharmaceutical companies to develop companion diagnostic programs
                                            for the new cancer sub-types we discover.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our CELsignia tests do not achieve an adequate level of acceptance, we may never generate significant product revenues and we may not
become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
CELsignia related business, operational and financial goals may not be attainable if the market opportunities for our CELsignia tests
or our pharmaceutical company partners are smaller than we expect. Our internal research and estimates on market opportunities have not
been verified by independent sources, and we have not independently verified market and industry data from third-parties that we have
relied on.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total market opportunities that we believe exist are based on a variety of assumptions and estimates, including the number of potential
companion diagnostic programs we will be able to successfully pursue, the amount of potential milestone payments that we could receive
in companion diagnostic programs, the number of patients we will test in clinical trials, the price we will be able to charge for our
tests and the total annual number of cancer patients with undiagnosed abnormal cell signaling. In addition, we have relied on third-party
publications, research, surveys and studies for information related to determining market opportunities, including without limitation,
information on the number of cancer patients and those receiving various forms of treatment, the cost of drug therapy, the amount of
revenue generated from various types of drug therapy, the objective response rates of drug therapies, the number of deaths caused by
cancer and the expected growth in cancer drug therapy and diagnostic markets. Our internal research and estimates on market opportunities
have not been verified by independent sources, and we have not independently verified market and industry data from third-parties that
we have relied on. Any or all of our assumptions and/or estimates may prove to be incorrect for several reasons, such as inaccurate reports
or information that we have relied on, potential patients or providers not being amenable to using our CELsignia platform for diagnostic
testing or such patients becoming difficult to identify and access, limited reimbursement for companion diagnostics, pricing pressure
due to availability of alternative diagnostic tests, or an inability of the CELsignia tests&#8217; companion drugs to obtain the necessary
regulatory approvals for new indications. If any or all of our assumptions and estimates prove inaccurate, we and our companion diagnostic
pharmaceutical partners may not attain our business, operational and financial goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
expected selling price range of our CELsignia tests is an estimate. We have not yet sold any such tests and the actual price we are able
to charge may be substantially lower than our expected price range.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have estimated the selling price range of our CELsignia tests based on the pricing of other diagnostic tests currently available and
assumptions regarding the efficacy and market acceptance of our tests. We have not yet sold our CELsignia tests and cannot be certain
of the actual price we may be able to charge. The availability and price of our competitors&#8217; products could limit the demand and
the price we are able to charge. We may not achieve our business plan if acceptance is inhibited by price competition, if pharmaceutical
companies refuse to pay our expected prices for CELsignia tests in clinical trials, if physicians are reluctant to switch from other
diagnostic tests to our CELsignia tests or if physicians switch to other new products or choose to reserve our CELsignia tests for use
in limited circumstances. Furthermore, reductions in the reimbursement rate of third-party payors have occurred and may occur in the
future. Each of these factors could cause our selling price to be substantially lower than expected, and we may fail to generate revenue
or become profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
insurance coverage and reimbursement status of new diagnostic products is uncertain. Failure to obtain or maintain adequate coverage
and reimbursement for CELsignia tests could limit our ability to market those CELsignia tests and decrease our ability to generate revenue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive
diagnostic tests and treatments. Sales of any of our potential CELsignia tests will depend substantially, both in the United States and
internationally, on the extent to which the costs of our CELsignia tests will be paid by health maintenance, managed care, and similar
healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers
and other third-party payors. Reimbursement by a payor may depend on a number of factors, including a payor&#8217;s determination that
the CELsignia tests are neither experimental nor investigational, appropriate for the specific patient, cost-effective, supported by
peer-reviewed publications, and included in clinical practice guidelines.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
reimbursement is not available, or is available only to a limited amount, we may not be able to successfully commercialize our CELsignia
tests at expected levels, or potentially at all. Even if coverage is provided, the approved reimbursement amount may not be high enough
to allow us to establish or maintain pricing sufficient to realize a sufficient return on our research and development investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved diagnostic products. In the United States,
the principal decisions about reimbursement for new diagnostic products and services are typically made by CMS. CMS decides whether and
to what extent a new product or service will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial
degree. As such, a significant portion of our potential revenue depends on CMS approving coverage and reimbursement of our CELsignia
tests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the United States, international operations are generally subject to extensive governmental price controls and other market regulations,
and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to
put pressure on the pricing and usage of diagnostic tests such as our potential CELsignia tests. In many countries, particularly the
countries of the European Union, the prices of medical products are subject to varying price control mechanisms as part of national health
systems. In these countries, pricing negotiations with governmental authorities can take considerable time. To obtain reimbursement or
pricing approval in some countries, we may be required to demonstrate the cost-effectiveness of our CELsignia tests relative to other
available diagnostic tests. The prices of products under such systems may be substantially lower than in the United States. Other countries
allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other
changes in pricing regulation could restrict the amount that we are able to charge for our CELsignia tests. Accordingly, in markets outside
the United States, the reimbursement for our potential CELsignia tests may be reduced compared with the United States and may be insufficient
to generate commercially reasonable revenue and profit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce healthcare costs
may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not
cover or provide adequate payment for our potential CELsignia tests. The downward pressure on healthcare costs in general, particularly
prescription drugs and surgical procedures and other treatments, has become very intense. We expect to experience pricing pressures in
connection with the sale of any CELsignia tests due to the trend toward managed healthcare, the increasing influence of health maintenance
organizations and additional legislative changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may encounter difficulties in commercializing and marketing our CELsignia products, including in hiring and retaining a qualified sales
force.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to commercialize any CELsignia test, we must build marketing, sales, managerial and other non-technical capabilities or make arrangements
with third parties to perform these services, and we may not be successful in doing so. For each CELsignia test we develop, we intend
to pursue development agreements with the pharmaceutical companies that provide matching targeted therapies. Once we have completed the
analytical validation of a CELsignia test, we plan to target KOLs to build product awareness. Once we have clinical validation data available,
we expect to expand our sales and marketing efforts to target the broader market and coordinate our go-to-market activities with those
of our partner pharmaceutical companies. These activities will be expensive and time consuming and will require significant attention
of our executive officers to manage. In particular, there is intense competition for qualified sales personnel and our inability to hire
or retain an adequate number of sales representatives could limit our ability to maintain or expand our business and increase sales.
Furthermore, there is no guarantee that any new drug indications will require our CELsignia tests as a companion diagnostic or that any
pharmaceutical company will effectively coordinate sales and marketing activities with us. Any failure or delay in these activities,
including if we are unable to develop our marketing and sales networks or if our sales personnel do not perform as expected, would adversely
impact the commercialization our CELsignia platform, and our business, financial condition, results of operations and prospects may be
materially and adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
face significant competition from other diagnostic companies and our operating results will suffer if we fail to compete effectively.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
diagnostic testing industry is intensely competitive. We have competitors both in the United States and abroad, including universities
and other research institutions and providers of diagnostics that focus on developing genomic or proteomic analyses of a patient&#8217;s
diseased cells or theranostic tests to predict specific patient responses to a drug therapy. Many of our competitors have substantially
greater financial, technical and other resources, such as larger research and development staff and well-established marketing and sales
forces. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, products or services that are more
effective or less costly than the CELsignia tests that we are currently developing or that we may develop. In addition, established medical
technology, biotechnology and/or pharmaceutical companies may invest heavily to accelerate discovery and development of diagnostic tests
that could make our CELsignia tests less competitive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to compete successfully will depend largely on our ability to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discover
                                            and develop CELsignia tests for cancer sub-types that are superior to other products in the
                                            market;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstrate
                                            compelling advantages in the efficacy and convenience of our CELsignia tests on a cost competitive
                                            basis;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
                                            qualified scientific, product development and commercial personnel;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                            and maintain patent and other proprietary protection as necessary for our CELsignia platform;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
                                            required U.S. and international regulatory approvals;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            collaborate with research institutions and pharmaceutical companies in the discovery, development
                                            and commercialization of our current and future CELsignia tests; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 16.6pt"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16.4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
                                            expand our operations and build a sales force to support commercialization.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our sole laboratory facility becomes inoperable, we will be unable to perform our tests and our business will be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have redundant laboratory facilities. We perform all of our diagnostic services in our laboratory located in Minneapolis, Minnesota.
Our facility and the equipment we use to perform our tests would be costly to replace and could require substantial lead time to repair
or replace. The facility may be harmed or rendered inoperable by physical damage from fire, floods, tornadoes, power loss, telecommunications
failures, break-ins and similar events, which may render it difficult or impossible for us to perform our tests for some period of time.
The inability to perform our tests may result in the loss of customers or harm our reputation, and we may be unable to regain those customers
in the future. Although we possess insurance for damage to our property and the disruption of our business, this insurance may not be
sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to rely on a third party to perform our tests, we could only use another facility with established state licensure and CLIA accreditation
under the scope of which our potential CELsignia tests could be performed following validation and other required procedures. We cannot
assure you that we would be able to find another CLIA-certified facility willing to adopt CELsignia tests and comply with the required
procedures, or that this laboratory would be willing to perform the tests for us on commercially reasonable terms.<b><i></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our instrument
or reagent suppliers may fail to meet our quality requirements for the items we purchase or fail to provide a continuous supply of the
items we utilize to perform our CELsignia tests.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
utilize highly specialized reagents and instruments to perform our CELsignia tests. We may be unable to find suitable replacement reagents
and instruments on a timely basis, if at all. Interruption in the supply of these items or degradation in their quality could delay analytical
and clinical studies, and/or render us unable to deliver CELsignia tests. This would interrupt sales and adversely affect our business,
results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance
issues or price increases by our shipping carriers could adversely affect our business, results of operations and financial condition,
and harm our reputation and ability to provide our CELsignia tests on a timely basis.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expedited,
reliable shipping is essential to our operations. Should our shipping carrier encounter delivery performance issues such as loss, damage
or destruction of a sample, such occurrences may damage our reputation and lead to decreased demand for our services and increased cost
and expense to our business. In addition, any significant increase in shipping rates could adversely affect our operating margins and
results of operations. Similarly, strikes, severe weather, natural disasters or other service interruptions by delivery services we use
would adversely affect our ability to receive and process patient samples on a timely basis. There are only a few providers of overnight
nationwide transport services, and there can be no assurance that we will be able to maintain arrangements with providers on acceptable
terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
CELsignia tests represent a novel approach to companion diagnostics, which could result in heightened regulatory scrutiny, delays in
clinical development, or delays in our ability to commercialize any products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
unique and proprietary CELsignia technology is the first cancer diagnostic platform we are aware of that can detect the underlying signaling
dysfunction driving a patient&#8217;s cancer. Because this is a novel approach to companion diagnostics, there can be no assurance as
to the length of a clinical trial period, the number of patients the FDA or another applicable regulatory authority will require to be
enrolled in the trials in order to establish the safety and efficacy of our CELsignia tests and the companion drugs, or that the data
generated in these trials will be acceptable to the FDA or another applicable regulatory authority to support marketing approval of new
indications for the companion drugs. This could delay or prohibit our clinical trials and/or commercialization of our CELsignia tests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the FDA were to begin regulating our tests, we could incur substantial costs and delays associated with trying to obtain premarket clearance
or approval.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
LDTs are not currently subject to FDA regulation, although reagents, instruments, software or components provided by third parties and
used to perform LDTs may be subject to regulation. We believe that the CELsignia tests are LDTs, which is a term that describes tests
that are designed and performed within a single laboratory. As a result, we believe the CELsignia tests are not currently subject to
regulation by the FDA in accordance with the FDA&#8217;s current policy of exercising enforcement discretion regarding LDTs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
the FDA has not required laboratories that furnish only LDTs to comply with the agency&#8217;s requirements for medical devices (e.g.,
establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and post-market controls).
In mid-2014, the FDA published a draft Guidance Document describing a proposed approach for a regulatory framework for LDTs, but in late
2016, the FDA indicated it did not intend to finalize the LDT Guidance Document at that time. It is not clear when or if the FDA will
seek to alter the current LDT regulatory framework in the future. We cannot provide any assurance that FDA regulation, including premarket
review, will not be required in the future for our tests, whether through additional guidance issued by the FDA, new enforcement policies
adopted by the FDA or new legislation enacted by Congress. We cannot predict with certainty the timing or content of future legislation
enacted or guidance issued regarding LDTs, or how it will affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
premarket review is required by the FDA at a future date or if we decide to voluntarily pursue FDA premarket review of our CELsignia
tests, there can be no assurance that our CELsignia tests or any tests we may develop in the future will be cleared or approved by the
FDA on a timely basis, if at all, nor can there be assurance that labeling claims will be consistent with our current claims or adequate
to support continued adoption of and reimbursement for our CELsignia tests. If our CELsignia tests are allowed to remain on the market
but there is uncertainty in the marketplace about our tests, if they are labeled investigational by the FDA, or if labeling claims the
FDA allows us to make are more limited than we expect, reimbursement may be adversely affected and we may not be able to sell our CELsignia
tests. Compliance with FDA regulations would increase the cost of conducting our business and subject us to heightened regulation and
scrutiny by the FDA and penalties for failure to comply with these requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we fail to obtain required federal and state laboratory licenses, we could lose the ability to perform our tests.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
laboratory tests, including our CELsignia tests, are regulated under CLIA. CLIA is a federal law that regulates clinical laboratories
that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment
of disease. CLIA regulations mandate specific standards for laboratories in the areas of personnel qualifications, administration, and
participation in proficiency testing, patient test management and quality assurance. CLIA certification is also required in order for
us to be eligible to bill state and federal healthcare programs, as well as many private third-party payers, for any tests we launch.
We will also be required to maintain state licenses in certain states to conduct testing in our laboratories. While we currently have
CLIA certification for our Minnesota laboratory, failure to maintain this certification would adversely affect our ability to launch
our CELsignia tests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CELsignia
Risks Related to Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to obtain and maintain intellectual property protection for our CELsignia technology, or if the scope of the intellectual
property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and diagnostic tests
similar or identical to ours, and our ability to successfully commercialize our technology and diagnostic tests may be impaired.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to compete successfully will depend in part on our ability to obtain and enforce patent protection for our products, preserve
our trade secrets and operate without infringing the proprietary rights of third parties. We have applied for patents that protect our
technology. Our patent portfolio includes three issued U.S. patents, five issued international patents, five pending U.S. patent applications,
23 pending non-U.S. patent applications, one pending international PCT patent application, and numerous corresponding non-U.S. patent
applications. Each patent and patent application covers methods of use. However, we cannot assure you that our intellectual property
position will not be challenged or that all patents for which we have applied will be granted. The validity and breadth of claims in
patents involve complex legal and factual questions and, therefore, may be highly uncertain. Uncertainties and risks that we face include
the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            pending or future patent applications may not result in the issuance of patents;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            scope of any existing or future patent protection may not exclude competitors or provide
                                            competitive advantages to us;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
                                            patents may not be held valid if subsequently challenged;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                            parties may claim that our products and designs infringe the proprietary rights of others,
                                            and even if we are successful in defending our patents and proprietary rights, such litigation
                                            may be costly; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
                                            parties may develop similar products, duplicate our products, or design around our patents.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent prosecution process is expensive and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all
necessary or desirable patent applications at a reasonable cost or in a timely manner, or in all jurisdictions. We may choose not to
seek patent protection for certain innovations and may choose not to pursue patent protection in certain jurisdictions, and under the
laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope. It is also possible
that we will fail to identify patentable aspects of our discovery and nonclinical development output before it is too late to obtain
patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
patent position of companies like ours is highly uncertain, involves complex legal and factual questions and has in recent years been
the subject of much litigation. The U.S. Patent and Trademark Office, or U.S. PTO, has not established a consistent policy regarding
the breadth of claims that it will allow in medical technology patents. In addition, the laws of foreign jurisdictions may not protect
our rights to the same extent as the laws of the United States. For example, India and China do not allow patents for methods of treating
the human body. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications
in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore,
we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent
applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity,
enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result
in patents being issued that protect our technology or CELsignia tests, in whole or in part, or which effectively prevent others from
commercializing competitive technologies and diagnostic tests. Changes in either the patent laws or interpretation of the patent laws
in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we may be subject to a third-party pre-issuance submission of prior art to the U.S. PTO or patent offices in foreign jurisdictions, or
become involved in opposition, derivation, reexamination, inter parties review, post-grant review or interference proceedings challenging
our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce
the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology and compete directly with us, without
payment to us, or result in our inability to commercialize CELsignia platform without infringing third-party patent rights. In addition,
if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from
collaborating with us to develop or commercialize current or future CELsignia tests.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our owned patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection,
prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent
our owned patents by developing similar or alternative technologies or products in a non-infringing manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned patents may be challenged
in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate
or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others
from using or commercializing similar or identical technology and product candidates, or limit the duration of the patent protection
of our technology and potential diagnostic tests. Given the amount of time required for the development, testing and regulatory review
of new diagnostic tests, patents protecting such tests might expire before or shortly after such candidates are commercialized. As a
result, our owned patent portfolio may not provide us with sufficient rights to exclude others from commercializing diagnostic tests
similar or identical to ours.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third
parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would
be uncertain and could have a material adverse effect on the success of our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commercial success of CELsignia tests depends upon our ability, and the ability of our collaborators, to develop, manufacture, market
and sell our CELsignia tests and use our proprietary technologies without infringing the proprietary rights of third parties. There is
considerable intellectual property litigation in the medical technology, biotechnology and pharmaceutical industries. We may become party
to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our CELsignia
platform, including interference or derivation proceedings before the U.S. PTO and similar bodies in other jurisdictions. Third parties
may assert infringement claims against us based on existing patents or patents that may be granted in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third
party to continue developing and marketing our CELsignia platform and CELsignia tests. However, we may not be able to obtain any required
license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving
our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing
the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217;
fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our CELsignia
platform or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated
the confidential information or trade secrets of third parties could have a similar negative impact on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are not able to prevent disclosure of our trade secrets and other proprietary information, the value of our CELsignia platform could
be significantly diminished.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on trade secret protection to protect our interests in proprietary know-how and in processes for which patents are difficult to
obtain or enforce. We may not be able to protect our trade secrets adequately. We have a policy of requiring our consultants, advisors
and strategic partners to enter into confidentiality agreements and our employees to enter into invention, non-disclosure and non-compete
agreements. However, no assurance can be given that we have entered into appropriate agreements with all parties that have had access
to our trade secrets, know-how or other proprietary information. There is also no assurance that such agreements will provide meaningful
protection of our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure of information.
Furthermore, we cannot provide assurance that any of our employees, consultants, contract personnel, or strategic partners, either accidentally
or through willful misconduct, will not cause serious damage to our programs and/or our strategy, for example by disclosing important
trade secrets, know-how or proprietary information to our competitors. It is also possible that our trade secrets, know-how or other
proprietary information could be obtained by third parties as a result of breaches of our physical or electronic security systems. Any
disclosure of confidential data into the public domain or to third parties could allow our competitors to learn our trade secrets and
use the information in competition against us. In addition, others may independently discover our trade secrets and proprietary information.
Any action to enforce our rights is likely to be time consuming and expensive, and may ultimately be unsuccessful, or may result in a
remedy that is not commercially valuable. These risks are accentuated in foreign countries where laws or law enforcement practices may
not protect proprietary rights as fully as in the United States. Any unauthorized disclosure of our trade secrets or proprietary information
could harm our competitive position.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other
Risks Related to Government Regulation for Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to comply with the HIPAA security and privacy regulations may increase our operational costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
portion of the data that we obtain and handle for or on behalf of our clients is considered protected health information, or PHI, subject
to HIPAA. Under HIPAA and our contractual agreements with our HIPAA-covered entity health plan customers, we are considered a &#8220;business
associate&#8221; to those customers, and are required to maintain the privacy and security of PHI in accordance with HIPAA and the terms
of our business associate agreements with our clients, including by implementing HIPAA-required administrative, technical and physical
safeguards. We are also required to maintain similar business associate agreements with our subcontractors that have access to PHI of
our customers in rendering services to us or on our behalf. We will incur significant costs to establish and maintain these safeguards
and, if additional safeguards are required to comply with HIPAA regulations or our clients&#8217; requirements, our costs could increase
further, which would negatively affect our operating results. Furthermore, we cannot guarantee that such safeguards have been and will
continue to be adequate under applicable laws. If we have failed, or fail in the future, to maintain adequate safeguards, or we or our
agents or subcontractors use or disclose PHI in a manner prohibited or not permitted by HIPAA, our subcontractor business associate agreements,
or our business associate agreements with our customers, or if the privacy or security of PHI that we obtain and handle is otherwise
compromised, we could be subject to significant liabilities and consequences.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will also need to expend a considerable amount of resources complying with other federal, state and foreign laws and regulations. If
we are unable to comply or have not complied with such laws, we could face substantial penalties or other adverse actions.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operations are subject, directly or indirectly, to other federal, state and foreign laws and regulations that are complex and their application
to our specific products, services and relationships may not be clear and may be applied to our business in ways that we do not anticipate.
Compliance with laws and regulations will require us to expend considerable resources implementing internal policies and procedures for
compliance and ongoing monitoring and will require significant attention of our management team. This will be challenging as an early-stage
company with limited financial resources and human capital. These laws include, for example:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
                                            XI of the Social Security Act, commonly referred to as the federal Anti-Kickback Statute,
                                            which prohibits the knowing and willful offer, payment, solicitation or receipt of remuneration,
                                            directly or indirectly, in cash or in kind, in return for or to reward the referral of patients
                                            or arranging for the referral of patients, or in return for the recommendation, arrangement,
                                            purchase, lease or order of items or services that are covered, in whole or in part, by a
                                            federal healthcare program such as Medicare or Medicaid;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            civil False Claims Act, that forbids the knowing submission or &#8220;causing the submission&#8221;
                                            of false or fraudulent information or the failure to disclose information in connection with
                                            the submission and payment of claims for reimbursement to Medicare, Medicaid, federal healthcare
                                            programs or private health plans;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            federal Physician Self-referral Law, commonly known as the Stark Law, which prohibits physicians
                                            from referring Medicare or Medicaid patients to providers of &#8220;designated health services&#8221;
                                            with whom the physician or a member of the physician&#8217;s immediate family has an ownership
                                            interest or compensation arrangement, unless a statutory or regulatory exception applies,
                                            and similar state equivalents that may apply regardless of payor; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery
                                            statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, and the USA PATRIOT Act,
                                            which among other things, prohibit companies and their employees, agents, third-party intermediaries,
                                            joint venture partners and collaborators from authorizing, promising, offering, or providing,
                                            directly or indirectly, improper payments or benefits to recipients in the public or private
                                            sector.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
states and foreign governments have adopted similar laws and regulations. Violations of law could subject us to civil or criminal penalties,
monetary fines, disgorgement, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings
and curtailment of our operations. We could also be required to change or terminate some portions of operations or business or could
be disqualified from providing services to healthcare providers doing business with government programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Reliance on Third Parties</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
will rely on third parties to conduct certain aspects of our preclinical studies and clinical trials. If these third parties do not successfully
carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory
approval for, or commercialize, any potential product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will depend upon third parties to conduct certain aspects of our preclinical studies and depend on third parties, including independent
investigators, to conduct our clinical trials, under agreements with universities, medical institutions, contract research organizations,
or CROs, strategic partners and others. We expect to negotiate budgets and contracts with such third parties, which may result in delays
to our development timelines and increased costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to build our infrastructure and hire personnel necessary to execute our operational plans. We will rely especially heavily on
third parties over the course of our clinical trials, and, as a result, may have limited control over the clinical investigators and
limited visibility into their day-to-day activities, including with respect to their compliance with the approved clinical protocol.
Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol,
legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities.
We and these third parties are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and
comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCP requirements
through periodic inspections of clinical trial sponsors, clinical investigators and clinical trial sites. If we or any of these third
parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable
and the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional preclinical
studies or clinical trials before approving our marketing applications. We cannot be certain that, upon inspection, such regulatory authorities
will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with
product produced under cGMP requirements and may require a large number of patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure or any failure by these third parties to comply with these regulations may require us to repeat clinical trials, which would
delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal
or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
third parties conducting aspects of our preclinical studies or our clinical trials will not be our employees and, except for remedies
that may be available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time
and resources to our preclinical studies and clinical programs. These third parties may also have relationships with other commercial
entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which
could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations
or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the preclinical or clinical data they obtain
is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons, our development timelines,
including clinical development timelines, may be extended, delayed or terminated and we may not be able to complete development of, obtain
regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects
for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed or precluded
entirely.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
pharmaceutical companies that we partner with may not be successful in receiving regulatory approval for drug indications or may not
commercialize their companion therapies for our expected companion diagnostic programs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we intend to provide our pharmaceutical company partners with new patient populations for such partners&#8217; existing or investigational
targeted therapies, there can be no assurances that such partners will be able to obtain regulatory approval for new indications to treat
these patient populations or otherwise be successful in commercializing these new therapies. The pharmaceutical companies we partner
with:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            not meet clinical trial endpoint targets in evaluating efficacy of a targeted therapy in
                                            the patient population;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            encounter regulatory or production difficulties that could constrain the supply of the companion
                                            therapies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            have difficulties gaining acceptance of the use of the companion therapies in the clinical
                                            community;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            not pursue commercialization of any companion therapies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            elect not to continue or renew commercialization programs based on changes in their strategic
                                            focus or available funding, or external factors, such as an acquisition, that divert resources
                                            or create competing priorities;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            not commit sufficient resources to the marketing and distribution of such companion therapies;
                                            or</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">may
                                            terminate their relationship with us.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these factors could adversely affect our commercialization strategy, business, results of operations and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
reliance on third parties to formulate and manufacture our drug product will expose us to a number of risks that may delay the development,
regulatory approval and commercialization of our drug product or result in higher product costs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have no direct experience in drug formulation or manufacturing and do not intend to establish our own manufacturing facilities. We lack
the resources and expertise to formulate or manufacture our own product candidates. Instead, we will contract with one or more manufacturers
to manufacture, supply, store and distribute drug supplies for our clinical trials. If our drug product receives FDA approval, we will
rely on one or more third-party contractors to manufacture our drugs. Our anticipated future reliance on a limited number of third-party
manufacturers exposes us to risks that, among other things, we may be unable to identify manufacturers on acceptable terms or at all
because the number of potential manufacturers is limited and the FDA must approve any replacement contractor; our third-party manufacturers
might be unable to formulate and manufacture our drugs in the volume and of the quality required to meet our clinical and/or commercial
needs, if any; our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for
the time required to supply our clinical trials or to successfully produce, store and distribute our products; and our contract manufacturers
may fail to comply with good manufacturing practice and other government regulations and corresponding foreign standards. Each of these
risks could delay our clinical trials, the approval, if any, of our product candidates by the FDA, or the commercialization of our product
candidates or result in higher costs or deprive us of potential product revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Patent
reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement
or defense of our issued patents.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a
number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and
may also affect patent litigation. The U.S. PTO recently developed new regulations and procedures to govern administration of the Leahy-Smith
Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions,
only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation
of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution
of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on
our business and financial condition. Depending on future actions by the U.S. Congress, the federal courts, and the U.S. PTO, the laws
and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce
our existing patents and patents that we might obtain in the future. In addition, there may be patent law reforms in foreign jurisdictions
that could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense
of our issued patents in those foreign jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming
ownership of what we regard as our own intellectual property.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current and future employees may have been previously employed at universities or other biotechnology, diagnostic technology or pharmaceutical
companies, including our competitors or potential competitors and strategic partners. Although we try to ensure that our employees do
not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we
have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s
former employer. Litigation may be necessary to defend against these claims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, while it is our policy to require our employees and contractors who may be involved in the development of intellectual property
to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party
who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or
may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine
the ownership of what we regard as our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property
rights or personnel. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial
costs and be a distraction to management.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Any
lawsuits relating to infringement of intellectual property rights necessary to defend ourselves or enforce our rights will be costly
and time consuming and could be unsuccessful.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
competition in our industry is intense, competitors may infringe or otherwise violate our issued patents, patents of our licensors or
other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be
expensive and time consuming, and could distract our technical and management personnel from their normal responsibilities. Any claims
we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their
patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole
or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds
that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our
patents at risk of being invalidated or interpreted narrowly. We may also elect to enter into license agreements in order to settle patent
infringement claims or to resolve disputes prior to litigation, and any such license agreements may require us to pay royalties and other
fees that could be significant. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Provisions
in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders,
more difficult and may prevent attempts by our stockholders to replace or remove our current management.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control
of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your
shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock,
thereby depressing the market price of our common stock. In addition, because our board of directors will be responsible for appointing
the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our
current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these
provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allow
                                            the authorized number of our directors to be changed only by resolution of our board of directors;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
                                            the manner in which stockholders can remove directors from our board of directors;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establish
                                            advance notice requirements for stockholder proposals that can be acted on at stockholder
                                            meetings and nominations to our board of directors;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            that stockholder actions must be effected at a duly called stockholder meeting and prohibit
                                            actions by our stockholders by written consent;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit
                                            who may call stockholder meetings;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize
                                            our board of directors to issue preferred stock without stockholder approval, which could
                                            be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership
                                            of a potential hostile acquirer, effectively preventing acquisitions that have not been approved
                                            by our board of directors; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">require
                                            the approval of the holders of at least two-thirds of the votes that all our stockholders
                                            would be entitled to cast to amend or repeal specified provisions of our certificate of incorporation
                                            or bylaws.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess
of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction
in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed
manner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
of these provisions of our charter documents or Delaware law could, under certain circumstances, depress the market price of our common
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our
common stock or could subject us to securities litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
stock price may be extremely volatile. The stock market in general and the market for smaller medical technology companies in particular
have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of
this volatility, investors may not be able to sell our common stock at or above the price they paid for such stock. The market price
for our common stock may be influenced by many factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            success of competitive products or technologies;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
                                            of planned clinical trials for gedatolisib, as well as our CELsignia HER2 Pathway Activity Test, CELsignia Multi-Pathway
                                            Activity Test or other CELsignia tests may develop in the future;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
                                            or legal developments in the United States and other countries;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
                                            or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            recruitment or departure of key personnel;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            level of expenses related to any of our CELsignia tests or clinical development programs;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
                                            or anticipated changes in estimates as to financial results, development timelines or recommendations
                                            by securities analysts;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
                                            results that fail to meet expectations of securities analysts that cover our company;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">variations
                                            in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
                                            in the structure of healthcare payment systems;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
                                            conditions in the pharmaceutical, biotechnology and medical technology sectors;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
                                            of our stock by us, our insiders and our other stockholders;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general
                                            economic and market conditions; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
companies that have experienced volatility in the market price of their stock have been subject to an increased incidence of securities
class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result
in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities or industry analysts do not publish research or reports about our business, or publish negative reports about our business,
our stock price and trading volume could decline.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
trading market for our common stock depends in part on the research and reports that securities or industry analysts publish about us
or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable
coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our stock price would
likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose
visibility in the financial markets, which could cause our stock price or trading volume to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are an &#8220;emerging growth company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make
our common stock less attractive to investors.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and may remain an emerging growth company for up to five years.
For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements
that are applicable to other public companies that are not emerging growth companies. These exemptions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
                                            permitted to provide only two years of audited financial statements, in addition to any required
                                            unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s
                                            Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            being required to comply with the auditor attestation requirements in the assessment of our
                                            internal control over financial reporting of Section 404(b) of the Sarbanes-Oxley Act;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
                                            being required to comply with any requirement that may be adopted by the Public Company Accounting
                                            Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s
                                            report providing additional information about the audit and the financial statements;</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
                                            disclosure obligations regarding executive compensation; and</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
                                            from the requirements of holding a nonbinding advisory vote on executive compensation and
                                            stockholder approval of any golden parachute payments not previously approved.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have taken advantage of reduced reporting burdens in this report. We cannot predict whether investors will find our common stock less
attractive if we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active
trading market for our common stock and our stock price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to
new compliance initiatives and corporate governance practices.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, and particularly after we are no longer an emerging growth company, we will incur significant legal, accounting and
other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection
Act, the continued listing requirements of The Nasdaq Stock Market and other applicable securities rules and regulations impose various
requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate
governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives.
Moreover, these rules and regulations have increased our ongoing legal and financial compliance costs and will make some activities more
time-consuming and costly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our internal control
over financial reporting. Depending upon our filer status, if we cease to be an emerging growth company, we could also be required to
include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm
as required by Section 404(b). While we, as of September 30, 2022, concluded that our internal control over financial reporting was effective,
we may need to dedicate additional internal resources and engage outside consultants to maintain compliance with Section 404 in the future.
Any material weaknesses that we may identify in the future could result in an adverse reaction in the financial markets due to a loss
of confidence in the reliability of our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="ed_001"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
2. Unregistered Sales of Equity Securities and Use of Proceeds</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Unregistered Sales of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="ed_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
3. Defaults Upon Senior Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="ed_003"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
4. Mine Safety Disclosures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="ed_004"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
5. Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span id="ed_005"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ITEM
6. Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
INDEX</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex2-1.htm" style="-sec-extract: exhibit">Form of Plan of Conversion (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Registration Statement on Form S-1/A filed with the SEC on September 12, 2017).</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex3-1.htm">Certificate
    of Incorporation of the Company, as amended.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000114420417058480/tv478251_ex3-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws, incorporated by reference from Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on November 13, 2017.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007846/t1702519_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Certificate representing shares of common stock of Celcuity Inc., incorporated by reference from Exhibit 4.1 to the Company&#8217;s Registration Statement<span style="background-color: white"> on Form S-1/A filed September 12, 2017.</span></span></a></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495420002595/celc_ex42.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Description of Registered Securities (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 13, 2020).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000157104917007662/t1702400_ex10-9.htm" style="-sec-extract: exhibit">Form of Warrant to Purchase Units of Membership Interest issued by Celcuity LLC to Cedar Point Capital, LLC, as placement agent of membership units and unsecured convertible promissory notes of Celcuity LLC (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on August 23, 2017).</a></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000114420417049520/v475747_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Form of Warrant to Purchase Shares of Common Stock issued by Celcuity Inc. in connection with the conversion of 1.25% Unsecured Convertible Promissory Notes (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on September 25, 2017).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000114420417049520/v475747_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Representative&#8217;s Warrant to Purchase Common Stock (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on September 25, 2017).</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex42.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant, incorporated by reference from Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 8, 2021.</span></a></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222025891/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Representative&#8217;s Warrant, dated September 13, 2022, between Celcuity Inc. and Craig Hallum Capital Group, incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on September 14, 2022.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421003990/celc_ex41.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Grant Agreement, dated April 8, 2021, between the Company and Pfizer, Inc., incorporated by reference from Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 8, 2021.</span></a></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000165495421008769/celc_ex102.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan and Security Agreement, dated as of April 8, 2021, by and between the Company and Innovatus Life Sciences Lending Fund I, LP., incorporated by reference from Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed with the SEC on August 11, 2021.</span></a></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222014348/ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant, incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 18, 2022.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222014348/ex4-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock filed May 16, 2022, incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on May 18, 2022.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222020778/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third Amendment to Lease, dated July 27, 2022, by and between Celcuity Inc. and West Glen Development I, LLC, incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed with the SEC on July 29, 2022.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1603454/000149315222022062/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The First Amendment to Loan and Security Agreement, dated August 9, 2022, by and among the Company and Innovatus Life Sciences Lending Fund I, LP, incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on August 11, 2022.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-1.htm">Certification
    of Chairman and Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex31-2.htm">Certification
    of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification
    of Chairman and Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-2.htm">Certification
    of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
                                            statements from the Quarterly Report on Form 10-Q of the Company for the quarter ended September
                                            30, 2022, formatted in Inline XBRL: (i) the Condensed Balance Sheets, (ii) the Condensed
                                            Statements of Operations, (iii) the Condensed Statements of Changes in Stockholders&#8217;
                                            Equity, (iv) the Condensed Statements of Cash Flows, and (v) the Notes to Condensed Financial
                                            Statements.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
                                            herewith.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished
                                            herewith.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="ed_006"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    November 10, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CELCUITY
    INC.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Brian F. Sullivan</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    F. Sullivan</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</span></td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Vicky Hahne</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicky
    Hahne</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</span></td></tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -22pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -22pt"></p>

<!-- Field: Page; Sequence: 48; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right; text-indent: -22pt"></p>
</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex3-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF INCORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned, being of full age, for the purpose of forming a corporation under and pursuant to the Delaware General Corporation Law,
as amended (the &ldquo;<U>DGCL</U>&rdquo;), hereby adopts the following Certificate of Incorporation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE
1<BR>
NAME</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name of the corporation is Celcuity Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE
2<BR>
REGISTERED OFFICE AND AGENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
address of the registered office of the corporation in the State of Delaware is 1209 Orange Street, City of Wilmington, County of New
Castle, Delaware 19801. The name of the registered agent of the corporation at such address is The Corporation Trust Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE
3<BR>
PURPOSE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
purpose of this corporation is to engage in any lawful act or activity for which a corporation may be organized under the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE
4<BR>
CAPITAL STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1
The aggregate number of shares the corporation has authority to issue is 50,000,000 shares, par value of $0.001 per share, consisting
of 45,000,000 shares of Common Stock and 5,000,000 shares of undesignated Preferred Stock. The Board of Directors of the corporation
has the authority, without first obtaining approval of the stockholders of the corporation or any class thereof, to establish from the
undesignated shares of Preferred Stock, by resolution adopted and filed in the manner provided by law, one or more series of Preferred
Stock and to fix the number of shares, the voting powers, designations, preferences and relative, participating, optional or other special
rights, and the qualifications, limitations or restrictions of such class or series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2
The Board of Directors is expressly authorized to increase or decrease the number of shares of any series subsequent to the issuance
of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series
shall be decreased in accordance with the foregoing sentence, the shares constituting such decrease shall resume the status that they
had prior to the adoption of the resolution originally fixing the number of shares of such series. The number of authorized shares of
Common Stock or Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative
vote of the holders of a majority of the votes represented by all outstanding shares of stock of the Company entitled to vote, irrespective
of the provisions of Section 242(b)(2) of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3
Unless and except to the extent set forth in a resolution adopted and filed in the manner provided by law establishing one or more series
of Preferred Stock, no holder of shares of the corporation of any class or series now or hereafter authorized has any preferential or
preemptive right provided under applicable law to subscribe for, purchase or receive any shares of the corporation of any class or series
now or hereafter authorized, or any options or warrants for such shares, that may at any time be issued, sold or offered for sale by
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4
No holder of shares of the Company of any class now or hereafter authorized will be entitled to cumulative voting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE
5<BR>
MEETINGS AND BOOKS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1
Meetings of the stockholders may be held within or outside the State of Delaware, as the Bylaws may provide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2
Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting
of the stockholders of the corporation shall be given in the manner provided in the Bylaws of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.3
The books of the corporation may be kept within or (subject to any provision contained in the statutes) outside the State of Delaware
at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE
6<BR>
INCORPORATOR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
name and mailing address of the incorporator are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annette
Peterson-Igbinovia</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fredrikson
&amp; Byron, P.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200
South Sixth Street, Suite 4000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minneapolis,
MN 55402-1425</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE
7<BR>
DIRECTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1
The management of the business and the conduct of the affairs of the corporation shall be vested in its Board of Directors. The number
of directors which shall constitute the Board of Directors shall be fixed exclusively by resolutions adopted by a majority of the authorized
number of directors then constituting the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2
The directors of the corporation need not be elected by written ballot unless the Bylaws so provide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3
To the fullest extent permitted by law, any past or present director of the corporation shall not be personally liable to the corporation
or its stockholders for monetary damages for any breach of fiduciary duty by such director as a director. If the DGCL is amended to authorize
corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the corporation
shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. No amendment to, modification of or repeal
of this Article 7 will apply to or have any effect on the liability or alleged liability of any past or present director of the Company
for or with respect to any acts or omissions of such director occurring prior to such amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE
8<BR>
BYLAWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors is expressly empowered to adopt, amend or repeal the Bylaws of the corporation. The stockholders shall also have power
to adopt, amend or repeal the Bylaws of the corporation; provided, however, that, in addition to any vote of the holders of any class
or series of stock of the corporation required by law or by this Certificate of Incorporation, the affirmative vote of the holders of
at least sixty-six and two-thirds percent (66 2/3%) of the voting power of all of the then-outstanding shares of the capital stock of
the corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required to adopt,
amend or repeal any provision of the Bylaws of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE
9<BR>
SHAREHOLDER ACTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
action required or permitted to be taken by the stockholders of the corporation must be effected at an annual or special meeting of stockholders
called in accordance with the Bylaws and may not be effected by any consent in writing by such stockholders pursuant to Section 228 of
the DGCL or any other provision of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>ARTICLE
10<BR>
AMENDMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1
The corporation reserves the right to amend, alter or repeal any provision contained in this Certificate of Incorporation in the manner
now or hereafter prescribed by statute, except as provided in Section 10.2, and all rights conferred upon the stockholders herein are
granted subject to this reservation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2
Notwithstanding any other provisions of this Certificate of Incorporation or any provision of law which might otherwise permit a lesser
vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the corporation required
by law or by this Certificate of Incorporation or any certificate of designation filed with respect to a series of Preferred Stock, the
affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2/3%) of the voting power of all of the then-outstanding
shares of capital stock of the corporation entitled to vote generally in the election of directors, voting together as a single class,
shall be required to alter, amend or repeal Articles 5, 7, 8, 9 and 10.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE
UNDERSIGNED, being the incorporator named herein, for the purpose of forming a corporation pursuant to the DGCL, makes this Certificate,
hereby declaring and certifying that this is his or her act and deed and the facts herein stated are true, and accordingly has hereunto
set his or her hand on September 15, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Annette Peterson-Igbinovia</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annette
    Peterson-Igbinovia, Incorporator</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF AMENDMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF INCORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
Inc., a corporation organized and existing under and by the virtue of the Delaware General Corporation Law, as amended, through its duly
authorized officer and by the authority of its Board of Directors does hereby certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FIRST:
</B>The name of the corporation is Celcuity Inc. (the &ldquo;Corporation&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECOND:
</B>The Corporation&rsquo;s Certificate of Incorporation was originally filed with the Delaware Secretary of State on September 15, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIRD:
</B>This amendment to the Certificate of Incorporation has been duly authorized by the directors and the requisite stockholders of the
Corporation in accordance with the provisions of Sections 228 and 242 of the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOURTH:
</B>&nbsp;The Certificate of Incorporation is hereby amended by deleting the text of Section 4.1 of Article 4 in its entirety and replacing
such text with the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">4.1
The aggregate number of shares the corporation has authority to issue is 27,500,000 shares, par value of $0.001 per share, consisting
of 25,000,000 shares of Common Stock and 2,500,000 shares of undesignated Preferred Stock. The Board of Directors of the Corporation
has the authority, without first obtaining approval of the stockholders of the corporation or any&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">class&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">thereof,
to establish from the undesignated&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">shares&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">of
Preferred Stock, by resolution adopted and filed in the manner provided by law, one or more series of Preferred Stock and to fix the
number of shares, the&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">voting&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">powers,
designations, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions
of&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">such&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">class
or&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
page follows]</I></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed on May 11, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian F. Sullivan</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    F. Sullivan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR STYLE="clear: both"></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF AMENDMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF INCORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
Inc., a corporation organized and existing under and by the virtue of the Delaware General Corporation Law, as amended, through its duly
authorized officer and by the authority of its Board of Directors does hereby certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FIRST:
</B>The name of the corporation is Celcuity Inc. (the &ldquo;Corporation&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECOND:
</B>The Corporation&rsquo;s certificate of incorporation was originally filed with the Delaware Secretary of State on September 15, 2017
and was amended on May 11, 2018 (as amended, the &ldquo;Certificate of Incorporation&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIRD:
</B>This amendment to the Certificate of Incorporation has been duly authorized by the directors and the requisite stockholders of the
Corporation in accordance with the provisions of Sections 228 and 242 of the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOURTH:
&nbsp;The Certificate of Incorporation is hereby amended by deleting the text of Section 4.1 of Article 4 in its entirety and replacing
such text with the following:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">4.1
The aggregate number of shares the corporation has authority to issue is 32,500,000 shares, par value of $0.001 per share, consisting
of 30,000,000 shares of Common Stock and 2,500,000 shares of undesignated Preferred Stock. The Board of Directors of the Corporation
has the authority, without first obtaining approval of the stockholders of the corporation or any </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">class
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">thereof, to establish from the undesignated
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">shares </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">of
Preferred Stock, by resolution adopted and filed in the manner provided by law, one or more series of Preferred Stock and to fix the
number of shares, the </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">voting </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">powers,
designations, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions
of </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">such </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">class
or </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
page follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed on May 12, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY INC.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian F. Sullivan</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    F. Sullivan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF AMENDMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATE
OF INCORPORATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
Inc., a corporation organized and existing under and by the virtue of the Delaware General Corporation Law, as amended, through its duly
authorized officer and by the authority of its Board of Directors does hereby certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FIRST:
</B>The name of the corporation is Celcuity Inc. (the &ldquo;Corporation&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECOND:
</B>The Corporation&rsquo;s certificate of incorporation was originally filed with the Delaware Secretary of State on September 15, 2017
and was amended on May 11, 2018 and May 12, 2022 (as amended, the &ldquo;Certificate of Incorporation&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THIRD:
</B>This amendment to the Certificate of Incorporation has been duly authorized by the directors and the requisite stockholders of the
Corporation in accordance with the provisions of Sections 228 and 242 of the Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOURTH:
&nbsp;The Certificate of Incorporation is hereby amended by deleting the text of Section 4.1 of Article 4 in its entirety and replacing
such text with the following:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">4.1
The aggregate number of shares the corporation has authority to issue is 67,500,000 shares, par value of $0.001 per share, consisting
of 65,000,000 shares of Common Stock and 2,500,000 shares of Preferred Stock, which includes 1,850,000 shares that have been designated
as Series A Convertible Preferred Stock and 650,000 shares of undesignated Preferred Stock. The Board of Directors of the Corporation
has the authority, without first obtaining approval of the stockholders of the corporation or any </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">class
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">thereof, to establish from the undesignated
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">shares </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">of
Preferred Stock, by resolution adopted and filed in the manner provided by law, one or more series of Preferred Stock and to fix the
number of shares, the </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">voting </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">powers,
designations, preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions
of </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">such </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #060606">class
or </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #18161B">series.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>[Signature
page follows]</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>




<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be signed on September 1, 2022.&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELCUITY
  INC.&nbsp;</B></FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><I>/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
  F. Sullivan</FONT></I></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
  F. Sullivan</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
  Executive Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: -22pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: -22pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Brian F. Sullivan, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this Quarterly Report on Form 10-Q of Celcuity Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: November 10, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian F. Sullivan</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    F. Sullivan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: -22pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: -22pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: -22pt"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: -22pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION UNDER SECTION 302 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">I, Vicky Hahne, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this Quarterly Report on Form 10-Q of Celcuity Inc.;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -27.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in">&nbsp;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 50%">Dated: November 10, 2022</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Vicky Hahne</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicky Hahne</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In connection with the filing of the Quarterly Report
on Form 10-Q for the quarter ended September 30, 2022 (the &ldquo;Report&rdquo;) by Celcuity Inc. (&ldquo;Registrant&rdquo;), I, Brian
F. Sullivan, the Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C.
Section 1350, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies
  with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -9pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of
  the Registrant.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    November 10, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian F. Sullivan</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    F. Sullivan</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -9pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the filing of the Quarterly Report
on Form 10-Q for the quarter ended September 30, 2022 (the &ldquo;Report&rdquo;) by Celcuity Inc. (&ldquo;Registrant&rdquo;), I, Vicky
Hahne, the Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section
1350, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies
  with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
  <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
  information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of
  the Registrant.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: November 10, 2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; vertical-align: top; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Vicky Hahne</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicky Hahne</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -9pt"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -9pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>celc-20220930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWayECbP9z5Z8WekhvWB0bakaDygqfKb1xC0bkvFW0RgF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/srt-sup/2022q3" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:CELC="http://celcuity.com/20220930" elementFormDefault="qualified" targetNamespace="http://celcuity.com/20220930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://celcuity.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" id="StatementsOfCashFlowsParenthetical">
	  <link:definition>00000007 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/Organization" id="Organization">
	  <link:definition>00000008 - Disclosure - Organization</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" id="BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements">
	  <link:definition>00000009 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
	  <link:definition>00000010 - Disclosure - Net Loss Per Common Share</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/Commitments" id="Commitments">
	  <link:definition>00000011 - Disclosure - Commitments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000012 - Disclosure - Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/Stock-basedCompensation" id="Stock-basedCompensation">
	  <link:definition>00000013 - Disclosure - Stock-Based Compensation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/Debt" id="Debt">
	  <link:definition>00000014 - Disclosure - Debt</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/LicenseAgreement" id="LicenseAgreement">
	  <link:definition>00000015 - Disclosure - License Agreement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" id="BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies">
	  <link:definition>00000016 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/Stock-basedCompensationTables" id="Stock-basedCompensationTables">
	  <link:definition>00000017 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/DebtTables" id="DebtTables">
	  <link:definition>00000018 - Disclosure - Debt (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" id="BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative">
	  <link:definition>00000019 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" id="NetLossPerCommonShareDetailsNarrative">
	  <link:definition>00000020 - Disclosure - Net Loss Per Common Share (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" id="CommitmentsDetailsNarrative">
	  <link:definition>00000021 - Disclosure - Commitments (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000022 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" id="ScheduleOfStockOptionsActivityDetails">
	  <link:definition>00000023 - Disclosure - Schedule of Stock Options Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" id="ScheduleOfStockOptionsOutstandingAndExercisableDetails">
	  <link:definition>00000024 - Disclosure - Schedule of Stock Options Outstanding and Exercisable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" id="ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails">
	  <link:definition>00000025 - Disclosure - Schedule of Assumptions for Fair Value of Equity-based Awards (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" id="ScheduleOfUnrecognizedCompensationCostDetails">
	  <link:definition>00000026 - Disclosure - Schedule of Unrecognized Compensation Cost (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" id="ScheduleOfStock-basedCompensationExpenseDetails">
	  <link:definition>00000027 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" id="Stock-basedCompensationDetailsNarrative">
	  <link:definition>00000028 - Disclosure - Stock-Based Compensation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" id="ScheduleOfLong-termDebtDetails">
	  <link:definition>00000029 - Disclosure - Schedule of Long-term Debt (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" id="ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails">
	  <link:definition>00000030 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/DebtDetailsNarrative" id="DebtDetailsNarrative">
	  <link:definition>00000031 - Disclosure - Debt (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://celcuity.com/role/LicenseAgreementDetailsNarrative" id="LicenseAgreementDetailsNarrative">
	  <link:definition>00000032 - Disclosure - License Agreement (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="celc-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="celc-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="celc-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="celc-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap-sup/2022q3" schemaLocation="https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/srt-sup/2022q3" schemaLocation="https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
    <element id="CELC_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PurchaseAgreementMember" name="PurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_OpenMarketSaleAgreementMember" name="OpenMarketSaleAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_JefferiesLLCMember" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_FollowOnOfferingMember" name="FollowOnOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_UnderwriterMember" name="UnderwriterMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_AtmAgreementMember" name="AtmAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PlacementSharesMember" name="PlacementSharesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_InMayTwoThousandTwentyTwoMember" name="InMayTwoThousandTwentyTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_InDecemberTwoThousandTwentyOneMember" name="InDecemberTwoThousandTwentyOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_InMayTwoThousandTwentyMember" name="InMayTwoThousandTwentyMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TwoThousandSeventeenPlanMember" name="TwoThousandSeventeenPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LoanAgreementMember" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_InnovatusLifeSciencesMember" name="InnovatusLifeSciencesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_AmendedLoanAgreementMember" name="AmendedLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermBLoanMember" name="TermBLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermCLoanMember" name="TermCLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermDLoanMember" name="TermDLoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermELoanMember" name="TermELoanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_OriginalAndAmendedLoanAgreementMember" name="OriginalAndAmendedLoanAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PfizerIncMember" name="PfizerIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PayrollTaxReceivable" name="PayrollTaxReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" name="StockIssuedDuringPeriodValueStockWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" name="StockIssuedDuringPeriodSharesStockWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_IssuanceOfCommonStockLicensingAgreement" name="IssuanceOfCommonStockLicensingAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense" name="IncreaseDecreaseInNonCashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_IncreaseDecreaseInPayrollTaxReceivable" name="IncreaseDecreaseInPayrollTaxReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ProceedsFromEmployeeStockPurchases" name="ProceedsFromEmployeeStockPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" name="ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_GrossProceedsFromAnAtmOffering" name="GrossProceedsFromAnAtmOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PaymentsForRegistrationStatementCosts" name="PaymentsForRegistrationStatementCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PaymentsForFinanceLeases" name="PaymentsForFinanceLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PropertyAndEquipmentIncludedInAccountsPayable" name="PropertyAndEquipmentIncludedInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" name="OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses" name="DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DisclosureLicenseAgreementAbstract" name="DisclosureLicenseAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LicenseAgreementDisclosureTextBlock" name="LicenseAgreementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" name="ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_DeemedDividend" name="DeemedDividend" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_IncreasedNetLossPerShareBasicAndDiluted" name="IncreasedNetLossPerShareBasicAndDiluted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EstimatedIncrementalFairValueOfWarrants" name="EstimatedIncrementalFairValueOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PercentageOfWarrantExercisePrice" name="PercentageOfWarrantExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_SaleOfStockTransactionFee" name="SaleOfStockTransactionFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_CommissionPercentage" name="CommissionPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses" name="GrossProceedsNetOfCommissionsAndOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_AverageSellingPricePerShare" name="AverageSellingPricePerShare" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" name="EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" name="EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" name="EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" name="EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" name="EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockOptionAwardsSharesModified" name="StockOptionAwardsSharesModified" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_ModifiedStockOptionExercisePrice" name="ModifiedStockOptionExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_RemainingStockBasedCompensationExpenseRelatedToModification" name="RemainingStockBasedCompensationExpenseRelatedToModification" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PaymentInKindInterestDebt" name="PaymentInKindInterestDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_NotesPayableFinalFee" name="NotesPayableFinalFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_NonContingentTermALoanFunded" name="NonContingentTermALoanFunded" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo" name="TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree" name="TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_FinalFeePayableToLenderAmount" name="FinalFeePayableToLenderAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_IncreaseFromOriginalLoanAmount" name="IncreaseFromOriginalLoanAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_UnfundedContingentLoanAmount" name="UnfundedContingentLoanAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_LoanConvertibleToStockPercentageDescription" name="LoanConvertibleToStockPercentageDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_PrepaymentFeePercentage" name="PrepaymentFeePercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_UpfrontFees" name="UpfrontFees" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant" name="StockIssuedDuringPeriodValueNewIssuesForEquityGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CELC_MilestonePayable" name="MilestonePayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>celc-20220930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celcuity.com/role/Cover" xlink:href="celc-20220930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BalanceSheets" xlink:href="celc-20220930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:href="celc-20220930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfOperations" xlink:href="celc-20220930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="celc-20220930.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfCashFlows" xlink:href="celc-20220930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:href="celc-20220930.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Organization" xlink:href="celc-20220930.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:href="celc-20220930.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShare" xlink:href="celc-20220930.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Commitments" xlink:href="celc-20220930.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquity" xlink:href="celc-20220930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensation" xlink:href="celc-20220930.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Debt" xlink:href="celc-20220930.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/LicenseAgreement" xlink:href="celc-20220930.xsd#LicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:href="celc-20220930.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensationTables" xlink:href="celc-20220930.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/DebtTables" xlink:href="celc-20220930.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:href="celc-20220930.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="celc-20220930.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:href="celc-20220930.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:href="celc-20220930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:href="celc-20220930.xsd#ScheduleOfStockOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:href="celc-20220930.xsd#ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:href="celc-20220930.xsd#ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" xlink:href="celc-20220930.xsd#ScheduleOfUnrecognizedCompensationCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="celc-20220930.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="celc-20220930.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:href="celc-20220930.xsd#ScheduleOfLong-termDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:href="celc-20220930.xsd#ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/DebtDetailsNarrative" xlink:href="celc-20220930.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/LicenseAgreementDetailsNarrative" xlink:href="celc-20220930.xsd#LicenseAgreementDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PayrollTaxReceivable" xlink:label="loc_CELCPayrollTaxReceivable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_CELCPayrollTaxReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Statements of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IssuanceOfCommonStockLicensingAgreement" xlink:label="loc_CELCIssuanceOfCommonStockLicensingAgreement" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELCIssuanceOfCommonStockLicensingAgreement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:label="loc_CELCIncreaseDecreaseInNonCashOperatingLeaseExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELCIncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IncreaseDecreaseInPayrollTaxReceivable" xlink:label="loc_CELCIncreaseDecreaseInPayrollTaxReceivable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CELCIncreaseDecreaseInPayrollTaxReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_ProceedsFromEmployeeStockPurchases" xlink:label="loc_CELCProceedsFromEmployeeStockPurchases" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELCProceedsFromEmployeeStockPurchases" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_CELCProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELCProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_GrossProceedsFromAnAtmOffering" xlink:label="loc_CELCGrossProceedsFromAnAtmOffering" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELCGrossProceedsFromAnAtmOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PaymentsForRegistrationStatementCosts" xlink:label="loc_CELCPaymentsForRegistrationStatementCosts" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELCPaymentsForRegistrationStatementCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PaymentsForFinanceLeases" xlink:label="loc_CELCPaymentsForFinanceLeases" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_CELCPaymentsForFinanceLeases" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Organization" xlink:title="00000008 - Disclosure - Organization" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:title="00000009 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShare" xlink:title="00000010 - Disclosure - Net Loss Per Common Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Commitments" xlink:title="00000011 - Disclosure - Commitments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquity" xlink:title="00000012 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensation" xlink:title="00000013 - Disclosure - Stock-Based Compensation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Debt" xlink:title="00000014 - Disclosure - Debt" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/LicenseAgreement" xlink:title="00000015 - Disclosure - License Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:title="00000016 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationTables" xlink:title="00000017 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtTables" xlink:title="00000018 - Disclosure - Debt (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:title="00000019 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="00000020 - Disclosure - Net Loss Per Common Share (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:title="00000021 - Disclosure - Commitments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="00000023 - Disclosure - Schedule of Stock Options Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:title="00000024 - Disclosure - Schedule of Stock Options Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:title="00000025 - Disclosure - Schedule of Assumptions for Fair Value of Equity-based Awards (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" xlink:title="00000026 - Disclosure - Schedule of Unrecognized Compensation Cost (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000027 - Disclosure - Schedule of Stock-based Compensation Expense (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000028 - Disclosure - Stock-Based Compensation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:title="00000029 - Disclosure - Schedule of Long-term Debt (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:title="00000030 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtDetailsNarrative" xlink:title="00000031 - Disclosure - Debt (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://celcuity.com/role/LicenseAgreementDetailsNarrative" xlink:title="00000032 - Disclosure - License Agreement (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>celc-20220930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celcuity.com/role/Cover" xlink:href="celc-20220930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BalanceSheets" xlink:href="celc-20220930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:href="celc-20220930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfOperations" xlink:href="celc-20220930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="celc-20220930.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfCashFlows" xlink:href="celc-20220930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:href="celc-20220930.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Organization" xlink:href="celc-20220930.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:href="celc-20220930.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShare" xlink:href="celc-20220930.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Commitments" xlink:href="celc-20220930.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquity" xlink:href="celc-20220930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensation" xlink:href="celc-20220930.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Debt" xlink:href="celc-20220930.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/LicenseAgreement" xlink:href="celc-20220930.xsd#LicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:href="celc-20220930.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensationTables" xlink:href="celc-20220930.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/DebtTables" xlink:href="celc-20220930.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:href="celc-20220930.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="celc-20220930.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:href="celc-20220930.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:href="celc-20220930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:href="celc-20220930.xsd#ScheduleOfStockOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:href="celc-20220930.xsd#ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:href="celc-20220930.xsd#ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" xlink:href="celc-20220930.xsd#ScheduleOfUnrecognizedCompensationCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="celc-20220930.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="celc-20220930.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:href="celc-20220930.xsd#ScheduleOfLong-termDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:href="celc-20220930.xsd#ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/DebtDetailsNarrative" xlink:href="celc-20220930.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/LicenseAgreementDetailsNarrative" xlink:href="celc-20220930.xsd#LicenseAgreementDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_CELCStockIssuedDuringPeriodValueStockWarrantsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueStockWarrantsExercised_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_CELCStockIssuedDuringPeriodSharesStockWarrantsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesStockWarrantsExercised_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_50" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" xlink:label="loc_CELCStockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement_50" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares" xlink:label="loc_CELCStockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares_50" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Organization" xlink:title="00000008 - Disclosure - Organization" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:title="00000009 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShare" xlink:title="00000010 - Disclosure - Net Loss Per Common Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Commitments" xlink:title="00000011 - Disclosure - Commitments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquity" xlink:title="00000012 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensation" xlink:title="00000013 - Disclosure - Stock-Based Compensation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Debt" xlink:title="00000014 - Disclosure - Debt" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/LicenseAgreement" xlink:title="00000015 - Disclosure - License Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:title="00000016 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationTables" xlink:title="00000017 - Disclosure - Stock-Based Compensation (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtTables" xlink:title="00000018 - Disclosure - Debt (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:title="00000019 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="00000020 - Disclosure - Net Loss Per Common Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_DeemedDividend" xlink:label="loc_CELCDeemedDividend_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_CELCDeemedDividend_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IncreasedNetLossPerShareBasicAndDiluted" xlink:label="loc_CELCIncreasedNetLossPerShareBasicAndDiluted_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_CELCIncreasedNetLossPerShareBasicAndDiluted_150" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:title="00000021 - Disclosure - Commitments (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_SecuritiesPurchaseAgreementMember" xlink:label="loc_CELCSecuritiesPurchaseAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCSecuritiesPurchaseAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PurchaseAgreementMember" xlink:label="loc_CELCPurchaseAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCPurchaseAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_OpenMarketSaleAgreementMember" xlink:label="loc_CELCOpenMarketSaleAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCOpenMarketSaleAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_JefferiesLLCMember" xlink:label="loc_CELCJefferiesLLCMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CELCJefferiesLLCMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_FollowOnOfferingMember" xlink:label="loc_CELCFollowOnOfferingMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CELCFollowOnOfferingMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_UnderwriterMember" xlink:label="loc_CELCUnderwriterMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELCUnderwriterMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:label="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:label="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis" xlink:to="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:label="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis" xlink:to="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_AtmAgreementMember" xlink:label="loc_CELCAtmAgreementMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain" xlink:to="loc_CELCAtmAgreementMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PlacementSharesMember" xlink:label="loc_CELCPlacementSharesMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_CELCPlacementSharesMember_210" xlink:type="arc" order="212" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_280" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EstimatedIncrementalFairValueOfWarrants" xlink:label="loc_CELCEstimatedIncrementalFairValueOfWarrants_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CELCEstimatedIncrementalFairValueOfWarrants_280" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_280" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction_280" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_280" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice_280" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PercentageOfWarrantExercisePrice" xlink:label="loc_CELCPercentageOfWarrantExercisePrice_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CELCPercentageOfWarrantExercisePrice_280" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_SaleOfStockTransactionFee" xlink:label="loc_CELCSaleOfStockTransactionFee_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CELCSaleOfStockTransactionFee_280" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_280" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_CommissionPercentage" xlink:label="loc_CELCCommissionPercentage_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CELCCommissionPercentage_280" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_280" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_280" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses" xlink:label="loc_CELCGrossProceedsNetOfCommissionsAndOfferingExpenses_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CELCGrossProceedsNetOfCommissionsAndOfferingExpenses_280" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaapPaymentsForUnderwritingExpense_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsForUnderwritingExpense_280" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_280" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_280" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_AverageSellingPricePerShare" xlink:label="loc_CELCAverageSellingPricePerShare_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CELCAverageSellingPricePerShare_280" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="00000023 - Disclosure - Schedule of Stock Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_70" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:title="00000024 - Disclosure - Schedule of Stock Options Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:title="00000025 - Disclosure - Schedule of Assumptions for Fair Value of Equity-based Awards (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" xlink:title="00000026 - Disclosure - Schedule of Unrecognized Compensation Cost (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000027 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000028 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeStockPurchasePlanMember" xlink:label="loc_CELCEmployeeStockPurchasePlanMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCEmployeeStockPurchasePlanMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_InMayTwoThousandTwentyTwoMember" xlink:label="loc_CELCInMayTwoThousandTwentyTwoMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_CELCInMayTwoThousandTwentyTwoMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_InDecemberTwoThousandTwentyOneMember" xlink:label="loc_CELCInDecemberTwoThousandTwentyOneMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_CELCInDecemberTwoThousandTwentyOneMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_InMayTwoThousandTwentyMember" xlink:label="loc_CELCInMayTwoThousandTwentyMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_CELCInMayTwoThousandTwentyMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TwoThousandSeventeenPlanMember" xlink:label="loc_CELCTwoThousandSeventeenPlanMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCTwoThousandSeventeenPlanMember_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_410" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockOptionAwardsSharesModified" xlink:label="loc_CELCStockOptionAwardsSharesModified_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCStockOptionAwardsSharesModified_410" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_ModifiedStockOptionExercisePrice" xlink:label="loc_CELCModifiedStockOptionExercisePrice_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCModifiedStockOptionExercisePrice_410" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_410" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:label="loc_CELCRemainingStockBasedCompensationExpenseRelatedToModification_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCRemainingStockBasedCompensationExpenseRelatedToModification_410" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_410" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_410" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_410" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_410" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_410" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_410" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:title="00000029 - Disclosure - Schedule of Long-term Debt (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:title="00000030 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtDetailsNarrative" xlink:title="00000031 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LoanAgreementMember" xlink:label="loc_CELCLoanAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCLoanAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_AmendedLoanAgreementMember" xlink:label="loc_CELCAmendedLoanAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCAmendedLoanAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_OriginalAndAmendedLoanAgreementMember" xlink:label="loc_CELCOriginalAndAmendedLoanAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCOriginalAndAmendedLoanAgreementMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_InnovatusLifeSciencesMember" xlink:label="loc_CELCInnovatusLifeSciencesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELCInnovatusLifeSciencesMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LoanAgreementMember" xlink:label="loc_CELCLoanAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCLoanAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_AmendedLoanAgreementMember" xlink:label="loc_CELCAmendedLoanAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCAmendedLoanAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermBLoanMember" xlink:label="loc_CELCTermBLoanMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermBLoanMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermCLoanMember" xlink:label="loc_CELCTermCLoanMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermCLoanMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermDLoanMember" xlink:label="loc_CELCTermDLoanMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermDLoanMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermELoanMember" xlink:label="loc_CELCTermELoanMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermELoanMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_NonContingentTermALoanFunded" xlink:label="loc_CELCNonContingentTermALoanFunded_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCNonContingentTermALoanFunded_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo" xlink:label="loc_CELCTermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCTermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree" xlink:label="loc_CELCTermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCTermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_FinalFeePayableToLenderAmount" xlink:label="loc_CELCFinalFeePayableToLenderAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCFinalFeePayableToLenderAmount_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IncreaseFromOriginalLoanAmount" xlink:label="loc_CELCIncreaseFromOriginalLoanAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCIncreaseFromOriginalLoanAmount_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_UnfundedContingentLoanAmount" xlink:label="loc_CELCUnfundedContingentLoanAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCUnfundedContingentLoanAmount_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_150" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LoanConvertibleToStockPercentageDescription" xlink:label="loc_CELCLoanConvertibleToStockPercentageDescription_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCLoanConvertibleToStockPercentageDescription_150" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms_150" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PrepaymentFeePercentage" xlink:label="loc_CELCPrepaymentFeePercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCPrepaymentFeePercentage_150" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet_150" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://celcuity.com/role/LicenseAgreementDetailsNarrative" xlink:title="00000032 - Disclosure - License Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LicenseAgreementMember" xlink:label="loc_CELCLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PfizerIncMember" xlink:label="loc_CELCPfizerIncMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CELCPfizerIncMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_UpfrontFees" xlink:label="loc_CELCUpfrontFees_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCUpfrontFees_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant" xlink:label="loc_CELCStockIssuedDuringPeriodValueNewIssuesForEquityGrant_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueNewIssuesForEquityGrant_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_MilestonePayable" xlink:label="loc_CELCMilestonePayable_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCMilestonePayable_40" xlink:type="arc" order="2" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>celc-20220930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_SecuritiesPurchaseAgreementMember" xlink:label="CELC_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SecuritiesPurchaseAgreementMember" xlink:to="CELC_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PurchaseAgreementMember" xlink:label="CELC_PurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PurchaseAgreementMember" xlink:to="CELC_PurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PurchaseAgreementMember_lbl" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_OpenMarketSaleAgreementMember" xlink:label="CELC_OpenMarketSaleAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OpenMarketSaleAgreementMember" xlink:to="CELC_OpenMarketSaleAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_OpenMarketSaleAgreementMember_lbl" xml:lang="en-US">Open Market Sale Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_JefferiesLLCMember" xlink:label="CELC_JefferiesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_JefferiesLLCMember" xlink:to="CELC_JefferiesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_JefferiesLLCMember_lbl" xml:lang="en-US">Jefferies LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_FollowOnOfferingMember" xlink:label="CELC_FollowOnOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FollowOnOfferingMember" xlink:to="CELC_FollowOnOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_FollowOnOfferingMember_lbl" xml:lang="en-US">Follow-on Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_UnderwriterMember" xlink:label="CELC_UnderwriterMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_UnderwriterMember" xlink:to="CELC_UnderwriterMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_UnderwriterMember_lbl" xml:lang="en-US">Underwriter [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:label="us-gaap_OtherInvestmentNotReadilyMarketableAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:to="us-gaap_OtherInvestmentNotReadilyMarketableAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherInvestmentNotReadilyMarketableAxis_lbl" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_AtmAgreementMember" xlink:label="CELC_AtmAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AtmAgreementMember" xlink:to="CELC_AtmAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AtmAgreementMember_lbl" xml:lang="en-US">ATM Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PlacementSharesMember" xlink:label="CELC_PlacementSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PlacementSharesMember" xlink:to="CELC_PlacementSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PlacementSharesMember_lbl" xml:lang="en-US">Placement Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_InMayTwoThousandTwentyTwoMember" xlink:label="CELC_InMayTwoThousandTwentyTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InMayTwoThousandTwentyTwoMember" xlink:to="CELC_InMayTwoThousandTwentyTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_InMayTwoThousandTwentyTwoMember_lbl" xml:lang="en-US">In May 2022 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_InDecemberTwoThousandTwentyOneMember" xlink:label="CELC_InDecemberTwoThousandTwentyOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InDecemberTwoThousandTwentyOneMember" xlink:to="CELC_InDecemberTwoThousandTwentyOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_InDecemberTwoThousandTwentyOneMember_lbl" xml:lang="en-US">In December 2021 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_InMayTwoThousandTwentyMember" xlink:label="CELC_InMayTwoThousandTwentyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InMayTwoThousandTwentyMember" xlink:to="CELC_InMayTwoThousandTwentyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_InMayTwoThousandTwentyMember_lbl" xml:lang="en-US">In May 2020 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TwoThousandSeventeenPlanMember" xlink:label="CELC_TwoThousandSeventeenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TwoThousandSeventeenPlanMember" xlink:to="CELC_TwoThousandSeventeenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TwoThousandSeventeenPlanMember_lbl" xml:lang="en-US">2017 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeStockPurchasePlanMember" xlink:label="CELC_EmployeeStockPurchasePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeStockPurchasePlanMember" xlink:to="CELC_EmployeeStockPurchasePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LoanAgreementMember" xlink:label="CELC_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LoanAgreementMember" xlink:to="CELC_LoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_LoanAgreementMember_lbl" xml:lang="en-US">Security and Loan agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_InnovatusLifeSciencesMember" xlink:label="CELC_InnovatusLifeSciencesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InnovatusLifeSciencesMember" xlink:to="CELC_InnovatusLifeSciencesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_InnovatusLifeSciencesMember_lbl" xml:lang="en-US">Innovatus Life Sciences [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_AmendedLoanAgreementMember" xlink:label="CELC_AmendedLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AmendedLoanAgreementMember" xlink:to="CELC_AmendedLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AmendedLoanAgreementMember_lbl" xml:lang="en-US">Amended Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermBLoanMember" xlink:label="CELC_TermBLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermBLoanMember" xlink:to="CELC_TermBLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermBLoanMember_lbl" xml:lang="en-US">Term B Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermCLoanMember" xlink:label="CELC_TermCLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermCLoanMember" xlink:to="CELC_TermCLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermCLoanMember_lbl" xml:lang="en-US">Term C Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermDLoanMember" xlink:label="CELC_TermDLoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermDLoanMember" xlink:to="CELC_TermDLoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermDLoanMember_lbl" xml:lang="en-US">Term D Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermELoanMember" xlink:label="CELC_TermELoanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermELoanMember" xlink:to="CELC_TermELoanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermELoanMember_lbl" xml:lang="en-US">Term E Loan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_OriginalAndAmendedLoanAgreementMember" xlink:label="CELC_OriginalAndAmendedLoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OriginalAndAmendedLoanAgreementMember" xlink:to="CELC_OriginalAndAmendedLoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_OriginalAndAmendedLoanAgreementMember_lbl" xml:lang="en-US">Original and Amended Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LicenseAgreementMember" xlink:label="CELC_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicenseAgreementMember" xlink:to="CELC_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PfizerIncMember" xlink:label="CELC_PfizerIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PfizerIncMember" xlink:to="CELC_PfizerIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PfizerIncMember_lbl" xml:lang="en-US">Pfizer, Inc. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred transaction costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PayrollTaxReceivable" xlink:label="CELC_PayrollTaxReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PayrollTaxReceivable" xlink:to="CELC_PayrollTaxReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PayrollTaxReceivable_lbl" xml:lang="en-US">Payroll tax receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable, non-current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 4)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value: 2,500,000 shares authorized; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value: 65,000,000 and 25,000,000 shares authorized as of September 30, 2022 and December 31, 2021, respectively; 14,942,958 and 14,918,887 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par or stated value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par or stated value per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xml:lang="en-US">Loss on sale of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income (expense), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options, net of shares withheld for exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of common stock options, net of shares withheld for exercise price, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US">Employee stock purchases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US">Employee stock purchases, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised_lbl" xml:lang="en-US">Exercise of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised_lbl" xml:lang="en-US">Exercise of common stock warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock in an at-the-market (&#8220;ATM&#8221;) offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock in an at-the-market ("ATM") offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Issuance costs associated with ATM offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Issuance of common stock warrants, note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" xlink:label="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" xlink:to="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement_lbl" xml:lang="en-US">Issuance of common stock, licensing agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares" xlink:label="CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares" xlink:to="CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares_lbl" xml:lang="en-US">Issuance of common stock, licensing agreement, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used for operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IssuanceOfCommonStockLicensingAgreement" xlink:label="CELC_IssuanceOfCommonStockLicensingAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IssuanceOfCommonStockLicensingAgreement" xlink:to="CELC_IssuanceOfCommonStockLicensingAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELC_IssuanceOfCommonStockLicensingAgreement_lbl" xml:lang="en-US">Issuance of common stock, licensing agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaidInKindInterest_lbl" xml:lang="en-US">Payment-in-Kind interest</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:label="CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:to="CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense_lbl" xml:lang="en-US">Non-cash operating lease, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_2_lbl" xml:lang="en-US">Loss on sale of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IncreaseDecreaseInPayrollTaxReceivable" xlink:label="CELC_IncreaseDecreaseInPayrollTaxReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IncreaseDecreaseInPayrollTaxReceivable" xlink:to="CELC_IncreaseDecreaseInPayrollTaxReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELC_IncreaseDecreaseInPayrollTaxReceivable_lbl" xml:lang="en-US">Payroll tax receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid assets and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used for operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used for investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of common stock warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of employee stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_ProceedsFromEmployeeStockPurchases" xlink:label="CELC_ProceedsFromEmployeeStockPurchases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ProceedsFromEmployeeStockPurchases" xlink:to="CELC_ProceedsFromEmployeeStockPurchases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ProceedsFromEmployeeStockPurchases_lbl" xml:lang="en-US">Proceeds from employee stock purchases</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts_lbl" xml:lang="en-US">Proceeds from follow-on offering, net of underwriting discounts and offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from note payable, net of debt issuance costs and discount of $652,061</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Payments for debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_GrossProceedsFromAnAtmOffering" xlink:label="CELC_GrossProceedsFromAnAtmOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_GrossProceedsFromAnAtmOffering" xlink:to="CELC_GrossProceedsFromAnAtmOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_GrossProceedsFromAnAtmOffering_lbl" xml:lang="en-US">Gross proceeds from an ATM offering</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PaymentsForRegistrationStatementCosts" xlink:label="CELC_PaymentsForRegistrationStatementCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentsForRegistrationStatementCosts" xlink:to="CELC_PaymentsForRegistrationStatementCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELC_PaymentsForRegistrationStatementCosts_lbl" xml:lang="en-US">Payments for secondary registration statement costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PaymentsForFinanceLeases" xlink:label="CELC_PaymentsForFinanceLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentsForFinanceLeases" xlink:to="CELC_PaymentsForFinanceLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="CELC_PaymentsForFinanceLeases_lbl" xml:lang="en-US">Payments for finance leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash (used for) provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and cash equivalents:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">End of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PropertyAndEquipmentIncludedInAccountsPayable" xlink:label="CELC_PropertyAndEquipmentIncludedInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PropertyAndEquipmentIncludedInAccountsPayable" xlink:to="CELC_PropertyAndEquipmentIncludedInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PropertyAndEquipmentIncludedInAccountsPayable_lbl" xml:lang="en-US">Property and equipment included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:label="CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:to="CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable_lbl" xml:lang="en-US">Offering and registration statement costs included in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses" xlink:label="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses" xlink:to="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses_lbl" xml:lang="en-US">Deferred financing costs and offering and registration statement costs included in accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Issuance of common stock warrants and final fee recognized as discount to note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xml:lang="en-US">Debt issuance costs and discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_DisclosureLicenseAgreementAbstract" xlink:label="CELC_DisclosureLicenseAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DisclosureLicenseAgreementAbstract" xlink:to="CELC_DisclosureLicenseAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DisclosureLicenseAgreementAbstract_lbl" xml:lang="en-US">License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LicenseAgreementDisclosureTextBlock" xlink:label="CELC_LicenseAgreementDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicenseAgreementDisclosureTextBlock" xlink:to="CELC_LicenseAgreementDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CELC_LicenseAgreementDisclosureTextBlock_lbl" xml:lang="en-US">License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Clinical Trial Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" xlink:label="CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" xlink:to="CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_lbl" xml:lang="en-US">Application of New or Revised Accounting Standards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Options Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Assumptions for Fair Value of Equity-based Awards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xml:lang="en-US">Schedule of Unrecognized Compensation Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Long-term Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Long Term Debt Future Principal Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Incremental fair value of warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_DeemedDividend" xlink:label="CELC_DeemedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeemedDividend" xlink:to="CELC_DeemedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IncreasedNetLossPerShareBasicAndDiluted" xlink:label="CELC_IncreasedNetLossPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IncreasedNetLossPerShareBasicAndDiluted" xlink:to="CELC_IncreasedNetLossPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_IncreasedNetLossPerShareBasicAndDiluted_lbl" xml:lang="en-US">Increased net loss per share basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapital_lbl" xml:lang="en-US">Increase in operating ROU asset and lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Non-cancelable contractual commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Common stock issuable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrants maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EstimatedIncrementalFairValueOfWarrants" xlink:label="CELC_EstimatedIncrementalFairValueOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EstimatedIncrementalFairValueOfWarrants" xlink:to="CELC_EstimatedIncrementalFairValueOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EstimatedIncrementalFairValueOfWarrants_lbl" xml:lang="en-US">Estimated incremental fair value of the warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Issuance of public offering price per shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xml:lang="en-US">Conversion price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PercentageOfWarrantExercisePrice" xlink:label="CELC_PercentageOfWarrantExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PercentageOfWarrantExercisePrice" xlink:to="CELC_PercentageOfWarrantExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PercentageOfWarrantExercisePrice_lbl" xml:lang="en-US">Percentage of warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_SaleOfStockTransactionFee" xlink:label="CELC_SaleOfStockTransactionFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SaleOfStockTransactionFee" xlink:to="CELC_SaleOfStockTransactionFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_SaleOfStockTransactionFee_lbl" xml:lang="en-US">Incurred transaction fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate offering price, common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_CommissionPercentage" xlink:label="CELC_CommissionPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_CommissionPercentage" xlink:to="CELC_CommissionPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_CommissionPercentage_lbl" xml:lang="en-US">Aggregate offering price, commission percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of stock number of shares issued in transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses" xlink:label="CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses" xlink:to="CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses_lbl" xml:lang="en-US">Gross proceeds net of commissions and offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="us-gaap_PaymentsForUnderwritingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForUnderwritingExpense" xlink:to="us-gaap_PaymentsForUnderwritingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForUnderwritingExpense_lbl" xml:lang="en-US">Deducting underwriting discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Offering expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock par value</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_AverageSellingPricePerShare" xlink:label="CELC_AverageSellingPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AverageSellingPricePerShare" xlink:to="CELC_AverageSellingPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_AverageSellingPricePerShare_lbl" xml:lang="en-US">Average selling price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options outstanding shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Options outstanding shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options outstanding shares, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercisable, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value for options granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding, weighted average remaining contractual life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Options outstanding, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options exercisable, weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total estimated compensation cost to be recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Recognized stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockOptionAwardsSharesModified" xlink:label="CELC_StockOptionAwardsSharesModified" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockOptionAwardsSharesModified" xlink:to="CELC_StockOptionAwardsSharesModified_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockOptionAwardsSharesModified_lbl" xml:lang="en-US">Stock option awards shares modified</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_ModifiedStockOptionExercisePrice" xlink:label="CELC_ModifiedStockOptionExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ModifiedStockOptionExercisePrice" xlink:to="CELC_ModifiedStockOptionExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_ModifiedStockOptionExercisePrice_lbl" xml:lang="en-US">Stock option exercise price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US">Stock based compensation expense related to modification</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:label="CELC_RemainingStockBasedCompensationExpenseRelatedToModification" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:to="CELC_RemainingStockBasedCompensationExpenseRelatedToModification_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_RemainingStockBasedCompensationExpenseRelatedToModification_lbl" xml:lang="en-US">Remaining stock based compensation expense related to modification</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Restricted stock awards outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Restricted stock awards vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock, shares reserved for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Stock option description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares authorized under plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PaymentInKindInterestDebt" xlink:label="CELC_PaymentInKindInterestDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentInKindInterestDebt" xlink:to="CELC_PaymentInKindInterestDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PaymentInKindInterestDebt_lbl" xml:lang="en-US">Add: Payment-in-Kind interest (added to principal)</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_NotesPayableFinalFee" xlink:label="CELC_NotesPayableFinalFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_NotesPayableFinalFee" xlink:to="CELC_NotesPayableFinalFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_NotesPayableFinalFee_lbl" xml:lang="en-US">Add: final fee</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Less: unamortized debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Less: unamortized debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermNotesPayable_2_lbl" xml:lang="en-US">Total long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of credit faciltiy, maximum borrowing capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_NonContingentTermALoanFunded" xlink:label="CELC_NonContingentTermALoanFunded" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_NonContingentTermALoanFunded" xlink:to="CELC_NonContingentTermALoanFunded_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_NonContingentTermALoanFunded_lbl" xml:lang="en-US">Non contigent term A loan, funded</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo" xlink:label="CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo" xlink:to="CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo_lbl" xml:lang="en-US">Term B loan to be funded before March 31, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree" xlink:label="CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree" xlink:to="CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree_lbl" xml:lang="en-US">Term C loan to be funded before March 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xml:lang="en-US">Warrant or Right, Reason for Issuance, Description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_FinalFeePayableToLenderAmount" xlink:label="CELC_FinalFeePayableToLenderAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinalFeePayableToLenderAmount" xlink:to="CELC_FinalFeePayableToLenderAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_FinalFeePayableToLenderAmount_lbl" xml:lang="en-US">Final fee payable to lender, amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Debt discount, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IncreaseFromOriginalLoanAmount" xlink:label="CELC_IncreaseFromOriginalLoanAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IncreaseFromOriginalLoanAmount" xlink:to="CELC_IncreaseFromOriginalLoanAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_IncreaseFromOriginalLoanAmount_lbl" xml:lang="en-US">Increase from original loan amount</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_UnfundedContingentLoanAmount" xlink:label="CELC_UnfundedContingentLoanAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_UnfundedContingentLoanAmount" xlink:to="CELC_UnfundedContingentLoanAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_UnfundedContingentLoanAmount_lbl" xml:lang="en-US">Unfunded contingent loan, amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LoanConvertibleToStockPercentageDescription" xlink:label="CELC_LoanConvertibleToStockPercentageDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LoanConvertibleToStockPercentageDescription" xlink:to="CELC_LoanConvertibleToStockPercentageDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_LoanConvertibleToStockPercentageDescription_lbl" xml:lang="en-US">Loan convertible to stock percentage, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US">Debt instrument interest rate description</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PrepaymentFeePercentage" xlink:label="CELC_PrepaymentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PrepaymentFeePercentage" xlink:to="CELC_PrepaymentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PrepaymentFeePercentage_lbl" xml:lang="en-US">Prepayment fee, percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_UpfrontFees" xlink:label="CELC_UpfrontFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_UpfrontFees" xlink:to="CELC_UpfrontFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_UpfrontFees_lbl" xml:lang="en-US">Upfront fees</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant" xlink:label="CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant" xlink:to="CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant_lbl" xml:lang="en-US">Value of shares issued for equity grant</link:label>
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_MilestonePayable" xlink:label="CELC_MilestonePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_MilestonePayable" xlink:to="CELC_MilestonePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_MilestonePayable_lbl" xml:lang="en-US">Milestone payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised_doc" xml:lang="en-US">Stock issued during period shares stock warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodValueStockWarrantsExercised_doc" xml:lang="en-US">Stock issued during period value stock warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" xlink:to="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement_doc" xml:lang="en-US">Issuance of common stock for agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares" xlink:to="CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares_doc" xml:lang="en-US">Issuance of common stock for agreement, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IssuanceOfCommonStockLicensingAgreement" xlink:to="CELC_IssuanceOfCommonStockLicensingAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_IssuanceOfCommonStockLicensingAgreement_doc" xml:lang="en-US">Issuance of common stock for agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:to="CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense_doc" xml:lang="en-US">Increase decrease in non cash operating lease expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ProceedsFromEmployeeStockPurchases" xlink:to="CELC_ProceedsFromEmployeeStockPurchases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ProceedsFromEmployeeStockPurchases_doc" xml:lang="en-US">Proceeds from employee stock purchases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:to="CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts_doc" xml:lang="en-US">Proceeds from follow on offering net of underwriting discounts and offering costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_GrossProceedsFromAnAtmOffering" xlink:to="CELC_GrossProceedsFromAnAtmOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_GrossProceedsFromAnAtmOffering_doc" xml:lang="en-US">Gross proceeds from an Atm offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentsForRegistrationStatementCosts" xlink:to="CELC_PaymentsForRegistrationStatementCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PaymentsForRegistrationStatementCosts_doc" xml:lang="en-US">Payments for registration statement costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentsForFinanceLeases" xlink:to="CELC_PaymentsForFinanceLeases_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PaymentsForFinanceLeases_doc" xml:lang="en-US">Payments for finance leases.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:to="CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable_doc" xml:lang="en-US">Offering and registration statement costs included in accounts payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PropertyAndEquipmentIncludedInAccountsPayable" xlink:to="CELC_PropertyAndEquipmentIncludedInAccountsPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PropertyAndEquipmentIncludedInAccountsPayable_doc" xml:lang="en-US">Property and equipment included in accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses" xlink:to="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses_doc" xml:lang="en-US">Deferred financing costs and offering and registration statement costs included in accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" xlink:to="CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_doc" xml:lang="en-US">Application Of New Or Revised Accounting Standards [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_DeemedDividend" xlink:to="CELC_DeemedDividend_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_DeemedDividend_doc" xml:lang="en-US">Deemed dividend</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IncreasedNetLossPerShareBasicAndDiluted" xlink:to="CELC_IncreasedNetLossPerShareBasicAndDiluted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_IncreasedNetLossPerShareBasicAndDiluted_doc" xml:lang="en-US">Increased net loss per share basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PurchaseAgreementMember" xlink:to="CELC_PurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PurchaseAgreementMember_doc" xml:lang="en-US">Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PercentageOfWarrantExercisePrice" xlink:to="CELC_PercentageOfWarrantExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PercentageOfWarrantExercisePrice_doc" xml:lang="en-US">Percentage of warrant exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OpenMarketSaleAgreementMember" xlink:to="CELC_OpenMarketSaleAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_OpenMarketSaleAgreementMember_doc" xml:lang="en-US">Open Market Sale Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_JefferiesLLCMember" xlink:to="CELC_JefferiesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_JefferiesLLCMember_doc" xml:lang="en-US">Jefferies LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_CommissionPercentage" xlink:to="CELC_CommissionPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_CommissionPercentage_doc" xml:lang="en-US">Commission percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FollowOnOfferingMember" xlink:to="CELC_FollowOnOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_FollowOnOfferingMember_doc" xml:lang="en-US">Follow-on Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_UnderwriterMember" xlink:to="CELC_UnderwriterMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_UnderwriterMember_doc" xml:lang="en-US">Underwriter [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AtmAgreementMember" xlink:to="CELC_AtmAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AtmAgreementMember_doc" xml:lang="en-US">ATM Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PlacementSharesMember" xlink:to="CELC_PlacementSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PlacementSharesMember_doc" xml:lang="en-US">Placement Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AverageSellingPricePerShare" xlink:to="CELC_AverageSellingPricePerShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AverageSellingPricePerShare_doc" xml:lang="en-US">Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockOptionAwardsSharesModified" xlink:to="CELC_StockOptionAwardsSharesModified_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockOptionAwardsSharesModified_doc" xml:lang="en-US">Stock option awards shares modified.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InMayTwoThousandTwentyTwoMember" xlink:to="CELC_InMayTwoThousandTwentyTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_InMayTwoThousandTwentyTwoMember_doc" xml:lang="en-US">In May 2022 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_ModifiedStockOptionExercisePrice" xlink:to="CELC_ModifiedStockOptionExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_ModifiedStockOptionExercisePrice_doc" xml:lang="en-US">Modified stock option exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:to="CELC_RemainingStockBasedCompensationExpenseRelatedToModification_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_RemainingStockBasedCompensationExpenseRelatedToModification_doc" xml:lang="en-US">Remaining stock based compensation expense related to modification.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InDecemberTwoThousandTwentyOneMember" xlink:to="CELC_InDecemberTwoThousandTwentyOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_InDecemberTwoThousandTwentyOneMember_doc" xml:lang="en-US">In December 2021 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InMayTwoThousandTwentyMember" xlink:to="CELC_InMayTwoThousandTwentyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_InMayTwoThousandTwentyMember_doc" xml:lang="en-US">In May 2020 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TwoThousandSeventeenPlanMember" xlink:to="CELC_TwoThousandSeventeenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TwoThousandSeventeenPlanMember_doc" xml:lang="en-US">2017 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeStockPurchasePlanMember" xlink:to="CELC_EmployeeStockPurchasePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EmployeeStockPurchasePlanMember_doc" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_doc" xml:lang="en-US">Employee service share based compensation non vested awards compensation cost not yet recognized remainder of fiscal year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear_doc" xml:lang="en-US">Employee service share based compensation non vested awards compensation cost not yet recognized within two years.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_doc" xml:lang="en-US">Employee service share based compensation non vested awards compensation cost not yet recognized within three years.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_doc" xml:lang="en-US">Employee service share based compensation non vested awards compensation cost not yet recognized within four years.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" xlink:to="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_doc" xml:lang="en-US">Employee service share based compensation non vested awards compensation cost not yet recognized within five years.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LoanAgreementMember" xlink:to="CELC_LoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_LoanAgreementMember_doc" xml:lang="en-US">Security and Loan agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_InnovatusLifeSciencesMember" xlink:to="CELC_InnovatusLifeSciencesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_InnovatusLifeSciencesMember_doc" xml:lang="en-US">Innovatus Life Sciences [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_NonContingentTermALoanFunded" xlink:to="CELC_NonContingentTermALoanFunded_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_NonContingentTermALoanFunded_doc" xml:lang="en-US">Non contingent term A loan, funded.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo" xlink:to="CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo_doc" xml:lang="en-US">Term B loan to be funded.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree" xlink:to="CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree_doc" xml:lang="en-US">Term C loan to be funded.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IncreaseFromOriginalLoanAmount" xlink:to="CELC_IncreaseFromOriginalLoanAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_IncreaseFromOriginalLoanAmount_doc" xml:lang="en-US">Increase from the original loan amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_UnfundedContingentLoanAmount" xlink:to="CELC_UnfundedContingentLoanAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_UnfundedContingentLoanAmount_doc" xml:lang="en-US">Unfunded contingent loan amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermBLoanMember" xlink:to="CELC_TermBLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermBLoanMember_doc" xml:lang="en-US">Term B Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermCLoanMember" xlink:to="CELC_TermCLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermCLoanMember_doc" xml:lang="en-US">Term C Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermELoanMember" xlink:to="CELC_TermELoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermELoanMember_doc" xml:lang="en-US">Term E Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LoanConvertibleToStockPercentageDescription" xlink:to="CELC_LoanConvertibleToStockPercentageDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_LoanConvertibleToStockPercentageDescription_doc" xml:lang="en-US">Loan convertible to stock percentage description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PrepaymentFeePercentage" xlink:to="CELC_PrepaymentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PrepaymentFeePercentage_doc" xml:lang="en-US">Prepayment fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentInKindInterestDebt" xlink:to="CELC_PaymentInKindInterestDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PaymentInKindInterestDebt_doc" xml:lang="en-US">Payment in kind interest debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_NotesPayableFinalFee" xlink:to="CELC_NotesPayableFinalFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_NotesPayableFinalFee_doc" xml:lang="en-US">Notes payable final fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicenseAgreementDisclosureTextBlock" xlink:to="CELC_LicenseAgreementDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_LicenseAgreementDisclosureTextBlock_doc" xml:lang="en-US">License agreement disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_UpfrontFees" xlink:to="CELC_UpfrontFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_UpfrontFees_doc" xml:lang="en-US">Upfront fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicenseAgreementMember" xlink:to="CELC_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_MilestonePayable" xlink:to="CELC_MilestonePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_MilestonePayable_doc" xml:lang="en-US">Milestone payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PfizerIncMember" xlink:to="CELC_PfizerIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PfizerIncMember_doc" xml:lang="en-US">Pfizer, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_TermDLoanMember" xlink:to="CELC_TermDLoanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_TermDLoanMember_doc" xml:lang="en-US">Term D Loan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SecuritiesPurchaseAgreementMember" xlink:to="CELC_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_SaleOfStockTransactionFee" xlink:to="CELC_SaleOfStockTransactionFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_SaleOfStockTransactionFee_doc" xml:lang="en-US">Sale of stock transaction fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_AmendedLoanAgreementMember" xlink:to="CELC_AmendedLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_AmendedLoanAgreementMember_doc" xml:lang="en-US">Amended Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_OriginalAndAmendedLoanAgreementMember" xlink:to="CELC_OriginalAndAmendedLoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_OriginalAndAmendedLoanAgreementMember_doc" xml:lang="en-US">Original and Amended Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PayrollTaxReceivable" xlink:to="CELC_PayrollTaxReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_PayrollTaxReceivable_doc" xml:lang="en-US">Payroll tax receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IncreaseDecreaseInPayrollTaxReceivable" xlink:to="CELC_IncreaseDecreaseInPayrollTaxReceivable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_IncreaseDecreaseInPayrollTaxReceivable_doc" xml:lang="en-US">Increase decrease in payroll tax receivable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses" xlink:to="CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses_doc" xml:lang="en-US">Gross proceeds net of commissions and offering expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_FinalFeePayableToLenderAmount" xlink:to="CELC_FinalFeePayableToLenderAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_FinalFeePayableToLenderAmount_doc" xml:lang="en-US">Final fee payable to lender, amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant" xlink:to="CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant_doc" xml:lang="en-US">Value of shares issued for equity grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_EstimatedIncrementalFairValueOfWarrants" xlink:to="CELC_EstimatedIncrementalFairValueOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CELC_EstimatedIncrementalFairValueOfWarrants_doc" xml:lang="en-US">Estimated incremental fair value of the warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IssuanceOfCommonStockLicensingAgreement" xlink:to="CELC_IssuanceOfCommonStockLicensingAgreement_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_IssuanceOfCommonStockLicensingAgreement_3_lbl" xml:lang="en-US">IssuanceOfCommonStockLicensingAgreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_IncreaseDecreaseInPayrollTaxReceivable" xlink:to="CELC_IncreaseDecreaseInPayrollTaxReceivable_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_IncreaseDecreaseInPayrollTaxReceivable_3_lbl" xml:lang="en-US">IncreaseDecreaseInPayrollTaxReceivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_2_lbl" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentsForRegistrationStatementCosts" xlink:to="CELC_PaymentsForRegistrationStatementCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PaymentsForRegistrationStatementCosts_3_lbl" xml:lang="en-US">PaymentsForRegistrationStatementCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_PaymentsForFinanceLeases" xlink:to="CELC_PaymentsForFinanceLeases_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_PaymentsForFinanceLeases_3_lbl" xml:lang="en-US">PaymentsForFinanceLeases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CELC_LicenseAgreementDisclosureTextBlock" xlink:to="CELC_LicenseAgreementDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CELC_LicenseAgreementDisclosureTextBlock_3_lbl" xml:lang="en-US">License agreement disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2_lbl" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long-Term Debt</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>celc-20220930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.16b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://celcuity.com/role/Cover" xlink:href="celc-20220930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BalanceSheets" xlink:href="celc-20220930.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:href="celc-20220930.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfOperations" xlink:href="celc-20220930.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="celc-20220930.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfCashFlows" xlink:href="celc-20220930.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:href="celc-20220930.xsd#StatementsOfCashFlowsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Organization" xlink:href="celc-20220930.xsd#Organization" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:href="celc-20220930.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShare" xlink:href="celc-20220930.xsd#NetLossPerCommonShare" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Commitments" xlink:href="celc-20220930.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquity" xlink:href="celc-20220930.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensation" xlink:href="celc-20220930.xsd#Stock-basedCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Debt" xlink:href="celc-20220930.xsd#Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/LicenseAgreement" xlink:href="celc-20220930.xsd#LicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:href="celc-20220930.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensationTables" xlink:href="celc-20220930.xsd#Stock-basedCompensationTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/DebtTables" xlink:href="celc-20220930.xsd#DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:href="celc-20220930.xsd#BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:href="celc-20220930.xsd#NetLossPerCommonShareDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:href="celc-20220930.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:href="celc-20220930.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:href="celc-20220930.xsd#ScheduleOfStockOptionsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:href="celc-20220930.xsd#ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:href="celc-20220930.xsd#ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" xlink:href="celc-20220930.xsd#ScheduleOfUnrecognizedCompensationCostDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:href="celc-20220930.xsd#ScheduleOfStock-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:href="celc-20220930.xsd#Stock-basedCompensationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:href="celc-20220930.xsd#ScheduleOfLong-termDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:href="celc-20220930.xsd#ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/DebtDetailsNarrative" xlink:href="celc-20220930.xsd#DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://celcuity.com/role/LicenseAgreementDetailsNarrative" xlink:href="celc-20220930.xsd#LicenseAgreementDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PayrollTaxReceivable" xlink:label="loc_CELCPayrollTaxReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_CELCPayrollTaxReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapFinanceLeaseLiabilityNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapFinanceLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_CELCStockIssuedDuringPeriodValueStockWarrantsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueStockWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_CELCStockIssuedDuringPeriodSharesStockWarrantsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" xlink:label="loc_CELCStockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares" xlink:label="loc_CELCStockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IssuanceOfCommonStockLicensingAgreement" xlink:label="loc_CELCIssuanceOfCommonStockLicensingAgreement" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELCIssuanceOfCommonStockLicensingAgreement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest" xlink:label="loc_us-gaapPaidInKindInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapPaidInKindInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:label="loc_CELCIncreaseDecreaseInNonCashOperatingLeaseExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CELCIncreaseDecreaseInNonCashOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaapGainLossOnDispositionOfAssets1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnDispositionOfAssets1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IncreaseDecreaseInPayrollTaxReceivable" xlink:label="loc_CELCIncreaseDecreaseInPayrollTaxReceivable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_CELCIncreaseDecreaseInPayrollTaxReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_ProceedsFromEmployeeStockPurchases" xlink:label="loc_CELCProceedsFromEmployeeStockPurchases" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELCProceedsFromEmployeeStockPurchases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:label="loc_CELCProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELCProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_GrossProceedsFromAnAtmOffering" xlink:label="loc_CELCGrossProceedsFromAnAtmOffering" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELCGrossProceedsFromAnAtmOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PaymentsForRegistrationStatementCosts" xlink:label="loc_CELCPaymentsForRegistrationStatementCosts" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELCPaymentsForRegistrationStatementCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PaymentsForFinanceLeases" xlink:label="loc_CELCPaymentsForFinanceLeases" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_CELCPaymentsForFinanceLeases" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaapCashAndCashEquivalentsAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PropertyAndEquipmentIncludedInAccountsPayable" xlink:label="loc_CELCPropertyAndEquipmentIncludedInAccountsPayable" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CELCPropertyAndEquipmentIncludedInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:label="loc_CELCOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CELCOfferingAndRegistrationStatementCostsIncludedInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses" xlink:label="loc_CELCDeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_CELCDeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StatementsOfCashFlowsParenthetical" xlink:title="00000007 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Organization" xlink:title="00000008 - Disclosure - Organization">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements" xlink:title="00000009 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShare" xlink:title="00000010 - Disclosure - Net Loss Per Common Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Commitments" xlink:title="00000011 - Disclosure - Commitments">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquity" xlink:title="00000012 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensation" xlink:title="00000013 - Disclosure - Stock-Based Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Debt" xlink:title="00000014 - Disclosure - Debt">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/LicenseAgreement" xlink:title="00000015 - Disclosure - License Agreement">
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_DisclosureLicenseAgreementAbstract" xlink:label="loc_CELCDisclosureLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LicenseAgreementDisclosureTextBlock" xlink:label="loc_CELCLicenseAgreementDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCDisclosureLicenseAgreementAbstract" xlink:to="loc_CELCLicenseAgreementDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies" xlink:title="00000016 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" xlink:label="loc_CELCApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CELCApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationTables" xlink:title="00000017 - Disclosure - Stock-Based Compensation (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtTables" xlink:title="00000018 - Disclosure - Debt (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative" xlink:title="00000019 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative" xlink:title="00000020 - Disclosure - Net Loss Per Common Share (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_DeemedDividend" xlink:label="loc_CELCDeemedDividend" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_CELCDeemedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IncreasedNetLossPerShareBasicAndDiluted" xlink:label="loc_CELCIncreasedNetLossPerShareBasicAndDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_CELCIncreasedNetLossPerShareBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/CommitmentsDetailsNarrative" xlink:title="00000021 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaapContractualObligation" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapContractualObligation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000022 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_SecuritiesPurchaseAgreementMember" xlink:label="loc_CELCSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PurchaseAgreementMember" xlink:label="loc_CELCPurchaseAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_OpenMarketSaleAgreementMember" xlink:label="loc_CELCOpenMarketSaleAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCOpenMarketSaleAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_deiLegalEntityAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_JefferiesLLCMember" xlink:label="loc_CELCJefferiesLLCMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CELCJefferiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_FollowOnOfferingMember" xlink:label="loc_CELCFollowOnOfferingMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_CELCFollowOnOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_UnderwriterMember" xlink:label="loc_CELCUnderwriterMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_CELCUnderwriterMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:label="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:label="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherInvestmentNotReadilyMarketableAxis" xlink:to="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_AtmAgreementMember" xlink:label="loc_CELCAtmAgreementMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherInvestmentNotReadilyMarketableNameDomain" xlink:to="loc_CELCAtmAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRestatementAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PlacementSharesMember" xlink:label="loc_CELCPlacementSharesMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_CELCPlacementSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EstimatedIncrementalFairValueOfWarrants" xlink:label="loc_CELCEstimatedIncrementalFairValueOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CELCEstimatedIncrementalFairValueOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaapPreferredStockConvertibleConversionPrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPreferredStockConvertibleConversionPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PercentageOfWarrantExercisePrice" xlink:label="loc_CELCPercentageOfWarrantExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CELCPercentageOfWarrantExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_SaleOfStockTransactionFee" xlink:label="loc_CELCSaleOfStockTransactionFee" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CELCSaleOfStockTransactionFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_CommissionPercentage" xlink:label="loc_CELCCommissionPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CELCCommissionPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses" xlink:label="loc_CELCGrossProceedsNetOfCommissionsAndOfferingExpenses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CELCGrossProceedsNetOfCommissionsAndOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForUnderwritingExpense" xlink:label="loc_us-gaapPaymentsForUnderwritingExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsForUnderwritingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_AverageSellingPricePerShare" xlink:label="loc_CELCAverageSellingPricePerShare" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_CELCAverageSellingPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails" xlink:title="00000023 - Disclosure - Schedule of Stock Options Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails" xlink:title="00000024 - Disclosure - Schedule of Stock Options Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails" xlink:title="00000025 - Disclosure - Schedule of Assumptions for Fair Value of Equity-based Awards (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails" xlink:title="00000026 - Disclosure - Schedule of Unrecognized Compensation Cost (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" xlink:label="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CELCEmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails" xlink:title="00000027 - Disclosure - Schedule of Stock-based Compensation Expense (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/Stock-basedCompensationDetailsNarrative" xlink:title="00000028 - Disclosure - Stock-Based Compensation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_EmployeeStockPurchasePlanMember" xlink:label="loc_CELCEmployeeStockPurchasePlanMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CELCEmployeeStockPurchasePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_InMayTwoThousandTwentyTwoMember" xlink:label="loc_CELCInMayTwoThousandTwentyTwoMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_CELCInMayTwoThousandTwentyTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_InDecemberTwoThousandTwentyOneMember" xlink:label="loc_CELCInDecemberTwoThousandTwentyOneMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_CELCInDecemberTwoThousandTwentyOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_InMayTwoThousandTwentyMember" xlink:label="loc_CELCInMayTwoThousandTwentyMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_CELCInMayTwoThousandTwentyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TwoThousandSeventeenPlanMember" xlink:label="loc_CELCTwoThousandSeventeenPlanMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCTwoThousandSeventeenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockOptionAwardsSharesModified" xlink:label="loc_CELCStockOptionAwardsSharesModified" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCStockOptionAwardsSharesModified" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_ModifiedStockOptionExercisePrice" xlink:label="loc_CELCModifiedStockOptionExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCModifiedStockOptionExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_RemainingStockBasedCompensationExpenseRelatedToModification" xlink:label="loc_CELCRemainingStockBasedCompensationExpenseRelatedToModification" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCRemainingStockBasedCompensationExpenseRelatedToModification" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLong-termDebtDetails" xlink:title="00000029 - Disclosure - Schedule of Long-term Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PaymentInKindInterestDebt" xlink:label="loc_CELCPaymentInKindInterestDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_CELCPaymentInKindInterestDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_NotesPayableFinalFee" xlink:label="loc_CELCNotesPayableFinalFee" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_CELCNotesPayableFinalFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails" xlink:title="00000030 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/DebtDetailsNarrative" xlink:title="00000031 - Disclosure - Debt (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LoanAgreementMember" xlink:label="loc_CELCLoanAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_AmendedLoanAgreementMember" xlink:label="loc_CELCAmendedLoanAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCAmendedLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_OriginalAndAmendedLoanAgreementMember" xlink:label="loc_CELCOriginalAndAmendedLoanAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CELCOriginalAndAmendedLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_InnovatusLifeSciencesMember" xlink:label="loc_CELCInnovatusLifeSciencesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CELCInnovatusLifeSciencesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LoanAgreementMember" xlink:label="loc_CELCLoanAgreementMember_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCLoanAgreementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_AmendedLoanAgreementMember" xlink:label="loc_CELCAmendedLoanAgreementMember_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCAmendedLoanAgreementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermBLoanMember" xlink:label="loc_CELCTermBLoanMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermBLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermCLoanMember" xlink:label="loc_CELCTermCLoanMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermCLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermDLoanMember" xlink:label="loc_CELCTermDLoanMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermDLoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermELoanMember" xlink:label="loc_CELCTermELoanMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CELCTermELoanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_NonContingentTermALoanFunded" xlink:label="loc_CELCNonContingentTermALoanFunded" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCNonContingentTermALoanFunded" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo" xlink:label="loc_CELCTermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCTermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree" xlink:label="loc_CELCTermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCTermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_FinalFeePayableToLenderAmount" xlink:label="loc_CELCFinalFeePayableToLenderAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCFinalFeePayableToLenderAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_IncreaseFromOriginalLoanAmount" xlink:label="loc_CELCIncreaseFromOriginalLoanAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCIncreaseFromOriginalLoanAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_UnfundedContingentLoanAmount" xlink:label="loc_CELCUnfundedContingentLoanAmount" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCUnfundedContingentLoanAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LoanConvertibleToStockPercentageDescription" xlink:label="loc_CELCLoanConvertibleToStockPercentageDescription" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCLoanConvertibleToStockPercentageDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:label="loc_us-gaapDebtInstrumentInterestRateTerms" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PrepaymentFeePercentage" xlink:label="loc_CELCPrepaymentFeePercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_CELCPrepaymentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://celcuity.com/role/LicenseAgreementDetailsNarrative" xlink:title="00000032 - Disclosure - License Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_DisclosureLicenseAgreementAbstract" xlink:label="loc_CELCDisclosureLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CELCDisclosureLicenseAgreementAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_LicenseAgreementMember" xlink:label="loc_CELCLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CELCLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_PfizerIncMember" xlink:label="loc_CELCPfizerIncMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CELCPfizerIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_UpfrontFees" xlink:label="loc_CELCUpfrontFees" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCUpfrontFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant" xlink:label="loc_CELCStockIssuedDuringPeriodValueNewIssuesForEquityGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCStockIssuedDuringPeriodValueNewIssuesForEquityGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="celc-20220930.xsd#CELC_MilestonePayable" xlink:label="loc_CELCMilestonePayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CELCMilestonePayable" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627646150512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Nov. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CELCUITY INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001603454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2863566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">16305
36th Avenue North; Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Minneapolis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(763)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">392-0767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CELC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,459,739<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627647955056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 57,483,776<span></span>
</td>
<td class="nump">$ 84,286,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">22,009<span></span>
</td>
<td class="nump">22,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred transaction costs</a></td>
<td class="nump">349,147<span></span>
</td>
<td class="nump">22,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PayrollTaxReceivable', window );">Payroll tax receivable</a></td>
<td class="nump">260,926<span></span>
</td>
<td class="nump">298,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid assets</a></td>
<td class="nump">6,578,252<span></span>
</td>
<td class="nump">722,677<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">64,694,110<span></span>
</td>
<td class="nump">85,351,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">302,005<span></span>
</td>
<td class="nump">312,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">295,535<span></span>
</td>
<td class="nump">241,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">65,291,650<span></span>
</td>
<td class="nump">85,906,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,168,198<span></span>
</td>
<td class="nump">1,507,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="nump">3,916<span></span>
</td>
<td class="nump">5,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">194,643<span></span>
</td>
<td class="nump">189,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,278,315<span></span>
</td>
<td class="nump">802,893<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,645,072<span></span>
</td>
<td class="nump">2,505,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">107,830<span></span>
</td>
<td class="nump">61,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, non-current</a></td>
<td class="nump">15,013,407<span></span>
</td>
<td class="nump">14,625,923<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">21,766,309<span></span>
</td>
<td class="nump">17,195,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value: 2,500,000 shares authorized; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 65,000,000 and 25,000,000 shares authorized as of September 30, 2022 and December 31, 2021, respectively; 14,942,958 and 14,918,887 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">14,943<span></span>
</td>
<td class="nump">14,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">128,225,939<span></span>
</td>
<td class="nump">124,622,405<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(84,715,541)<span></span>
</td>
<td class="num">(55,926,847)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">43,525,341<span></span>
</td>
<td class="nump">68,710,477<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 65,291,650<span></span>
</td>
<td class="nump">$ 85,906,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PayrollTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payroll tax receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PayrollTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627645888512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">65,000,000<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">14,942,958<span></span>
</td>
<td class="nump">14,918,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">14,942,958<span></span>
</td>
<td class="nump">14,918,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627645975680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 9,621,505<span></span>
</td>
<td class="nump">$ 4,960,515<span></span>
</td>
<td class="nump">$ 24,685,505<span></span>
</td>
<td class="nump">$ 20,266,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,022,050<span></span>
</td>
<td class="nump">639,271<span></span>
</td>
<td class="nump">3,066,382<span></span>
</td>
<td class="nump">1,768,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">10,643,555<span></span>
</td>
<td class="nump">5,599,786<span></span>
</td>
<td class="nump">27,751,887<span></span>
</td>
<td class="nump">22,035,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(10,643,555)<span></span>
</td>
<td class="num">(5,599,786)<span></span>
</td>
<td class="num">(27,751,887)<span></span>
</td>
<td class="num">(22,035,023)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(537,661)<span></span>
</td>
<td class="num">(433,072)<span></span>
</td>
<td class="num">(1,428,108)<span></span>
</td>
<td class="num">(824,283)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">287,495<span></span>
</td>
<td class="nump">5,612<span></span>
</td>
<td class="nump">391,301<span></span>
</td>
<td class="nump">7,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on sale of fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(250,166)<span></span>
</td>
<td class="num">(427,460)<span></span>
</td>
<td class="num">(1,036,807)<span></span>
</td>
<td class="num">(816,743)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(10,893,721)<span></span>
</td>
<td class="num">(6,027,246)<span></span>
</td>
<td class="num">(28,788,694)<span></span>
</td>
<td class="num">(22,851,766)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,893,721)<span></span>
</td>
<td class="num">$ (6,027,246)<span></span>
</td>
<td class="num">$ (28,788,694)<span></span>
</td>
<td class="num">$ (22,851,766)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (1.78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic and diluted</a></td>
<td class="nump">14,938,224<span></span>
</td>
<td class="nump">14,877,619<span></span>
</td>
<td class="nump">14,928,727<span></span>
</td>
<td class="nump">12,867,484<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627642678592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="nump">$ 38,013,551<span></span>
</td>
<td class="num">$ (26,321,581)<span></span>
</td>
<td class="nump">$ 11,702,270<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="nump">10,299,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">449,098<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">449,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price, shares</a></td>
<td class="nump">12,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,791,668)<span></span>
</td>
<td class="num">(2,791,668)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Exercise of common stock warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">11,256<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Exercise of common stock warrants, shares</a></td>
<td class="nump">1,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs</a></td>
<td class="nump">$ 1,971<span></span>
</td>
<td class="nump">25,766,522<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25,768,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares</a></td>
<td class="nump">1,971,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in an at-the-market (&#8220;ATM&#8221;) offering</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">38,959<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">38,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in an at-the-market ("ATM") offering, shares</a></td>
<td class="nump">3,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs associated with ATM offering</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(3,868)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,868)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 12,288<span></span>
</td>
<td class="nump">64,275,505<span></span>
</td>
<td class="num">(29,113,249)<span></span>
</td>
<td class="nump">35,174,544<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2021</a></td>
<td class="nump">12,287,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="nump">38,013,551<span></span>
</td>
<td class="num">(26,321,581)<span></span>
</td>
<td class="nump">11,702,270<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="nump">10,299,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,851,766)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 14,906<span></span>
</td>
<td class="nump">123,632,827<span></span>
</td>
<td class="num">(49,173,347)<span></span>
</td>
<td class="nump">74,474,386<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2021</a></td>
<td class="nump">14,905,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2021</a></td>
<td class="nump">$ 12,288<span></span>
</td>
<td class="nump">64,275,505<span></span>
</td>
<td class="num">(29,113,249)<span></span>
</td>
<td class="nump">35,174,544<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2021</a></td>
<td class="nump">12,287,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">540,314<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">540,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">2,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">36,850<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price, shares</a></td>
<td class="nump">9,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,032,852)<span></span>
</td>
<td class="num">(14,032,852)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchases</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">25,811<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchases, shares</a></td>
<td class="nump">5,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of common stock warrants, note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,839<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">289,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement', window );">Issuance of common stock, licensing agreement</a></td>
<td class="nump">$ 349<span></span>
</td>
<td class="nump">4,999,651<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares', window );">Issuance of common stock, licensing agreement, shares</a></td>
<td class="nump">349,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="nump">$ 12,655<span></span>
</td>
<td class="nump">70,167,970<span></span>
</td>
<td class="num">(43,146,101)<span></span>
</td>
<td class="nump">27,034,524<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="nump">12,654,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">699,916<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">699,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,099<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price, shares</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,027,246)<span></span>
</td>
<td class="num">(6,027,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs</a></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="nump">52,759,842<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">52,762,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares</a></td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2021</a></td>
<td class="nump">$ 14,906<span></span>
</td>
<td class="nump">123,632,827<span></span>
</td>
<td class="num">(49,173,347)<span></span>
</td>
<td class="nump">74,474,386<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2021</a></td>
<td class="nump">14,905,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 14,919<span></span>
</td>
<td class="nump">124,622,405<span></span>
</td>
<td class="num">(55,926,847)<span></span>
</td>
<td class="nump">68,710,477<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">14,918,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">756,271<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">756,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">7,413<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price, shares</a></td>
<td class="nump">1,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,934,447)<span></span>
</td>
<td class="num">(7,934,447)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 14,920<span></span>
</td>
<td class="nump">125,386,089<span></span>
</td>
<td class="num">(63,861,294)<span></span>
</td>
<td class="nump">61,539,715<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2022</a></td>
<td class="nump">14,920,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 14,919<span></span>
</td>
<td class="nump">124,622,405<span></span>
</td>
<td class="num">(55,926,847)<span></span>
</td>
<td class="nump">68,710,477<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="nump">14,918,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,788,694)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 14,943<span></span>
</td>
<td class="nump">128,225,939<span></span>
</td>
<td class="num">(84,715,541)<span></span>
</td>
<td class="nump">43,525,341<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="nump">14,942,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 14,920<span></span>
</td>
<td class="nump">125,386,089<span></span>
</td>
<td class="num">(63,861,294)<span></span>
</td>
<td class="nump">61,539,715<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2022</a></td>
<td class="nump">14,920,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,519,456<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,519,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">3,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">9,540<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price, shares</a></td>
<td class="nump">1,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,960,526)<span></span>
</td>
<td class="num">(9,960,526)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchases</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">80,525<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">80,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchases, shares</a></td>
<td class="nump">15,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 14,941<span></span>
</td>
<td class="nump">126,995,610<span></span>
</td>
<td class="num">(73,821,820)<span></span>
</td>
<td class="nump">53,188,731<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2022</a></td>
<td class="nump">14,941,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,223,054<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,223,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation, shares</a></td>
<td class="nump">250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">7,275<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, net of shares withheld for exercise price, shares</a></td>
<td class="nump">1,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,893,721)<span></span>
</td>
<td class="num">(10,893,721)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2022</a></td>
<td class="nump">$ 14,943<span></span>
</td>
<td class="nump">$ 128,225,939<span></span>
</td>
<td class="num">$ (84,715,541)<span></span>
</td>
<td class="nump">$ 43,525,341<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="nump">14,942,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for agreement, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodValueStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value stock warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodValueStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627642537856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (28,788,694)<span></span>
</td>
<td class="num">$ (22,851,766)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used for operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">161,981<span></span>
</td>
<td class="nump">240,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,498,784<span></span>
</td>
<td class="nump">1,689,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_IssuanceOfCommonStockLicensingAgreement', window );">Issuance of common stock, licensing agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and discount</a></td>
<td class="nump">284,184<span></span>
</td>
<td class="nump">173,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Payment-in-Kind interest</a></td>
<td class="nump">311,764<span></span>
</td>
<td class="nump">196,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense', window );">Non-cash operating lease, net</a></td>
<td class="num">(2,791)<span></span>
</td>
<td class="num">(7,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on sale of fixed assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_IncreaseDecreaseInPayrollTaxReceivable', window );">Payroll tax receivable</a></td>
<td class="nump">37,838<span></span>
</td>
<td class="num">(166,309)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid assets and deposits</a></td>
<td class="num">(5,855,575)<span></span>
</td>
<td class="num">(120,311)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,553,176<span></span>
</td>
<td class="nump">1,553,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,270,422<span></span>
</td>
<td class="nump">105,239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used for operating activities</a></td>
<td class="num">(26,528,911)<span></span>
</td>
<td class="num">(14,187,938)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(46,724)<span></span>
</td>
<td class="num">(71,959)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="num">(46,724)<span></span>
</td>
<td class="num">(71,459)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,257<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of employee stock options</a></td>
<td class="nump">24,233<span></span>
</td>
<td class="nump">41,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ProceedsFromEmployeeStockPurchases', window );">Proceeds from employee stock purchases</a></td>
<td class="nump">80,541<span></span>
</td>
<td class="nump">25,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts', window );">Proceeds from follow-on offering, net of underwriting discounts and offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">78,530,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from note payable, net of debt issuance costs and discount of $652,061</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,347,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments for debt issuance costs</a></td>
<td class="num">(8,463)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_GrossProceedsFromAnAtmOffering', window );">Gross proceeds from an ATM offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">38,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PaymentsForRegistrationStatementCosts', window );">Payments for secondary registration statement costs</a></td>
<td class="num">(318,897)<span></span>
</td>
<td class="num">(3,868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PaymentsForFinanceLeases', window );">Payments for finance leases</a></td>
<td class="num">(4,384)<span></span>
</td>
<td class="num">(4,353)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used for) provided by financing activities</a></td>
<td class="num">(226,970)<span></span>
</td>
<td class="nump">92,988,298<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(26,802,605)<span></span>
</td>
<td class="nump">78,728,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Beginning of period</a></td>
<td class="nump">84,286,381<span></span>
</td>
<td class="nump">11,637,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">End of period</a></td>
<td class="nump">57,483,776<span></span>
</td>
<td class="nump">90,366,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">832,161<span></span>
</td>
<td class="nump">454,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PropertyAndEquipmentIncludedInAccountsPayable', window );">Property and equipment included in accounts payable</a></td>
<td class="nump">104,818<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable', window );">Offering and registration statement costs included in accounts payable</a></td>
<td class="nump">11,230<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses', window );">Deferred financing costs and offering and registration statement costs included in accrued expenses</a></td>
<td class="nump">205,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock warrants and final fee recognized as discount to note payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 964,839<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred financing costs and offering and registration statement costs included in accrued expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_GrossProceedsFromAnAtmOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from an Atm offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_GrossProceedsFromAnAtmOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in non cash operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_IncreaseDecreaseInPayrollTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in payroll tax receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_IncreaseDecreaseInPayrollTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_IssuanceOfCommonStockLicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_IssuanceOfCommonStockLicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering and registration statement costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PaymentsForFinanceLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PaymentsForFinanceLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PaymentsForRegistrationStatementCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for registration statement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PaymentsForRegistrationStatementCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ProceedsFromEmployeeStockPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from employee stock purchases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ProceedsFromEmployeeStockPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from follow on offering net of underwriting discounts and offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PropertyAndEquipmentIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and equipment included in accounts payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PropertyAndEquipmentIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627649676944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows (Unaudited) (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Debt issuance costs and discount</a></td>
<td class="nump">$ 652,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627648840112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zw7MUWbS5I81" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. <span id="xdx_829_zhBT55h4gk46">Organization</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Nature
of Business</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celcuity
Inc., a Delaware corporation (the &#8220;Company&#8221;), is a clinical-stage biotechnology company focused on development of targeted
therapies for multiple solid tumor indications. The Company&#8217;s lead therapeutic candidate is gedatolisib, a potent, reversible dual
inhibitor that selectively targets all Class I PI3K isoforms and mTOR. Its mechanism of action and pharmacokinetic properties are highly
differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The Company initiated a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its CELsignia companion
diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit
from already approved targeted therapies. The Company was co-founded in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based
in Minnesota. The Company has not generated any revenues to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627648837360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_806_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zxQ7AMVz0DJk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. <span id="xdx_825_zGGnkadNp5Xl">Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfrANUBxlxji" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86C_zxtv3naAxj1b">Basis
of Presentation</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited financial statements include the accounts of the Company and have been prepared in accordance with Article 10
of Regulation S-X promulgated by the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, as permitted by Article 10,
the unaudited financial statements do not include all of the information required by accounting principles generally accepted in the
United States (&#8220;U.S. GAAP&#8221;). The balance sheet at December 31, 2021 was derived from the audited financial statements at
that date and does not include all the disclosures required by U.S. GAAP. In the opinion of management, all adjustments which are of
a normal recurring nature and necessary for a fair presentation have been reflected in the financial statements. These unaudited condensed
financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021
and the related footnotes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021. Operating
results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected during the
remainder of the current year or for any future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84A_eus-gaap--UseOfEstimates_zjVRsRnV9Mwk" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_z89nW2pJ8Wxe">Accounting
Estimates</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject
to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zqUToOfwFlx4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_860_zvmYCTBzhKP9">Risks
and Uncertainties</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the development stage including, but not limited to, dependency on, the clinical and
commercial success of its initial drug product, gedatolisib, the clinical and commercial success of its diagnostic tests, ability to
obtain regulatory approval of its drug product, gedatolisib, ability to obtain regulatory approval of its diagnostic tests, the need
for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians
and consumers, and significant competition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbMsd4XJPq63" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zCrGxj1rJxwg">Clinical
Trial Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers,
which includes the conduct of preclinical studies and clinical trials. These costs can be a significant component of the Company&#8217;s
research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in
accordance with service agreements with its third-party service providers. The Company makes significant judgments and estimates in determining
the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its prepaid assets or accrued
expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status
and timing of actual services performed, number of patients enrolled, and the rate of patient enrollments may vary from the Company&#8217;s
estimates, resulting in an adjustment to expense in future periods. Changes in these estimates that result in material changes to the
Company&#8217;s prepaid assets or accrued expenses could materially affect the Company&#8217;s results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p id="xdx_849_ecustom--ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_zhvoTjzrn2cl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zehZ66s6Orgh">Application
of New or Revised Accounting Standards</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), a company constituting an &#8220;emerging growth company&#8221;
is, among other things, entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company but has
irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or
revised accounting standards. As a result, the Company will comply with new or revised accounting standards on the relevant dates on
which adoption of such standards is required for public companies that are not emerging growth companies. The Company&#8217;s emerging
growth company filer status will cease on its Form 10-K filing for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zRIm0r2XZaQf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_863_zDXFXap8NjRa">Recently
Adopted Accounting Pronouncements</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU No. 2021-04, Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options, which provides guidance on how an issuer should account for modifications made to equity-classified written call
options. The guidance in the ASU requires the issuer to treat the modification of an equity-classified warrant that does not cause the
warrant to become liability-classified as an exchange of the original warrant for a new warrant. The issuer should measure the effect
of a modification as the difference between the fair value of the modified warrant and the fair value of that warrant immediately before
modification. The standard is effective for all entities for all fiscal years beginning after December 15, 2021. The Company adopted
this accounting standard effective January 1, 2022, and based on the standard, determined that the Representative&#8217;s Warrant amendment
was equity-classified, treated as a deemed dividend within Additional Paid-in Capital, and the estimated incremental fair value of the
modification for the Representative&#8217;s Warrant at the date of amendment was $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220913__20220913_zIluUtMtiSDa" title="Incremental fair value of warrant">271,988</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627646046064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zqU8sxSQtQDc" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <span id="xdx_820_z8yipxpIIx7h">Net Loss Per Common Share</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">Basic
and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average
common shares outstanding during the period. For all periods presented, the common shares underlying the options and warrants have been
excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to
calculate both basic and diluted loss per common share is the same.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the three and nine months ended September 30, 2022 and 2021, potentially dilutive securities excluded from the computations of diluted
weighted-average shares outstanding were options to purchase <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8EYhiPqkb98" title="Antidilutive securities excluded from computation of earnings per share"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z800QFPx29Aj" title="Antidilutive securities excluded from computation of earnings per share">1,919,114</span></span> and <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zifTRwaVUf79" title="Antidilutive securities excluded from computation of earnings per share"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zdDUSCTGb9r5" title="Antidilutive securities excluded from computation of earnings per share">1,184,721</span></span> shares of common stock, respectively, warrants to
purchase <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z1LPZsAjwyn8" title="Antidilutive securities excluded from computation of earnings per share"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z28vQTFPfbYh" title="Antidilutive securities excluded from computation of earnings per share">309,652</span></span> and <span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zz3gT6KkhOUe" title="Antidilutive securities excluded from computation of earnings per share"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2RqLufUauRi" title="Antidilutive securities excluded from computation of earnings per share">378,442</span> </span>shares of common stock, respectively, and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zkW2K0hdlhsg" title="Antidilutive securities excluded from computation of earnings per share"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zng2qg55EAXh" title="Antidilutive securities excluded from computation of earnings per share">3,273</span></span> and <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z6JfWqN4bBr3" title="Antidilutive securities excluded from computation of earnings per share"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z1HjuW97fuG2" title="Antidilutive securities excluded from computation of earnings per share">2,964</span></span> shares of restricted common stock, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASU 2021-04, for purposes of calculating basic and diluted net loss per share for the three- and nine-month periods ended
September 30, 2022, the reported net loss was increased by approximately $<span id="xdx_90E_ecustom--DeemedDividend_c20220101__20220930_zaYurw4ObVp4" title="Deemed dividend"><span id="xdx_90B_ecustom--DeemedDividend_c20220701__20220930_z6Ii1JRpd0Rb" title="Deemed dividend">272,000</span></span> related to the deemed dividend resulting from the amendment
to the warrant agreement as further discussed in Note 5. This adjustment increased the basic and diluted net loss per share by $<span id="xdx_907_ecustom--IncreasedNetLossPerShareBasicAndDiluted_c20220701__20220930_zDMk0jkSunKh" title="Increased net loss per share basic and diluted"><span id="xdx_903_ecustom--IncreasedNetLossPerShareBasicAndDiluted_c20220101__20220930_zOyE3fq1wkpc" title="Increased net loss per share basic and diluted">.02</span></span> for
the three- and nine-month periods ended September 30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627646046064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><p id="xdx_803_eus-gaap--CommitmentsDisclosureTextBlock_zWXa0xCTHHvf" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <span id="xdx_821_z7EBdCFi3EGf">Commitments</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 19.8pt; text-align: justify; text-indent: -19.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Operating
and Finance Leases</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 19.8pt; text-align: justify; text-indent: -19.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases its corporate space in Minneapolis, Minnesota. In September 2017, the Company entered into a non-cancelable operating
lease agreement for building space. The lease commenced, and the Company moved to the facility in May 2018, in conjunction with the termination
of its then existing lease. Rent expense is recorded on a straight-line basis over the lease term. In July 2020, the Company signed an
amendment to extend this lease through April 30, 2022. The lease amendment provides for monthly rent, real estate taxes and operating
expenses. As a result of the lease amendment, the Company recorded an incremental $<span id="xdx_90E_eus-gaap--IncreaseDecreaseInOperatingCapital_c20200701__20200731_zCRxHo4R7KO2" title="Increase in operating ROU asset and lease liability">197,211</span> in the operating right-of-use (&#8220;ROU&#8221;)
asset and lease liability. In July 2021, the Company signed the second amendment to extend this lease through April 30, 2023. The lease
amendment provides for monthly rent, real estate taxes and operating expenses. As a result of the lease amendment, the Company recorded
an incremental $<span id="xdx_90F_eus-gaap--IncreaseDecreaseInOperatingCapital_c20210701__20210731_zPScVKEnpaI8" title="Increase in operating ROU asset and lease liability">193,571</span> in the operating right-of-use (&#8220;ROU&#8221;) asset and lease liability. In July 2022, the Company signed
the third amendment to extend this lease through April 30, 2024. This amendment provides for monthly rent, real estate taxes and operating
expenses. The Company recorded an incremental $<span id="xdx_905_eus-gaap--IncreaseDecreaseInOperatingCapital_c20220701__20220731_zzVaBArDB4mh" title="Increase in operating ROU asset and lease liability">195,437</span> in the operating right-of-use (&#8220;ROU&#8221;) asset and lease liability pertaining
to this amendment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2018, the Company entered into a non-cancelable finance lease agreement for office equipment with a five-year term. The underlying
assets are included in furniture and equipment. The lease contains a bargain purchase option at the end of the lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
an implicit rate is not provided, the Company uses its incremental borrowing rate based on the information available at the lease commencement
date in determining the present value of the lease payments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Clinical
Research Studies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company enters into contracts in the normal course of business to conduct research and development programs internally and through third
parties that include, among others, arrangements with vendors, consultants, CMO&#8217;s, and CRO&#8217;s. The Company currently has five
Phase 2 clinical trial agreements in place to evaluate targeted therapies selected with one of our CELsignia tests. Timing of milestone
payments related to the Phase 2 clinical trials are uncertain and the contracts generally provide for termination following a certain
period after notice, therefore the Company believes that non-cancelable obligations under the agreements are not material. The Company
also has a license agreement in place with Pfizer to research, develop, manufacture and commercialize gedatolisib. In conjunction with
the license agreement, the Company continued a Phase 1b study &#8211; B2151009 related to gedatolisib. These patients subsequently transitioned
to an Expanded Access study &#8211; CELC-G-001. Contracts related to the Phase 1B study and the Expanded Access study, are generally
based on time and material. In addition, contracts related to the Company&#8217;s Phase 3 clinical study (VIKTORIA-1) are
generally cancelable with reasonable notice within 120 days and the Company&#8217;s obligations under these contracts are primarily based
on services performed through termination dates plus certain cancelation charges, if any, as defined in each of the respective agreements.
In addition, these agreements may, from time to time, be subjected to amendments as a result of any change orders executed by the parties.
As of September 30, 2022, the Company had only one material non-cancelable contractual commitment with respect to these arrangements,
which totaled approximately $<span id="xdx_90E_eus-gaap--ContractualObligation_iI_pn5n6_c20220930_zPrR7hpV2JLf" title="Non-cancelable contractual commitment">2.5</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627646046192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1LClExyCUUh" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5. <span id="xdx_82E_zoGrFvfP3ini">Stockholders&#8217;
Equity</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 13, 2022, the Company entered into a First Amendment to Representative&#8217;s Warrant (the &#8220;Warrant Amendment&#8221;)
with Craig-Hallum Capital Group LLC (&#8220;Craig-Hallum&#8221;), amending the terms of that certain Representative&#8217;s Warrant,
dated September 22, 2017 (the &#8220;Representative&#8217;s Warrant&#8221;) issued by the Company to Craig-Hallum in connection with
the Company&#8217;s initial public offering. Under the terms of the Warrant Amendment, (i) the number of shares of the Company&#8217;s
common stock issuable upon exercise of the Representative&#8217;s Warrant was reduced from <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220913__srt--RangeAxis__srt--MaximumMember_zF1CFQc9Aag6" title="Common stock issuable">138,000</span> shares to <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220913__srt--RangeAxis__srt--MinimumMember_zEoE6FgYnjt2" title="Common stock issuable">70,000</span> shares, and (ii)
the exercise period of the Representative&#8217;s Warrant was extended three years to <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220913_zeK3xhnjZmT1" title="Warrants maturity date">September 19, 2025</span>. There were no other material
amendments or modifications to the Representative&#8217;s Warrant. The estimated incremental fair value of the Representative&#8217;s
Warrant at the date of amendment was $<span id="xdx_901_ecustom--EstimatedIncrementalFairValueOfWarrants_c20220913__20220913_zOJPltQKlmA5" title="Estimated incremental fair value of the warrants">271,988</span>. As the Company has an accumulated deficit balance in Retained Earnings, the incremental
impact will be recorded as a deemed dividend, classified within Additional Paid-in Capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 1, 2022, the Company held a Special Meeting of Stockholders, at which the Company&#8217;s stockholders approved a proposal
to amend the Company&#8217;s Certificate of Incorporation to increase the authorized number of the Company&#8217;s Common Stock from
<span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220901__srt--RangeAxis__srt--MinimumMember_zsS6t1PSH463" title="Common stock, shares authorized">30,000,000</span> shares to <span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220901__srt--RangeAxis__srt--MaximumMember_zVhPwLaDeMS5" title="Common stock, shares authorized">65,000,000</span> shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 15, 2022, the Company entered into a securities purchase agreement with certain institutional and other accredited investors for
the sale of Company common stock, preferred stock that may be convertible into common stock and warrants initially exercisable for preferred
stock for $<span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20220515__20220515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zi8b80b3LzRa" title="Sale of stock, value">100</span> million in the aggregate, before deducting placement agent fees and other offering expenses. Pursuant to the securities
purchase agreement, investors will purchase shares of common stock and preferred stock at a price per share of $<span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_c20220515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zeUaOPo6FYHk" title="Sale of stock price per share">5.75</span> (on an as converted
to common stock basis). For each share of common stock and each 1/10 of a share of preferred stock purchased, investors will receive
a warrant exercisable for<span id="xdx_90B_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20220515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBD2r5QMIc09" title="Conversion price per share"> 0.40</span> shares of common stock. The exercise price of the warrants will be at a <span id="xdx_90D_ecustom--PercentageOfWarrantExercisePrice_iI_pid_dp_uPure_c20220515__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zwvJjZLxptyi" title="Percentage of warrant exercise price">40%</span> premium to the price paid
by investors for the initial shares of common stock purchased in the private placement. The preferred stock will be convertible into
common stock at the holder&#8217;s election, subject to certain limitations such as beneficial ownership. The closing of the private
placement is conditioned on, among other customary items, the first patient enrolled in the Company&#8217;s Phase 3 clinical
study (VIKTORIA-1) having received their first dose of treatment at a clinical site located in the United States, provided that if such
date does not occur on or before December 31, 2022, each investor will have the right to terminate its obligation to purchase securities
under the securities purchase agreement. The Company also entered into a customary registration rights agreement with the investors pursuant
to which it agreed to file a registration statement with the SEC registering the resale of (i) the shares of common stock to be issued
and sold in the private placement, (ii) the shares of common stock issuable upon conversion of the preferred stock purchased in the private
placement and (iii) the shares of common stock issuable upon conversion of the shares of preferred stock that may be issued upon exercise
of warrants purchased in the private placement. As of September 30, 2022, the Company has incurred $<span id="xdx_902_ecustom--SaleOfStockTransactionFee_iI_c20220930_zW12ZCCoNdia" title="Incurred transaction fee">142,241</span> in fees related to the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 4, 2022, the Company entered into an Open Market Sale Agreement<sup>SM</sup> with Jefferies LLC, as agent (&#8220;Jefferies&#8221;),
pursuant to which we may offer and sell, from time to time, through Jefferies, shares of our common stock having an aggregate offering
price of up to $<span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220204__20220204__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_z5NN1CxPvd53" title="Aggregate offering price, common stock shares">50,000,000</span>. The Company will pay Jefferies a commission equal to <span id="xdx_900_ecustom--CommissionPercentage_iI_pid_dp_uPure_c20220204__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zsAJDimyeWh4" title="Aggregate offering price, commission percentage">3.0%</span> of the aggregate gross proceeds from each sale
of such shares. On October 12, 2022, pursuant to the above agreement, the Company sold <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20221012__20221012__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zV16oqAstL53" title="Sale of stock number of shares issued in transaction">500,000</span> shares of common stock in a single transaction
at a price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20221012__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIMOBa3O3Hz7" title="Sale of stock price per shares">10.35</span> per share, generating gross proceeds of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20221012__20221012__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9gbieHF9Q2g" title="Gross proceeds from public offering">5.2</span> million ($<span id="xdx_901_ecustom--GrossProceedsNetOfCommissionsAndOfferingExpenses_pn5n6_c20221012__20221012__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBXhydOGzIK1" title="Gross proceeds net of commissions and offering expenses">4.8</span> million net of commissions and offering expenses).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">On
July 1, 2021, the Company completed a follow-on offering whereby it sold <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210701__20210702__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zvOB5HpzNaF4" title="Sale of stock">2,250,000</span> shares of common stock at a public offering price
of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20210701__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_z0c7UKs8cB76" title="Issuance of public offering price per shares">25.00</span> per share. The offering generated approximately $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210701__20210701__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zMte52NkxjO4" title="Gross proceeds from public offering">56.3</span> million before deducting underwriting discounts of approximately $<span id="xdx_909_eus-gaap--PaymentsForUnderwritingExpense_pn5n6_c20210701__20210701__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_z7INJy2BOfxl" title="Underwriting discounts">3.4</span>
million and offering expenses of approximately $<span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20210701__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zCTS9rMaUrp4" title="Offering expenses">0.1</span> million.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 26, 2021, the Company completed a follow-on offering whereby it sold <span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210226__20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zTFbfEDHBS9f" title="Sale of stock">1,971,100</span> shares of common stock (including <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210226__20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zcfTPmt4T8Pc" title="Sale of stock number of shares issued in transaction">257,100</span> shares
of common stock in connection with the full exercise of the underwriters&#8217; option to purchase additional shares) at a public offering
price of $<span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zJkjNdPBEZDg" title="Issuance of public offering price per shares">14.00</span> per share. The aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares
pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, was approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210226__20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zSq8xcrBdnwb" title="Gross proceeds from public offering">27.6</span> million before
deducting underwriting discounts of approximately $<span id="xdx_90A_eus-gaap--PaymentsForUnderwritingExpense_pn5n6_c20210225__20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zhVPFwh0iJTa" title="Deducting underwriting discounts">1.6</span> million and offering expenses of approximately $<span id="xdx_905_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zzjxQRvudk3j" title="Offering expenses">0.2</span> million.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">On
June 5, 2020, the Company entered into an At Market Issuance Sales Agreement (the &#8220;ATM Agreement&#8221;) with B. Riley FBR, Inc.
(the &#8220;Agent&#8221;). Pursuant to the ATM Agreement, the Company was able to offer and sell from time to time, at its option, shares
of common stock having an aggregate offering price of up to $<span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20200605__20200605__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember__srt--RestatementAxis__custom--PlacementSharesMember_zBZ06rhN0sca" title="Aggregate offering price, common stock shares">10,000,000</span>, par value $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20200605__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember__srt--RestatementAxis__custom--PlacementSharesMember_zQ4cFnQUnlq8" title="Common stock par value">0.001</span> per share (the &#8220;Placement Shares&#8221;),
through the Agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">During
the nine months ended September 30, 2022 and 2021, the Company sold<span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220101__20220930__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember_z2pnYh62TvCa" title="Sale of stock number of shares issued in transaction"> 0</span> and <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210101__20210930__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember_zCARXh8zCj74" title="Sale of stock number of shares issued in transaction">3,082</span> shares, respectively, of common stock pursuant to the
ATM Agreement, at an average selling price of $<span id="xdx_900_ecustom--AverageSellingPricePerShare_iI_pid_c20220930__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember_zhaCWxjn6Mw3" title="Average selling price per share"><span id="xdx_901_ecustom--AverageSellingPricePerShare_iI_pid_c20210930__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember_z3K6shU1BAT8" title="Average selling price per share">12.64</span> </span>per share. On February 23, 2021, in conjunction with the Company&#8217;s follow-on
offering, the ATM Agreement was terminated through the Agent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627727175136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z6UB62rPNOBe" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6. <span id="xdx_82F_zOIXLcdCIUZ5">Stock-Based Compensation</span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXKRuVCbhS02" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity for all stock options outstanding for the nine months ended September 30:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zdSt5uUNIXZ9" style="display: none">Schedule
of Stock Options Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; padding-left: 0pt">Options outstanding at beginning of year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrSCzwii4Kzb" style="width: 10%; text-align: right" title="Options outstanding beginning balance">1,315,321</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmG3tyVwNtA9" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, beginning balance">11.97</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWx4nS4S9Woi" style="width: 10%; text-align: right" title="Options outstanding beginning balance">849,949</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7kTOrfTJbX5" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, beginning balance">9.33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z24bDTEAooDb" style="text-align: right" title="Options outstanding shares, Granted">720,047</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoylRQYZJfY9" style="text-align: right" title="Weighted Average Exercise Price, Granted">7.19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEP0ol8c0Ztl" style="text-align: right" title="Options outstanding shares, Granted">402,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB4wUqGVw9Ia" style="text-align: right" title="Weighted Average Exercise Price, Granted">23.04</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1OruBtbAq8g" style="text-align: right" title="Options outstanding shares, Exercised">(4,660</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHD4IcmxjWWh" style="text-align: right" title="Weighted Average Exercise Price, Exercised">5.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgmXMz0byNYh" style="text-align: right" title="Options outstanding shares, Exercised">(40,620</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsJqcpimauh5" style="text-align: right" title="Weighted Average Exercise Price, Exercised">7.26</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaY9De5qD7Mi" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding shares, Forfeited">(111,594</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWKU3C96ypi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">10.86</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxtm3Yyu4rJj" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding shares, Forfeited">(27,158</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm09d9yhCHfc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">19.07</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt">Balance at September 30</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGne0HUh0gpi" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding ending balance">1,919,114</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziwFvkBcgfff" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, ending balance">6.08</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx6aSSNQFs51" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding ending balance">1,184,721</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgGaml9ho3j9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, ending balance">13.84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Options exercisable at September 30:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUhW99Mu70Tb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, ending balance">882,215</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zI25OtkO4F1b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercisable, ending balance">5.92</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmdmu8OU9Rj1" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, ending balance">560,915</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za9XuG27QAMh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercisable, ending balance">9.45</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Weighted Average Grant Date Fair Value for options granted during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjfrX6Ysl6ie" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted">4.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted">15.28</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_z2AOOaCgIouk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zoQy3AYiKgE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
following table summarizes additional information about stock options outstanding and exercisable at September 30, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BB_znZyJLodyZig" style="display: none">Schedule
of Stock Options Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOL8fsPOb8yg" style="width: 13%; text-align: center" title="Options outstanding">1,919,114</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEv8n7Gm0i4l" title="Options outstanding, weighted average remaining contractual life">7.98</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLxtS2Xgalb6" style="width: 11%; text-align: right" title="Options outstanding, weighted average exercise price">6.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlyBlU1AP091" style="width: 11%; text-align: right" title="Options outstanding, aggregate intrinsic value">7,791,703</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjQeS3QHL4w4" style="width: 12%; text-align: center" title="Options exercisable">882,215</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEh8N1UvUQZe" style="width: 10%; text-align: right" title="Options exercisable, weighted average exercise price">5.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zImAuNvoARlj" style="width: 10%; text-align: right" title="Options exercisable, aggregate intrinsic value">3,779,591</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_z4CfFqdHaSrf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized stock-based compensation expense for stock options of $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAK0dPfSBFz2" title="Stock-based compensation expense">1,162,751</span> and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSFCafLS0qDf" title="Stock-based compensation expense">673,022</span> for the three months ended September
30, 2022 and 2021, respectively and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZe47tGM0jrf" title="Stock-based compensation expense">3,329,969</span> and $<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Stock-based compensation expense">1,611,575</span> for the nine months ended September 30, 2022 and 2021, respectively. In
May 2022, the Company modified the exercise price on <span id="xdx_903_ecustom--StockOptionAwardsSharesModified_c20220531__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_pdd" title="Stock option awards shares modified">776,324</span> stock option awards to $<span id="xdx_908_ecustom--ModifiedStockOptionExercisePrice_c20220531__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_pdd" title="Stock option exercise price per share">5.50</span>, the closing market price on the Nasdaq Capital
Market on May 17, 2022. The effect of this modification on stock-based compensation was $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20220701__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_zf3ht9msEeXf" title="Modification on stock-based compensation">49,088</span> for the three months ending September
30, 2022 and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20220101__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_zkmb53GlDmAi" title="Modification on stock-based compensation">477,431</span> for the nine months ending September 30, 2022. The effect of this modification on stock-based compensation over
the remaining service period will be approximately $<span id="xdx_90E_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_pdp0_c20220101__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_zJw3K86iQogk" title="Remaining stock based compensation expense related to modification">389,000</span>. In December 2021, the Company modified the exercise price on <span id="xdx_908_ecustom--StockOptionAwardsSharesModified_c20211231__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_pdd" title="Stock option awards shares modified">311,000</span> stock
option awards to $<span id="xdx_901_ecustom--ModifiedStockOptionExercisePrice_c20211231__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_pdd" title="Stock option exercise price per share">13.44</span>, the closing market price on the Nasdaq Capital Market on December 15, 2021. No director or officer awards were
modified. The effect of this modification on stock-based compensation was $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20220701__20220930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_zG37NdoIA3S9" title="Modification on stock-based compensation">21,778</span> and $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20210701__20210930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_zwpaitmJbdq2" title="Modification on stock-based compensation">0</span> for the three months ended September 30, 2022
and 2021, respectively and $<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20220101__20220930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_zBjO7YAWKebf" title="Modification on stock-based compensation">75,562</span> and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20210101__20210930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_zg2Fq2Rbyai4" title="Modification on stock-based compensation">0</span> for the nine months ended September 30, 2022 and 2021, respectively. The effect of this modification
on stock-based compensation over the remaining service period will be approximately $<span id="xdx_90B_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_pdp0_c20220101__20220930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_z2scb6adw252" title="Remaining stock based compensation expense related to modification">219,000</span>. In May 2020, the Company modified the exercise
price on <span id="xdx_902_ecustom--StockOptionAwardsSharesModified_c20200531__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_pdd" title="Stock option awards shares modified">203,750</span> stock option awards to $<span id="xdx_909_ecustom--ModifiedStockOptionExercisePrice_c20200531__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_pdd" title="Stock option exercise price per share">5.10</span>, the closing market price on the Nasdaq Capital Market on May 14, 2020. No director or
officer awards were modified. The effect of this modification on stock-based compensation was $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20220701__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_zmm1nhLhElac" title="Stock based compensation expense related to modification">7,681</span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20210701__20210930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_zvg30821IeBf" title="Stock based compensation expense related to modification">12,602</span> for the three months
ended September 30, 2022 and 2021, respectively and $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20220101__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_zk4Je60sKHtl" title="Stock based compensation expense related to modification">30,897</span> and $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20210101__20210930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_zAHjbcXvfNof" title="Stock based compensation expense related to modification">34,396</span> for the nine months ended September 30, 2022 and 2021. The effect
of this modification on stock-based compensation over the remaining service period will be approximately $<span id="xdx_90D_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_c20220101__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_pp0p0" title="Remaining stock based compensation expense related to modification">27,000</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z9UDxxKJQwg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Black-Scholes option-pricing model was used to estimate the grant date fair value of equity-based awards with the following weighted-average
assumptions for the nine months ended September 30:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zRtXAuSVZuD9" style="display: none">Schedule
of Assumptions for Fair Value of Equity-based Awards</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_ztDYIhGZ9d81" title="Risk-free interest rate">1.68</span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zhlccm75GFb3" title="Risk-free interest rate">3.93</span></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_zrhyCssAWLvc" title="Risk-free interest rate">0.63</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_z0XOL4D44oul" title="Risk-free interest rate">1.16%</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zhz9fIEUQC82" title="Expected volatility">76.2</span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zM0sHkmKRRn" title="Expected volatility">79.6%</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_z5TZleI7sOqa" title="Expected volatility">76.6</span>% - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_ztYCAenRGsV1" title="Expected volatility">76.9%</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zvsIlC59A2ig" title="Expected life (years)">5.29</span> to <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_z0Lf6IOqg6N9" title="Expected life (years)">6.25</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_z6iXcr5GsyLk" title="Expected life (years)">5.0</span> to <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_z0hnYf9aWiyi" title="Expected life (years)">6.08</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt">Expected dividend yield</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930_zLtew7ruHLdi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Expected dividend yield">0%</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210930_zMXjb4JBSQSi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Expected dividend yield">0%</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zvggBn5mqZX9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
inputs for the Black-Scholes valuation model require management&#8217;s significant assumptions. Prior to the Company&#8217;s initial
public offering, the price per share of common stock was determined by the Company&#8217;s board based on recent prices of common stock
sold in private offerings. Subsequent to the initial public offering, the price per share of common stock is determined by using the
closing market price on the Nasdaq Capital Market on the grant date. The risk-free interest rates are based on the rate for U.S. Treasury
securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life is
based on the simplified method in accordance with the SEC Staff Accounting Bulletin Nos. 107 and 110. The expected volatility is estimated
based on historical volatility information of peer companies that are publicly available in combination with the Company&#8217;s calculated
volatility since being publicly traded.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumptions used for
options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options issued in connection
with the agreements would also be cancelled.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWcVavv2naSk" title="Restricted stock awards outstanding">3,273</span> and <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXuzyC9VjK53" title="Restricted stock awards outstanding">2,964</span> shares of restricted stock outstanding as of September 30, 2022 and 2021, respectively, and <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWiSqwz30QA3" title="Restricted stock awards vested">250</span> and <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zms9SGSqxkXg" title="Restricted stock awards vested">0</span> shares
of restricted stock vested during the three months ended September 30, 2022 and 2021. The Company recognized stock-based compensation
expense for restricted stock of $<span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pp0p0" title="Recognized stock-based compensation expense">7,245</span> and $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zc6dzIGeXS9j" title="Recognized stock-based compensation expense">20,792</span> for the three months ended September 30, 2022 and 2021, respectively and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pp0p0" title="Recognized stock-based compensation expense">36,686</span> and
$<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pp0p0" title="Recognized stock-based compensation expense">59,359</span> for the nine months ended September 30, 2022 and 2021, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company initially reserved a maximum of <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20171025__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zetR1SO8ohM7" title="Common stock, shares reserved for issuance">750,000</span> shares of common stock for issuance under the 2017 Amended and Restated Stock Incentive
Plan (the &#8220;2017 Plan&#8221;). The number of shares reserved for issuance was automatically increased by <span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20200101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zkAsYA1wbPFj" title="Increase in number of shares reserved for issuance">102,540</span>, <span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_ztT5DeoIX6Ol" title="Increase in number of shares reserved for issuance">102,998</span> and <span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zj6XN6vz8t4" title="Increase in number of shares reserved for issuance">149,189</span>
shares on January 1, 2020, 2021 and 2022, respectively, and will<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20171024__20171025__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_ztmUDAshJJB2" title="Stock option description"> increase automatically on January 1 each year from 2023 through 2027
by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding
December 31</span>. At the Annual Meeting held on May 12, 2021 and May 12, 2022, the stockholders approved a one-time, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20210511__20210512__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zGjxZJ02LvK4" title="Additional shares authorized under plan">500,000</span> increase each
year for a total increase of <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210512__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zCovsXtxhoNk" title="Number of shares reserved for issuance">1,000,000</span> to the number of shares reserved for issuance under the 2017 Plan. However, the Company&#8217;s
board may reduce the amount of the increase in any particular year. The total remaining shares available for grant under the Company&#8217;s
2017 Plan as of September 30, 2022 was <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zf9avpulotPh" title="Shares available for grant under the 2017 Plan">325,094</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_zs2M9xn82wi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
unrecognized compensation cost related to stock options and restricted stock is estimated to be recognized as follows for the year ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z5Anm6SF7JPa" style="display: none">Schedule
of Unrecognized Compensation Cost</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20220930_zS9IIv1QzhC3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_iI_pp0p0_maESSBCz4AO_z19kAJ5fFKx4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,116,837</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear_iI_pp0p0_maESSBCz4AO_z0vwGnH7SMxd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,277,254</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_iI_pp0p0_maESSBCz4AO_zqm7R22ELJB5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,130,739</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_iI_pp0p0_maESSBCz4AO_zAn3k5whQCfe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,333,749</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_iI_pp0p0_maESSBCz4AO_z7t9Gflps688" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">176,866</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iTI_pp0p0_mtESSBCz4AO_zR07yCLDDgHh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total estimated compensation cost to be recognized</b></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,035,445</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A5_zOXLhAEw9Hk5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized stock-based compensation expense related to its employee stock purchase plan of $<span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_pp0p0" title="Recognized stock-based compensation expense">53,058</span> and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20210930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_pp0p0" title="Recognized stock-based compensation expense">6,102</span> for the three months
ended September 30, 2022 and 2021, respectively and $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zQqNkw4Tpe8e" title="Recognized stock-based compensation expense">132,129</span> and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zbKMndYp0QRj" title="Recognized stock-based compensation expense">18,397</span> for the nine months ended September 30, 2022 and 2021, respectively.
The Company initially reserved a total of <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20180510__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_pdd" title="Common stock, shares reserved for issuance">100,000</span> shares for issuance under the employee stock purchase plan. The number of shares reserved
for issuance was automatically increased by <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20200101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zJtgFytBFeS9" title="Common stock, shares reserved for issuance">51,270</span>, <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zmaYiPQLkmNg" title="Common stock, shares reserved for issuance">51,499</span> and <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zILi5CZUiaK7" title="Common stock, shares reserved for issuance">74,594</span> shares on January 1, 2020, 2021 and 2022, respectively, and will
increase automatically on each subsequent January 1 by <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zZw14CMUmRwe" title="Stock option description">the number of shares equal to 0.5% of the total outstanding number of shares</span> of
Company common stock as of the immediately preceding December 31. However, the Company&#8217;s board may reduce the amount of the increase
in any particular year. The total remaining shares available for issuance under the employee stock purchase plan as of September 30,
2022 was <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_z8eBTO69ADXf" title="Shares available for issuance">208,929</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_znTevyzLbkY4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized total stock-based compensation expense as follows for the three and nine months ended September 30:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zyqj1H369I9j" style="display: none">Schedule of Stock-based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220701__20220930_z6aPTmK7hdK" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210701__20210930_zlkjrihu6ZO7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20220930_zPjxEGuS9ZVg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20210930_z58qM5soSdba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense in operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrpIe4TThLch" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">676,524</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">434,597</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,937,707</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,017,855</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQtyiiTlTWO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">546,530</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">265,319</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,561,077</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">671,476</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_z5ThuDlj7Iei" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,223,054</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">699,916</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,498,784</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,689,331</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zqqrnSF5MODg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627650972176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zVMkAPbuDKu7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. <span id="xdx_82C_zAZeOe7h8Sce">Debt</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 8, 2021, the Company entered into a loan and security agreement (the &#8220;Loan Agreement&#8221;) with Innovatus Life Sciences
Lending Fund I, LP, a Delaware limited partnership (&#8220;Innovatus&#8221;) in its capacity as Collateral Agent and sole Lender. The
Lender agreed to loan up to $<span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zzfwTxSNil7b" title="Line of credit faciltiy, maximum borrowing capacity">25</span> million in three tranches consisting of (i) a $<span id="xdx_90D_ecustom--NonContingentTermALoanFunded_iI_pn6n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zGu5jhyeGrsg" title="Non contingent term A loan, funded">15.0</span> million non-contingent term A loan that was funded
on April 8, 2021, (ii) a $<span id="xdx_909_ecustom--TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo_iI_pn6n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zRwe3BKO65h2" title="Term B loan to be funded before March 31, 2022">5</span> million term B loan to be funded upon request of the Company no later than March 31, 2022, and (iii) a $<span id="xdx_90B_ecustom--TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree_iI_pn6n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zM6bq93rvq6f" title="Term C loan to be funded before March 31, 2023">5</span>
million term C loan to be funded upon request of the Company no later than March 31, 2023 (collectively the &#8220;Term Loans&#8221;).
The Company is no longer eligible to draw on the term B loan. Funding of the term C is subject to the Company&#8217;s ability to achieve
certain milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210407__20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zK9qT0Nlql62" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Loan Agreement also contains certain events of default, warranties and covenants of the Company. In connection with each funding of
the Term Loans, the Company is required to issue Innovatus a warrant (the &#8220;Warrants&#8221;) to purchase a number of shares of
the Company&#8217;s stock equal to 2.5% of the principal amount of the relevant Term Loan funded by the exercise price, which will
be based on the lower of (i) $14.40 per share or (ii) the volume weighted price per share of the Company&#8217;s stock for the
five-trading day period ending on the last trading day immediately preceding the funding date of the Term C loan</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The warrants may be exercised on a cashless basis and are immediately exercisable through the tenth anniversary of the applicable
funding date. In connection with the first tranche of the Term Loans, the Company issued a warrant to Innovatus to purchase <span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z6698ZyWczUi">26,042 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of the Company&#8217;s common stock at an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zaeppbZ3P0ng">14.40 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share. The company evaluated the warrant under ASC 470, debt, and recognized an additional debt discount of approximately $<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn5n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zKJmPnIXIP5b">0.3 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million
based on the relative fair value of the base instruments and warrants. The company calculated the fair value of the warrant using
the Black-Scholes model. In connection with the funding of the first tranche of the Term Loans, a final fee of approximately $<span id="xdx_90F_ecustom--FinalFeePayableToLenderAmount_iI_pn5n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zZfurxJObuR1" title="Final fee payable to lender, amount">0.7</span>
million was recorded as additional principal as a debt discount, and a facility fee of approximately $<span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zL9IvyET5Mj4" title="Debt discount, amount">0.1</span>
million was recorded as additional debt discount. The Company is also required to maintain a minimum cash balance in agreement with
the term loans&#8217; default terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2022, the Company amended the Loan Agreement. Under the amended Loan Agreement, Innovatus, as Lender, has agreed to loan up
to $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20220809__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zaZYsiKv85n6" title="Face amount">75</span> million, a $<span id="xdx_90E_ecustom--IncreaseFromOriginalLoanAmount_iI_pn6n6_c20220809__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zSA1ywUATHIe" title="Increase from original loan amount">50</span> million increase from the original Loan Amount, in five tranches consisting of: (i) a $<span id="xdx_90B_ecustom--NonContingentTermALoanFunded_iI_pn6n6_c20210408__us-gaap--PlanNameAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z19Sd4urRey7" title="Non contigent term A loan, funded">15</span> million term A loan that
was funded on April 8, 2021 upon entering into the original Loan Agreement, (ii) a $<span id="xdx_90E_ecustom--UnfundedContingentLoanAmount_iI_pn6n6_c20220809__us-gaap--PlanNameAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermBLoanMember_z7H4tT48xq89" title="Unfunded contingent loan, amount">20</span> million term B loan to be funded upon request
of the Company no later than December 31, 2022, with such funding conditioned upon the closing of the Company&#8217;s $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20220516__20220516__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zty9UH6Qm9Fh" title="Private placement value">100</span> million private
placement announced on May 16, 2022, (iii) a $<span id="xdx_908_ecustom--UnfundedContingentLoanAmount_iI_pn6n6_c20220809__us-gaap--PlanNameAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermCLoanMember_zUq4gZmdjvbf" title="Unfunded contingent loan, amount">10</span> million term C loan to be funded upon request of the Company no later than April 1,
2024, (iv) a $<span id="xdx_903_ecustom--UnfundedContingentLoanAmount_iI_pn6n6_c20220809__us-gaap--PlanNameAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_z48AqmjDMT2k" title="Unfunded contingent loan, amount">20</span> million term D loan to be funded upon request of the Company no later than November 1, 2024, and (v) a $<span id="xdx_905_ecustom--UnfundedContingentLoanAmount_iI_pn6n6_c20220809__us-gaap--PlanNameAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_zg55QHBusuwc" title="Unfunded contingent loan, amount">10</span> million term
E loan to be funded upon request of the Company no later than February 28, 2025. Funding of the term B loan is conditioned upon the closing
of the Company&#8217;s $<span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20220516__20220516_zAA7L8Vj8RVa" title="Private placement">100</span> million private placement announced on May 16, 2022, and funding of the term C, D, and E loans are conditioned
upon satisfaction of certain clinical trial milestones and certain financial covenants determined on a pro forma as-funded basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the amended Loan Agreement, Innovatus has the right, at its election and until August 9, 2025, the third anniversary of the loan amendment
date, to convert into Common Stock up to <span id="xdx_907_ecustom--LoanConvertibleToStockPercentageDescription_c20220807__20220809__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zC86WYImKVRd" title="Loan convertible to stock percentage, description">(1) 20% of the outstanding principal amount of term A loan, and (ii) an additional 7% of the
amount by which the aggregate principal amount of the funded term B, C, D, and E loans exceed $35 million, provided that the aggregate
outstanding principal amount of all term loans is at least $35 million, which such conversion based upon a price per share equal to $10.00</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateTerms_pid_dp_c20220808__20220809__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zQA0BzkYi9qi" title="Debt instrument interest rate description">The
Company is entitled to make interest-only payments for forty-eight months, or up to sixty months from the original Loan Agreement date
if certain conditions are met. The Term Loans will mature on April 8, 2027, the sixth anniversary of the initial funding date, and will
bear interest at a rate equal to the sum of (a) the greater of (i) Prime Rate (as defined in the amended Loan Agreement) or (ii) 3.25%,
plus 5.7%. Additionally, the Company elected to make 4.95% of the interest rate as payable in-kind, which shall accrue as principal monthly.
The Amended Loan Agreement includes certain other fees, such as a final fee of 4.5% of the funded loan amounts not converted into equity
by the lender, which apply if prepayment, an event of default, or change of control occurs prior to August 9, 2025, the third anniversary
of the Amendment date</span>. Subject to certain other conditions, no final fee will be payable after August 9, 2025. The Company has the option
to prepay the loan at any time following the first anniversary of the amended loan agreement date, with tiered prepayment fees ranging
from 0 to 1% based on when the prepayment occurs. Upon a change in control or event of default, mandatory prepayment will be required,
and if such an event occurs prior to the first anniversary of the Amendment date, an additional prepayment fee of <span id="xdx_909_ecustom--PrepaymentFeePercentage_pid_dp_uPure_c20220808__20220809_z0ZjeKbhgKPi" title="Prepayment fee, percentage">3.0</span>% applies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amended Loan Agreement remains secured by all assets of the Company. Proceeds will be used for working capital purposes and to fund the
Company&#8217;s general business requirements. The amended Loan Agreement contains customary representations and warranties and covenants,
subject to customary carve outs, and includes financial covenants related to or based upon liquidity, trailing twelve months revenue
and the funded loan amounts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the original and amended Loan Agreement and the funding of the first tranche of the Term Loans, the Company incurred
debt issuance costs of approximately $<span id="xdx_90F_eus-gaap--DeferredFinanceCostsNet_iI_pn5n6_c20220930__us-gaap--TypeOfArrangementAxis__custom--OriginalAndAmendedLoanAgreementMember_zCkwEM33pdq" title="Debt issuance costs">0.7</span> million. The debt issuance costs, and the debt discount are amortized to interest expense using
the effective interest method over the life of the Term Loans. The carrying value of the debt approximates fair value as of September
30, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_z3hywg2T9Sxg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
debt consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zwQdiXEVN5H2" style="display: none">Schedule of Long-term Debt</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220930_zSdtxMAoWKBf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_zybcH2Zrfoa3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left; padding-left: 0pt">Note payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">15,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PaymentInKindInterestDebt_iI_pp0p0_z4m5s1Q3Ftvg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Add: Payment-in-Kind interest (added to principal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">611,765</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--NotesPayableFinalFee_iI_pp0p0_zipceAQgQnM1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Add: final fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_zUNaJdvNygJk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Less: unamortized debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(481,304</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_zezllae4Aubl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt">Less: unamortized debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(792,054</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermNotesPayable_iI_pp0p0_zUheqJ7AMeol" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total long-term debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,013,407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AC_zMk3ZtldIhae" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zhnlFTHiOxbd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
principal payments, including the final fee, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zHuPh91ALB1h" style="display: none">Schedule
of Long Term Debt Future Principal Payments</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220930_z09LQuF2GXyf" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ending</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDz4sG_zto0sL3raXBh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,854,412</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDz4sG_zt7yblrzK9Gk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,805,882</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDz4sG_z17m7x6XjMDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,626,471</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDz4sG_zuDbGb81iiil" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,286,765</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zgK8pDPU1rt1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627650849472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DisclosureLicenseAgreementAbstract', window );"><strong>License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_LicenseAgreementDisclosureTextBlock', window );">License Agreement</a></td>
<td class="text"><p id="xdx_809_ecustom--LicenseAgreementDisclosureTextBlock_z2okYjVSxaMc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. <span id="xdx_823_z7fGJVbc0gOa">License
Agreement</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 8, 2021, the Company entered into a license agreement with Pfizer to research, develop, manufacture and commercialize gedatolisib,
a potent, well-tolerated, reversible dual inhibitor that selectively targets all Class I PI3K isoforms and mTOR. The Company paid Pfizer
$<span id="xdx_90C_ecustom--UpfrontFees_iI_pn5n6_c20210408__us-gaap--PlanNameAxis__custom--LicenseAgreementMember_zpzhxhNPT9Ph" title="Upfront fees">5.0</span> million in upfront fees and issued to Pfizer $<span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueNewIssuesForEquityGrant_pn5n6_c20210407__20210408__us-gaap--PlanNameAxis__custom--LicenseAgreementMember_zLHu5w4JkEXk" title="Value of shares issued for equity grant">5.0</span> million of shares of the Company&#8217;s common stock pursuant to an Equity Grant
Agreement. The upfront payment and the issuance of shares were expensed to research &amp; development in full for the three months ending
June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events,
up to an aggregate of $<span id="xdx_900_ecustom--MilestonePayable_pn5n6_c20210407__20210408__us-gaap--RelatedPartyTransactionAxis__custom--PfizerIncMember_zcH3aGBA11k9" title="Milestone payments">335.0</span> million. Additionally, the Company will pay Pfizer tiered royalties on sales of gedatolisib at percentages
ranging from the low to mid-teens, which may be subject to deductions for expiration of valid claims, amounts due under third-party licenses
and generic competition. Unless earlier terminated, the license agreement will expire upon the expiration of all royalty obligations.
The royalty period will expire on a country-by-country basis upon the later of (a) 12 years following the date of first commercial sale
of such product in such country, (b) the expiration of all regulatory or data exclusivity in such country for such product or (c) the
date upon which the manufacture, use, sale, offer for sale or importation of such product in such country would no longer infringe, but
for the license granted in the license agreement, a valid claim of a licensed patent right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has the right to terminate the license agreement for convenience upon 90 days&#8217; prior written notice. Pfizer may not terminate
the agreement for convenience. Either the Company or Pfizer may terminate the license agreement if the other party is in material breach
and such breach is not cured within the specified cure period. In addition, either the Company or Pfizer may terminate the license agreement
in the event of specified insolvency events involving the other party.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DisclosureLicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DisclosureLicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627647884000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfrANUBxlxji" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86C_zxtv3naAxj1b">Basis
of Presentation</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying unaudited financial statements include the accounts of the Company and have been prepared in accordance with Article 10
of Regulation S-X promulgated by the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, as permitted by Article 10,
the unaudited financial statements do not include all of the information required by accounting principles generally accepted in the
United States (&#8220;U.S. GAAP&#8221;). The balance sheet at December 31, 2021 was derived from the audited financial statements at
that date and does not include all the disclosures required by U.S. GAAP. In the opinion of management, all adjustments which are of
a normal recurring nature and necessary for a fair presentation have been reflected in the financial statements. These unaudited condensed
financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021
and the related footnotes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021. Operating
results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected during the
remainder of the current year or for any future period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_84A_eus-gaap--UseOfEstimates_zjVRsRnV9Mwk" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_z89nW2pJ8Wxe">Accounting
Estimates</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject
to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zqUToOfwFlx4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_860_zvmYCTBzhKP9">Risks
and Uncertainties</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is subject to risks common to companies in the development stage including, but not limited to, dependency on, the clinical and
commercial success of its initial drug product, gedatolisib, the clinical and commercial success of its diagnostic tests, ability to
obtain regulatory approval of its drug product, gedatolisib, ability to obtain regulatory approval of its diagnostic tests, the need
for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians
and consumers, and significant competition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Clinical Trial Costs</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbMsd4XJPq63" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zCrGxj1rJxwg">Clinical
Trial Costs</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers,
which includes the conduct of preclinical studies and clinical trials. These costs can be a significant component of the Company&#8217;s
research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in
accordance with service agreements with its third-party service providers. The Company makes significant judgments and estimates in determining
the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its prepaid assets or accrued
expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status
and timing of actual services performed, number of patients enrolled, and the rate of patient enrollments may vary from the Company&#8217;s
estimates, resulting in an adjustment to expense in future periods. Changes in these estimates that result in material changes to the
Company&#8217;s prepaid assets or accrued expenses could materially affect the Company&#8217;s results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock', window );">Application of New or Revised Accounting Standards</a></td>
<td class="text"><p id="xdx_849_ecustom--ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_zhvoTjzrn2cl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zehZ66s6Orgh">Application
of New or Revised Accounting Standards</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), a company constituting an &#8220;emerging growth company&#8221;
is, among other things, entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company but has
irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or
revised accounting standards. As a result, the Company will comply with new or revised accounting standards on the relevant dates on
which adoption of such standards is required for public companies that are not emerging growth companies. The Company&#8217;s emerging
growth company filer status will cease on its Form 10-K filing for the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zRIm0r2XZaQf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_863_zDXFXap8NjRa">Recently
Adopted Accounting Pronouncements</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2021, the FASB issued ASU No. 2021-04, Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options, which provides guidance on how an issuer should account for modifications made to equity-classified written call
options. The guidance in the ASU requires the issuer to treat the modification of an equity-classified warrant that does not cause the
warrant to become liability-classified as an exchange of the original warrant for a new warrant. The issuer should measure the effect
of a modification as the difference between the fair value of the modified warrant and the fair value of that warrant immediately before
modification. The standard is effective for all entities for all fiscal years beginning after December 15, 2021. The Company adopted
this accounting standard effective January 1, 2022, and based on the standard, determined that the Representative&#8217;s Warrant amendment
was equity-classified, treated as a deemed dividend within Additional Paid-in Capital, and the estimated incremental fair value of the
modification for the Representative&#8217;s Warrant at the date of amendment was $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220913__20220913_zIluUtMtiSDa" title="Incremental fair value of warrant">271,988</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Application Of New Or Revised Accounting Standards [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627647807456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXKRuVCbhS02" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the activity for all stock options outstanding for the nine months ended September 30:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zdSt5uUNIXZ9" style="display: none">Schedule
of Stock Options Activity</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left; padding-left: 0pt">Options outstanding at beginning of year</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrSCzwii4Kzb" style="width: 10%; text-align: right" title="Options outstanding beginning balance">1,315,321</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmG3tyVwNtA9" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, beginning balance">11.97</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWx4nS4S9Woi" style="width: 10%; text-align: right" title="Options outstanding beginning balance">849,949</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7kTOrfTJbX5" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, beginning balance">9.33</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z24bDTEAooDb" style="text-align: right" title="Options outstanding shares, Granted">720,047</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoylRQYZJfY9" style="text-align: right" title="Weighted Average Exercise Price, Granted">7.19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEP0ol8c0Ztl" style="text-align: right" title="Options outstanding shares, Granted">402,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB4wUqGVw9Ia" style="text-align: right" title="Weighted Average Exercise Price, Granted">23.04</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1OruBtbAq8g" style="text-align: right" title="Options outstanding shares, Exercised">(4,660</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHD4IcmxjWWh" style="text-align: right" title="Weighted Average Exercise Price, Exercised">5.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgmXMz0byNYh" style="text-align: right" title="Options outstanding shares, Exercised">(40,620</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsJqcpimauh5" style="text-align: right" title="Weighted Average Exercise Price, Exercised">7.26</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaY9De5qD7Mi" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding shares, Forfeited">(111,594</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWKU3C96ypi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">10.86</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxtm3Yyu4rJj" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding shares, Forfeited">(27,158</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm09d9yhCHfc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited">19.07</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt">Balance at September 30</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGne0HUh0gpi" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding ending balance">1,919,114</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziwFvkBcgfff" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, ending balance">6.08</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx6aSSNQFs51" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding ending balance">1,184,721</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgGaml9ho3j9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, ending balance">13.84</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Options exercisable at September 30:</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUhW99Mu70Tb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, ending balance">882,215</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zI25OtkO4F1b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercisable, ending balance">5.92</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmdmu8OU9Rj1" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, ending balance">560,915</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za9XuG27QAMh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercisable, ending balance">9.45</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 5.4pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Weighted Average Grant Date Fair Value for options granted during the period:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjfrX6Ysl6ie" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted">4.87</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted">15.28</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of Stock Options Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zoQy3AYiKgE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">The
following table summarizes additional information about stock options outstanding and exercisable at September 30, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BB_znZyJLodyZig" style="display: none">Schedule
of Stock Options Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Exercisable</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOL8fsPOb8yg" style="width: 13%; text-align: center" title="Options outstanding">1,919,114</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEv8n7Gm0i4l" title="Options outstanding, weighted average remaining contractual life">7.98</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLxtS2Xgalb6" style="width: 11%; text-align: right" title="Options outstanding, weighted average exercise price">6.08</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlyBlU1AP091" style="width: 11%; text-align: right" title="Options outstanding, aggregate intrinsic value">7,791,703</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjQeS3QHL4w4" style="width: 12%; text-align: center" title="Options exercisable">882,215</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEh8N1UvUQZe" style="width: 10%; text-align: right" title="Options exercisable, weighted average exercise price">5.92</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zImAuNvoARlj" style="width: 10%; text-align: right" title="Options exercisable, aggregate intrinsic value">3,779,591</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions for Fair Value of Equity-based Awards</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z9UDxxKJQwg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Black-Scholes option-pricing model was used to estimate the grant date fair value of equity-based awards with the following weighted-average
assumptions for the nine months ended September 30:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zRtXAuSVZuD9" style="display: none">Schedule
of Assumptions for Fair Value of Equity-based Awards</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_ztDYIhGZ9d81" title="Risk-free interest rate">1.68</span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zhlccm75GFb3" title="Risk-free interest rate">3.93</span></span>%</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_zrhyCssAWLvc" title="Risk-free interest rate">0.63</span>% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_z0XOL4D44oul" title="Risk-free interest rate">1.16%</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zhz9fIEUQC82" title="Expected volatility">76.2</span>% - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zM0sHkmKRRn" title="Expected volatility">79.6%</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_z5TZleI7sOqa" title="Expected volatility">76.6</span>% - <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_ztYCAenRGsV1" title="Expected volatility">76.9%</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life (years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zvsIlC59A2ig" title="Expected life (years)">5.29</span> to <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_z0Lf6IOqg6N9" title="Expected life (years)">6.25</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_z6iXcr5GsyLk" title="Expected life (years)">5.0</span> to <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_z0hnYf9aWiyi" title="Expected life (years)">6.08</span></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-bottom: 1pt">Expected dividend yield</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930_zLtew7ruHLdi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Expected dividend yield">0%</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210930_zMXjb4JBSQSi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Expected dividend yield">0%</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of Unrecognized Compensation Cost</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_zs2M9xn82wi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
unrecognized compensation cost related to stock options and restricted stock is estimated to be recognized as follows for the year ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BD_z5Anm6SF7JPa" style="display: none">Schedule
of Unrecognized Compensation Cost</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20220930_zS9IIv1QzhC3" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_iI_pp0p0_maESSBCz4AO_z19kAJ5fFKx4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 82%; text-align: left">2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,116,837</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear_iI_pp0p0_maESSBCz4AO_z0vwGnH7SMxd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,277,254</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_iI_pp0p0_maESSBCz4AO_zqm7R22ELJB5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,130,739</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_iI_pp0p0_maESSBCz4AO_zAn3k5whQCfe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,333,749</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_iI_pp0p0_maESSBCz4AO_z7t9Gflps688" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">176,866</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iTI_pp0p0_mtESSBCz4AO_zR07yCLDDgHh" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total estimated compensation cost to be recognized</b></span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,035,445</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_znTevyzLbkY4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognized total stock-based compensation expense as follows for the three and nine months ended September 30:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B4_zyqj1H369I9j" style="display: none">Schedule of Stock-based Compensation Expense</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_490_20220701__20220930_z6aPTmK7hdK" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_496_20210701__20210930_zlkjrihu6ZO7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_497_20220101__20220930_zPjxEGuS9ZVg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20210930_z58qM5soSdba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Three Months Ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30,</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock-based compensation expense in operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrpIe4TThLch" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">676,524</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">434,597</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,937,707</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">1,017,855</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQtyiiTlTWO7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">General and administrative</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">546,530</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">265,319</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,561,077</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">671,476</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ShareBasedCompensation_z5ThuDlj7Iei" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,223,054</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">699,916</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,498,784</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,689,331</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627648859072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Long-term Debt</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_z3hywg2T9Sxg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term
debt consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8BE_zwQdiXEVN5H2" style="display: none">Schedule of Long-term Debt</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20220930_zSdtxMAoWKBf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2022</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_zybcH2Zrfoa3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left; padding-left: 0pt">Note payable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">15,000,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--PaymentInKindInterestDebt_iI_pp0p0_z4m5s1Q3Ftvg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Add: Payment-in-Kind interest (added to principal)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">611,765</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--NotesPayableFinalFee_iI_pp0p0_zipceAQgQnM1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Add: final fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_zUNaJdvNygJk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: 10pt; padding-left: 0pt">Less: unamortized debt issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(481,304</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_zezllae4Aubl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt">Less: unamortized debt discount</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(792,054</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermNotesPayable_iI_pp0p0_zUheqJ7AMeol" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt">Total long-term debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">15,013,407</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Long Term Debt Future Principal Payments</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zhnlFTHiOxbd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
principal payments, including the final fee, are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B1_zHuPh91ALB1h" style="display: none">Schedule
of Long Term Debt Future Principal Payments</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" id="xdx_49C_20220930_z09LQuF2GXyf" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ending</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,</b></span></p></td><td style="padding-bottom: 1pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDz4sG_zto0sL3raXBh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">5,854,412</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDz4sG_zt7yblrzK9Gk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,805,882</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDz4sG_z17m7x6XjMDk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left">2026</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,626,471</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDz4sG_zuDbGb81iiil" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">16,286,765</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627650972176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Sep. 13, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Incremental fair value of warrant</a></td>
<td class="nump">$ 271,988<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627646312544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_DeemedDividend', window );">Deemed dividend</a></td>
<td class="nump">$ 272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 272,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_IncreasedNetLossPerShareBasicAndDiluted', window );">Increased net loss per share basic and diluted</a></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,919,114<span></span>
</td>
<td class="nump">1,184,721<span></span>
</td>
<td class="nump">1,919,114<span></span>
</td>
<td class="nump">1,184,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">309,652<span></span>
</td>
<td class="nump">378,442<span></span>
</td>
<td class="nump">309,652<span></span>
</td>
<td class="nump">378,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">3,273<span></span>
</td>
<td class="nump">2,964<span></span>
</td>
<td class="nump">3,273<span></span>
</td>
<td class="nump">2,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_IncreasedNetLossPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increased net loss per share basic and diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_IncreasedNetLossPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627650932288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">Increase in operating ROU asset and lease liability</a></td>
<td class="nump">$ 195,437<span></span>
</td>
<td class="nump">$ 193,571<span></span>
</td>
<td class="nump">$ 197,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Non-cancelable contractual commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627642016864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2022</div></th>
<th class="th"><div>Sep. 13, 2022</div></th>
<th class="th"><div>May 15, 2022</div></th>
<th class="th"><div>Feb. 04, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 01, 2021</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
<th class="th"><div>Jun. 05, 2020</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 19,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_EstimatedIncrementalFairValueOfWarrants', window );">Estimated incremental fair value of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_SaleOfStockTransactionFee', window );">Incurred transaction fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=CELC_AtmAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_AverageSellingPricePerShare', window );">Average selling price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.64<span></span>
</td>
<td class="nump">$ 12.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=CELC_AtmAgreementMember', window );">ATM Agreement [Member] | Placement Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering price, common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CELC_FollowOnOfferingMember', window );">Follow-on Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Issuance of public offering price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,971,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,300,000<span></span>
</td>
<td class="nump">$ 27,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Deducting underwriting discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=CELC_FollowOnOfferingMember', window );">Follow-on Offering [Member] | Underwriter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Issuance of public offering price per shares</a></td>
<td class="nump">$ 10.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock number of shares issued in transaction</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from public offering</a></td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses', window );">Gross proceeds net of commissions and offering expenses</a></td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Issuance of public offering price per shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_PurchaseAgreementMember', window );">Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PercentageOfWarrantExercisePrice', window );">Percentage of warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember', window );">Open Market Sale Agreement [Member] | Jefferies LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering price, common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_CommissionPercentage', window );">Aggregate offering price, commission percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Common stock issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_AverageSellingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_AverageSellingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_CommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_CommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_EstimatedIncrementalFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated incremental fair value of the warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_EstimatedIncrementalFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds net of commissions and offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PercentageOfWarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of warrant exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PercentageOfWarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_SaleOfStockTransactionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock transaction fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_SaleOfStockTransactionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=CELC_AtmAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=CELC_AtmAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=CELC_PlacementSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=CELC_PlacementSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=CELC_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=CELC_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=CELC_UnderwriterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=CELC_UnderwriterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_OpenMarketSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CELC_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CELC_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627647927456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Options Activity (Details) - Share-Based Payment Arrangement, Option [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding beginning balance</a></td>
<td class="nump">1,315,321<span></span>
</td>
<td class="nump">849,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, beginning balance</a></td>
<td class="nump">$ 11.97<span></span>
</td>
<td class="nump">$ 9.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options outstanding shares, Granted</a></td>
<td class="nump">720,047<span></span>
</td>
<td class="nump">402,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 7.19<span></span>
</td>
<td class="nump">$ 23.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options outstanding shares, Exercised</a></td>
<td class="num">(4,660)<span></span>
</td>
<td class="num">(40,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="nump">$ 7.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options outstanding shares, Forfeited</a></td>
<td class="num">(111,594)<span></span>
</td>
<td class="num">(27,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">$ 10.86<span></span>
</td>
<td class="nump">$ 19.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding ending balance</a></td>
<td class="nump">1,919,114<span></span>
</td>
<td class="nump">1,184,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, ending balance</a></td>
<td class="nump">$ 6.08<span></span>
</td>
<td class="nump">$ 13.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, ending balance</a></td>
<td class="nump">882,215<span></span>
</td>
<td class="nump">560,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercisable, ending balance</a></td>
<td class="nump">$ 5.92<span></span>
</td>
<td class="nump">$ 9.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value for options granted</a></td>
<td class="nump">$ 4.87<span></span>
</td>
<td class="nump">$ 15.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627646311200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Options Outstanding and Exercisable (Details) - Share-Based Payment Arrangement, Option [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="nump">1,919,114<span></span>
</td>
<td class="nump">1,315,321<span></span>
</td>
<td class="nump">1,184,721<span></span>
</td>
<td class="nump">849,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted average remaining contractual life</a></td>
<td class="text">7 years 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted average exercise price</a></td>
<td class="nump">$ 6.08<span></span>
</td>
<td class="nump">$ 11.97<span></span>
</td>
<td class="nump">$ 13.84<span></span>
</td>
<td class="nump">$ 9.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 7,791,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable</a></td>
<td class="nump">882,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, weighted average exercise price</a></td>
<td class="nump">$ 5.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 3,779,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627645980528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Assumptions for Fair Value of Equity-based Awards (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">0.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">76.20%<span></span>
</td>
<td class="nump">76.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 3 months 14 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.93%<span></span>
</td>
<td class="nump">1.16%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.60%<span></span>
</td>
<td class="nump">76.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627641951424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Unrecognized Compensation Cost (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 1,116,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear', window );">2023</a></td>
<td class="nump">3,277,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears', window );">2024</a></td>
<td class="nump">2,130,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears', window );">2025</a></td>
<td class="nump">1,333,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears', window );">2026</a></td>
<td class="nump">176,866<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total estimated compensation cost to be recognized</a></td>
<td class="nump">$ 8,035,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation non vested awards compensation cost not yet recognized remainder of fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation non vested awards compensation cost not yet recognized within five years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation non vested awards compensation cost not yet recognized within four years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation non vested awards compensation cost not yet recognized within three years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation non vested awards compensation cost not yet recognized within two years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627645954560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 1,223,054<span></span>
</td>
<td class="nump">$ 699,916<span></span>
</td>
<td class="nump">$ 3,498,784<span></span>
</td>
<td class="nump">$ 1,689,331<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">676,524<span></span>
</td>
<td class="nump">434,597<span></span>
</td>
<td class="nump">1,937,707<span></span>
</td>
<td class="nump">1,017,855<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 546,530<span></span>
</td>
<td class="nump">$ 265,319<span></span>
</td>
<td class="nump">$ 1,561,077<span></span>
</td>
<td class="nump">$ 671,476<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627643265472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 12, 2021</div></th>
<th class="th"><div>Oct. 25, 2017</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>May 10, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenPlanMember', window );">2017 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock option description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">increase automatically on January 1 each year from 2023 through 2027
by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding
December 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized under plan</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=CELC_InMayTwoThousandTwentyTwoMember', window );">In May 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockOptionAwardsSharesModified', window );">Stock option awards shares modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ModifiedStockOptionExercisePrice', window );">Stock option exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Stock based compensation expense related to modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 477,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_RemainingStockBasedCompensationExpenseRelatedToModification', window );">Remaining stock based compensation expense related to modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=CELC_InDecemberTwoThousandTwentyOneMember', window );">In December 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockOptionAwardsSharesModified', window );">Stock option awards shares modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ModifiedStockOptionExercisePrice', window );">Stock option exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Stock based compensation expense related to modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,778<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">75,562<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_RemainingStockBasedCompensationExpenseRelatedToModification', window );">Remaining stock based compensation expense related to modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=CELC_InMayTwoThousandTwentyMember', window );">In May 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockOptionAwardsSharesModified', window );">Stock option awards shares modified</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_ModifiedStockOptionExercisePrice', window );">Stock option exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Stock based compensation expense related to modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,681<span></span>
</td>
<td class="nump">12,602<span></span>
</td>
<td class="nump">30,897<span></span>
</td>
<td class="nump">34,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_RemainingStockBasedCompensationExpenseRelatedToModification', window );">Remaining stock based compensation expense related to modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,162,751<span></span>
</td>
<td class="nump">673,022<span></span>
</td>
<td class="nump">3,329,969<span></span>
</td>
<td class="nump">1,611,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,245<span></span>
</td>
<td class="nump">$ 20,792<span></span>
</td>
<td class="nump">$ 36,686<span></span>
</td>
<td class="nump">$ 59,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock awards outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,273<span></span>
</td>
<td class="nump">2,964<span></span>
</td>
<td class="nump">3,273<span></span>
</td>
<td class="nump">2,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted stock awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CELC_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,058<span></span>
</td>
<td class="nump">$ 6,102<span></span>
</td>
<td class="nump">$ 132,129<span></span>
</td>
<td class="nump">$ 18,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,270<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock option description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the number of shares equal to 0.5% of the total outstanding number of shares<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_ModifiedStockOptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Modified stock option exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_ModifiedStockOptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_RemainingStockBasedCompensationExpenseRelatedToModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining stock based compensation expense related to modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_RemainingStockBasedCompensationExpenseRelatedToModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockOptionAwardsSharesModified">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock option awards shares modified.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockOptionAwardsSharesModified</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_TwoThousandSeventeenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=CELC_InMayTwoThousandTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=CELC_InMayTwoThousandTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=CELC_InDecemberTwoThousandTwentyOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=CELC_InDecemberTwoThousandTwentyOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=CELC_InMayTwoThousandTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=CELC_InMayTwoThousandTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CELC_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CELC_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627650907504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Long-term Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Note payable</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PaymentInKindInterestDebt', window );">Add: Payment-in-Kind interest (added to principal)</a></td>
<td class="nump">611,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_NotesPayableFinalFee', window );">Add: final fee</a></td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">(481,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: unamortized debt discount</a></td>
<td class="num">(792,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total long-term debt</a></td>
<td class="nump">$ 15,013,407<span></span>
</td>
<td class="nump">$ 14,625,923<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_NotesPayableFinalFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes payable final fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_NotesPayableFinalFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PaymentInKindInterestDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment in kind interest debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PaymentInKindInterestDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627649918496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Long Term Debt Future Principal Payments (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">$ 5,854,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">7,805,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">2,626,471<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 16,286,765<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627640625600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 09, 2022</div></th>
<th class="th"><div>Aug. 09, 2022</div></th>
<th class="th"><div>May 16, 2022</div></th>
<th class="th"><div>Apr. 08, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 792,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_PrepaymentFeePercentage', window );">Prepayment fee, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_InnovatusLifeSciencesMember', window );">Innovatus Life Sciences [Member] | Security and Loan agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_NonContingentTermALoanFunded', window );">Non contigent term A loan, funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_InnovatusLifeSciencesMember', window );">Innovatus Life Sciences [Member] | Amended Loan Agreement [Member] | Term B Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_UnfundedContingentLoanAmount', window );">Unfunded contingent loan, amount</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_InnovatusLifeSciencesMember', window );">Innovatus Life Sciences [Member] | Amended Loan Agreement [Member] | Term C Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_UnfundedContingentLoanAmount', window );">Unfunded contingent loan, amount</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_InnovatusLifeSciencesMember', window );">Innovatus Life Sciences [Member] | Amended Loan Agreement [Member] | Term D Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_UnfundedContingentLoanAmount', window );">Unfunded contingent loan, amount</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_InnovatusLifeSciencesMember', window );">Innovatus Life Sciences [Member] | Amended Loan Agreement [Member] | Term E Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_UnfundedContingentLoanAmount', window );">Unfunded contingent loan, amount</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_LoanAgreementMember', window );">Security and Loan agreement [Member] | Innovatus Life Sciences [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit faciltiy, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_NonContingentTermALoanFunded', window );">Non contigent term A loan, funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo', window );">Term B loan to be funded before March 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree', window );">Term C loan to be funded before March 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrant or Right, Reason for Issuance, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Loan Agreement also contains certain events of default, warranties and covenants of the Company. In connection with each funding of
the Term Loans, the Company is required to issue Innovatus a warrant (the &#8220;Warrants&#8221;) to purchase a number of shares of
the Company&#8217;s stock equal to 2.5% of the principal amount of the relevant Term Loan funded by the exercise price, which will
be based on the lower of (i) $14.40 per share or (ii) the volume weighted price per share of the Company&#8217;s stock for the
five-trading day period ending on the last trading day immediately preceding the funding date of the Term C loan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Debt Instrument, Unamortized Discount (Premium), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_FinalFeePayableToLenderAmount', window );">Final fee payable to lender, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_AmendedLoanAgreementMember', window );">Amended Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_LoanConvertibleToStockPercentageDescription', window );">Loan convertible to stock percentage, description</a></td>
<td class="text">(1) 20% of the outstanding principal amount of term A loan, and (ii) an additional 7% of the
amount by which the aggregate principal amount of the funded term B, C, D, and E loans exceed $35 million, provided that the aggregate
outstanding principal amount of all term loans is at least $35 million, which such conversion based upon a price per share equal to $10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Debt instrument interest rate description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
Company is entitled to make interest-only payments for forty-eight months, or up to sixty months from the original Loan Agreement date
if certain conditions are met. The Term Loans will mature on April 8, 2027, the sixth anniversary of the initial funding date, and will
bear interest at a rate equal to the sum of (a) the greater of (i) Prime Rate (as defined in the amended Loan Agreement) or (ii) 3.25%,
plus 5.7%. Additionally, the Company elected to make 4.95% of the interest rate as payable in-kind, which shall accrue as principal monthly.
The Amended Loan Agreement includes certain other fees, such as a final fee of 4.5% of the funded loan amounts not converted into equity
by the lender, which apply if prepayment, an event of default, or change of control occurs prior to August 9, 2025, the third anniversary
of the Amendment date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_AmendedLoanAgreementMember', window );">Amended Loan Agreement [Member] | Innovatus Life Sciences [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_IncreaseFromOriginalLoanAmount', window );">Increase from original loan amount</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CELC_OriginalAndAmendedLoanAgreementMember', window );">Original and Amended Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_FinalFeePayableToLenderAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final fee payable to lender, amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_FinalFeePayableToLenderAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_IncreaseFromOriginalLoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase from the original loan amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_IncreaseFromOriginalLoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_LoanConvertibleToStockPercentageDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan convertible to stock percentage description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_LoanConvertibleToStockPercentageDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_NonContingentTermALoanFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non contingent term A loan, funded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_NonContingentTermALoanFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_PrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepayment fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_PrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term B loan to be funded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term C loan to be funded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_UnfundedContingentLoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unfunded contingent loan amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_UnfundedContingentLoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reason for issuing warrant or right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_InnovatusLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CELC_InnovatusLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermDLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermDLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CELC_TermELoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CELC_TermELoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_AmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_AmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CELC_OriginalAndAmendedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CELC_OriginalAndAmendedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139627646092672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License Agreement (Details Narrative)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Apr. 08, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=CELC_PfizerIncMember', window );">Pfizer, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_MilestonePayable', window );">Milestone payments</a></td>
<td class="nump">$ 335.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CELC_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_UpfrontFees', window );">Upfront fees</a></td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant', window );">Value of shares issued for equity grant</a></td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_MilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_MilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued for equity grant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CELC_UpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CELC_UpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CELC_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=CELC_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=CELC_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CELC_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CELC_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:CELC="http://celcuity.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="celc-20220930.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-07-012022-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-04-012022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2022-09-132022-09-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2022-09-13</startDate>
            <endDate>2022-09-13</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2020-07-012020-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-07-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-13_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-13</instant>
        </period>
    </context>
    <context id="AsOf2022-09-13_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-13</instant>
        </period>
    </context>
    <context id="AsOf2022-09-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <instant>2022-09-13</instant>
        </period>
    </context>
    <context id="AsOf2022-09-01_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-01</instant>
        </period>
    </context>
    <context id="AsOf2022-09-01_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-01</instant>
        </period>
    </context>
    <context id="From2022-05-152022-05-15_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-15</startDate>
            <endDate>2022-05-15</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-15_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-15</instant>
        </period>
    </context>
    <context id="AsOf2022-05-15_custom_PurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-15</instant>
        </period>
    </context>
    <context id="From2022-02-042022-02-04_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-04</startDate>
            <endDate>2022-02-04</endDate>
        </period>
    </context>
    <context id="AsOf2022-02-04_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OpenMarketSaleAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CELC:JefferiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-04</instant>
        </period>
    </context>
    <context id="From2022-10-122022-10-12_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-12</startDate>
            <endDate>2022-10-12</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-12_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-12</instant>
        </period>
    </context>
    <context id="From2021-07-012021-07-02_custom_FollowOnOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="AsOf2021-07-01_custom_FollowOnOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="From2021-07-012021-07-01_custom_FollowOnOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="From2021-02-262021-02-26_custom_FollowOnOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-26</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="From2021-02-262021-02-26_custom_FollowOnOfferingMember_custom_UnderwriterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">CELC:UnderwriterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-26</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-26_custom_FollowOnOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-26</instant>
        </period>
    </context>
    <context id="From2021-02-252021-02-26_custom_FollowOnOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">CELC:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="From2020-06-052020-06-05_custom_AtmAgreementMember_custom_PlacementSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">CELC:PlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">CELC:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-05</startDate>
            <endDate>2020-06-05</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-05_custom_AtmAgreementMember_custom_PlacementSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">CELC:PlacementSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">CELC:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-05</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_AtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">CELC:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_AtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">CELC:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_AtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">CELC:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_custom_AtmAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">CELC:AtmAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-31_custom_InMayTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_InMayTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_InMayTwoThousandTwentyTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_InDecemberTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InDecemberTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_InDecemberTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InDecemberTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_InDecemberTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InDecemberTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_InDecemberTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InDecemberTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_InDecemberTwoThousandTwentyOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InDecemberTwoThousandTwentyOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-05-31_custom_InMayTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_InMayTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_InMayTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_InMayTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_InMayTwoThousandTwentyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CELC:InMayTwoThousandTwentyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_RestrictedStockMember17143015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_RestrictedStockMember17143015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_RestrictedStockMember17143031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_RestrictedStockMember17143031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2017-10-25_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-25</instant>
        </period>
    </context>
    <context id="AsOf2020-01-01_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="AsOf2021-01-01_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="AsOf2022-01-01_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="From2017-10-242017-10-25_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-24</startDate>
            <endDate>2017-10-25</endDate>
        </period>
    </context>
    <context id="From2021-05-112021-05-12_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-11</startDate>
            <endDate>2021-05-12</endDate>
        </period>
    </context>
    <context id="AsOf2021-05-12_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-12</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_TwoThousandSeventeenPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:TwoThousandSeventeenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2018-05-10_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-10</instant>
        </period>
    </context>
    <context id="AsOf2020-01-01_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="AsOf2021-01-01_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="AsOf2022-01-01_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CELC:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-07-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-08</instant>
        </period>
    </context>
    <context id="From2021-04-072021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-07</startDate>
            <endDate>2021-04-08</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember17144187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:LoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-08</instant>
        </period>
    </context>
    <context id="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermBLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermBLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="From2022-05-162022-05-16_us-gaap_PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-16</startDate>
            <endDate>2022-05-16</endDate>
        </period>
    </context>
    <context id="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermCLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermDLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CELC:TermELoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CELC:InnovatusLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-09</instant>
        </period>
    </context>
    <context id="From2022-05-162022-05-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2022-05-16</startDate>
            <endDate>2022-05-16</endDate>
        </period>
    </context>
    <context id="From2022-08-072022-08-09_custom_AmendedLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-07</startDate>
            <endDate>2022-08-09</endDate>
        </period>
    </context>
    <context id="From2022-08-082022-08-09_custom_AmendedLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:AmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-08</startDate>
            <endDate>2022-08-09</endDate>
        </period>
    </context>
    <context id="From2022-08-082022-08-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
        </entity>
        <period>
            <startDate>2022-08-08</startDate>
            <endDate>2022-08-09</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-30_custom_OriginalAndAmendedLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CELC:OriginalAndAmendedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="AsOf2021-04-08_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-08</instant>
        </period>
    </context>
    <context id="From2021-04-072021-04-08_custom_LicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CELC:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-07</startDate>
            <endDate>2021-04-08</endDate>
        </period>
    </context>
    <context id="From2021-04-072021-04-08_custom_PfizerIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001603454</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CELC:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-07</startDate>
            <endDate>2021-04-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-09-30">0001603454</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-09-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0030">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-09-30" id="xdx2ixbrl0031">Yes</dei:EntityInteractiveDataCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0093"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0106"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-09-30"
      id="xdx2ixbrl0111"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0201"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0202"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0203"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-07-012022-09-30"
      id="xdx2ixbrl0216"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-07-012021-09-30"
      id="xdx2ixbrl0217"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0219"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0247"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0251"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0257"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0270"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0336"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0348"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0367"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0369"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0373"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0448"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:IssuanceOfCommonStockLicensingAgreement
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0514"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:GrossProceedsFromAnAtmOffering
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:PropertyAndEquipmentIncludedInAccountsPayable
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:OfferingAndRegistrationStatementCostsIncludedInAccountsPayable
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses
      contextRef="From2021-01-012021-09-30"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="From2022-01-01to2022-09-30"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2022-01-01to2022-09-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2022-01-01to2022-09-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-09-30">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-09-30">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-09-30">001-38207</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-09-30">CELCUITY INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-09-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-09-30">82-2863566</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-09-30">16305 36th Avenue North; Suite 100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-09-30">Minneapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-09-30">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-09-30">55446</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-09-30">(763)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-09-30">392-0767</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2022-01-01to2022-09-30">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-01-01to2022-09-30">CELC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-01-01to2022-09-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-09-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-09-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-09-30">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2022-01-01to2022-09-30">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-09-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-11-03" decimals="INF" unitRef="Shares">15459739</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">57483776</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">84286381</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">22009</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22009</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DeferredCostsCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">349147</us-gaap:DeferredCostsCurrent>
    <us-gaap:DeferredCostsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">22144</us-gaap:DeferredCostsCurrent>
    <CELC:PayrollTaxReceivable contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">260926</CELC:PayrollTaxReceivable>
    <CELC:PayrollTaxReceivable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">298764</CELC:PayrollTaxReceivable>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">6578252</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">722677</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">64694110</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">85351975</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">302005</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">312444</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">295535</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">241901</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">65291650</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">85906320</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3168198</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1507099</us-gaap:AccountsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3916</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5850</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">194643</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">189858</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3278315</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">802893</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">6645072</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2505700</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2449</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">107830</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">61771</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">15013407</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">14625923</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">21766309</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">17195843</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">2500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">65000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">65000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">14942958</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-09-30" decimals="INF" unitRef="Shares">14942958</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">14918887</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">14918887</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">14943</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">14919</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">128225939</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">124622405</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">-84715541</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-55926847</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">43525341</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">68710477</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">65291650</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">85906320</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">9621505</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">4960515</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">24685505</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">20266965</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">1022050</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">639271</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">3066382</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">1768058</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">10643555</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">5599786</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">27751887</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">22035023</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-10643555</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-5599786</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-27751887</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-22035023</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">537661</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">433072</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">1428108</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">824283</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">287495</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">5612</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">391301</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">7803</us-gaap:InvestmentIncomeInterest>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-263</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-250166</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-427460</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-1036807</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-816743</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-10893721</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-6027246</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-28788694</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-22851766</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-10893721</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-6027246</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-28788694</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-22851766</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="USDPShares">-0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-09-30"
      decimals="INF"
      unitRef="USDPShares">-1.95</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-09-30"
      decimals="INF"
      unitRef="USDPShares">-1.78</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="Shares">14938224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-07-012021-09-30"
      decimals="INF"
      unitRef="Shares">14877619</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-09-30"
      decimals="INF"
      unitRef="Shares">14928727</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-09-30"
      decimals="INF"
      unitRef="Shares">12867484</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">14918887</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">14919</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">124622405</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-55926847</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">68710477</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">756271</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">756271</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1415</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">7413</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">7414</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-7934447</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-03-31"
      decimals="0"
      unitRef="USD">-7934447</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">14920302</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">14920</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">125386089</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-63861294</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">61539715</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3273</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1519456</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">1519459</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">15888</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">16</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">80525</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">80541</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1871</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-04-012022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-04-012022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">9540</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">9542</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-9960526</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-04-012022-06-30"
      decimals="0"
      unitRef="USD">-9960526</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">14941334</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">14941</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">126995610</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-73821820</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-06-30" decimals="0" unitRef="USD">53188731</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">250</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1223054</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">1223054</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1374</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">7275</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">7277</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-10893721</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">-10893721</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">14942958</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">14943</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">128225939</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-84715541</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">43525341</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10299822</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">10300</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38013551</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-26321581</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">11702270</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">449098</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">449098</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <CELC:StockIssuedDuringPeriodSharesStockWarrantsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1185</CELC:StockIssuedDuringPeriodSharesStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</CELC:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">11256</CELC:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <CELC:StockIssuedDuringPeriodValueStockWarrantsExercised
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">11257</CELC:StockIssuedDuringPeriodValueStockWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12707</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">13</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-13</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1971100</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1971</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">25766522</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">25768493</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3082</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">38959</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">38962</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3868</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">3868</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2791668</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-2791668</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12287896</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">12288</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">64275505</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-29113249</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">35174544</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2964</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">540314</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">540317</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5496</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">25811</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">25817</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">9136</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">9</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">36850</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">36859</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">289839</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">289839</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <CELC:StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">349406</CELC:StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares>
    <CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">349</CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement>
    <CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4999651</CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement>
    <CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">5000000</CELC:StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-14032852</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-14032852</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">12654898</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">12655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">70167970</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-43146101</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">27034524</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">699916</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">699916</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5099</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">5100</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2250000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2250</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">52759842</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">52762092</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-6027246</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">-6027246</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">14905898</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">14906</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">123632827</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-49173347</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">74474386</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-28788694</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-22851766</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">161981</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">240206</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">3498784</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">1689331</us-gaap:ShareBasedCompensation>
    <CELC:IssuanceOfCommonStockLicensingAgreement
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">5000000</CELC:IssuanceOfCommonStockLicensingAgreement>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">284184</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">173361</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:PaidInKindInterest
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">311764</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">196348</us-gaap:PaidInKindInterest>
    <CELC:IncreaseDecreaseInNonCashOperatingLeaseExpense
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-2791</CELC:IncreaseDecreaseInNonCashOperatingLeaseExpense>
    <CELC:IncreaseDecreaseInNonCashOperatingLeaseExpense
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-7681</CELC:IncreaseDecreaseInNonCashOperatingLeaseExpense>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-263</us-gaap:GainLossOnDispositionOfAssets1>
    <CELC:IncreaseDecreaseInPayrollTaxReceivable
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-37838</CELC:IncreaseDecreaseInPayrollTaxReceivable>
    <CELC:IncreaseDecreaseInPayrollTaxReceivable
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">166309</CELC:IncreaseDecreaseInPayrollTaxReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">5855575</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">120311</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">1553176</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">1553381</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">2270422</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">105239</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-26528911</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-14187938</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">46724</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">71959</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">500</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-46724</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">-71459</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">11257</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">24233</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">41959</us-gaap:ProceedsFromStockOptionsExercised>
    <CELC:ProceedsFromEmployeeStockPurchases
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">80541</CELC:ProceedsFromEmployeeStockPurchases>
    <CELC:ProceedsFromEmployeeStockPurchases
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">25817</CELC:ProceedsFromEmployeeStockPurchases>
    <CELC:ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">78530585</CELC:ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">652061</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">14347939</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">8463</us-gaap:PaymentsOfDebtIssuanceCosts>
    <CELC:GrossProceedsFromAnAtmOffering
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">38962</CELC:GrossProceedsFromAnAtmOffering>
    <CELC:PaymentsForRegistrationStatementCosts
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">318897</CELC:PaymentsForRegistrationStatementCosts>
    <CELC:PaymentsForRegistrationStatementCosts
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">3868</CELC:PaymentsForRegistrationStatementCosts>
    <CELC:PaymentsForFinanceLeases
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">4384</CELC:PaymentsForFinanceLeases>
    <CELC:PaymentsForFinanceLeases
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">4353</CELC:PaymentsForFinanceLeases>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-226970</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">92988298</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">-26802605</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">78728901</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">84286381</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">11637911</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">57483776</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-09-30" decimals="0" unitRef="USD">90366812</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">832161</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">454573</us-gaap:InterestPaidNet>
    <CELC:PropertyAndEquipmentIncludedInAccountsPayable
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">104818</CELC:PropertyAndEquipmentIncludedInAccountsPayable>
    <CELC:OfferingAndRegistrationStatementCostsIncludedInAccountsPayable
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">11230</CELC:OfferingAndRegistrationStatementCostsIncludedInAccountsPayable>
    <CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">205000</CELC:DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses>
    <us-gaap:StockIssued1
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">964839</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_80C_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zw7MUWbS5I81" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1. &lt;span id="xdx_829_zhBT55h4gk46"&gt;Organization&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Nature
of Business&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Celcuity
Inc., a Delaware corporation (the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company focused on development of targeted
therapies for multiple solid tumor indications. The Company&#x2019;s lead therapeutic candidate is gedatolisib, a potent, reversible dual
inhibitor that selectively targets all Class I PI3K isoforms and mTOR. Its mechanism of action and pharmacokinetic properties are highly
differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The Company initiated a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its CELsignia companion
diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit
from already approved targeted therapies. The Company was co-founded in 2012 by Brian F. Sullivan and Dr. Lance G. Laing and is based
in Minnesota. The Company has not generated any revenues to date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_806_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zxQ7AMVz0DJk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2. &lt;span id="xdx_825_zGGnkadNp5Xl"&gt;Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfrANUBxlxji" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zxtv3naAxj1b"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited financial statements include the accounts of the Company and have been prepared in accordance with Article 10
of Regulation S-X promulgated by the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, as permitted by Article 10,
the unaudited financial statements do not include all of the information required by accounting principles generally accepted in the
United States (&#x201c;U.S. GAAP&#x201d;). The balance sheet at December 31, 2021 was derived from the audited financial statements at
that date and does not include all the disclosures required by U.S. GAAP. In the opinion of management, all adjustments which are of
a normal recurring nature and necessary for a fair presentation have been reflected in the financial statements. These unaudited condensed
financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021
and the related footnotes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021. Operating
results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected during the
remainder of the current year or for any future period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zjVRsRnV9Mwk" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_z89nW2pJ8Wxe"&gt;Accounting
Estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject
to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zqUToOfwFlx4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zvmYCTBzhKP9"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to risks common to companies in the development stage including, but not limited to, dependency on, the clinical and
commercial success of its initial drug product, gedatolisib, the clinical and commercial success of its diagnostic tests, ability to
obtain regulatory approval of its drug product, gedatolisib, ability to obtain regulatory approval of its diagnostic tests, the need
for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians
and consumers, and significant competition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbMsd4XJPq63" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zCrGxj1rJxwg"&gt;Clinical
Trial Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers,
which includes the conduct of preclinical studies and clinical trials. These costs can be a significant component of the Company&#x2019;s
research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in
accordance with service agreements with its third-party service providers. The Company makes significant judgments and estimates in determining
the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its prepaid assets or accrued
expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status
and timing of actual services performed, number of patients enrolled, and the rate of patient enrollments may vary from the Company&#x2019;s
estimates, resulting in an adjustment to expense in future periods. Changes in these estimates that result in material changes to the
Company&#x2019;s prepaid assets or accrued expenses could materially affect the Company&#x2019;s results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_zhvoTjzrn2cl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zehZ66s6Orgh"&gt;Application
of New or Revised Accounting Standards&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), a company constituting an &#x201c;emerging growth company&#x201d;
is, among other things, entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company but has
irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or
revised accounting standards. As a result, the Company will comply with new or revised accounting standards on the relevant dates on
which adoption of such standards is required for public companies that are not emerging growth companies. The Company&#x2019;s emerging
growth company filer status will cease on its Form 10-K filing for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zRIm0r2XZaQf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zDXFXap8NjRa"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the FASB issued ASU No. 2021-04, Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options, which provides guidance on how an issuer should account for modifications made to equity-classified written call
options. The guidance in the ASU requires the issuer to treat the modification of an equity-classified warrant that does not cause the
warrant to become liability-classified as an exchange of the original warrant for a new warrant. The issuer should measure the effect
of a modification as the difference between the fair value of the modified warrant and the fair value of that warrant immediately before
modification. The standard is effective for all entities for all fiscal years beginning after December 15, 2021. The Company adopted
this accounting standard effective January 1, 2022, and based on the standard, determined that the Representative&#x2019;s Warrant amendment
was equity-classified, treated as a deemed dividend within Additional Paid-in Capital, and the estimated incremental fair value of the
modification for the Representative&#x2019;s Warrant at the date of amendment was $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220913__20220913_zIluUtMtiSDa" title="Incremental fair value of warrant"&gt;271,988&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_843_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zfrANUBxlxji" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86C_zxtv3naAxj1b"&gt;Basis
of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
accompanying unaudited financial statements include the accounts of the Company and have been prepared in accordance with Article 10
of Regulation S-X promulgated by the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, as permitted by Article 10,
the unaudited financial statements do not include all of the information required by accounting principles generally accepted in the
United States (&#x201c;U.S. GAAP&#x201d;). The balance sheet at December 31, 2021 was derived from the audited financial statements at
that date and does not include all the disclosures required by U.S. GAAP. In the opinion of management, all adjustments which are of
a normal recurring nature and necessary for a fair presentation have been reflected in the financial statements. These unaudited condensed
financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021
and the related footnotes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021. Operating
results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected during the
remainder of the current year or for any future period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_84A_eus-gaap--UseOfEstimates_zjVRsRnV9Mwk" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_z89nW2pJ8Wxe"&gt;Accounting
Estimates&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject
to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zqUToOfwFlx4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zvmYCTBzhKP9"&gt;Risks
and Uncertainties&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is subject to risks common to companies in the development stage including, but not limited to, dependency on, the clinical and
commercial success of its initial drug product, gedatolisib, the clinical and commercial success of its diagnostic tests, ability to
obtain regulatory approval of its drug product, gedatolisib, ability to obtain regulatory approval of its diagnostic tests, the need
for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians
and consumers, and significant competition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zbMsd4XJPq63" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zCrGxj1rJxwg"&gt;Clinical
Trial Costs&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company records prepaid assets or accrued expenses for prepaid or estimated clinical trial costs conducted by third-party service providers,
which includes the conduct of preclinical studies and clinical trials. These costs can be a significant component of the Company&#x2019;s
research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in
accordance with service agreements with its third-party service providers. The Company makes significant judgments and estimates in determining
the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its prepaid assets or accrued
expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status
and timing of actual services performed, number of patients enrolled, and the rate of patient enrollments may vary from the Company&#x2019;s
estimates, resulting in an adjustment to expense in future periods. Changes in these estimates that result in material changes to the
Company&#x2019;s prepaid assets or accrued expenses could materially affect the Company&#x2019;s results of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <CELC:ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_849_ecustom--ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock_zhvoTjzrn2cl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_867_zehZ66s6Orgh"&gt;Application
of New or Revised Accounting Standards&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), a company constituting an &#x201c;emerging growth company&#x201d;
is, among other things, entitled to rely upon certain reduced reporting requirements. The Company is an emerging growth company but has
irrevocably elected not to take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or
revised accounting standards. As a result, the Company will comply with new or revised accounting standards on the relevant dates on
which adoption of such standards is required for public companies that are not emerging growth companies. The Company&#x2019;s emerging
growth company filer status will cease on its Form 10-K filing for the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</CELC:ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_844_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zRIm0r2XZaQf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zDXFXap8NjRa"&gt;Recently
Adopted Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2021, the FASB issued ASU No. 2021-04, Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified
Written Call Options, which provides guidance on how an issuer should account for modifications made to equity-classified written call
options. The guidance in the ASU requires the issuer to treat the modification of an equity-classified warrant that does not cause the
warrant to become liability-classified as an exchange of the original warrant for a new warrant. The issuer should measure the effect
of a modification as the difference between the fair value of the modified warrant and the fair value of that warrant immediately before
modification. The standard is effective for all entities for all fiscal years beginning after December 15, 2021. The Company adopted
this accounting standard effective January 1, 2022, and based on the standard, determined that the Representative&#x2019;s Warrant amendment
was equity-classified, treated as a deemed dividend within Additional Paid-in Capital, and the estimated incremental fair value of the
modification for the Representative&#x2019;s Warrant at the date of amendment was $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_c20220913__20220913_zIluUtMtiSDa" title="Incremental fair value of warrant"&gt;271,988&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-09-132022-09-13"
      decimals="0"
      unitRef="USD">271988</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_80D_eus-gaap--EarningsPerShareTextBlock_zqU8sxSQtQDc" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3. &lt;span id="xdx_820_z8yipxpIIx7h"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;Basic
and diluted net loss per common share is determined by dividing net loss attributable to common stockholders by the weighted-average
common shares outstanding during the period. For all periods presented, the common shares underlying the options and warrants have been
excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average shares outstanding used to
calculate both basic and diluted loss per common share is the same.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three and nine months ended September 30, 2022 and 2021, potentially dilutive securities excluded from the computations of diluted
weighted-average shares outstanding were options to purchase &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z8EYhiPqkb98" title="Antidilutive securities excluded from computation of earnings per share"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_z800QFPx29Aj" title="Antidilutive securities excluded from computation of earnings per share"&gt;1,919,114&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zifTRwaVUf79" title="Antidilutive securities excluded from computation of earnings per share"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zdDUSCTGb9r5" title="Antidilutive securities excluded from computation of earnings per share"&gt;1,184,721&lt;/span&gt;&lt;/span&gt; shares of common stock, respectively, warrants to
purchase &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z1LPZsAjwyn8" title="Antidilutive securities excluded from computation of earnings per share"&gt;&lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z28vQTFPfbYh" title="Antidilutive securities excluded from computation of earnings per share"&gt;309,652&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zz3gT6KkhOUe" title="Antidilutive securities excluded from computation of earnings per share"&gt;&lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z2RqLufUauRi" title="Antidilutive securities excluded from computation of earnings per share"&gt;378,442&lt;/span&gt; &lt;/span&gt;shares of common stock, respectively, and &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220701__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zkW2K0hdlhsg" title="Antidilutive securities excluded from computation of earnings per share"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20220930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_zng2qg55EAXh" title="Antidilutive securities excluded from computation of earnings per share"&gt;3,273&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210701__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z6JfWqN4bBr3" title="Antidilutive securities excluded from computation of earnings per share"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20210101__20210930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockMember_z1HjuW97fuG2" title="Antidilutive securities excluded from computation of earnings per share"&gt;2,964&lt;/span&gt;&lt;/span&gt; shares of restricted common stock, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with ASU 2021-04, for purposes of calculating basic and diluted net loss per share for the three- and nine-month periods ended
September 30, 2022, the reported net loss was increased by approximately $&lt;span id="xdx_90E_ecustom--DeemedDividend_c20220101__20220930_zaYurw4ObVp4" title="Deemed dividend"&gt;&lt;span id="xdx_90B_ecustom--DeemedDividend_c20220701__20220930_z6Ii1JRpd0Rb" title="Deemed dividend"&gt;272,000&lt;/span&gt;&lt;/span&gt; related to the deemed dividend resulting from the amendment
to the warrant agreement as further discussed in Note 5. This adjustment increased the basic and diluted net loss per share by $&lt;span id="xdx_907_ecustom--IncreasedNetLossPerShareBasicAndDiluted_c20220701__20220930_zDMk0jkSunKh" title="Increased net loss per share basic and diluted"&gt;&lt;span id="xdx_903_ecustom--IncreasedNetLossPerShareBasicAndDiluted_c20220101__20220930_zOyE3fq1wkpc" title="Increased net loss per share basic and diluted"&gt;.02&lt;/span&gt;&lt;/span&gt; for
the three- and nine-month periods ended September 30, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1919114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1919114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-07-012021-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1184721</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1184721</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012022-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">309652</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">309652</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-07-012021-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">378442</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-09-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">378442</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012022-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">3273</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">3273</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">2964</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">2964</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <CELC:DeemedDividend
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">272000</CELC:DeemedDividend>
    <CELC:DeemedDividend
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">272000</CELC:DeemedDividend>
    <CELC:IncreasedNetLossPerShareBasicAndDiluted
      contextRef="From2022-07-012022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.02</CELC:IncreasedNetLossPerShareBasicAndDiluted>
    <CELC:IncreasedNetLossPerShareBasicAndDiluted
      contextRef="From2022-01-01to2022-09-30"
      decimals="INF"
      unitRef="USDPShares">0.02</CELC:IncreasedNetLossPerShareBasicAndDiluted>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_803_eus-gaap--CommitmentsDisclosureTextBlock_zWXa0xCTHHvf" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4. &lt;span id="xdx_821_z7EBdCFi3EGf"&gt;Commitments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 19.8pt; text-align: justify; text-indent: -19.8pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Operating
and Finance Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 19.8pt; text-align: justify; text-indent: -19.8pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company leases its corporate space in Minneapolis, Minnesota. In September 2017, the Company entered into a non-cancelable operating
lease agreement for building space. The lease commenced, and the Company moved to the facility in May 2018, in conjunction with the termination
of its then existing lease. Rent expense is recorded on a straight-line basis over the lease term. In July 2020, the Company signed an
amendment to extend this lease through April 30, 2022. The lease amendment provides for monthly rent, real estate taxes and operating
expenses. As a result of the lease amendment, the Company recorded an incremental $&lt;span id="xdx_90E_eus-gaap--IncreaseDecreaseInOperatingCapital_c20200701__20200731_zCRxHo4R7KO2" title="Increase in operating ROU asset and lease liability"&gt;197,211&lt;/span&gt; in the operating right-of-use (&#x201c;ROU&#x201d;)
asset and lease liability. In July 2021, the Company signed the second amendment to extend this lease through April 30, 2023. The lease
amendment provides for monthly rent, real estate taxes and operating expenses. As a result of the lease amendment, the Company recorded
an incremental $&lt;span id="xdx_90F_eus-gaap--IncreaseDecreaseInOperatingCapital_c20210701__20210731_zPScVKEnpaI8" title="Increase in operating ROU asset and lease liability"&gt;193,571&lt;/span&gt; in the operating right-of-use (&#x201c;ROU&#x201d;) asset and lease liability. In July 2022, the Company signed
the third amendment to extend this lease through April 30, 2024. This amendment provides for monthly rent, real estate taxes and operating
expenses. The Company recorded an incremental $&lt;span id="xdx_905_eus-gaap--IncreaseDecreaseInOperatingCapital_c20220701__20220731_zzVaBArDB4mh" title="Increase in operating ROU asset and lease liability"&gt;195,437&lt;/span&gt; in the operating right-of-use (&#x201c;ROU&#x201d;) asset and lease liability pertaining
to this amendment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
May 2018, the Company entered into a non-cancelable finance lease agreement for office equipment with a five-year term. The underlying
assets are included in furniture and equipment. The lease contains a bargain purchase option at the end of the lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
an implicit rate is not provided, the Company uses its incremental borrowing rate based on the information available at the lease commencement
date in determining the present value of the lease payments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;Clinical
Research Studies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company enters into contracts in the normal course of business to conduct research and development programs internally and through third
parties that include, among others, arrangements with vendors, consultants, CMO&#x2019;s, and CRO&#x2019;s. The Company currently has five
Phase 2 clinical trial agreements in place to evaluate targeted therapies selected with one of our CELsignia tests. Timing of milestone
payments related to the Phase 2 clinical trials are uncertain and the contracts generally provide for termination following a certain
period after notice, therefore the Company believes that non-cancelable obligations under the agreements are not material. The Company
also has a license agreement in place with Pfizer to research, develop, manufacture and commercialize gedatolisib. In conjunction with
the license agreement, the Company continued a Phase 1b study &#x2013; B2151009 related to gedatolisib. These patients subsequently transitioned
to an Expanded Access study &#x2013; CELC-G-001. Contracts related to the Phase 1B study and the Expanded Access study, are generally
based on time and material. In addition, contracts related to the Company&#x2019;s Phase 3 clinical study (VIKTORIA-1) are
generally cancelable with reasonable notice within 120 days and the Company&#x2019;s obligations under these contracts are primarily based
on services performed through termination dates plus certain cancelation charges, if any, as defined in each of the respective agreements.
In addition, these agreements may, from time to time, be subjected to amendments as a result of any change orders executed by the parties.
As of September 30, 2022, the Company had only one material non-cancelable contractual commitment with respect to these arrangements,
which totaled approximately $&lt;span id="xdx_90E_eus-gaap--ContractualObligation_iI_pn5n6_c20220930_zPrR7hpV2JLf" title="Non-cancelable contractual commitment"&gt;2.5&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="From2020-07-012020-07-31"
      decimals="0"
      unitRef="USD">197211</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="From2021-07-012021-07-31"
      decimals="0"
      unitRef="USD">193571</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:IncreaseDecreaseInOperatingCapital
      contextRef="From2022-07-012022-07-31"
      decimals="0"
      unitRef="USD">195437</us-gaap:IncreaseDecreaseInOperatingCapital>
    <us-gaap:ContractualObligation contextRef="AsOf2022-09-30" decimals="-5" unitRef="USD">2500000</us-gaap:ContractualObligation>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z1LClExyCUUh" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5. &lt;span id="xdx_82E_zoGrFvfP3ini"&gt;Stockholders&#x2019;
Equity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 13, 2022, the Company entered into a First Amendment to Representative&#x2019;s Warrant (the &#x201c;Warrant Amendment&#x201d;)
with Craig-Hallum Capital Group LLC (&#x201c;Craig-Hallum&#x201d;), amending the terms of that certain Representative&#x2019;s Warrant,
dated September 22, 2017 (the &#x201c;Representative&#x2019;s Warrant&#x201d;) issued by the Company to Craig-Hallum in connection with
the Company&#x2019;s initial public offering. Under the terms of the Warrant Amendment, (i) the number of shares of the Company&#x2019;s
common stock issuable upon exercise of the Representative&#x2019;s Warrant was reduced from &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220913__srt--RangeAxis__srt--MaximumMember_zF1CFQc9Aag6" title="Common stock issuable"&gt;138,000&lt;/span&gt; shares to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220913__srt--RangeAxis__srt--MinimumMember_zEoE6FgYnjt2" title="Common stock issuable"&gt;70,000&lt;/span&gt; shares, and (ii)
the exercise period of the Representative&#x2019;s Warrant was extended three years to &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220913_zeK3xhnjZmT1" title="Warrants maturity date"&gt;September 19, 2025&lt;/span&gt;. There were no other material
amendments or modifications to the Representative&#x2019;s Warrant. The estimated incremental fair value of the Representative&#x2019;s
Warrant at the date of amendment was $&lt;span id="xdx_901_ecustom--EstimatedIncrementalFairValueOfWarrants_c20220913__20220913_zOJPltQKlmA5" title="Estimated incremental fair value of the warrants"&gt;271,988&lt;/span&gt;. As the Company has an accumulated deficit balance in Retained Earnings, the incremental
impact will be recorded as a deemed dividend, classified within Additional Paid-in Capital.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 1, 2022, the Company held a Special Meeting of Stockholders, at which the Company&#x2019;s stockholders approved a proposal
to amend the Company&#x2019;s Certificate of Incorporation to increase the authorized number of the Company&#x2019;s Common Stock from
&lt;span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220901__srt--RangeAxis__srt--MinimumMember_zsS6t1PSH463" title="Common stock, shares authorized"&gt;30,000,000&lt;/span&gt; shares to &lt;span id="xdx_907_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20220901__srt--RangeAxis__srt--MaximumMember_zVhPwLaDeMS5" title="Common stock, shares authorized"&gt;65,000,000&lt;/span&gt; shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 15, 2022, the Company entered into a securities purchase agreement with certain institutional and other accredited investors for
the sale of Company common stock, preferred stock that may be convertible into common stock and warrants initially exercisable for preferred
stock for $&lt;span id="xdx_902_eus-gaap--SaleOfStockConsiderationReceivedPerTransaction_pn6n6_c20220515__20220515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zi8b80b3LzRa" title="Sale of stock, value"&gt;100&lt;/span&gt; million in the aggregate, before deducting placement agent fees and other offering expenses. Pursuant to the securities
purchase agreement, investors will purchase shares of common stock and preferred stock at a price per share of $&lt;span id="xdx_908_eus-gaap--SaleOfStockPricePerShare_iI_c20220515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zeUaOPo6FYHk" title="Sale of stock price per share"&gt;5.75&lt;/span&gt; (on an as converted
to common stock basis). For each share of common stock and each 1/10 of a share of preferred stock purchased, investors will receive
a warrant exercisable for&lt;span id="xdx_90B_eus-gaap--PreferredStockConvertibleConversionPrice_iI_c20220515__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zBD2r5QMIc09" title="Conversion price per share"&gt; 0.40&lt;/span&gt; shares of common stock. The exercise price of the warrants will be at a &lt;span id="xdx_90D_ecustom--PercentageOfWarrantExercisePrice_iI_pid_dp_uPure_c20220515__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember_zwvJjZLxptyi" title="Percentage of warrant exercise price"&gt;40%&lt;/span&gt; premium to the price paid
by investors for the initial shares of common stock purchased in the private placement. The preferred stock will be convertible into
common stock at the holder&#x2019;s election, subject to certain limitations such as beneficial ownership. The closing of the private
placement is conditioned on, among other customary items, the first patient enrolled in the Company&#x2019;s Phase 3 clinical
study (VIKTORIA-1) having received their first dose of treatment at a clinical site located in the United States, provided that if such
date does not occur on or before December 31, 2022, each investor will have the right to terminate its obligation to purchase securities
under the securities purchase agreement. The Company also entered into a customary registration rights agreement with the investors pursuant
to which it agreed to file a registration statement with the SEC registering the resale of (i) the shares of common stock to be issued
and sold in the private placement, (ii) the shares of common stock issuable upon conversion of the preferred stock purchased in the private
placement and (iii) the shares of common stock issuable upon conversion of the shares of preferred stock that may be issued upon exercise
of warrants purchased in the private placement. As of September 30, 2022, the Company has incurred $&lt;span id="xdx_902_ecustom--SaleOfStockTransactionFee_iI_c20220930_zW12ZCCoNdia" title="Incurred transaction fee"&gt;142,241&lt;/span&gt; in fees related to the transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 4, 2022, the Company entered into an Open Market Sale Agreement&lt;sup&gt;SM&lt;/sup&gt; with Jefferies LLC, as agent (&#x201c;Jefferies&#x201d;),
pursuant to which we may offer and sell, from time to time, through Jefferies, shares of our common stock having an aggregate offering
price of up to $&lt;span id="xdx_904_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220204__20220204__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_z5NN1CxPvd53" title="Aggregate offering price, common stock shares"&gt;50,000,000&lt;/span&gt;. The Company will pay Jefferies a commission equal to &lt;span id="xdx_900_ecustom--CommissionPercentage_iI_pid_dp_uPure_c20220204__us-gaap--TypeOfArrangementAxis__custom--OpenMarketSaleAgreementMember__dei--LegalEntityAxis__custom--JefferiesLLCMember_zsAJDimyeWh4" title="Aggregate offering price, commission percentage"&gt;3.0%&lt;/span&gt; of the aggregate gross proceeds from each sale
of such shares. On October 12, 2022, pursuant to the above agreement, the Company sold &lt;span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20221012__20221012__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zV16oqAstL53" title="Sale of stock number of shares issued in transaction"&gt;500,000&lt;/span&gt; shares of common stock in a single transaction
at a price of $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20221012__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zIMOBa3O3Hz7" title="Sale of stock price per shares"&gt;10.35&lt;/span&gt; per share, generating gross proceeds of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20221012__20221012__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9gbieHF9Q2g" title="Gross proceeds from public offering"&gt;5.2&lt;/span&gt; million ($&lt;span id="xdx_901_ecustom--GrossProceedsNetOfCommissionsAndOfferingExpenses_pn5n6_c20221012__20221012__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBXhydOGzIK1" title="Gross proceeds net of commissions and offering expenses"&gt;4.8&lt;/span&gt; million net of commissions and offering expenses).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;On
July 1, 2021, the Company completed a follow-on offering whereby it sold &lt;span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20210701__20210702__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zvOB5HpzNaF4" title="Sale of stock"&gt;2,250,000&lt;/span&gt; shares of common stock at a public offering price
of $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20210701__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_z0c7UKs8cB76" title="Issuance of public offering price per shares"&gt;25.00&lt;/span&gt; per share. The offering generated approximately $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210701__20210701__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zMte52NkxjO4" title="Gross proceeds from public offering"&gt;56.3&lt;/span&gt; million before deducting underwriting discounts of approximately $&lt;span id="xdx_909_eus-gaap--PaymentsForUnderwritingExpense_pn5n6_c20210701__20210701__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_z7INJy2BOfxl" title="Underwriting discounts"&gt;3.4&lt;/span&gt;
million and offering expenses of approximately $&lt;span id="xdx_90C_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20210701__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zCTS9rMaUrp4" title="Offering expenses"&gt;0.1&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 26, 2021, the Company completed a follow-on offering whereby it sold &lt;span id="xdx_906_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210226__20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zTFbfEDHBS9f" title="Sale of stock"&gt;1,971,100&lt;/span&gt; shares of common stock (including &lt;span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210226__20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember__srt--TitleOfIndividualAxis__custom--UnderwriterMember_zcfTPmt4T8Pc" title="Sale of stock number of shares issued in transaction"&gt;257,100&lt;/span&gt; shares
of common stock in connection with the full exercise of the underwriters&#x2019; option to purchase additional shares) at a public offering
price of $&lt;span id="xdx_905_eus-gaap--SaleOfStockPricePerShare_iI_c20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zJkjNdPBEZDg" title="Issuance of public offering price per shares"&gt;14.00&lt;/span&gt; per share. The aggregate gross proceeds from the sale of shares in the follow-on offering, including the sale of shares
pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, was approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20210226__20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zSq8xcrBdnwb" title="Gross proceeds from public offering"&gt;27.6&lt;/span&gt; million before
deducting underwriting discounts of approximately $&lt;span id="xdx_90A_eus-gaap--PaymentsForUnderwritingExpense_pn5n6_c20210225__20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zhVPFwh0iJTa" title="Deducting underwriting discounts"&gt;1.6&lt;/span&gt; million and offering expenses of approximately $&lt;span id="xdx_905_eus-gaap--DeferredOfferingCosts_iI_pn5n6_c20210226__us-gaap--SubsidiarySaleOfStockAxis__custom--FollowOnOfferingMember_zzjxQRvudk3j" title="Offering expenses"&gt;0.2&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;On
June 5, 2020, the Company entered into an At Market Issuance Sales Agreement (the &#x201c;ATM Agreement&#x201d;) with B. Riley FBR, Inc.
(the &#x201c;Agent&#x201d;). Pursuant to the ATM Agreement, the Company was able to offer and sell from time to time, at its option, shares
of common stock having an aggregate offering price of up to $&lt;span id="xdx_903_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20200605__20200605__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember__srt--RestatementAxis__custom--PlacementSharesMember_zBZ06rhN0sca" title="Aggregate offering price, common stock shares"&gt;10,000,000&lt;/span&gt;, par value $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20200605__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember__srt--RestatementAxis__custom--PlacementSharesMember_zQ4cFnQUnlq8" title="Common stock par value"&gt;0.001&lt;/span&gt; per share (the &#x201c;Placement Shares&#x201d;),
through the Agent.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;During
the nine months ended September 30, 2022 and 2021, the Company sold&lt;span id="xdx_902_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20220101__20220930__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember_z2pnYh62TvCa" title="Sale of stock number of shares issued in transaction"&gt; 0&lt;/span&gt; and &lt;span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20210101__20210930__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember_zCARXh8zCj74" title="Sale of stock number of shares issued in transaction"&gt;3,082&lt;/span&gt; shares, respectively, of common stock pursuant to the
ATM Agreement, at an average selling price of $&lt;span id="xdx_900_ecustom--AverageSellingPricePerShare_iI_pid_c20220930__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember_zhaCWxjn6Mw3" title="Average selling price per share"&gt;&lt;span id="xdx_901_ecustom--AverageSellingPricePerShare_iI_pid_c20210930__us-gaap--OtherInvestmentNotReadilyMarketableAxis__custom--AtmAgreementMember_z3K6shU1BAT8" title="Average selling price per share"&gt;12.64&lt;/span&gt; &lt;/span&gt;per share. On February 23, 2021, in conjunction with the Company&#x2019;s follow-on
offering, the ATM Agreement was terminated through the Agent.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-09-13_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">138000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-09-13_srt_MinimumMember"
      decimals="INF"
      unitRef="Shares">70000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2022-09-13">2025-09-19</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <CELC:EstimatedIncrementalFairValueOfWarrants
      contextRef="From2022-09-132022-09-13"
      decimals="0"
      unitRef="USD">271988</CELC:EstimatedIncrementalFairValueOfWarrants>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-09-01_srt_MinimumMember"
      decimals="INF"
      unitRef="Shares">30000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-09-01_srt_MaximumMember"
      decimals="INF"
      unitRef="Shares">65000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="From2022-05-152022-05-15_custom_SecuritiesPurchaseAgreementMember"
      decimals="-6"
      unitRef="USD">100000000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-05-15_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">5.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2022-05-15_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="USDPShares">0.40</us-gaap:PreferredStockConvertibleConversionPrice>
    <CELC:PercentageOfWarrantExercisePrice
      contextRef="AsOf2022-05-15_custom_PurchaseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.40</CELC:PercentageOfWarrantExercisePrice>
    <CELC:SaleOfStockTransactionFee contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">142241</CELC:SaleOfStockTransactionFee>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2022-02-042022-02-04_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <CELC:CommissionPercentage
      contextRef="AsOf2022-02-04_custom_OpenMarketSaleAgreementMember_custom_JefferiesLLCMember"
      decimals="INF"
      unitRef="Pure">0.030</CELC:CommissionPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-10-122022-10-12_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2022-10-12_us-gaap_SubsequentEventMember"
      decimals="INF"
      unitRef="USDPShares">10.35</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-10-122022-10-12_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">5200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <CELC:GrossProceedsNetOfCommissionsAndOfferingExpenses
      contextRef="From2022-10-122022-10-12_us-gaap_SubsequentEventMember"
      decimals="-5"
      unitRef="USD">4800000</CELC:GrossProceedsNetOfCommissionsAndOfferingExpenses>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-07-012021-07-02_custom_FollowOnOfferingMember"
      decimals="INF"
      unitRef="Shares">2250000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-07-01_custom_FollowOnOfferingMember"
      decimals="INF"
      unitRef="USDPShares">25.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-07-012021-07-01_custom_FollowOnOfferingMember"
      decimals="-5"
      unitRef="USD">56300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="From2021-07-012021-07-01_custom_FollowOnOfferingMember"
      decimals="-5"
      unitRef="USD">3400000</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2021-07-01_custom_FollowOnOfferingMember"
      decimals="-5"
      unitRef="USD">100000</us-gaap:DeferredOfferingCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-02-262021-02-26_custom_FollowOnOfferingMember"
      decimals="INF"
      unitRef="Shares">1971100</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-02-262021-02-26_custom_FollowOnOfferingMember_custom_UnderwriterMember"
      decimals="INF"
      unitRef="Shares">257100</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2021-02-26_custom_FollowOnOfferingMember"
      decimals="INF"
      unitRef="USDPShares">14.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-02-262021-02-26_custom_FollowOnOfferingMember"
      decimals="-5"
      unitRef="USD">27600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="From2021-02-252021-02-26_custom_FollowOnOfferingMember"
      decimals="-5"
      unitRef="USD">1600000</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2021-02-26_custom_FollowOnOfferingMember"
      decimals="-5"
      unitRef="USD">200000</us-gaap:DeferredOfferingCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2020-06-052020-06-05_custom_AtmAgreementMember_custom_PlacementSharesMember"
      decimals="0"
      unitRef="USD">10000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-06-05_custom_AtmAgreementMember_custom_PlacementSharesMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2022-01-012022-09-30_custom_AtmAgreementMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2021-01-012021-09-30_custom_AtmAgreementMember"
      decimals="INF"
      unitRef="Shares">3082</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <CELC:AverageSellingPricePerShare
      contextRef="AsOf2022-09-30_custom_AtmAgreementMember"
      decimals="INF"
      unitRef="USDPShares">12.64</CELC:AverageSellingPricePerShare>
    <CELC:AverageSellingPricePerShare
      contextRef="AsOf2021-09-30_custom_AtmAgreementMember"
      decimals="INF"
      unitRef="USDPShares">12.64</CELC:AverageSellingPricePerShare>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_805_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z6UB62rPNOBe" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6. &lt;span id="xdx_82F_zOIXLcdCIUZ5"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXKRuVCbhS02" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity for all stock options outstanding for the nine months ended September 30:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zdSt5uUNIXZ9" style="display: none"&gt;Schedule
of Stock Options Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left; padding-left: 0pt"&gt;Options outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrSCzwii4Kzb" style="width: 10%; text-align: right" title="Options outstanding beginning balance"&gt;1,315,321&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmG3tyVwNtA9" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, beginning balance"&gt;11.97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWx4nS4S9Woi" style="width: 10%; text-align: right" title="Options outstanding beginning balance"&gt;849,949&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7kTOrfTJbX5" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, beginning balance"&gt;9.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z24bDTEAooDb" style="text-align: right" title="Options outstanding shares, Granted"&gt;720,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoylRQYZJfY9" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;7.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEP0ol8c0Ztl" style="text-align: right" title="Options outstanding shares, Granted"&gt;402,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB4wUqGVw9Ia" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;23.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1OruBtbAq8g" style="text-align: right" title="Options outstanding shares, Exercised"&gt;(4,660&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHD4IcmxjWWh" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;5.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgmXMz0byNYh" style="text-align: right" title="Options outstanding shares, Exercised"&gt;(40,620&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsJqcpimauh5" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;7.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaY9De5qD7Mi" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding shares, Forfeited"&gt;(111,594&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWKU3C96ypi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;10.86&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxtm3Yyu4rJj" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding shares, Forfeited"&gt;(27,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm09d9yhCHfc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;19.07&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;Balance at September 30&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGne0HUh0gpi" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding ending balance"&gt;1,919,114&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziwFvkBcgfff" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, ending balance"&gt;6.08&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx6aSSNQFs51" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding ending balance"&gt;1,184,721&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgGaml9ho3j9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, ending balance"&gt;13.84&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Options exercisable at September 30:&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUhW99Mu70Tb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, ending balance"&gt;882,215&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zI25OtkO4F1b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercisable, ending balance"&gt;5.92&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmdmu8OU9Rj1" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, ending balance"&gt;560,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za9XuG27QAMh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercisable, ending balance"&gt;9.45&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Weighted Average Grant Date Fair Value for options granted during the period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjfrX6Ysl6ie" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted"&gt;4.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted"&gt;15.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z2AOOaCgIouk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 5pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zoQy3AYiKgE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes additional information about stock options outstanding and exercisable at September 30, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BB_znZyJLodyZig" style="display: none"&gt;Schedule
of Stock Options Outstanding and Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOL8fsPOb8yg" style="width: 13%; text-align: center" title="Options outstanding"&gt;1,919,114&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEv8n7Gm0i4l" title="Options outstanding, weighted average remaining contractual life"&gt;7.98&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLxtS2Xgalb6" style="width: 11%; text-align: right" title="Options outstanding, weighted average exercise price"&gt;6.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlyBlU1AP091" style="width: 11%; text-align: right" title="Options outstanding, aggregate intrinsic value"&gt;7,791,703&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjQeS3QHL4w4" style="width: 12%; text-align: center" title="Options exercisable"&gt;882,215&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEh8N1UvUQZe" style="width: 10%; text-align: right" title="Options exercisable, weighted average exercise price"&gt;5.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zImAuNvoARlj" style="width: 10%; text-align: right" title="Options exercisable, aggregate intrinsic value"&gt;3,779,591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_z4CfFqdHaSrf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized stock-based compensation expense for stock options of $&lt;span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAK0dPfSBFz2" title="Stock-based compensation expense"&gt;1,162,751&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSFCafLS0qDf" title="Stock-based compensation expense"&gt;673,022&lt;/span&gt; for the three months ended September
30, 2022 and 2021, respectively and $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZe47tGM0jrf" title="Stock-based compensation expense"&gt;3,329,969&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_pp0p0" title="Stock-based compensation expense"&gt;1,611,575&lt;/span&gt; for the nine months ended September 30, 2022 and 2021, respectively. In
May 2022, the Company modified the exercise price on &lt;span id="xdx_903_ecustom--StockOptionAwardsSharesModified_c20220531__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_pdd" title="Stock option awards shares modified"&gt;776,324&lt;/span&gt; stock option awards to $&lt;span id="xdx_908_ecustom--ModifiedStockOptionExercisePrice_c20220531__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_pdd" title="Stock option exercise price per share"&gt;5.50&lt;/span&gt;, the closing market price on the Nasdaq Capital
Market on May 17, 2022. The effect of this modification on stock-based compensation was $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20220701__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_zf3ht9msEeXf" title="Modification on stock-based compensation"&gt;49,088&lt;/span&gt; for the three months ending September
30, 2022 and $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pdp0_c20220101__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_zkmb53GlDmAi" title="Modification on stock-based compensation"&gt;477,431&lt;/span&gt; for the nine months ending September 30, 2022. The effect of this modification on stock-based compensation over
the remaining service period will be approximately $&lt;span id="xdx_90E_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_pdp0_c20220101__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyTwoMember_zJw3K86iQogk" title="Remaining stock based compensation expense related to modification"&gt;389,000&lt;/span&gt;. In December 2021, the Company modified the exercise price on &lt;span id="xdx_908_ecustom--StockOptionAwardsSharesModified_c20211231__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_pdd" title="Stock option awards shares modified"&gt;311,000&lt;/span&gt; stock
option awards to $&lt;span id="xdx_901_ecustom--ModifiedStockOptionExercisePrice_c20211231__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_pdd" title="Stock option exercise price per share"&gt;13.44&lt;/span&gt;, the closing market price on the Nasdaq Capital Market on December 15, 2021. No director or officer awards were
modified. The effect of this modification on stock-based compensation was $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20220701__20220930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_zG37NdoIA3S9" title="Modification on stock-based compensation"&gt;21,778&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20210701__20210930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_zwpaitmJbdq2" title="Modification on stock-based compensation"&gt;0&lt;/span&gt; for the three months ended September 30, 2022
and 2021, respectively and $&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20220101__20220930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_zBjO7YAWKebf" title="Modification on stock-based compensation"&gt;75,562&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20210101__20210930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_zg2Fq2Rbyai4" title="Modification on stock-based compensation"&gt;0&lt;/span&gt; for the nine months ended September 30, 2022 and 2021, respectively. The effect of this modification
on stock-based compensation over the remaining service period will be approximately $&lt;span id="xdx_90B_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_pdp0_c20220101__20220930__us-gaap--AwardDateAxis__custom--InDecemberTwoThousandTwentyOneMember_z2scb6adw252" title="Remaining stock based compensation expense related to modification"&gt;219,000&lt;/span&gt;. In May 2020, the Company modified the exercise
price on &lt;span id="xdx_902_ecustom--StockOptionAwardsSharesModified_c20200531__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_pdd" title="Stock option awards shares modified"&gt;203,750&lt;/span&gt; stock option awards to $&lt;span id="xdx_909_ecustom--ModifiedStockOptionExercisePrice_c20200531__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_pdd" title="Stock option exercise price per share"&gt;5.10&lt;/span&gt;, the closing market price on the Nasdaq Capital Market on May 14, 2020. No director or
officer awards were modified. The effect of this modification on stock-based compensation was $&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20220701__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_zmm1nhLhElac" title="Stock based compensation expense related to modification"&gt;7,681&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_c20210701__20210930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_zvg30821IeBf" title="Stock based compensation expense related to modification"&gt;12,602&lt;/span&gt; for the three months
ended September 30, 2022 and 2021, respectively and $&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20220101__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_zk4Je60sKHtl" title="Stock based compensation expense related to modification"&gt;30,897&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20210101__20210930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_zAHjbcXvfNof" title="Stock based compensation expense related to modification"&gt;34,396&lt;/span&gt; for the nine months ended September 30, 2022 and 2021. The effect
of this modification on stock-based compensation over the remaining service period will be approximately $&lt;span id="xdx_90D_ecustom--RemainingStockBasedCompensationExpenseRelatedToModification_c20220101__20220930__us-gaap--AwardDateAxis__custom--InMayTwoThousandTwentyMember_pp0p0" title="Remaining stock based compensation expense related to modification"&gt;27,000&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z9UDxxKJQwg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Black-Scholes option-pricing model was used to estimate the grant date fair value of equity-based awards with the following weighted-average
assumptions for the nine months ended September 30:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zRtXAuSVZuD9" style="display: none"&gt;Schedule
of Assumptions for Fair Value of Equity-based Awards&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_ztDYIhGZ9d81" title="Risk-free interest rate"&gt;1.68&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zhlccm75GFb3" title="Risk-free interest rate"&gt;3.93&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_zrhyCssAWLvc" title="Risk-free interest rate"&gt;0.63&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_z0XOL4D44oul" title="Risk-free interest rate"&gt;1.16%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zhz9fIEUQC82" title="Expected volatility"&gt;76.2&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zM0sHkmKRRn" title="Expected volatility"&gt;79.6%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_z5TZleI7sOqa" title="Expected volatility"&gt;76.6&lt;/span&gt;% - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_ztYCAenRGsV1" title="Expected volatility"&gt;76.9%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zvsIlC59A2ig" title="Expected life (years)"&gt;5.29&lt;/span&gt; to &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_z0Lf6IOqg6N9" title="Expected life (years)"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_z6iXcr5GsyLk" title="Expected life (years)"&gt;5.0&lt;/span&gt; to &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_z0hnYf9aWiyi" title="Expected life (years)"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1pt"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930_zLtew7ruHLdi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Expected dividend yield"&gt;0%&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210930_zMXjb4JBSQSi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Expected dividend yield"&gt;0%&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zvggBn5mqZX9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
inputs for the Black-Scholes valuation model require management&#x2019;s significant assumptions. Prior to the Company&#x2019;s initial
public offering, the price per share of common stock was determined by the Company&#x2019;s board based on recent prices of common stock
sold in private offerings. Subsequent to the initial public offering, the price per share of common stock is determined by using the
closing market price on the Nasdaq Capital Market on the grant date. The risk-free interest rates are based on the rate for U.S. Treasury
securities at the date of grant with maturity dates approximately equal to the expected life at the grant date. The expected life is
based on the simplified method in accordance with the SEC Staff Accounting Bulletin Nos. 107 and 110. The expected volatility is estimated
based on historical volatility information of peer companies that are publicly available in combination with the Company&#x2019;s calculated
volatility since being publicly traded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
assumptions used to calculate the grant date fair value of non-employee options are generally consistent with the assumptions used for
options granted to employees. In the event the Company terminates any of its consulting agreements, the unvested options issued in connection
with the agreements would also be cancelled.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWcVavv2naSk" title="Restricted stock awards outstanding"&gt;3,273&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXuzyC9VjK53" title="Restricted stock awards outstanding"&gt;2,964&lt;/span&gt; shares of restricted stock outstanding as of September 30, 2022 and 2021, respectively, and &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWiSqwz30QA3" title="Restricted stock awards vested"&gt;250&lt;/span&gt; and &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_pid_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zms9SGSqxkXg" title="Restricted stock awards vested"&gt;0&lt;/span&gt; shares
of restricted stock vested during the three months ended September 30, 2022 and 2021. The Company recognized stock-based compensation
expense for restricted stock of $&lt;span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pp0p0" title="Recognized stock-based compensation expense"&gt;7,245&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210701__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zc6dzIGeXS9j" title="Recognized stock-based compensation expense"&gt;20,792&lt;/span&gt; for the three months ended September 30, 2022 and 2021, respectively and $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pp0p0" title="Recognized stock-based compensation expense"&gt;36,686&lt;/span&gt; and
$&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_pp0p0" title="Recognized stock-based compensation expense"&gt;59,359&lt;/span&gt; for the nine months ended September 30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company initially reserved a maximum of &lt;span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20171025__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zetR1SO8ohM7" title="Common stock, shares reserved for issuance"&gt;750,000&lt;/span&gt; shares of common stock for issuance under the 2017 Amended and Restated Stock Incentive
Plan (the &#x201c;2017 Plan&#x201d;). The number of shares reserved for issuance was automatically increased by &lt;span id="xdx_90B_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20200101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zkAsYA1wbPFj" title="Increase in number of shares reserved for issuance"&gt;102,540&lt;/span&gt;, &lt;span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_ztT5DeoIX6Ol" title="Increase in number of shares reserved for issuance"&gt;102,998&lt;/span&gt; and &lt;span id="xdx_907_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220101__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zj6XN6vz8t4" title="Increase in number of shares reserved for issuance"&gt;149,189&lt;/span&gt;
shares on January 1, 2020, 2021 and 2022, respectively, and will&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20171024__20171025__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_ztmUDAshJJB2" title="Stock option description"&gt; increase automatically on January 1 each year from 2023 through 2027
by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding
December 31&lt;/span&gt;. At the Annual Meeting held on May 12, 2021 and May 12, 2022, the stockholders approved a one-time, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20210511__20210512__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zGjxZJ02LvK4" title="Additional shares authorized under plan"&gt;500,000&lt;/span&gt; increase each
year for a total increase of &lt;span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210512__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zCovsXtxhoNk" title="Number of shares reserved for issuance"&gt;1,000,000&lt;/span&gt; to the number of shares reserved for issuance under the 2017 Plan. However, the Company&#x2019;s
board may reduce the amount of the increase in any particular year. The total remaining shares available for grant under the Company&#x2019;s
2017 Plan as of September 30, 2022 was &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220930__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenPlanMember_zf9avpulotPh" title="Shares available for grant under the 2017 Plan"&gt;325,094&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_zs2M9xn82wi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
unrecognized compensation cost related to stock options and restricted stock is estimated to be recognized as follows for the year ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_z5Anm6SF7JPa" style="display: none"&gt;Schedule
of Unrecognized Compensation Cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20220930_zS9IIv1QzhC3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_iI_pp0p0_maESSBCz4AO_z19kAJ5fFKx4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,116,837&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear_iI_pp0p0_maESSBCz4AO_z0vwGnH7SMxd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,277,254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_iI_pp0p0_maESSBCz4AO_zqm7R22ELJB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,130,739&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_iI_pp0p0_maESSBCz4AO_zAn3k5whQCfe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,333,749&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_iI_pp0p0_maESSBCz4AO_z7t9Gflps688" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;176,866&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iTI_pp0p0_mtESSBCz4AO_zR07yCLDDgHh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total estimated compensation cost to be recognized&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,035,445&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A5_zOXLhAEw9Hk5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized stock-based compensation expense related to its employee stock purchase plan of $&lt;span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_pp0p0" title="Recognized stock-based compensation expense"&gt;53,058&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_c20210701__20210930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_pp0p0" title="Recognized stock-based compensation expense"&gt;6,102&lt;/span&gt; for the three months
ended September 30, 2022 and 2021, respectively and $&lt;span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20220101__20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zQqNkw4Tpe8e" title="Recognized stock-based compensation expense"&gt;132,129&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pp0p0_c20210101__20210930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zbKMndYp0QRj" title="Recognized stock-based compensation expense"&gt;18,397&lt;/span&gt; for the nine months ended September 30, 2022 and 2021, respectively.
The Company initially reserved a total of &lt;span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20180510__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_pdd" title="Common stock, shares reserved for issuance"&gt;100,000&lt;/span&gt; shares for issuance under the employee stock purchase plan. The number of shares reserved
for issuance was automatically increased by &lt;span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20200101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zJtgFytBFeS9" title="Common stock, shares reserved for issuance"&gt;51,270&lt;/span&gt;, &lt;span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20210101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zmaYiPQLkmNg" title="Common stock, shares reserved for issuance"&gt;51,499&lt;/span&gt; and &lt;span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20220101__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zILi5CZUiaK7" title="Common stock, shares reserved for issuance"&gt;74,594&lt;/span&gt; shares on January 1, 2020, 2021 and 2022, respectively, and will
increase automatically on each subsequent January 1 by &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20220101__20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_zZw14CMUmRwe" title="Stock option description"&gt;the number of shares equal to 0.5% of the total outstanding number of shares&lt;/span&gt; of
Company common stock as of the immediately preceding December 31. However, the Company&#x2019;s board may reduce the amount of the increase
in any particular year. The total remaining shares available for issuance under the employee stock purchase plan as of September 30,
2022 was &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20220930__us-gaap--AwardTypeAxis__custom--EmployeeStockPurchasePlanMember_z8eBTO69ADXf" title="Shares available for issuance"&gt;208,929&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_znTevyzLbkY4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized total stock-based compensation expense as follows for the three and nine months ended September 30:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zyqj1H369I9j" style="display: none"&gt;Schedule of Stock-based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220701__20220930_z6aPTmK7hdK" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210701__20210930_zlkjrihu6ZO7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20220930_zPjxEGuS9ZVg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20210930_z58qM5soSdba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense in operating expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrpIe4TThLch" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 44%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;676,524&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;434,597&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,937,707&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,017,855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQtyiiTlTWO7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;546,530&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;265,319&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,561,077&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;671,476&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_z5ThuDlj7Iei" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,223,054&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;699,916&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,498,784&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,689,331&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zqqrnSF5MODg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zXKRuVCbhS02" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the activity for all stock options outstanding for the nine months ended September 30:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zdSt5uUNIXZ9" style="display: none"&gt;Schedule
of Stock Options Activity&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left; padding-left: 0pt"&gt;Options outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrSCzwii4Kzb" style="width: 10%; text-align: right" title="Options outstanding beginning balance"&gt;1,315,321&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmG3tyVwNtA9" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, beginning balance"&gt;11.97&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWx4nS4S9Woi" style="width: 10%; text-align: right" title="Options outstanding beginning balance"&gt;849,949&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z7kTOrfTJbX5" style="width: 10%; text-align: right" title="Weighted Average Exercise Price, beginning balance"&gt;9.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z24bDTEAooDb" style="text-align: right" title="Options outstanding shares, Granted"&gt;720,047&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zoylRQYZJfY9" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;7.19&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEP0ol8c0Ztl" style="text-align: right" title="Options outstanding shares, Granted"&gt;402,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zB4wUqGVw9Ia" style="text-align: right" title="Weighted Average Exercise Price, Granted"&gt;23.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1OruBtbAq8g" style="text-align: right" title="Options outstanding shares, Exercised"&gt;(4,660&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHD4IcmxjWWh" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;5.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgmXMz0byNYh" style="text-align: right" title="Options outstanding shares, Exercised"&gt;(40,620&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zsJqcpimauh5" style="text-align: right" title="Weighted Average Exercise Price, Exercised"&gt;7.26&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zaY9De5qD7Mi" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding shares, Forfeited"&gt;(111,594&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zPWKU3C96ypi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;10.86&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxtm3Yyu4rJj" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding shares, Forfeited"&gt;(27,158&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zm09d9yhCHfc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, Forfeited"&gt;19.07&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; padding-left: 10pt"&gt;Balance at September 30&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zGne0HUh0gpi" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding ending balance"&gt;1,919,114&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ziwFvkBcgfff" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, ending balance"&gt;6.08&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zx6aSSNQFs51" style="border-bottom: Black 1pt solid; text-align: right" title="Options outstanding ending balance"&gt;1,184,721&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgGaml9ho3j9" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price, ending balance"&gt;13.84&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Options exercisable at September 30:&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUhW99Mu70Tb" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, ending balance"&gt;882,215&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zI25OtkO4F1b" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercisable, ending balance"&gt;5.92&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmdmu8OU9Rj1" style="border-bottom: Black 2.5pt double; text-align: right" title="Options exercisable, ending balance"&gt;560,915&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_za9XuG27QAMh" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercisable, ending balance"&gt;9.45&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Weighted Average Grant Date Fair Value for options granted during the period:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjfrX6Ysl6ie" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted"&gt;4.87&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20210101__20210930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Weighted Average Grant Date Fair Value for options granted"&gt;15.28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1315321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">11.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">849949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">9.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="Shares">720047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="USDPShares">7.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="Shares">402550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="USDPShares">23.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="Shares">4660</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="USDPShares">5.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="Shares">40620</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="USDPShares">7.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="Shares">111594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="USDPShares">10.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="Shares">27158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="USDPShares">19.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1919114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1184721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">13.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">882215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">560915</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">9.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="USDPShares">4.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-09-30_us-gaap_EmployeeStockOptionMember17140953"
      decimals="INF"
      unitRef="USDPShares">15.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_898_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_zoQy3AYiKgE" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes additional information about stock options outstanding and exercisable at September 30, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify; text-indent: 0in"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BB_znZyJLodyZig" style="display: none"&gt;Schedule
of Stock Options Outstanding and Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="9" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Outstanding&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Options Exercisable&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOL8fsPOb8yg" style="width: 13%; text-align: center" title="Options outstanding"&gt;1,919,114&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEv8n7Gm0i4l" title="Options outstanding, weighted average remaining contractual life"&gt;7.98&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zLxtS2Xgalb6" style="width: 11%; text-align: right" title="Options outstanding, weighted average exercise price"&gt;6.08&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlyBlU1AP091" style="width: 11%; text-align: right" title="Options outstanding, aggregate intrinsic value"&gt;7,791,703&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjQeS3QHL4w4" style="width: 12%; text-align: center" title="Options exercisable"&gt;882,215&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEh8N1UvUQZe" style="width: 10%; text-align: right" title="Options exercisable, weighted average exercise price"&gt;5.92&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20220930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zImAuNvoARlj" style="width: 10%; text-align: right" title="Options exercisable, aggregate intrinsic value"&gt;3,779,591&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">1919114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953">P7Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">6.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">7791703</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">882215</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">5.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2022-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">3779591</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">1162751</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-07-012021-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">673022</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">3329969</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-09-30_us-gaap_StockOptionMember"
      decimals="0"
      unitRef="USD">1611575</us-gaap:AllocatedShareBasedCompensationExpense>
    <CELC:StockOptionAwardsSharesModified
      contextRef="AsOf2022-05-31_custom_InMayTwoThousandTwentyTwoMember"
      decimals="INF"
      unitRef="Shares">776324</CELC:StockOptionAwardsSharesModified>
    <CELC:ModifiedStockOptionExercisePrice
      contextRef="AsOf2022-05-31_custom_InMayTwoThousandTwentyTwoMember"
      decimals="INF"
      unitRef="USDPShares">5.50</CELC:ModifiedStockOptionExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-07-012022-09-30_custom_InMayTwoThousandTwentyTwoMember"
      decimals="0"
      unitRef="USD">49088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-012022-09-30_custom_InMayTwoThousandTwentyTwoMember"
      decimals="0"
      unitRef="USD">477431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <CELC:RemainingStockBasedCompensationExpenseRelatedToModification
      contextRef="From2022-01-012022-09-30_custom_InMayTwoThousandTwentyTwoMember"
      decimals="0"
      unitRef="USD">389000</CELC:RemainingStockBasedCompensationExpenseRelatedToModification>
    <CELC:StockOptionAwardsSharesModified
      contextRef="AsOf2021-12-31_custom_InDecemberTwoThousandTwentyOneMember"
      decimals="INF"
      unitRef="Shares">311000</CELC:StockOptionAwardsSharesModified>
    <CELC:ModifiedStockOptionExercisePrice
      contextRef="AsOf2021-12-31_custom_InDecemberTwoThousandTwentyOneMember"
      decimals="INF"
      unitRef="USDPShares">13.44</CELC:ModifiedStockOptionExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-07-012022-09-30_custom_InDecemberTwoThousandTwentyOneMember"
      decimals="0"
      unitRef="USD">21778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2021-07-012021-09-30_custom_InDecemberTwoThousandTwentyOneMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-012022-09-30_custom_InDecemberTwoThousandTwentyOneMember"
      decimals="0"
      unitRef="USD">75562</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2021-01-012021-09-30_custom_InDecemberTwoThousandTwentyOneMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <CELC:RemainingStockBasedCompensationExpenseRelatedToModification
      contextRef="From2022-01-012022-09-30_custom_InDecemberTwoThousandTwentyOneMember"
      decimals="0"
      unitRef="USD">219000</CELC:RemainingStockBasedCompensationExpenseRelatedToModification>
    <CELC:StockOptionAwardsSharesModified
      contextRef="AsOf2020-05-31_custom_InMayTwoThousandTwentyMember"
      decimals="INF"
      unitRef="Shares">203750</CELC:StockOptionAwardsSharesModified>
    <CELC:ModifiedStockOptionExercisePrice
      contextRef="AsOf2020-05-31_custom_InMayTwoThousandTwentyMember"
      decimals="INF"
      unitRef="USDPShares">5.10</CELC:ModifiedStockOptionExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-07-012022-09-30_custom_InMayTwoThousandTwentyMember"
      decimals="0"
      unitRef="USD">7681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2021-07-012021-09-30_custom_InMayTwoThousandTwentyMember"
      decimals="0"
      unitRef="USD">12602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2022-01-012022-09-30_custom_InMayTwoThousandTwentyMember"
      decimals="0"
      unitRef="USD">30897</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="From2021-01-012021-09-30_custom_InMayTwoThousandTwentyMember"
      decimals="0"
      unitRef="USD">34396</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <CELC:RemainingStockBasedCompensationExpenseRelatedToModification
      contextRef="From2022-01-012022-09-30_custom_InMayTwoThousandTwentyMember"
      decimals="0"
      unitRef="USD">27000</CELC:RemainingStockBasedCompensationExpenseRelatedToModification>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z9UDxxKJQwg1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Black-Scholes option-pricing model was used to estimate the grant date fair value of equity-based awards with the following weighted-average
assumptions for the nine months ended September 30:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zRtXAuSVZuD9" style="display: none"&gt;Schedule
of Assumptions for Fair Value of Equity-based Awards&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_ztDYIhGZ9d81" title="Risk-free interest rate"&gt;1.68&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zhlccm75GFb3" title="Risk-free interest rate"&gt;3.93&lt;/span&gt;&lt;/span&gt;%&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_zrhyCssAWLvc" title="Risk-free interest rate"&gt;0.63&lt;/span&gt;% - &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_z0XOL4D44oul" title="Risk-free interest rate"&gt;1.16%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zhz9fIEUQC82" title="Expected volatility"&gt;76.2&lt;/span&gt;% - &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_zM0sHkmKRRn" title="Expected volatility"&gt;79.6%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_z5TZleI7sOqa" title="Expected volatility"&gt;76.6&lt;/span&gt;% - &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_ztYCAenRGsV1" title="Expected volatility"&gt;76.9%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected life (years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MinimumMember_zvsIlC59A2ig" title="Expected life (years)"&gt;5.29&lt;/span&gt; to &lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20220930__srt--RangeAxis__srt--MaximumMember_z0Lf6IOqg6N9" title="Expected life (years)"&gt;6.25&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MinimumMember_z6iXcr5GsyLk" title="Expected life (years)"&gt;5.0&lt;/span&gt; to &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210930__srt--RangeAxis__srt--MaximumMember_z0hnYf9aWiyi" title="Expected life (years)"&gt;6.08&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1pt"&gt;Expected dividend yield&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220930_zLtew7ruHLdi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Expected dividend yield"&gt;0%&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210930_zMXjb4JBSQSi" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Expected dividend yield"&gt;0%&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-09-30_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-01-012022-09-30_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-09-30_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.0063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-09-30_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.0116</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-09-30_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-01-012022-09-30_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.796</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-09-30_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-09-30_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-09-30_srt_MinimumMember">P5Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2022-01-012022-09-30_srt_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-09-30_srt_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-09-30_srt_MaximumMember">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-01-01to2022-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-09-30"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">3273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-09-30_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">2964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2022-07-012022-09-30_us-gaap_RestrictedStockMember17143015"
      decimals="INF"
      unitRef="Shares">250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember17143015"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30_us-gaap_RestrictedStockMember17143015"
      decimals="0"
      unitRef="USD">7245</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-07-012021-09-30_us-gaap_RestrictedStockMember17143015"
      decimals="0"
      unitRef="USD">20792</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30_us-gaap_RestrictedStockMember17143031"
      decimals="0"
      unitRef="USD">36686</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-09-30_us-gaap_RestrictedStockMember17143031"
      decimals="0"
      unitRef="USD">59359</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2017-10-25_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      unitRef="Shares">750000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-01-01_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      unitRef="Shares">102540</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-01-01_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      unitRef="Shares">102998</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-01-01_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      unitRef="Shares">149189</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2017-10-242017-10-25_custom_TwoThousandSeventeenPlanMember">increase automatically on January 1 each year from 2023 through 2027
by the number of shares equal to 1.0% of the aggregate number of outstanding shares of Company common stock as of the immediately preceding
December 31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2021-05-112021-05-12_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-05-12_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-09-30_custom_TwoThousandSeventeenPlanMember"
      decimals="INF"
      unitRef="Shares">325094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_892_eus-gaap--ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_zs2M9xn82wi1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
unrecognized compensation cost related to stock options and restricted stock is estimated to be recognized as follows for the year ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BD_z5Anm6SF7JPa" style="display: none"&gt;Schedule
of Unrecognized Compensation Cost&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20220930_zS9IIv1QzhC3" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear_iI_pp0p0_maESSBCz4AO_z19kAJ5fFKx4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 82%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,116,837&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear_iI_pp0p0_maESSBCz4AO_z0vwGnH7SMxd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,277,254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears_iI_pp0p0_maESSBCz4AO_zqm7R22ELJB5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,130,739&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears_iI_pp0p0_maESSBCz4AO_zAn3k5whQCfe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,333,749&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears_iI_pp0p0_maESSBCz4AO_z7t9Gflps688" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;176,866&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iTI_pp0p0_mtESSBCz4AO_zR07yCLDDgHh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total estimated compensation cost to be recognized&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;8,035,445&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">1116837</CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear>
    <CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">3277254</CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear>
    <CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">2130739</CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears>
    <CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">1333749</CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears>
    <CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">176866</CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">8035445</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-07-012022-09-30_custom_EmployeeStockPurchasePlanMember"
      decimals="0"
      unitRef="USD">53058</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-07-012021-09-30_custom_EmployeeStockPurchasePlanMember"
      decimals="0"
      unitRef="USD">6102</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-09-30_custom_EmployeeStockPurchasePlanMember"
      decimals="0"
      unitRef="USD">132129</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-09-30_custom_EmployeeStockPurchasePlanMember"
      decimals="0"
      unitRef="USD">18397</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2018-05-10_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      unitRef="Shares">100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-01-01_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      unitRef="Shares">51270</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2021-01-01_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      unitRef="Shares">51499</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2022-01-01_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      unitRef="Shares">74594</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2022-01-012022-09-30_custom_EmployeeStockPurchasePlanMember">the number of shares equal to 0.5% of the total outstanding number of shares</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2022-09-30_custom_EmployeeStockPurchasePlanMember"
      decimals="INF"
      unitRef="Shares">208929</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_89B_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_znTevyzLbkY4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized total stock-based compensation expense as follows for the three and nine months ended September 30:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B4_zyqj1H369I9j" style="display: none"&gt;Schedule of Stock-based Compensation Expense&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20220701__20220930_z6aPTmK7hdK" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20210701__20210930_zlkjrihu6ZO7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20220101__20220930_zPjxEGuS9ZVg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210101__20210930_z58qM5soSdba" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Three Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock-based compensation expense in operating expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zrpIe4TThLch" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 44%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;676,524&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;434,597&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,937,707&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,017,855&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zQtyiiTlTWO7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;546,530&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;265,319&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,561,077&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;671,476&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--ShareBasedCompensation_z5ThuDlj7Iei" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,223,054&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;699,916&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,498,784&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,689,331&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">676524</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-07-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">434597</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">1937707</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-09-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">1017855</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">546530</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-07-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">265319</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">1561077</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-09-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">671476</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012022-09-30"
      decimals="0"
      unitRef="USD">1223054</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-07-012021-09-30"
      decimals="0"
      unitRef="USD">699916</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-09-30"
      decimals="0"
      unitRef="USD">3498784</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-09-30"
      decimals="0"
      unitRef="USD">1689331</us-gaap:ShareBasedCompensation>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_80A_eus-gaap--DebtDisclosureTextBlock_zVMkAPbuDKu7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7. &lt;span id="xdx_82C_zAZeOe7h8Sce"&gt;Debt&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 8, 2021, the Company entered into a loan and security agreement (the &#x201c;Loan Agreement&#x201d;) with Innovatus Life Sciences
Lending Fund I, LP, a Delaware limited partnership (&#x201c;Innovatus&#x201d;) in its capacity as Collateral Agent and sole Lender. The
Lender agreed to loan up to $&lt;span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pn6n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zzfwTxSNil7b" title="Line of credit faciltiy, maximum borrowing capacity"&gt;25&lt;/span&gt; million in three tranches consisting of (i) a $&lt;span id="xdx_90D_ecustom--NonContingentTermALoanFunded_iI_pn6n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zGu5jhyeGrsg" title="Non contingent term A loan, funded"&gt;15.0&lt;/span&gt; million non-contingent term A loan that was funded
on April 8, 2021, (ii) a $&lt;span id="xdx_909_ecustom--TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo_iI_pn6n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zRwe3BKO65h2" title="Term B loan to be funded before March 31, 2022"&gt;5&lt;/span&gt; million term B loan to be funded upon request of the Company no later than March 31, 2022, and (iii) a $&lt;span id="xdx_90B_ecustom--TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree_iI_pn6n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zM6bq93rvq6f" title="Term C loan to be funded before March 31, 2023"&gt;5&lt;/span&gt;
million term C loan to be funded upon request of the Company no later than March 31, 2023 (collectively the &#x201c;Term Loans&#x201d;).
The Company is no longer eligible to draw on the term B loan. Funding of the term C is subject to the Company&#x2019;s ability to achieve
certain milestones.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20210407__20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zK9qT0Nlql62" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Loan Agreement also contains certain events of default, warranties and covenants of the Company. In connection with each funding of
the Term Loans, the Company is required to issue Innovatus a warrant (the &#x201c;Warrants&#x201d;) to purchase a number of shares of
the Company&#x2019;s stock equal to 2.5% of the principal amount of the relevant Term Loan funded by the exercise price, which will
be based on the lower of (i) $14.40 per share or (ii) the volume weighted price per share of the Company&#x2019;s stock for the
five-trading day period ending on the last trading day immediately preceding the funding date of the Term C loan&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The warrants may be exercised on a cashless basis and are immediately exercisable through the tenth anniversary of the applicable
funding date. In connection with the first tranche of the Term Loans, the Company issued a warrant to Innovatus to purchase &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z6698ZyWczUi"&gt;26,042 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of the Company&#x2019;s common stock at an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zaeppbZ3P0ng"&gt;14.40 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share. The company evaluated the warrant under ASC 470, debt, and recognized an additional debt discount of approximately $&lt;span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumNet_iI_pn5n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zKJmPnIXIP5b"&gt;0.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;million
based on the relative fair value of the base instruments and warrants. The company calculated the fair value of the warrant using
the Black-Scholes model. In connection with the funding of the first tranche of the Term Loans, a final fee of approximately $&lt;span id="xdx_90F_ecustom--FinalFeePayableToLenderAmount_iI_pn5n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zZfurxJObuR1" title="Final fee payable to lender, amount"&gt;0.7&lt;/span&gt;
million was recorded as additional principal as a debt discount, and a facility fee of approximately $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_pn5n6_c20210408__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zL9IvyET5Mj4" title="Debt discount, amount"&gt;0.1&lt;/span&gt;
million was recorded as additional debt discount. The Company is also required to maintain a minimum cash balance in agreement with
the term loans&#x2019; default terms.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 9, 2022, the Company amended the Loan Agreement. Under the amended Loan Agreement, Innovatus, as Lender, has agreed to loan up
to $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pn6n6_c20220809__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zaZYsiKv85n6" title="Face amount"&gt;75&lt;/span&gt; million, a $&lt;span id="xdx_90E_ecustom--IncreaseFromOriginalLoanAmount_iI_pn6n6_c20220809__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_zSA1ywUATHIe" title="Increase from original loan amount"&gt;50&lt;/span&gt; million increase from the original Loan Amount, in five tranches consisting of: (i) a $&lt;span id="xdx_90B_ecustom--NonContingentTermALoanFunded_iI_pn6n6_c20210408__us-gaap--PlanNameAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember_z19Sd4urRey7" title="Non contigent term A loan, funded"&gt;15&lt;/span&gt; million term A loan that
was funded on April 8, 2021 upon entering into the original Loan Agreement, (ii) a $&lt;span id="xdx_90E_ecustom--UnfundedContingentLoanAmount_iI_pn6n6_c20220809__us-gaap--PlanNameAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermBLoanMember_z7H4tT48xq89" title="Unfunded contingent loan, amount"&gt;20&lt;/span&gt; million term B loan to be funded upon request
of the Company no later than December 31, 2022, with such funding conditioned upon the closing of the Company&#x2019;s $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20220516__20220516__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zty9UH6Qm9Fh" title="Private placement value"&gt;100&lt;/span&gt; million private
placement announced on May 16, 2022, (iii) a $&lt;span id="xdx_908_ecustom--UnfundedContingentLoanAmount_iI_pn6n6_c20220809__us-gaap--PlanNameAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermCLoanMember_zUq4gZmdjvbf" title="Unfunded contingent loan, amount"&gt;10&lt;/span&gt; million term C loan to be funded upon request of the Company no later than April 1,
2024, (iv) a $&lt;span id="xdx_903_ecustom--UnfundedContingentLoanAmount_iI_pn6n6_c20220809__us-gaap--PlanNameAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermDLoanMember_z48AqmjDMT2k" title="Unfunded contingent loan, amount"&gt;20&lt;/span&gt; million term D loan to be funded upon request of the Company no later than November 1, 2024, and (v) a $&lt;span id="xdx_905_ecustom--UnfundedContingentLoanAmount_iI_pn6n6_c20220809__us-gaap--PlanNameAxis__custom--AmendedLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovatusLifeSciencesMember__us-gaap--DebtInstrumentAxis__custom--TermELoanMember_zg55QHBusuwc" title="Unfunded contingent loan, amount"&gt;10&lt;/span&gt; million term
E loan to be funded upon request of the Company no later than February 28, 2025. Funding of the term B loan is conditioned upon the closing
of the Company&#x2019;s $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20220516__20220516_zAA7L8Vj8RVa" title="Private placement"&gt;100&lt;/span&gt; million private placement announced on May 16, 2022, and funding of the term C, D, and E loans are conditioned
upon satisfaction of certain clinical trial milestones and certain financial covenants determined on a pro forma as-funded basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under
the amended Loan Agreement, Innovatus has the right, at its election and until August 9, 2025, the third anniversary of the loan amendment
date, to convert into Common Stock up to &lt;span id="xdx_907_ecustom--LoanConvertibleToStockPercentageDescription_c20220807__20220809__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zC86WYImKVRd" title="Loan convertible to stock percentage, description"&gt;(1) 20% of the outstanding principal amount of term A loan, and (ii) an additional 7% of the
amount by which the aggregate principal amount of the funded term B, C, D, and E loans exceed $35 million, provided that the aggregate
outstanding principal amount of all term loans is at least $35 million, which such conversion based upon a price per share equal to $10.00&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateTerms_pid_dp_c20220808__20220809__us-gaap--TypeOfArrangementAxis__custom--AmendedLoanAgreementMember_zQA0BzkYi9qi" title="Debt instrument interest rate description"&gt;The
Company is entitled to make interest-only payments for forty-eight months, or up to sixty months from the original Loan Agreement date
if certain conditions are met. The Term Loans will mature on April 8, 2027, the sixth anniversary of the initial funding date, and will
bear interest at a rate equal to the sum of (a) the greater of (i) Prime Rate (as defined in the amended Loan Agreement) or (ii) 3.25%,
plus 5.7%. Additionally, the Company elected to make 4.95% of the interest rate as payable in-kind, which shall accrue as principal monthly.
The Amended Loan Agreement includes certain other fees, such as a final fee of 4.5% of the funded loan amounts not converted into equity
by the lender, which apply if prepayment, an event of default, or change of control occurs prior to August 9, 2025, the third anniversary
of the Amendment date&lt;/span&gt;. Subject to certain other conditions, no final fee will be payable after August 9, 2025. The Company has the option
to prepay the loan at any time following the first anniversary of the amended loan agreement date, with tiered prepayment fees ranging
from 0 to 1% based on when the prepayment occurs. Upon a change in control or event of default, mandatory prepayment will be required,
and if such an event occurs prior to the first anniversary of the Amendment date, an additional prepayment fee of &lt;span id="xdx_909_ecustom--PrepaymentFeePercentage_pid_dp_uPure_c20220808__20220809_z0ZjeKbhgKPi" title="Prepayment fee, percentage"&gt;3.0&lt;/span&gt;% applies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
amended Loan Agreement remains secured by all assets of the Company. Proceeds will be used for working capital purposes and to fund the
Company&#x2019;s general business requirements. The amended Loan Agreement contains customary representations and warranties and covenants,
subject to customary carve outs, and includes financial covenants related to or based upon liquidity, trailing twelve months revenue
and the funded loan amounts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the original and amended Loan Agreement and the funding of the first tranche of the Term Loans, the Company incurred
debt issuance costs of approximately $&lt;span id="xdx_90F_eus-gaap--DeferredFinanceCostsNet_iI_pn5n6_c20220930__us-gaap--TypeOfArrangementAxis__custom--OriginalAndAmendedLoanAgreementMember_zCkwEM33pdq" title="Debt issuance costs"&gt;0.7&lt;/span&gt; million. The debt issuance costs, and the debt discount are amortized to interest expense using
the effective interest method over the life of the Term Loans. The carrying value of the debt approximates fair value as of September
30, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_z3hywg2T9Sxg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term
debt consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zwQdiXEVN5H2" style="display: none"&gt;Schedule of Long-term Debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220930_zSdtxMAoWKBf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_zybcH2Zrfoa3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-left: 0pt"&gt;Note payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;15,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--PaymentInKindInterestDebt_iI_pp0p0_z4m5s1Q3Ftvg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 10pt; padding-left: 0pt"&gt;Add: Payment-in-Kind interest (added to principal)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;611,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--NotesPayableFinalFee_iI_pp0p0_zipceAQgQnM1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 10pt; padding-left: 0pt"&gt;Add: final fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_zUNaJdvNygJk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 10pt; padding-left: 0pt"&gt;Less: unamortized debt issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(481,304&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_zezllae4Aubl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt"&gt;Less: unamortized debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(792,054&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LongTermNotesPayable_iI_pp0p0_zUheqJ7AMeol" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Total long-term debt&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,013,407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zMk3ZtldIhae" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zhnlFTHiOxbd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
principal payments, including the final fee, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zHuPh91ALB1h" style="display: none"&gt;Schedule
of Long Term Debt Future Principal Payments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220930_z09LQuF2GXyf" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years Ending&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDz4sG_zto0sL3raXBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,854,412&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDz4sG_zt7yblrzK9Gk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,805,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDz4sG_z17m7x6XjMDk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,626,471&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDz4sG_zuDbGb81iiil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,286,765&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zgK8pDPU1rt1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-6"
      unitRef="USD">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <CELC:NonContingentTermALoanFunded
      contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-6"
      unitRef="USD">15000000.0</CELC:NonContingentTermALoanFunded>
    <CELC:TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo
      contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-6"
      unitRef="USD">5000000</CELC:TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo>
    <CELC:TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree
      contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-6"
      unitRef="USD">5000000</CELC:TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2021-04-072021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember">The
Loan Agreement also contains certain events of default, warranties and covenants of the Company. In connection with each funding of
the Term Loans, the Company is required to issue Innovatus a warrant (the &#x201c;Warrants&#x201d;) to purchase a number of shares of
the Company&#x2019;s stock equal to 2.5% of the principal amount of the relevant Term Loan funded by the exercise price, which will
be based on the lower of (i) $14.40 per share or (ii) the volume weighted price per share of the Company&#x2019;s stock for the
five-trading day period ending on the last trading day immediately preceding the funding date of the Term C loan</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="INF"
      unitRef="Shares">26042</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="INF"
      unitRef="USDPShares">14.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-5"
      unitRef="USD">300000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <CELC:FinalFeePayableToLenderAmount
      contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-5"
      unitRef="USD">700000</CELC:FinalFeePayableToLenderAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-5"
      unitRef="USD">100000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-6"
      unitRef="USD">75000000</us-gaap:DebtInstrumentFaceAmount>
    <CELC:IncreaseFromOriginalLoanAmount
      contextRef="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember"
      decimals="-6"
      unitRef="USD">50000000</CELC:IncreaseFromOriginalLoanAmount>
    <CELC:NonContingentTermALoanFunded
      contextRef="AsOf2021-04-08_custom_LoanAgreementMember_custom_InnovatusLifeSciencesMember17144187"
      decimals="-6"
      unitRef="USD">15000000</CELC:NonContingentTermALoanFunded>
    <CELC:UnfundedContingentLoanAmount
      contextRef="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermBLoanMember"
      decimals="-6"
      unitRef="USD">20000000</CELC:UnfundedContingentLoanAmount>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2022-05-162022-05-16_us-gaap_PrivatePlacementMember"
      decimals="-6"
      unitRef="USD">100000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <CELC:UnfundedContingentLoanAmount
      contextRef="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermCLoanMember"
      decimals="-6"
      unitRef="USD">10000000</CELC:UnfundedContingentLoanAmount>
    <CELC:UnfundedContingentLoanAmount
      contextRef="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermDLoanMember"
      decimals="-6"
      unitRef="USD">20000000</CELC:UnfundedContingentLoanAmount>
    <CELC:UnfundedContingentLoanAmount
      contextRef="AsOf2022-08-09_custom_AmendedLoanAgreementMember_custom_InnovatusLifeSciencesMember_custom_TermELoanMember"
      decimals="-6"
      unitRef="USD">10000000</CELC:UnfundedContingentLoanAmount>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2022-05-162022-05-16"
      decimals="-6"
      unitRef="USD">100000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <CELC:LoanConvertibleToStockPercentageDescription contextRef="From2022-08-072022-08-09_custom_AmendedLoanAgreementMember">(1) 20% of the outstanding principal amount of term A loan, and (ii) an additional 7% of the
amount by which the aggregate principal amount of the funded term B, C, D, and E loans exceed $35 million, provided that the aggregate
outstanding principal amount of all term loans is at least $35 million, which such conversion based upon a price per share equal to $10.00</CELC:LoanConvertibleToStockPercentageDescription>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="From2022-08-082022-08-09_custom_AmendedLoanAgreementMember">The
Company is entitled to make interest-only payments for forty-eight months, or up to sixty months from the original Loan Agreement date
if certain conditions are met. The Term Loans will mature on April 8, 2027, the sixth anniversary of the initial funding date, and will
bear interest at a rate equal to the sum of (a) the greater of (i) Prime Rate (as defined in the amended Loan Agreement) or (ii) 3.25%,
plus 5.7%. Additionally, the Company elected to make 4.95% of the interest rate as payable in-kind, which shall accrue as principal monthly.
The Amended Loan Agreement includes certain other fees, such as a final fee of 4.5% of the funded loan amounts not converted into equity
by the lender, which apply if prepayment, an event of default, or change of control occurs prior to August 9, 2025, the third anniversary
of the Amendment date</us-gaap:DebtInstrumentInterestRateTerms>
    <CELC:PrepaymentFeePercentage
      contextRef="From2022-08-082022-08-09"
      decimals="INF"
      unitRef="Pure">0.030</CELC:PrepaymentFeePercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2022-09-30_custom_OriginalAndAmendedLoanAgreementMember"
      decimals="-5"
      unitRef="USD">700000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_z3hywg2T9Sxg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term
debt consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8BE_zwQdiXEVN5H2" style="display: none"&gt;Schedule of Long-term Debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20220930_zSdtxMAoWKBf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_zybcH2Zrfoa3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left; padding-left: 0pt"&gt;Note payable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;15,000,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--PaymentInKindInterestDebt_iI_pp0p0_z4m5s1Q3Ftvg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 10pt; padding-left: 0pt"&gt;Add: Payment-in-Kind interest (added to principal)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;611,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--NotesPayableFinalFee_iI_pp0p0_zipceAQgQnM1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: 10pt; padding-left: 0pt"&gt;Add: final fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iNI_pp0p0_di_zUNaJdvNygJk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; text-indent: 10pt; padding-left: 0pt"&gt;Less: unamortized debt issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(481,304&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_pp0p0_di_zezllae4Aubl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt; padding-left: 0pt"&gt;Less: unamortized debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(792,054&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LongTermNotesPayable_iI_pp0p0_zUheqJ7AMeol" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 0pt"&gt;Total long-term debt&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;15,013,407&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">15000000</us-gaap:ConvertibleNotesPayable>
    <CELC:PaymentInKindInterestDebt contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">611765</CELC:PaymentInKindInterestDebt>
    <CELC:NotesPayableFinalFee contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">675000</CELC:NotesPayableFinalFee>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">481304</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">792054</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">15013407</us-gaap:LongTermNotesPayable>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_896_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zhnlFTHiOxbd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Future
principal payments, including the final fee, are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B1_zHuPh91ALB1h" style="display: none"&gt;Schedule
of Long Term Debt Future Principal Payments&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20220930_z09LQuF2GXyf" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years Ending&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_maLTDz4sG_zto0sL3raXBh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;5,854,412&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_maLTDz4sG_zt7yblrzK9Gk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,805,882&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_maLTDz4sG_z17m7x6XjMDk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,626,471&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LongTermDebt_iTI_pp0p0_mtLTDz4sG_zuDbGb81iiil" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;16,286,765&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">5854412</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">7805882</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">2626471</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt contextRef="AsOf2022-09-30" decimals="0" unitRef="USD">16286765</us-gaap:LongTermDebt>
    <CELC:LicenseAgreementDisclosureTextBlock contextRef="From2022-01-01to2022-09-30">&lt;p id="xdx_809_ecustom--LicenseAgreementDisclosureTextBlock_z2okYjVSxaMc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8. &lt;span id="xdx_823_z7fGJVbc0gOa"&gt;License
Agreement&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 8, 2021, the Company entered into a license agreement with Pfizer to research, develop, manufacture and commercialize gedatolisib,
a potent, well-tolerated, reversible dual inhibitor that selectively targets all Class I PI3K isoforms and mTOR. The Company paid Pfizer
$&lt;span id="xdx_90C_ecustom--UpfrontFees_iI_pn5n6_c20210408__us-gaap--PlanNameAxis__custom--LicenseAgreementMember_zpzhxhNPT9Ph" title="Upfront fees"&gt;5.0&lt;/span&gt; million in upfront fees and issued to Pfizer $&lt;span id="xdx_90E_ecustom--StockIssuedDuringPeriodValueNewIssuesForEquityGrant_pn5n6_c20210407__20210408__us-gaap--PlanNameAxis__custom--LicenseAgreementMember_zLHu5w4JkEXk" title="Value of shares issued for equity grant"&gt;5.0&lt;/span&gt; million of shares of the Company&#x2019;s common stock pursuant to an Equity Grant
Agreement. The upfront payment and the issuance of shares were expensed to research &amp;amp; development in full for the three months ending
June 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events,
up to an aggregate of $&lt;span id="xdx_900_ecustom--MilestonePayable_pn5n6_c20210407__20210408__us-gaap--RelatedPartyTransactionAxis__custom--PfizerIncMember_zcH3aGBA11k9" title="Milestone payments"&gt;335.0&lt;/span&gt; million. Additionally, the Company will pay Pfizer tiered royalties on sales of gedatolisib at percentages
ranging from the low to mid-teens, which may be subject to deductions for expiration of valid claims, amounts due under third-party licenses
and generic competition. Unless earlier terminated, the license agreement will expire upon the expiration of all royalty obligations.
The royalty period will expire on a country-by-country basis upon the later of (a) 12 years following the date of first commercial sale
of such product in such country, (b) the expiration of all regulatory or data exclusivity in such country for such product or (c) the
date upon which the manufacture, use, sale, offer for sale or importation of such product in such country would no longer infringe, but
for the license granted in the license agreement, a valid claim of a licensed patent right.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has the right to terminate the license agreement for convenience upon 90 days&#x2019; prior written notice. Pfizer may not terminate
the agreement for convenience. Either the Company or Pfizer may terminate the license agreement if the other party is in material breach
and such breach is not cured within the specified cure period. In addition, either the Company or Pfizer may terminate the license agreement
in the event of specified insolvency events involving the other party.&lt;/span&gt;&lt;/p&gt;

</CELC:LicenseAgreementDisclosureTextBlock>
    <CELC:UpfrontFees
      contextRef="AsOf2021-04-08_custom_LicenseAgreementMember"
      decimals="-5"
      unitRef="USD">5000000.0</CELC:UpfrontFees>
    <CELC:StockIssuedDuringPeriodValueNewIssuesForEquityGrant
      contextRef="From2021-04-072021-04-08_custom_LicenseAgreementMember"
      decimals="-5"
      unitRef="USD">5000000.0</CELC:StockIssuedDuringPeriodValueNewIssuesForEquityGrant>
    <CELC:MilestonePayable
      contextRef="From2021-04-072021-04-08_custom_PfizerIncMember"
      decimals="-5"
      unitRef="USD">335000000.0</CELC:MilestonePayable>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MJ#*4V@OY?9/?BP*<USZOMZ:BUI3=[O=+%H<\B./H;'&_[Y$KR$/*HX"33O
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M8#3;H_CMC5%U>YI]JXQ197NYE@(<L +P^TH!J^]N[ %Y]X?(\C]02P,$%
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M;0+]_6U9-C_>M#^]<O@QG^O_ 5!+ P04    " "8BFI5UDN.#%X(   *)P
M&    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;*U::W/;-A;]*QRULY/,1!$!
M\.FU-6,[;3>SFZZGWK2?:1*2T% $"U"6W5^_ "@)(O%0Y%%F'$ORQ=5]X9YS
M05QO*?O&5QAWP<NZ;OC-9-5U[=5LQLL57A?\(VUQ(_ZRH&Q==.(M6\YXRW!1
MJ47K>@;#,)FM"]),YM?JLP<VOZ:;KB8-?F !WZS7!7N]PS7=WDS 9/_!;V2Y
MZN0'L_EU6RSQ(^Z^M@],O)L=M%1DC1M.:!,PO+B9W(*K^RB2"Y3$[P1O^='K
M0+KR1.DW^>9S=3,)I46XQF4G513BUS.^QW4M-0D[_MHIG1R^4RX\?KW7_K-R
M7CCS5'!\3^L_2-6M;B;9)*CPHMC4W6]T^R^\<RB6^DI:<_5_L-W)AI.@W/".
MKG>+A05KTO2_BY==((X6"#WV!7"W (X71(X%:+< *4=[RY1;GXJNF%\SN@V8
ME!;:Y L5&[5:>$,:F<;'CHF_$K&NF]_3IA))P57PV!4=%@GJ>$ 7P7W!5\'/
M(LD\>/>U*385Z7#U/I@&7Q\_!>]^?'\]Z\2W2QVS<O=-=_TW0<<WY<$7VG0K
M'OPDOK$:KI\)JP^FP[WI=]"K\!&W'P,4?@A@"*'%GOOO7PX\YJ!#))'2AUR1
ME!%;J(@M&%T'8J>QHB/-LB]5TA',KVQAZ]5&=K5R&U_QMBCQS43L4X[9,Y[,
M__$#2,)_VGR^D+)!!*)#!"*?]OFOHNO4E'.;D_W*1*V4K>5Y/H59FF5)'EW/
MGH\]L$G"+ 9IDAPD!^;%!_-B;X)NJS_%?NHKO*.B!Y6T*4F-@V9GM_Q4OBYE
M)C=R3X@VN<\C;>S9BR^9O0LI&X0G.80G\6;O$Q9*2Z)<M3G:KXZ/\@(2D&=@
ME#Y3#$8A#!VY2P_&I5[C'CM:?IO*?ET%)5T+$.-.0U/# A3EHM;&A6;*@23+
M$0)V4[.#J9G7U,^<;XJFQ+*+"E/7 JNXM/Y#4)-2XI_L"$N&5:^UV>]5;R^"
MP%9,F>%?'*I_=O_R@W^YU[_;-64=^5N%7_I8X:<N('NG2\K%]BJ:*J@(+^G&
M[F)N%DD6 2-#IAA($4H<"0*AQKS0Z\)#\2J#/R7-]-]$F$J:#HM86DW=J1J4
M$Q#-:&RK10[D"8HRA[%'  W\794V4]61-*#46&R$#[)762T&AB53F.;CC6H3
M2Y/,%5RH[85>>_\C.ZDL^J)6>V!!7L2F+3C'G149_.K.J/>=HD%5)<CACD9U
M< +65T6SQ%S4R#&B*V]4F=>D>"*U&]W!1>']4MJ&P=  #_P(+S8.HW4==,6+
MQ$],GHNG&EO=CLQMDV8H&Q>A*38%28+"W)$W#?; "Y;S!X;;@E3'J:IP2SEQ
M5&%L&A)G<1RG\=ADBR2 H6@*#I,U  ,_ M^6JF'RH"U>G7&UP' <(]&0QF;:
M!9%S@VLH!GXL%F:RC=C2^$7",+:'TP17"-,PDD1]:*8%A<,8(E?^-0H#/PS_
MZB)R T)NM=T$SBE,8ICEP.BA%E$@@"S-D:OO:Y@%^5GS!&F>!41]QSP!O/A]
M=L>YD+;AB*>A&IZ Z@TK5P+MU%#:,IG#[E7M9OS7AK0N#@5--)Y&20K'J&V3
M2T$>.\H/:M2&?M1^8+3$N-KE;H^%9SC@57\&*D(3YF,7!80:Y*$?Y,W=92M/
MJV,F2MLS8Y%+0>3,C 9T>-Z<OB"-8*[?L:_@19'\4MJ&4=!(#D\@^: ^\0MF
M)>'&S!)L"\:*Q@Z9_F\XIT1-$@  C%-'IC4%@*<H@,M'O&YK^HKQSDO:JOG>
MZJ2)]C"""(VKU12+/&U$4P+HIP0C%X9FM_O>:#7<Q/\LC*,Q@EG$8)P!5^PU
M28!^DC T?"%((]U.U<"XP$QL-C6]R%1LF@JS+2.J=>QGQIZO[67[H=+JI->(
M<TK0I"%I%J-04$!')#01@7XB,HQ$0SN\YW>'&)P:H:7,CX*!? @38 W#I8X,
MH,EG0(0B06=<E:SI#/0?&^QF;J[ PN*PU2_S &":18FQ^=Y 40)/%T6:G2 _
M._F%R6&W'62X:(+;_WTY%*_UQ->K]8Q\(<OA1)8GT)XLI-D+.L%>CI/%Y4%I
M5;!7,?(M">_ZTU#1@W;/"]SY0Y8C!@2R+$]'&;0*9HF#0R--4Y"?I@S\Z($>
M]Z<G=GMMW 09QU)VL=AQU(".'B!X,5^3JG=[5O5>UM8SJ<2[IU<K4[&Z@2P#
M#$SR-!P[8@KF,,\R\>/P1?,+=/I90*F.3N3)B?)*=C3U0A+?9\&(';P"6<X$
M8)*%, G'L[A%-,U2,:F%CBD7:?* _$\+[ETFVY_A7/0QP*6T#5W7I /Y2<>=
MV.9-(^M,CBRBB]'*ZK.%840P2Y#Q3, B"4""TMQU9H(TST!^GO&3X@D^*TUD
MC],H0ZEQ8F*1S$.4)!EP]5/- 5#F+:;'3=O6JED6M4+UFO(-Z^GV?AP1^Z1_
M*B^:J[W&WH#RGAJ[D+9A1#0=0'XZ\'EWY![(0SJKMR;V9PB"Q*@M4RZ*HSAU
M=.-(8WL4OB5GZB"BV9_)'TV]HA"_>Y2,WD  W*F\E+9AH#19B$X>=5@.-41H
MRGHCD8O(RQJG3S8CDP. ,,K ^,C8;\WY;"_2;"+RLXG_[N<1Z:B/"YWON\DH
MQ 2,QGCMM^\-KFMJ$OFIR2<L7&?XN,3UF$+?&I>3Q\B125!@&!\_PMP%Y@V'
M*=[ '%UY\/,<U]/>P\G)H3'4P4),[O+6P;(A?ZM'8GK DS</CB9#:RPN==P2
MF3<L\D0@XGC$FQW=*EICME27K7B@#.YOZ1P^/5SHNE77F$:?WX&K^_Y:EE;3
MWQ+[4C!!-;B@Y NA,OR8BDRS_N)5_Z:CK;J[]$2[CJ[5RQ4N*LRD@/C[@HJH
M[=[(+SA<?YO_'U!+ P04    " "8BFI54_SV4!<"   _!   &    'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;'U4P8Z;,!#]%<NMJJQ4Q00:6J6 M$FT:@^5
MHHW2'JH>'!B"M6!3>PC;OZ]M"(I6V;U@CSWOS9OQ#$FO]).I ) \-[4T*:T0
MVQ5C)J^@X6:N6I#VIE2ZX6A-?6*FU< +#VIJ%@9!S!HN),T2?[;36:(ZK(6$
MG2:F:QJN_ZVA5GU*%_1R\"A.%;H#EB4M/\$>\-#NM+78Q%*(!J012A(-94KO
M%ZMUY/R]PT\!O;G:$Y?)4:DG9WPO4AHX05!#CHZ!V^4,&ZAK1V1E_!TYZ132
M :_W%_8'G[O-Y<@-;%3]2Q18I?0+)064O*OQ4?7?8,QGZ?AR51O_)?W@&T>4
MY)U!U8Q@JZ 1<ECY\UB'*T 8O@((1T#H=0^!O,HM1YXE6O5$.V_+YC8^58^V
MXH1TC[)';6^%Q6&V4;*P)8:"[)$CV'*C(:HD&VXJ\F"?S)#90?*N$ C%'9GM
MN+8N%:#(>7V7,+0:'!/+QWCK(5[X2KP]M',2!1])&(0A.>RW9/;^!0VS*4QY
MA%,>H>>-7N.]J'\A_O?]T:"V;__GEM:!\]-M3C</*]/R'%)J&]Z /@/-/KQ;
MQ,'7-Q1'D^+H+?9L"T<DPIB.RQQ(KHPM/)<%*83)52?QEMZ!,?:,;MS.6;P,
M@WB1L/.U$G;5#VZT?G!]$M*0&DH+#.:?EY3HH5T' U7K6^2HT#:<WU9VPD$[
M!WM?*H47PW7=],_(_@-02P,$%     @ F(IJ5;1/\B1,!   XP@  !@   !X
M;"]W;W)K<VAE971S+W-H965T."YX;6R-5MMNW#80??=7#!0@:%%G+[)SJ2\+
MV!L[,9HTAIVV#T4?N-)H19@B%9+:S>;K>X:2-VO =?/B)4><PS-GAC,^63M_
M%VKF2%\;8\-I5L?8'HW'H:BY46'D6K;X4CG?J(BM7XY#ZUF5R:DQXWPR>35N
ME+;9["39KOWLQ'71:,O7GD+7-,IOSMFX]6DVS>X--WI91S&,9R>M6O(MQS_:
M:X_=>(M2ZH9MT,Z2Y^HT.YL>G1_*^73@3\WKL+,FB63AW)ULKLK3;"*$V' 1
M!4'A9\5S-D: 0./+@)EMKQ3'W?4]^F6*';$L5."Y,W_I,M:GV9N,2JY49^*-
M6[_G(9Z7@E<X$])?6@]G)QD578BN&9S!H-&V_U5?!QU^Q"$?'/+$N[\HL7RK
MHIJ=>+<F+Z>!)HL4:O(&.6TE*;?1XZN&7YQ]\DME]3<E$IV,(Q#%/BX&[_/>
M._\/[U_IH[.Q#G1A2RX?^H_!9$LGOZ=SGC\)>,OMB XF^Y1/\OP)O(-M> <)
M[^ 'PMNGN;/!&5VJOB!L2=>> ]O8&UQ%E]HJ6VAEZ!9&1O7%0'^?+4+TJ)]_
M'E.H)W#X. %Y4T>A506?9JW<Y5><S9X_F[Z:'#\1WN$VO,.GT/\W>T]Z/\YM
M.J)=5/I=Q<[S'K0Y[P( 0B"\H:+3<;-W98O1/BEZRT:ME6<JG&^=[QU_BC73
M\V=O\GQR/'=-J^PF[:;'/^^3#G K0$@7RKP($>^?%MI%+FKKC%MN )5<J')X
M!5P2$$M>H8FTDA3)551^R9'+/5SD5:LYX+"G!N]1MX8II9IBU\"H;8F;A%<8
MT6<0VV$T?7T<R*"A40_$7=0%%2@/J106KDO&"G!!+R3>%D1MW$=36K&'#9>5
MG3)[VM9ZH2/NB[6*-/0>D-X,9!&U,30W"BI>T?75P6] =]):0RK'YO.GFQ%=
MX5P#)9"$T$BDJM@6;%LK]*+"W2$50K/UZ,\^2O"2@!I-R&SV2EU5[,%1(X"2
M*N^ (]&AI7BQ@Y%JX;O"5X'5=L4AZF62"-7_7=(42<^^)RP2@R8B<99E%QV^
MX?P#88&HA]L57=?HFW1 (7;EAGBE3(>+[')75SA0"VMZ<6L=:WI_\\OX_<5-
M_H)4N<*K!-0"<R=$R4W!DM34)GK!YA<?@EY:K8;*01R002VM"TDGHZ+H+-GL
MK/[225*49"XZ**#,YAN30:[N20R%4V!>!#FC2Y&SVI#%I%EZU[5!4C-0V3(W
M^BZEV]&"+5<Z[B7QE9&)N2/Z??%^5_JA?&L5$,B+RG726?M0ISDM-G3NM;)T
M.:+;SH"PZNOB+>3_(%SHG2Q$W)37D&96B=*DC]KB^;JH'MZ$W)!U$;FP8)(2
M!JN4MNTXA2ZO8$2/M:OQSN!I&!'-DUP%6,=^!FVMVPE^U@^N[\?[\?\1@F@K
M#[&"ZV3T^F5&OA^I_2:Z-HVQA8L8BFE90U/V<@#?*X=7.6SD@NW_-;-_ 5!+
M P04    " "8BFI5=D(R+.T*  !D'   &    'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;,5976\;-Q9]GU]!J(NB"\BRK"1-FM@&9#=IDT4:PTJV"RSV@9JA
M)"8SY)3D6/&_WW,O.=1(_DB>=E]L:8:\G^>>>TF=;JW[XC=*!?&UJ8T_&VU"
M:%\>'_MRHQKI)[95!F]6UC4RX*M;'_O6*5GQIJ8^GDVG/Q\W4IO1^2D_NW+G
MI[8+M3;JR@G?-8UTMQ>JMMNST<FH?W"MUYM #X[/3UNY5@L5/K57#M^.LY1*
M-\IX;8UP:G4VFI^\O'A*ZWG!/[7:^L%G09XLK?U"7]Y69Z,I&:1J50:2(/'O
M1EVJNB9!,..O)'.45=+&X>=>^AOV';XLI5>7MOY35V%S-GHQ$I5:R:X.UW;[
MNTK^/"-YI:T]_Q7;M'8Z$F7G@VW29EC0:!/_RZ\I#M^S898VS-CNJ(BM_%4&
M>7[J[%8X6@UI](%=Y=TP3AM*RB(XO-78%\XOI-=>V)6X<LHK$R3%:BP6,4?T
M8J'71J]T*4T0\[*TG0G:K,65K76IE1?25.):E>K@M;,&GTN%! 9_>AQ@*VD\
M+I-=%]&NV0-V_2+>6Q,V7KPVE:KV]Q_#Q^SHK'?T8O:HP(5J)^+)="QFT]GL
M$7E/<N">L+PG#\B[+Q3_GB]]< #:?^YS.,I[>K\\*KZ7OI6E.ANUE IWHT;G
M/_YP\O/TU2/6/LW6/GU,^O\QS8_:=;_7LXGXW]@;U10':L3'C2HD]C2M-+>T
MJS.RJW10E5AI(TVI92T\%B<IVI1U5RD1-DK(J(MMI^^740J;LY$W2BR5,@*^
MMM)!GC:\PU60JE#Z82/F+NBR5N)D2H9=JW571[,61__"1MMT]5J2+<M;UK!0
M9>=TZ'U^_;7<2+-FS8WV3)X__?C#B]EL^FKQ^I(_G;SZ^X2CXBJX5]^.A?2B
M5:[1(0G>&3$N2,DW(E!986S(@9!UW?NO36P<D</_ZK2+"N0N)ZW#/MW6<&"M
MC'+8S>]5&V*$(*?X9%C[@G3Z[-"GR6(B?IO/KW9N(7F@Z9KC&=N:#.)7 *%9
M*B>>G# !G(@M/*Z40T> 2PAJ3-YC/LJ 2$!6A2<<Z<K"DD.W24RE?5E;WP%3
M>SYG:R?B+7LE;*L-10;!:J1!$R158Q8DJ\]@_ZAZN]'E1@ P6%A(Z$1$:XA&
MXAU%T,@ 96R4@:?>4XT@[D**E=1.M$-T[U"(_D?-,0?Y7K\YHGZ(@-*"DHU7
M57%OG/S&=C7\58*&!!*-#9]1<ZR=(?[M6'/]D#_D!2V_5=()1;W@;C(+6DB+
MG*JY,E;6!B0&X<=3IX+M4Y0]365)L#EY_LJ+N3$=3+A6K75!P$YJ^4#_T3^^
MRX*)^(#RD03G K'&1.#SOK!Q*N4&Y">:V-:BH 5A/$I*G8FS3*#J$ZE1#-I4
M(#H:7_JRZI7 -01:?6UC'JN.\4 %XQ2-9(!XOX7 0FS(?L VQ@>8:=4Q>&"_
MMM5D0);%:Q]TP_7V/H.SZ#R^J_R&_)(>(UU+Z24N3.26[+@?.0_QZ!TR')3,
MQXV%L*RY.-0L5RL$(46'T@@ULLEDC*4J1'MK+9>Z9LH<'Q0LK825Y#[%ZJ%-
M.\!%18CVC3)=B@>E UYZ"F;HN%)CMDJNC$K#4M>SSIY367!<HR@.95].M,(A
M9).]WH? -BBZ;OD9WA? @^_ %8\E:->L;F3=15* VQ@URR]'-.%2HAIR(;XC
M"9Q371%ND"+7T1KT<I@ RB.CL,4365QK_R7FYA.,=P$8Y-9$/;7OA3K;2_AU
MM(,THC+H>^R[M"?5:H78UK8EC!!:UBKY@!R-Q;(+7"ZU;AABP8ZQH:7R,B4&
M!1,SG(V%907I4BZBKRNIS,A_S0A$@O&X<AWU)5MU)>AXK<#YF"N\7MZ5)AZ6
M5FFY-@B++@4R$0@W#"'T;5O8)<4&T.#^;D'8LH5&I"1O?]B(G1SQ'7+NF$$^
M&$4$;NE\AJ$52"('9(5"1<[Q,54H5;%%SC<:66!Q:RMKR.AR>GD<6SH+LI>5
M;7L\T=IHBJIZ-[!/$Z]CXD _;#>W'L.:-!$PJ#O 5+E47WX <L9C8-,FXC)%
MO_C(P+LDX.WA"XT1).(S:%,5#[#;5RB3X #;?=G<CV[FKZ[,LY=VU1&8#@&@
MP56C5LE;79$+1>S9J=I\A$W<3L&!SJS!!V Y5>J^VMQ\DWIIB ?DG=!80[6Q
M/W'VK8WZ$1B?Y@>:60:UM*.IC\-!E4.4VU=6'HD!J5WA?&.=CSPCA[T@&4#'
M<#:K5LS!AKIN<<CL?<CD&NTQC3GTG&#S:&CWS6WD%V@>!N1S5ZW3%$%<G*U#
MD50P"$.NH>:6AG6&PX#;\^R(Y0JP3Q3/<VK?(3W=)709%4O K5'BB[';Q#8Y
MECS#>?;I03 6]^=A(^-P26^=IDY0B>AP[ *#%D$FA"U-=)F;V3"F_J&E0",-
M ?#A=[L%$EPTEUIP%VL0P2)7J5_&C2G\?#R@25Y58V$Z'ED(QN@0'&IEG*UK
M>IE;(XW)NR5I14Q,(V_1>VA&[2?O0]#FM(U3\R2K:#XP@\&8F"D%C][M#3*(
MYB6?@_HVLM=F>9"/@NEUCFF9MD!PV!%*GA*_@U!BM^X%TD%F-Y8<BNO' D3)
MQO$1# A\M6W-XYXU= +\0VU)T[6ZT52!@\,L#D.FDL1T5YWS'<!?1,/%.[1[
M9!6C[(?.B8O.8_)$7UK0HZ[U-)>0UMGT9"9^H@WI//7NP\6"7O;'*:0S]>-;
MIF=0<,>JD8>T!;7KUO1H[>P6]5ONG(2$0A.;H[,#4S2+4VF;-9XA?3K4W+!I
M;+\5'5A,I):")R!*O-P57SI'[8XD8C!-P)H'S.#Y *54:.#^QI9R"54JG7JH
MO"A@H!"@Z@;QH^$BL9CZ&N*,'AP:%+>>!"U**:AL=P+OHY9'?DW<U^03%R0:
M3B*-B9S$P>G7]TF,Q)) L<\C6UW7D5%O(TE&<>(Q<435Z4RDR#4^M]+3U)F&
MK9JI?+=3#XZMW""[)0 Y&,RX?/J#ROV1UP=\ED'?+R\.$K72-> 1J2@YK-!R
MR VBS\%Y#$P-;=]Q+)M-T@U0?5O,R=W]\CFX"WIKBO?@)3K.Q>B_F2\N$ M/
M]3U??!)_V F_/9H^'8NW]-SMSH\[L6389<+Q>UMQ6XJC-U[TMS-<]&_0^3CJ
MM.TU AYNCRYKD OVH"_\Z>@ZQHA+N@[X$,?W<;H+2-T0TUBG8U.ED[W=4BFP
MR:X_AR=LL%G-GCF-I&, *#1J+K-FL4V:,8C4181)RF96EV9SBDO"2IQQDG(J
M*QS_(^\-U<9S_7TZI7,$TWC'TE^ME!+G3>;B_-[V#;?OVGMB9&2#_A(L%;-U
M&I@#P?=2XN4(E5%Z$MW;#UT# %)'83I@&B<^EOO^2']X8.N;,=^HT/4+';.R
M*7'SP.&^81XN11CZ)1HG#$SQ@7ARJ6"[*H8V1-O[^J7RC=;2?0$["OPPW^HT
MU]&#%<Z\" B5#\T/"(]A8E^A<^TJZ>19?\&Q-R/&8L(,1>1[EWP&^M])TU&G
M3Q49YX,\2X:!W>,\GA'I;A)VKM7N\NI&Y7K[LP\>:K?B>PFZT+N#JG%$8<(%
M%*#6Z0!.M0,[B$L!Y/GNU'.%]GZDJ>9:'62]&V=V)P,,4;$/T2'I,+U[><D<
M]2TGHJM5FIBR3WQ)^3<Q>WXR_N7%"W'?SP#'@U]^B%CY]RV>0DR(/P+EI_DG
MM'G\Y6BW//[^]EX2+WM1JQ6V3B?/GXUP-N??M.*78%O^'6EI0[ -?]PH<(BC
M!7A/MV[]%U*0?U@\_R]02P,$%     @ F(IJ5;@FA;+" P  B @  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3 N>&ULE59-;^,V$+W[5PS4HB?9^K 2QZEM
M($ZWZ +=(EAWVT/1 TV-+2(4J9)4E/S[#BE;ZV!MH[U8I#3S^.8-9\:+3IMG
M6R$Z>*VELLNH<JZY3Q++*ZR9G>@&%7W9:5,S1UNS3VQCD)7!J99)GJ:W2<V$
MBE:+\.[)K!:Z=5(H?#)@V[IFYFV-4G?+*(N.+SZ+?>7\BV2U:-@>-^B^-$^&
M=LF 4HH:E15:@<'=,GK([M>%MP\&?PCL[,D:?"1;K9_]YF.YC%)/""5RYQ$8
M/5[P$:7T0$3CGP-F-!SI'4_71_2?0^P4RY99?-3R3U&Z:AG=15#BCK72?=;=
M+WB(Y\;C<2UM^(6NMYVF$?#6.ET?G(E!+53_9*\''4X<[BXYY >'//#N#PHL
M?V*.K19&=V"\-:'Y10@U>!,YH7Q2-L[05T%^;O4;Y?U7;2T\H8%'7=>DU*9B
M!A>)(WAOE/ #U+J'RB] S>&35JZR\$&56+[W3XC6P"T_<EOG5P$WV$Q@FL:0
MIWE^!6\ZQ#H->-,+>!^844+M^UA#D/#7P]8Z0U?C[W/Q]G#%>3A?+O>V81R7
M$=6#1?."T>J'[[+;],<K9(N!;'$-_?\EYBK4>:+3"5P\ M;,"CYBJH12R-9A
M"8ILI;=MR);WMC;8"DM5X-#0Y22[[1NYO(B2=/[JPYPS8MLZMI4(3@_^3O/G
M2LL2C?6.KD+H0AEA.68O:*@KC$[/LD!MQ3KBY>'+UOB']R)20I<3H$(%)N5A
M3V1]N(K@XF#V'JNE:VKDVQ%#-[Y-$%F*NF/&,.4L5$0#MHAJA*]<MG2O86=T
MW:,QR5O)0G/9(F>M1?]>&,#=CIH.]:-6DB)(D$Z,@Y+4@2;P>X74>K3!^&S(
MYV(E[)*4&QW/)%+:5;X?"0ZG>;J8(W^2934&D49^YRJ#&)RI*A#JOGC1%R]0
MZ3FLMX1SK+]@2(LLAD8[$E60T&]PC HL<LJ'$T3\C%2Z;BC]O<!Z=V0[^B^A
M=R36D!RZ/$UK>$5]&+)XGLWC+"MHE=T5\2S/B.T\OKW)83J[BXN"GG$^FT(>
MSV\+^*A&C'-M2J8XJ2Y(OX?-EQ#3."UBH(QX\$9;#"2'_!*);X5^5Q"]RAY@
M$'8\*#L.R@YW,@@\^E;@_C(8;+1YA]\Q"T)QFKBVKR_6-$:_"II(2 GX'O)9
M'J=I"I,TAW.-)SF9#C6:?9B!EG+2*M</BN'M,&8?^NGRU;R?T9^8V0M*@\0=
MN::3V4T$II][_<;I)LP:NITTN<*RHK\*:+P!?=]INCN'C3]@^/.Q^A=02P,$
M%     @ F(IJ522 CV\5!P  7A   !D   !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&ULC5A=<^,T%'WWK] $AH&9-%]MZ7ZTG6G+ @OL;*>[P /#@V(KL4"6
MO)*<)OQZSKVR':>$PDL=R]+]./?<(ZF7C\[_&4JEHMA6QH:K41EC_6HZ#7FI
M*ADFKE867U;.5S+BU:^GH?9*%KRH,M/%;/;UM)+:CJXO>>S>7U^Z)AIMU;T7
MH:DJZ7>WRKC'J]%\U T\Z'49:6!Z?5G+M?J@XL_UO<?;M+=2Z$K9H)T57JVN
M1C?S5[=G-)\G_*+58QC\%I3)TKD_Z>5M<36:44#*J#R2!8G'1MTI8\@0POC4
MVASU+FGA\'=G_5O.';DL95!WSORJBUA>C5Z,1*%6LC'QP3U^K]I\SLE>[DS@
MO^(QS3U?C$3>A.BJ=C$BJ+1-3[EM<1@L>#'[EP6+=L&"XTZ..,IO9)37E]X]
M"D^S88U^<*J\&L%I2T7Y$#V^:JR+UW>NJG0$RC%<3B,,TO T;Q??IL6+?UG\
M4KQS-I9!O+&%*@[73Q%('\VBB^9V\:S!#ZJ>B-/96"QFB\4S]D[[[$[9WNE_
M9R>D+<0=PM5VK6RN51#?Z) ;%QJOQ&\WRQ ]*/+[,122D[/C3JAM7H5:YNIJ
MA+X(RF_4Z/J+S^9?SUX_D\)9G\+9<];_JT#/+CX>VME$#'%Y7RLO"96,$/I6
M6VES)7Y2H'H0'TN587(M[4Z8-*2Q)G>^=EBE!%L7VHIWVEHE:V=T&*>7X**<
MB+=6H*I154OE4=;YQ5C$4HG.*$)07A6P$)V0PCI[DE, 1BZ-$JZ/C9T+N?9*
M4=@"<B26C38%/J8@)A1L"A+Q59B5JV+,91\ZK-P&[N",!E<RUT;''2<@=Q3?
MBS&]Y,[^T=@D'(\ZECP;D:(#)0UF;L5 8-@*M=6!@DS.)^*! E1;Z"9"T0':
M!;S0(()42!#/2"I.J%BD*)B!F#R[2.&3(T;NA\904(O9(6A!KRW,29M)I%DP
M(,A(;:/B;&&Q-51ZUZQ+<5-[;?K&&B*U-U![M]$%"DS05M37\.WQ98R_T@@5
M(A4\RJU*S;0O3IMKF(@;?,+T $T4@"C^T\]A)CTTT@+VW'-QX>QS,7]Y,5[,
MYWB>CL\OZ'D^/CN] "K9OE+_GTFKEM?'>.16*XU/ZE.C:Q[DBDNLV:B3G9*^
M+0BAUD#IO-EQNX2@2%<\\3\W3<'.Q:KQ5D<2%0*I-WI(3R2I+6&UE'Z-GZ)N
M?%[2-U>GW2IR<E3/(8X3\2L8EQ%:56UTKJ/@-D3%K>MK6!PBTW1M.T1XZ3R4
MB%C+!FAG8X+20FW3;L^!;*1.$+8A'7886<L*#L%B-TPM0E9I*FL.\-Q(TZA#
M/M1RQ_(#+4(?Z%R:[ &3)5 0'V)3Z"?BP]4-J;@$'VDUO;))2]$:C#<^L)]E
M$]!<(8@TNVCR2*Q,YJDLA=K@/%)WQ%][6;%QY:TTX'U2C=0\Z"=?9+7TD8**
M)7!HZPUU0:.LA4,0'K(GO9?879*N,HDV**"C3XB"FD+BRUC<O7O_Q6<O%O.+
MUR$)U-U#/Y!XTJ6=-YY:$!&!'$S([)YILA!YBYN(7N-O3VE&I38DRZ0)A'WJ
M6[]&>5@,O:PIE70VPA"'ZBQ#!PS%W9N?2&*T!/$#U>BCKJBF^%QI@R',S;H*
M E@CXUY3C\>7^@22JCQ1OY?E?2VQ*R,P K]E,??F0'/Q;DRBK!2MG0P:I!WD
M8X6)U )H9"8_SG;.JX,V6"JC4?:VA$]WFJ71:W834H_ST@&H%#ZU&-I"44('
M=<J0H.,228&N9.'?:TQ?#\;Y?J7_(O.N9^2XH^,8UFV#3:F7#VXSG\,?%@$B
M=!KML'K)V\/372KC_GKJ_U ,<CX"-22Y;:GF2^Q)3;$33,'Y:W&[F)_/9[.7
MP\H>N$;FW,)H"((F-,L G4L\135Q8J>05)&1$EOQ9@O/I(XW>4Y->>@-9+L[
M^>YD-IM/^'R6V'"45//;=FW'GJ.6QURKGD[97MIPF^"E^QH"1%D4'.YXP,4G
MWEOLNA9MHSG=4SQ%]>4O;W_\^/[A[<W)_"N*(=M3>L T)@%VU. LOR?2\C"(
M,E_,1"%WX>FYI?=]E*AAV$B4/?9[W+$T/'/V&;*GTQ\<!8&6(7E7 X4;-!EI
M.>:8)G0]U@7/G[%)04<@6WJ%$ GK0)<@;=/FIR0$MA5ZT+M6?.D:]-$D.X \
MQ3YHLTK"YLJ[*E6+"H#G&,U+-/LCZ171JCM/!"$/SQQ,\I)T6-#1 IN&VJJ\
MH77+7=J6DI1/,IQ6L&!_/.T.2(<=4TIB#Z DA>RH\U0_.O@;WH>ZTW57; :B
M91/E.]@GQMECJ0%:Q&G94%?6D+^M)C]P^;E83,[%L6O$='#G@T2L^69+)_/&
MQG3]ZT?[R_--NC/NIZ>;]SN4E$XC1JVP=#:Y.!\)GVZSZ26ZFF^02Q=Q'^6?
MI9+ EB;@^\JYV+V0@_Y?"M=_ U!+ P04    " "8BFI5C3\17%P%  #4#
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MI,6^+SPG6Y_;2N46_%&13B8(6?SRUCWMOEO>Q,]UF^7QH^=OTBV("XR:0Q1
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MH,U*7-M:EUIY(4TE;E2I=EX[:_"Y5#C X,4O_?)?7Y\$F$W*3\IDXF4T<?:
MB2_$>VO"VHNWIE+5]OX3N)M]GO4^7\X."IRK]E@\.IV*V>EL=D#>HQS#1RSO
MT0/R]D7EOQ<+'QQR[G_['([R'N^71W7XTK>R5&\F+9V*NU63\Y]_.GMZ^NJ
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MA8 2@)\DMA^%/ W!MSW*NDF0\33B)B&@%!&::0Q>0I)Q;!DO]+1^ZH(G=AQ
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MM[09+E'D*'D#?9\WC=Y.^(#=OT/._@=02P,$%     @ F(IJ54""J_,Z P
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M3J"Y6L66*-U&7(WPNP&>O0!_#>^5M <#/\D:Z__C8Y(RZ<E.>NZRBX0/V-W
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M5AS:%C>"YOI4\H$*05-]N08< U,=Y/,EI6)_HQQ41^>3?P!02P,$%     @
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ML^6'DRHC;[.RS.;K+Q]$,A5Y?8?J[^^RK'S^II[@*<L_KQ_.U7\!4$L#!!0
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MX]-*6U^JB.M+VUME).%TBYBY.%% "TJAF@'53*AF034;JCE0S85J'E3SH5H
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ME1:ATF(LFMU&6J?)"W!#.JKEA$H+46D1*BW&HMDRM^Z4Y[:G?N0F<INXGNO
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MJ2@RT^<%?]"#]R<#!V43[?%I8SI"FS=]'/H'-.V,R3[Y;CF%VC:#*LI*>5S
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M              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ F(IJ56>95& $!@  T!\  !@              ("!# @  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( )B*:E7D@[KN#@8  !P9   8
M              " @48.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " "8BFI5;9SJ&>X"   ""@  &               @(&*%   >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ F(IJ5?X)3[X;!0
M218  !@              ("!KA<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( )B*:E55XOJUX0P  -AG   8              " @?\<
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "8BFI5UDN.
M#%X(   *)P  &               @($6*@  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ F(IJ55/\]E 7 @  /P0  !@
M ("!JC(  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( )B*
M:E6T3_(D3 0  .,(   8              " @?<T  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " "8BFI5=D(R+.T*  !D'   &
M        @(%Y.0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ F(IJ5;@FA;+" P  B @  !D              ("!G$0  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "8BFI5)("/;Q4'  !>$
M&0              @(&52   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( )B*:E6-/Q%<7 4  -0,   9              " @>%/  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ F(IJ5?2*FR=Y
M"0  Q18  !D              ("!=%4  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " "8BFI5>_:'=@8)  #9%0  &0
M@($D7P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( )B*
M:E64TW9UH0,  $H(   9              " @6%H  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ F(IJ5? FX'MD"P   1\  !D
M         ("!.6P  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " "8BFI5WV -7$(&   :$0  &0              @('4=P  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( )B*:E5 @JOS.@,  'H'
M   9              " @4U^  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ F(IJ5>D21"<N @  > 0  !D              ("!OH$
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "8BFI5$K%I
MYS$$  !&%P  &0              @($CA   >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( )B*:E4Y>#3"W0(  #,)   9
M  " @8N(  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MF(IJ58BXIY%-#@  ,-T  !D              ("!GXL  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " "8BFI5(P61#!T$  #U#@  &0
M            @($CF@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( )B*:E4?/,M+\0,  #X0   9              " @7>>  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ F(IJ50B1D_N/ P
M> X  !D              ("!GZ(  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " "8BFI5YQ&A\H4"  !Z!@  &0              @(%E
MI@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( )B*:E7G
M95'KI ,  ),0   9              " @2&I  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ F8IJ59VPAV;G#   <ZD  !D
M     ("!_*P  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )F*:E7;I]7[*0,  $H2   -              "
M ;G.  !X;"]S='EL97,N>&UL4$L! A0#%     @ F8IJ59>*NQS     $P(
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9>&UL4$L%!@     H "@ SPH  +C9      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>175</ContextCount>
  <ElementCount>230</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>40</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StatementsOfCashFlowsParenthetical</Role>
      <ShortName>Condensed Statements of Cash Flows (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Stock-basedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/LicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Stock-basedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/Stock-basedCompensation</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://celcuity.com/role/Debt</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Net Loss Per Common Share (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative</Role>
      <ShortName>Net Loss Per Common Share (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/NetLossPerCommonShare</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/CommitmentsDetailsNarrative</Role>
      <ShortName>Commitments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/Commitments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Schedule of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails</Role>
      <ShortName>Schedule of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Schedule of Stock Options Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Stock Options Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Schedule of Assumptions for Fair Value of Equity-based Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails</Role>
      <ShortName>Schedule of Assumptions for Fair Value of Equity-based Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Schedule of Unrecognized Compensation Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails</Role>
      <ShortName>Schedule of Unrecognized Compensation Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails</Role>
      <ShortName>Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Stock-Based Compensation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/Stock-basedCompensationDetailsNarrative</Role>
      <ShortName>Stock-Based Compensation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/Stock-basedCompensationTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Schedule of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfLong-termDebtDetails</Role>
      <ShortName>Schedule of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails</Role>
      <ShortName>Schedule of Long Term Debt Future Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Debt (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/DebtDetailsNarrative</Role>
      <ShortName>Debt (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/DebtTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - License Agreement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://celcuity.com/role/LicenseAgreementDetailsNarrative</Role>
      <ShortName>License Agreement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://celcuity.com/role/LicenseAgreement</ParentRole>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="form10-q.htm">form10-q.htm</File>
    <File>celc-20220930.xsd</File>
    <File>celc-20220930_cal.xml</File>
    <File>celc-20220930_def.xml</File>
    <File>celc-20220930_lab.xml</File>
    <File>celc-20220930_pre.xml</File>
    <File>ex3-1.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="499">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>50
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 175,
   "dts": {
    "calculationLink": {
     "local": [
      "celc-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "celc-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "celc-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "celc-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "celc-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 368,
   "entityCount": 1,
   "hidden": {
    "http://celcuity.com/20220930": 8,
    "http://fasb.org/us-gaap/2022": 56,
    "http://xbrl.sec.gov/dei/2022": 6,
    "total": 70
   },
   "keyCustom": 47,
   "keyStandard": 183,
   "memberCustom": 23,
   "memberStandard": 13,
   "nsprefix": "CELC",
   "nsuri": "http://celcuity.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://celcuity.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Net Loss Per Common Share",
     "role": "http://celcuity.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Commitments",
     "role": "http://celcuity.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://celcuity.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Stock-Based Compensation",
     "role": "http://celcuity.com/role/Stock-basedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Debt",
     "role": "http://celcuity.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "CELC:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - License Agreement",
     "role": "http://celcuity.com/role/LicenseAgreement",
     "shortName": "License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "CELC:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)",
     "role": "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://celcuity.com/role/Stock-basedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Debt (Tables)",
     "role": "http://celcuity.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-09-132022-09-13",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)",
     "role": "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-09-132022-09-13",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Balance Sheets",
     "role": "http://celcuity.com/role/BalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "CELC:DeemedDividend",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-07-012022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "CELC:DeemedDividend",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Net Loss Per Common Share (Details Narrative)",
     "role": "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative",
     "shortName": "Net Loss Per Common Share (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "CELC:DeemedDividend",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-07-012022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "CELC:DeemedDividend",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-07-012022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInOperatingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Commitments (Details Narrative)",
     "role": "http://celcuity.com/role/CommitmentsDetailsNarrative",
     "shortName": "Commitments (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-07-012022-07-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInOperatingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-13",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "role": "http://celcuity.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-13",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstandingMaturityDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Schedule of Stock Options Activity (Details)",
     "role": "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
     "shortName": "Schedule of Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Schedule of Stock Options Outstanding and Exercisable (Details)",
     "role": "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails",
     "shortName": "Schedule of Stock Options Outstanding and Exercisable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-012022-09-30_us-gaap_EmployeeStockOptionMember17140953",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Schedule of Assumptions for Fair Value of Equity-based Awards (Details)",
     "role": "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
     "shortName": "Schedule of Assumptions for Fair Value of Equity-based Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Schedule of Unrecognized Compensation Cost (Details)",
     "role": "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails",
     "shortName": "Schedule of Unrecognized Compensation Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "CELC:EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-07-012022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
     "shortName": "Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-07-012022-09-30_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-05-12_custom_TwoThousandSeventeenPlanMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Stock-Based Compensation (Details Narrative)",
     "role": "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative",
     "shortName": "Stock-Based Compensation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-05-12_custom_TwoThousandSeventeenPlanMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertibleNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Schedule of Long-term Debt (Details)",
     "role": "http://celcuity.com/role/ScheduleOfLong-termDebtDetails",
     "shortName": "Schedule of Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConvertibleNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "role": "http://celcuity.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Schedule of Long Term Debt Future Principal Payments (Details)",
     "role": "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails",
     "shortName": "Schedule of Long Term Debt Future Principal Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscount",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Debt (Details Narrative)",
     "role": "http://celcuity.com/role/DebtDetailsNarrative",
     "shortName": "Debt (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-05-162022-05-16",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "CELC:LicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-072021-04-08_custom_PfizerIncMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "CELC:MilestonePayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - License Agreement (Details Narrative)",
     "role": "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
     "shortName": "License Agreement (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "CELC:LicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-072021-04-08_custom_PfizerIncMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "CELC:MilestonePayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-07-012022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)",
     "role": "http://celcuity.com/role/StatementsOfOperations",
     "shortName": "Condensed Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-07-012022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited)",
     "role": "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
     "shortName": "Condensed Statements of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)",
     "role": "http://celcuity.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000007 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical)",
     "role": "http://celcuity.com/role/StatementsOfCashFlowsParenthetical",
     "shortName": "Condensed Statements of Cash Flows (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2022-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Organization",
     "role": "http://celcuity.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
     "role": "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2022-01-01to2022-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 40,
   "tag": {
    "CELC_AmendedLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Loan Agreement [Member]",
        "label": "Amended Loan Agreement [Member]"
       }
      }
     },
     "localname": "AmendedLoanAgreementMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Application Of New Or Revised Accounting Standards [Policy Text Block]",
        "label": "Application of New or Revised Accounting Standards"
       }
      }
     },
     "localname": "ApplicationOfNewOrRevisedAccountingStandardsPolicyTextBlock",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "CELC_AtmAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Agreement [Member]",
        "label": "ATM Agreement [Member]"
       }
      }
     },
     "localname": "AtmAgreementMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_AverageSellingPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Average selling price per share"
       }
      }
     },
     "localname": "AverageSellingPricePerShare",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "CELC_CommissionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission percentage.",
        "label": "Aggregate offering price, commission percentage"
       }
      }
     },
     "localname": "CommissionPercentage",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "CELC_DeemedDividend": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend",
        "label": "Deemed dividend"
       }
      }
     },
     "localname": "DeemedDividend",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred financing costs and offering and registration statement costs included in accrued expenses",
        "label": "Deferred financing costs and offering and registration statement costs included in accrued expenses"
       }
      }
     },
     "localname": "DeferredFinancingCostsAndOfferingAndRegistrationStatementCostsIncludedInAccruedExpenses",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_DisclosureLicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Agreement"
       }
      }
     },
     "localname": "DisclosureLicenseAgreementAbstract",
     "nsuri": "http://celcuity.com/20220930",
     "xbrltype": "stringItemType"
    },
    "CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation non vested awards compensation cost not yet recognized remainder of fiscal year.",
        "label": "2022"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation non vested awards compensation cost not yet recognized within five years.",
        "label": "2026"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation non vested awards compensation cost not yet recognized within four years.",
        "label": "2025"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation non vested awards compensation cost not yet recognized within three years.",
        "label": "2024"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation non vested awards compensation cost not yet recognized within two years.",
        "label": "2023"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYear",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_EstimatedIncrementalFairValueOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated incremental fair value of the warrants.",
        "label": "Estimated incremental fair value of the warrants"
       }
      }
     },
     "localname": "EstimatedIncrementalFairValueOfWarrants",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_FinalFeePayableToLenderAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final fee payable to lender, amount.",
        "label": "Final fee payable to lender, amount"
       }
      }
     },
     "localname": "FinalFeePayableToLenderAmount",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_FollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on Offering [Member]",
        "label": "Follow-on Offering [Member]"
       }
      }
     },
     "localname": "FollowOnOfferingMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_GrossProceedsFromAnAtmOffering": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds from an Atm offering.",
        "label": "Gross proceeds from an ATM offering"
       }
      }
     },
     "localname": "GrossProceedsFromAnAtmOffering",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_GrossProceedsNetOfCommissionsAndOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross proceeds net of commissions and offering expenses.",
        "label": "Gross proceeds net of commissions and offering expenses"
       }
      }
     },
     "localname": "GrossProceedsNetOfCommissionsAndOfferingExpenses",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_InDecemberTwoThousandTwentyOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In December 2021 [Member]",
        "label": "In December 2021 [Member]"
       }
      }
     },
     "localname": "InDecemberTwoThousandTwentyOneMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_InMayTwoThousandTwentyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In May 2020 [Member]",
        "label": "In May 2020 [Member]"
       }
      }
     },
     "localname": "InMayTwoThousandTwentyMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_InMayTwoThousandTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In May 2022 [Member]",
        "label": "In May 2022 [Member]"
       }
      }
     },
     "localname": "InMayTwoThousandTwentyTwoMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_IncreaseDecreaseInNonCashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in non cash operating lease expense.",
        "label": "Non-cash operating lease, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInNonCashOperatingLeaseExpense",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_IncreaseDecreaseInPayrollTaxReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in payroll tax receivable.",
        "label": "IncreaseDecreaseInPayrollTaxReceivable",
        "negatedLabel": "Payroll tax receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInPayrollTaxReceivable",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_IncreaseFromOriginalLoanAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase from the original loan amount.",
        "label": "Increase from original loan amount"
       }
      }
     },
     "localname": "IncreaseFromOriginalLoanAmount",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_IncreasedNetLossPerShareBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increased net loss per share basic and diluted",
        "label": "Increased net loss per share basic and diluted"
       }
      }
     },
     "localname": "IncreasedNetLossPerShareBasicAndDiluted",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "CELC_InnovatusLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innovatus Life Sciences [Member]",
        "label": "Innovatus Life Sciences [Member]"
       }
      }
     },
     "localname": "InnovatusLifeSciencesMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_IssuanceOfCommonStockLicensingAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for agreement.",
        "label": "IssuanceOfCommonStockLicensingAgreement",
        "verboseLabel": "Issuance of common stock, licensing agreement"
       }
      }
     },
     "localname": "IssuanceOfCommonStockLicensingAgreement",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC [Member]",
        "label": "Jefferies LLC [Member]"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_LicenseAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement disclosure [Text Block]",
        "label": "License agreement disclosure [Text Block]",
        "verboseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDisclosureTextBlock",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "CELC_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Member]",
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_LoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security and Loan agreement [Member]",
        "label": "Security and Loan agreement [Member]"
       }
      }
     },
     "localname": "LoanAgreementMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_LoanConvertibleToStockPercentageDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan convertible to stock percentage description.",
        "label": "Loan convertible to stock percentage, description"
       }
      }
     },
     "localname": "LoanConvertibleToStockPercentageDescription",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "CELC_MilestonePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payable.",
        "label": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayable",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_ModifiedStockOptionExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modified stock option exercise price.",
        "label": "Stock option exercise price per share"
       }
      }
     },
     "localname": "ModifiedStockOptionExercisePrice",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "CELC_NonContingentTermALoanFunded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non contingent term A loan, funded.",
        "label": "Non contigent term A loan, funded"
       }
      }
     },
     "localname": "NonContingentTermALoanFunded",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_NotesPayableFinalFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes payable final fee.",
        "label": "Add: final fee"
       }
      }
     },
     "localname": "NotesPayableFinalFee",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_OfferingAndRegistrationStatementCostsIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering and registration statement costs included in accounts payable.",
        "label": "Offering and registration statement costs included in accounts payable"
       }
      }
     },
     "localname": "OfferingAndRegistrationStatementCostsIncludedInAccountsPayable",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_OpenMarketSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sale Agreement [Member]",
        "label": "Open Market Sale Agreement [Member]"
       }
      }
     },
     "localname": "OpenMarketSaleAgreementMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_OriginalAndAmendedLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Original and Amended Loan Agreement [Member]",
        "label": "Original and Amended Loan Agreement [Member]"
       }
      }
     },
     "localname": "OriginalAndAmendedLoanAgreementMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_PaymentInKindInterestDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment in kind interest debt",
        "label": "Add: Payment-in-Kind interest (added to principal)"
       }
      }
     },
     "localname": "PaymentInKindInterestDebt",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_PaymentsForFinanceLeases": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for finance leases.",
        "label": "PaymentsForFinanceLeases",
        "negatedLabel": "Payments for finance leases"
       }
      }
     },
     "localname": "PaymentsForFinanceLeases",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_PaymentsForRegistrationStatementCosts": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for registration statement costs.",
        "label": "PaymentsForRegistrationStatementCosts",
        "negatedLabel": "Payments for secondary registration statement costs"
       }
      }
     },
     "localname": "PaymentsForRegistrationStatementCosts",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_PayrollTaxReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll tax receivable.",
        "label": "Payroll tax receivable"
       }
      }
     },
     "localname": "PayrollTaxReceivable",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_PercentageOfWarrantExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of warrant exercise price.",
        "label": "Percentage of warrant exercise price"
       }
      }
     },
     "localname": "PercentageOfWarrantExercisePrice",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "CELC_PfizerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer, Inc. [Member]",
        "label": "Pfizer, Inc. [Member]"
       }
      }
     },
     "localname": "PfizerIncMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_PlacementSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement Shares [Member]",
        "label": "Placement Shares [Member]"
       }
      }
     },
     "localname": "PlacementSharesMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_PrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment fee percentage.",
        "label": "Prepayment fee, percentage"
       }
      }
     },
     "localname": "PrepaymentFeePercentage",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "CELC_ProceedsFromEmployeeStockPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from employee stock purchases.",
        "label": "Proceeds from employee stock purchases"
       }
      }
     },
     "localname": "ProceedsFromEmployeeStockPurchases",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from follow on offering net of underwriting discounts and offering costs.",
        "label": "Proceeds from follow-on offering, net of underwriting discounts and offering costs"
       }
      }
     },
     "localname": "ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_PropertyAndEquipmentIncludedInAccountsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment included in accounts payable",
        "label": "Property and equipment included in accounts payable"
       }
      }
     },
     "localname": "PropertyAndEquipmentIncludedInAccountsPayable",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase Agreement [Member]",
        "label": "Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_RemainingStockBasedCompensationExpenseRelatedToModification": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining stock based compensation expense related to modification.",
        "label": "Remaining stock based compensation expense related to modification"
       }
      }
     },
     "localname": "RemainingStockBasedCompensationExpenseRelatedToModification",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_SaleOfStockTransactionFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock transaction fee.",
        "label": "Incurred transaction fee"
       }
      }
     },
     "localname": "SaleOfStockTransactionFee",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for agreement, shares.",
        "label": "Issuance of common stock, licensing agreement, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockLicensingAgreementShares",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "CELC_StockIssuedDuringPeriodSharesStockWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares stock warrants exercised.",
        "label": "Exercise of common stock warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "CELC_StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for agreement.",
        "label": "Issuance of common stock, licensing agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockLicensingAgreement",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_StockIssuedDuringPeriodValueNewIssuesForEquityGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued for equity grant.",
        "label": "Value of shares issued for equity grant"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesForEquityGrant",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_StockIssuedDuringPeriodValueStockWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value stock warrants exercised.",
        "label": "Exercise of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_StockOptionAwardsSharesModified": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option awards shares modified.",
        "label": "Stock option awards shares modified"
       }
      }
     },
     "localname": "StockOptionAwardsSharesModified",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "CELC_TermBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term B Loan [Member]",
        "label": "Term B Loan [Member]"
       }
      }
     },
     "localname": "TermBLoanMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term B loan to be funded.",
        "label": "Term B loan to be funded before March 31, 2022"
       }
      }
     },
     "localname": "TermBLoanToBeFundedBeforeMarchTwoThousandTwentyTwo",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_TermCLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term C Loan [Member]",
        "label": "Term C Loan [Member]"
       }
      }
     },
     "localname": "TermCLoanMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term C loan to be funded.",
        "label": "Term C loan to be funded before March 31, 2023"
       }
      }
     },
     "localname": "TermCLoansToBeFundedBeforeMarchTwoThousandTwentyThree",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_TermDLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term D Loan [Member]",
        "label": "Term D Loan [Member]"
       }
      }
     },
     "localname": "TermDLoanMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_TermELoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term E Loan [Member]",
        "label": "Term E Loan [Member]"
       }
      }
     },
     "localname": "TermELoanMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_TwoThousandSeventeenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Plan [Member]",
        "label": "2017 Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandSeventeenPlanMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_UnderwriterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriter [Member]",
        "label": "Underwriter [Member]"
       }
      }
     },
     "localname": "UnderwriterMember",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "CELC_UnfundedContingentLoanAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unfunded contingent loan amount.",
        "label": "Unfunded contingent loan, amount"
       }
      }
     },
     "localname": "UnfundedContingentLoanAmount",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "CELC_UpfrontFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fees.",
        "label": "Upfront fees"
       }
      }
     },
     "localname": "UpfrontFees",
     "nsuri": "http://celcuity.com/20220930",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r380",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://celcuity.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r156",
      "r191",
      "r209",
      "r210",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r353",
      "r354",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r139",
      "r156",
      "r191",
      "r209",
      "r210",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r353",
      "r354",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r133",
      "r136",
      "r137",
      "r138",
      "r139",
      "r156",
      "r191",
      "r207",
      "r209",
      "r210",
      "r241",
      "r242",
      "r243",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r353",
      "r354",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r133",
      "r136",
      "r137",
      "r138",
      "r139",
      "r156",
      "r191",
      "r207",
      "r209",
      "r210",
      "r241",
      "r242",
      "r243",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r353",
      "r354",
      "r366",
      "r367"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r1",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r98",
      "r125",
      "r126",
      "r262",
      "r272",
      "r273",
      "r274",
      "r275",
      "r293",
      "r296",
      "r297",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r1",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r83",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r98",
      "r125",
      "r126",
      "r262",
      "r272",
      "r273",
      "r274",
      "r275",
      "r293",
      "r296",
      "r297",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364"
     ],
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r121",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23",
      "r304"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r304"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r254",
      "r255",
      "r256",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r203",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Issuance costs associated with ATM offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r152",
      "r203",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Issuance of common stock warrants, note payable"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used for operations:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Recognized stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r58",
      "r176",
      "r184",
      "r185",
      "r289"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of debt issuance costs and discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r9",
      "r69",
      "r113",
      "r115",
      "r119",
      "r123",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r266",
      "r268",
      "r277",
      "r302",
      "r304",
      "r329",
      "r342"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r22",
      "r69",
      "r123",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r266",
      "r268",
      "r277",
      "r302",
      "r304"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation, Summary of Significant Accounting Policies and Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r8",
      "r60"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r53",
      "r60",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r53",
      "r278"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosures of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Common stock issuable",
        "verboseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of reason for issuing warrant or right.",
        "label": "Warrant or Right, Reason for Issuance, Description"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r333",
      "r348"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies (Note 4)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common stock, shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par or stated value per share",
        "verboseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r304"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value: 65,000,000 and 25,000,000 shares authorized as of September 30, 2022 and December 31, 2021, respectively; 14,942,958 and 14,918,887 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r104",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Non-cancelable contractual commitment"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r12",
      "r331",
      "r343",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Note payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r170",
      "r177",
      "r178",
      "r179",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r68",
      "r71",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r160",
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r182",
      "r183",
      "r184",
      "r185",
      "r291",
      "r330",
      "r331",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r153",
      "r182",
      "r183",
      "r288",
      "r291",
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.",
        "label": "Debt instrument interest rate description"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r30",
      "r68",
      "r71",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r160",
      "r166",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r182",
      "r183",
      "r184",
      "r185",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r166",
      "r287",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt discount, amount",
        "negatedLabel": "Less: unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "auth_ref": [
      "r287",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.",
        "label": "Debt issuance costs and discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r166",
      "r180",
      "r182",
      "r183",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: unamortized debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r166",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.",
        "label": "Deferred transaction costs"
       }
      }
     },
     "localname": "DeferredCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r166",
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Offering expenses"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r58",
      "r130"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r214",
      "r215",
      "r247",
      "r248",
      "r251",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r42",
      "r78",
      "r79",
      "r81",
      "r82",
      "r83",
      "r89",
      "r90",
      "r92",
      "r93",
      "r94",
      "r98",
      "r99",
      "r274",
      "r275",
      "r336",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r250"
     ],
     "calculation": {
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "totalLabel": "Total estimated compensation cost to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfUnrecognizedCompensationCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r36",
      "r37",
      "r38",
      "r73",
      "r74",
      "r75",
      "r77",
      "r84",
      "r87",
      "r101",
      "r124",
      "r203",
      "r205",
      "r254",
      "r255",
      "r256",
      "r261",
      "r262",
      "r273",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r297",
      "r355",
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r58",
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Incremental fair value of warrant"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://celcuity.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Loss on sale of fixed assets",
        "negatedLabel": "Loss on sale of fixed assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows",
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r40",
      "r113",
      "r114",
      "r117",
      "r118",
      "r120",
      "r327",
      "r334",
      "r338",
      "r351"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r132",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r70",
      "r86",
      "r87",
      "r112",
      "r260",
      "r263",
      "r264",
      "r352"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income tax benefits"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapital": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.",
        "label": "Increase in operating ROU asset and lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid assets and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r39",
      "r111",
      "r286",
      "r289",
      "r337"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r52",
      "r54",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r45",
      "r110"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r69",
      "r116",
      "r123",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r267",
      "r268",
      "r269",
      "r277",
      "r302",
      "r303"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r69",
      "r123",
      "r277",
      "r304",
      "r332",
      "r346"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r28",
      "r69",
      "r123",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r267",
      "r268",
      "r269",
      "r277",
      "r302",
      "r303",
      "r304"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of credit faciltiy, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r12",
      "r167",
      "r181",
      "r182",
      "r183",
      "r331",
      "r344"
     ],
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r71",
      "r140",
      "r172"
     ],
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r71",
      "r140",
      "r172"
     ],
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r71",
      "r140",
      "r172"
     ],
     "calculation": {
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfLongTermDebtFuturePrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Note payable, non-current",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/ScheduleOfLong-termDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used for) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used for investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r53",
      "r56",
      "r59"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used for operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r34",
      "r35",
      "r38",
      "r41",
      "r59",
      "r69",
      "r76",
      "r78",
      "r79",
      "r81",
      "r82",
      "r86",
      "r87",
      "r91",
      "r113",
      "r114",
      "r117",
      "r118",
      "r120",
      "r123",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r275",
      "r277",
      "r335",
      "r349"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://celcuity.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity",
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r113",
      "r114",
      "r117",
      "r118",
      "r120"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r295"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r294"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableAxis": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group of items that represent other investments not readily marketable, including description of investment, fair value, and value as measured by quoted value method.",
        "label": "Other Investment Not Readily Marketable [Axis]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the investment category or actual investment title."
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Payment-in-Kind interest"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForUnderwritingExpense": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.",
        "label": "Deducting underwriting discounts"
       }
      }
     },
     "localname": "PaymentsForUnderwritingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments for debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Conversion price per share"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par or stated value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13",
      "r304"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.001 par value: 2,500,000 shares authorized; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r20",
      "r127",
      "r128"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from note payable, net of debt issuance costs and discount of $652,061"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Gross proceeds from public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r253"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of employee stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from exercise of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r131",
      "r304",
      "r339",
      "r347"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r208",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r208",
      "r298",
      "r299",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party."
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r208",
      "r298",
      "r301",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r259",
      "r313",
      "r368"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Clinical Trial Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r205",
      "r304",
      "r345",
      "r359",
      "r364"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r73",
      "r74",
      "r75",
      "r77",
      "r84",
      "r87",
      "r124",
      "r254",
      "r255",
      "r256",
      "r261",
      "r262",
      "r273",
      "r355",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Aggregate offering price, common stock shares"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of stock, value"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of stock number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Issuance of public offering price per shares"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r245",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Long Term Debt Future Principal Payments"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r211",
      "r212",
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r218",
      "r233",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Assumptions for Fair Value of Equity-based Awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Schedule of Unrecognized Compensation Cost"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://celcuity.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Total",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStock-basedCompensationExpenseDetails",
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Stock option description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Restricted stock awards outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Restricted stock awards vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/LicenseAgreementDetailsNarrative",
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Additional shares authorized under plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Shares available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options exercisable, ending balance",
        "verboseLabel": "Options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercisable, ending balance",
        "verboseLabel": "Options exercisable, weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options outstanding shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options outstanding shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted Average Grant Date Fair Value for options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Options outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Options outstanding",
        "periodEndLabel": "Options outstanding ending balance",
        "periodStartLabel": "Options outstanding beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r219",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Options outstanding, weighted average exercise price",
        "periodEndLabel": "Weighted Average Exercise Price, ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Schedule of Stock Options Outstanding and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Stock based compensation expense related to modification"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails",
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfAssumptionsForFairValueOfEquity-basedAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Options exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options outstanding, weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r33",
      "r36",
      "r37",
      "r38",
      "r73",
      "r74",
      "r75",
      "r77",
      "r84",
      "r87",
      "r101",
      "r124",
      "r203",
      "r205",
      "r254",
      "r255",
      "r256",
      "r261",
      "r262",
      "r273",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r297",
      "r355",
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r101",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Issuance of common stock warrants and final fee recognized as discount to note payable"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r13",
      "r14",
      "r203",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Employee stock purchases, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r203",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock in an at-the-market (\"ATM\") offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r203",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock-based compensation, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r203",
      "r205",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of common stock options, net of shares withheld for exercise price, shares",
        "negatedLabel": "Options outstanding shares, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/ScheduleOfStockOptionsActivityDetails",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r13",
      "r14",
      "r203",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Employee stock purchases"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r203",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock in an at-the-market (\u201cATM\u201d) offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Issuance of common stock upon closing of follow-on offering, net of underwriting discounts and offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r203",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of common stock options, net of shares withheld for exercise price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/Stock-basedCompensationDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r69",
      "r122",
      "r123",
      "r277",
      "r304"
     ],
     "calculation": {
      "http://celcuity.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets",
      "http://celcuity.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r67",
      "r189",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r205",
      "r206",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r285",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r285",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r285",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/DebtDetailsNarrative",
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r102",
      "r103",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Accounting Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/BasisOfPresentationSummaryOfSignificantAccountingPoliciesAndRecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/NetLossPerCommonShareDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants maturity date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r89",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://celcuity.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28567-108399"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "820",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r369": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r370": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r371": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r372": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r373": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r374": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r375": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r376": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r377": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r378": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r379": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r380": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r381": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r382": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r383": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r384": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r385": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r386": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r387": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r388": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>51
<FILENAME>0001493152-22-031433-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-22-031433-xbrl.zip
M4$L#!!0    ( )F*:E7C>@6V,@T  ,2    1    8V5L8RTR,#(R,#DS,"YX
M<V3M7>MS(C<2_WQ7=?_#'%>5VZLZC+&S#SOKI#"8%!=L*(.SR7U)B9D&5!XD
M5M* O7_]J>?%O!ELLSLYO!^20>IN=?=/SQ[U^.-/#PO;6(&0E+.+6O/HN&8
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MFZ?.-D[WMWS2@'!?4HO'709%E"7X\;2>N4F9WJT?>"!@5WAJLT_H!>G&<[N
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MI2NNQ':T]\Y.C5-WE06I1;B#4LR9\V8 V3AL"AGO%!D IKG NN9T #42. J
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M2)HI9.B\?$^V77)[K]71)OY>#*/I%?LLC>3@MVP?D8YUWG7:]F&Z:+Y -I_
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MX$X ?^4*."4>$174\LXG !.+9[<AY)R'^3W2-!P52S+.AM/ D6V*UXD2&6,
M#3^W02U=*-C8X#-MQPK9F,$T.K8PVV\;#"EYXJOEDMZL@9&1]LOMEI)W:D%H
M2KD>\MYZ0DZG6"7 SKS:D4!##24LR2OC0IC&&GZD]Y0E$<T+@>XZ*ZG]L#-"
MW_GQZIAB26>O-LIHR#<6L10EV=+_MW_YPX?WO_\C$7:\$W13"/YP/<06\#7V
M+4T@:0./?N!.Z$-0T*C.O3 PPNUJU.DI[5XJH'-VNY-%-*3?2S&DG@ *QY]
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M#0.0!HDY=I"@\SZ#/\U690&SF\AD4;UFRJO,JH=Y!N6T=Z)H@$[/]HH(SZB
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MV>%:SV9WLL.U/\+C[E7O:\.7\,3<;YOE^6HH+G\/A@\B#[E4$7O))7Z%[P[
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MH=6%RYC5_?EL?7!P/S..ZC??*Y\2XD;*)YKK3ZBVLX1H=-ZQ -HHJ:]K@]_
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M!__(%@==! T^U(Y(F\>RUA45W/[3%?L7^W/])_9_X %4]I?_!U!+ P04
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M$0\)ZG.:A$%4].A<_"[1P]U2' HYRI[3*"8J[/\@ 0>#7BL,A1QE&VH0<<^
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MN/=_(U'T=Q8_LAL2)#$CLV*IK_/P*ZM 64 \0S2(BT+!KW&4"91X'@C*%6-
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M@_+1*(Z6JE4/;AL#"E'1B9!/B8W93/Y+IL]_"")I;<?I2<#YLYC^\M3Z:F*
MU=%ROH(XB+N(Y E_IV(!*0Q!LB6AFB]%<;34L!WXT4KL 1]B9<+E\P$)B(ZV
MTFB)8SNQH9:W+QDMK^&<79[\/@V>A2S1;? DWR(2 _2N-3I+EFTOBI8KU@9?
M=?<]T?0I)ZN SLI7/8RJKBB.ED6V@ZYK)4;G S@#=+/\PV_^.N!OLOBB[X4Q
MNBRD5O8P[UX:IT&4E\0;0?&*\/1Y&LG'UMA,+C=6<IE_1;0#25<++3^MS9(8
M(CCZ>"J?5V:+2Q(DY)HN[L7VZTM"<@G5]!BJH66RM>$')#HZ084H)DN'F=#6
M?IOX JS:)0WN:$33XKG(YJ. YMT^O 6\Q+G]/3.V.*&/MUJ'P8X;71V\%+Q=
M&5 2Z*MWIPPM2,1&0NX=S(M#17F\U+UPK&.0))X04Q@+DL^OE6S/1GKTM?!R
M_W8E"8(".E7;BR$X6:9Z>&F$N](%0P*=,#'T>2:62PWQM'9/504O!W$/TZ>7
M'YTA&VKZ<.+,:V'-"8B,0UOIMYKOJYB%G>:Q>D6\?,B#3F5-+#JS_4#X72R:
MQN1;8?\AC .JXB5='G@^?&&L5\\R7\4IJ9;3&G/=6AHOG_- 6ST-!C[-IJ!I
M%#//\^ [[Q<PC<KH0YKF46XR[B#.KP(0%FKYU%;"2R@]#+\ 1-!'71?'Y@"N
M3 <9J8?A[  <F-/*,.1]-40VM1;&RUT-1[EQ9JV2&9V/6MBU*<RL41(OJW57
M)E32HM,PGLWR\XH@F@9T=L%.@A5-6U-:5@X&506\M-==23'(CL[--4D#RLCL
M+.!,WA<9AV&VS"(9!7]*YC)7IYHF2%V\1-I=&8,C@DY>4S:;I0%F4NZNY*@E
M/N#UN6EAU/T@&S,_^. [,2TV@]*/>J%GFJ-Z3U(:UN:)K=L]'X&W>T;?;#7V
M?UYO^[A<[PNL)SSO[BQ??TT)SR_[0;< ZOJ'>SO(#B'T"76[N\55S7&6WL><
M_KD9S28BF_6P[Q$-QJ *$B^9RW/16;)6U<&^4#0P8]M0>,F6_BZX1K8NE\&=
M.;D&YLWU/?&>7A7[*0]4&?M^4@\2+<#QB4CX5*>MA'WQ:1CBO)WD&GTTS7#*
M"MBWHH8DRK.YS3+)B4JJ+K.:0R?:<'3!IK1];\$WZ:,G\S+LHO[\T];V^R_*
M[?>FE5$\'VW:&7WSA05%VFJD3;A,;[(DZ_Z9]]W*"LBA0>7E2$".#4T5Y VU
M@0Q5%)!*='23=RW0$Y^760U.R0.)XORN7=E=W?F!MAKVIMF,^^[! 0 %=*Y^
M(4R(%8E.CF=+RJ@42:94-K)EK(B]9;;E"X@$.F,-N2Q,'OZ&V)85I;0'?,"S
MEJDP_)=Q:Q[K70#JA;%WQ!UGK*:\!\SB5<SB;<%*%34O10!5L;?.=@R#L4"W
MGOFK 20QKT8:!;'WR'",8[T@74?>IV+D,;*0/BS4L7?!'H1$^=.9.1*5C#HZ
M536P-]/=>=5C@#[4?@DHD[9^PDYILBK= Y-YD7C@O69E::B'G7*D*V$P/-!I
M4XK783[#SS_2E2PC"@>\<MDLP\X%7$6X>R:?"EP[J([)/.:D*'<;/)'D[$F
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M<;I:J+>["T<'H-XF#%^5?K,]R'-[.;;3+9_"O[7EJQXK>3GXE4%-,APS"^X
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MXP;@D=CN_:/=D*RI?N 96/QA *O<L4#&CUC+88/5B"P6X%/;1O\G8HW6M#D
MS6(AK:2>5 (35+B+2]!'FPC?R76IVD5=&X@@I$5*],6#)?N A\()5ZK,#$)?
M,@Y_SU O6K"&!>9QY5B1JB&U%L5IL1:"J0$Y@B9GJ#&PNQ6&245^\4.).8Z?
M!]<B:0R F 5]&/F*D4A829FPV)L5)D\IYJ59>XLZDQB'*-F;D/(J%D#GQ9%J
M0O6;0,C?TD"J+_%!'P8)11AGAU0PCGJBB^3 2 ;ENRIJ!2\:YL^60H_M&4P
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MUJ._51^JO8%KV^;4!UJBWSZ!A%C!&(>F]%L63*+7B=JXPY+VP+2C\0C<:7J
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M?!W7VHV_2%Z_]+Y>7_X'4$L#!!0    ( )F*:E5<C+GH^P<  ,M#   *
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MVR(4 '^)7-V!RJ\YZB;:N0Z[2%W5?LC..'J21J-\-B?#/U>_WU["[I]IMLQ
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M Q&Q!F"FR^2@=MZ4F_+$3M=7&0QE=0PL>6F,-*$/U]J0>5\=L.7J=DR]3;3
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M[GDG>K^(PPGH&5%,2"<V8YVTL$XLY8P%/%\HX%R1R;CGL+DGEA++ HM.).Y
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M@B(OB'@32;A==W.VL-)BF&GL2VN<WPXOZ?6NN0E.4CFX2/NN]A+H6]<;D(5
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MSK7PV7KTJ0 FJ,FW\!NKB;_IO?;$"?.@#[I3$[]3Y,;L!)@HW'/BH)@G<3+
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MJHY$UN@#QU1"\9Z:06CDI,N#Q8=#[J4EPD7^)Y?#;B0@B^=8@^^!"_B<OR,
MU>,YEK_ ?O#R"'ZBL%S.T0BB]+IZ$]G<S+&WD1<0P)D F6(#5RK+=LVS*:KH
M;PB<X/P]_PZHY65^J$-8G$\7V)LD&GVT3.(?KW7[;X) \GAM5OEH (LD<Z^#
MU[KPYF#L FN-A_#])8WO2,(%5H-JSL)J344(S+MO^NS<A7Z9*19'J7SY#/'L
MA7(-\"^Y#H *$#Y[:%+,S72IP? <-A?5JR<6W,A#2+5X,B8YC5<F=Z=_8]8M
MG<M9BP;^I4T0^3-'QR '_JG:>CX]J=;*GZPDYP&LMU9O59JG)ZTZ5J[7KBNU
M9N4:NZG62K5RM72/-5NE5N6A4FLUL0\CA1^)T"D5/Q[,XC_<J-KI";*AK;X&
M76/D*-<D!6 /\.*^CE44%$,VP1!:U0[0,)K ,11.F1<B_^UP4.&(\/)R+.>R
M-AK FX7 D2;0!7Z(+ \,5,\6/.2ZUN-A &*&N&55,6VKM5VLB T-Z&@+PIJ0
M?>.X-M-(V+51TH)P7,G0V88+&$[#LL)<;5+4KVI/WO(/3S\[3;9:F+5LBLU)
MGB?\GY%N2-UQQ)0G/V'S?6D*5!%&KU<MENTSO1>&.[MT8W'*'KMA_-WCPU\2
M#F-]<P\S7P=#3-5*.)U;7;]DJ //+FN\ 5G_]$3M8E<C'7ZEZX=-_#V%D?$O
MK QD82098^B[*,(G'..Q:R#S;[R&FLUH0YOXV =D"?_WWP)%$1=E*]@T_R(O
M/N*8I,/;!,@9IE\,(TWHL78D&(<*?465U=X8L^-3^'K!/,P)GRB"5R"KUIX@
M9",#+AM #\*TN1H_E(!UQGLPD@UI"%U\4S]CQFA@S@(0X:O,*K5/T#X#S 42
MF;_0T8EP$;,>!$8&LDW0+"/U#A"P/0 _P<?I4@<M> @A50P<TR!$&OP.ODP<
M\?+IB:3TI8YDP!<:?1X&>D &:"\;R&,;7+AN6<;*,J_K6!5K5.EO\/$JRMA8
MF;5!J_[X":O"ZP8 '>^1] %:JYT;0E<,^[PVX 7U!<H0@M,>0H)6CTC0EWI]
M&=)&E% 6&$(IP26(5A,5%:T/$ZQ^6Q D?HA.QZ+4G2(ZF_$]$TDP_)\AU5R*
M!;X%,4(RA!,N187N#5JL"G^#U\^A%CY1LM_.8PW4O1&C(0..Q#$&7F'H; T8
M=&$6Y=>'\%OSM/Z;9/2QKX__W^>OE4<JA_'B*TI+BAB*\71TS!?^A<AJNE 6
MQJ!3C8Z02;S-/' =" ]\3U%U$U,R;R!,(X*.% E&F @'B'B&"E' R^,)P&1(
M+0<*FW?,T!!=(XD(G]TQID!A01G6H6X5@9FP3$&7I1>3X"K6 0KH2L;IB=7#
M1H:PBRZT.QP\P_4\ M]X'2XEUT6I7&O[@2)("IUDOM(D*,TWG[#F2(80\Q9K
M7$,"W)O9VUOTP=G<@,OM0.R+B#VQ!TF!NE<U^/E70?*@/! DAX*J.4V>&)O\
MK8RLY! 2A4\'J,Z\]?3G.4?U,@:_]8K7)1U-F)GYC="-;"(&[D)5I1CV]BBD
M8@/*AP"YP\]'Y5P^ZC:/;4_>O^=+#S\FQ/7=RV'XH]2R/\JV)[>WR@LOUH;L
M+_GLTL08DF,WSN!#1X,!:L8#?W!A#YNA#W/P9PK9(T"1U-S/FJK SX*30SUD
M9V?',9_-Y NL/+;^ZR,E#+TL)6L>T)YTM5+MZ>I=?O\C'88\!/;7%Z2&*T/E
M8+S2"E]Z_T-V;*DQW7FWV$Q)?[3,?@#K@W[!P@[1-%OGN3WD%$B8^T?3<B3D
MH;L<#*0C^SSTK3H 0#=/ T->FQ4P::+IMIA.7PEERZ%31A(F>SV"WDBV0HIF
M[A=R=Z&#WS-=%.@(H5<T 71I)</1Q,ZY>/3J@:3K9C!B!R+-2MD)0CZ9NEI#
M&P#R&$>[U]"-'DB&_> 9%+B5U%N# ]'<\9ZB GGY-@9<)P.@0V4.<S3?P,],
MQ5"#]Z&81;<=,%DV?T>Y0A-'!B+)DV*^WDPIZ=,E/7UJ?L)N2Z7&;&'(L>OP
MLHE2O0^@VPX=^&MHH*R\(VGF'4G3O83R+KTZ\8%)OU6+Y V$"_@P,RXRNP"K
M0%]:.'J.N^;7O>HIN-!G-]>%J4,)N>H(79 [820X,&,K]"!>1.QMO?NM+PE]
M,\11NY ]X4LA4F54@ #C&7,;T\PPF% I<*VZCJSW_\_>FSZGK72)P]]=Y?]!
MO\QSIY)Z95_$SLTSMPIOB1-O\9+MBTN  -E"(EILPU__]CF]J"4D$%A@O$S-
MS'5LJ=5]SNFS+V 0ZDI7-UV@.<&G)%)TC2X8:0+.B2='F'HR$4"O/LB7(5IU
M(JB\OA-8Y,20(J'CVN2-&Z(.X.>1T&>#&V\1)ER@16DH(T-W%0.M@0E\$J#8
M:$J0+UK4Z',<GP5WB8%A@ 4CI3+Y"59PT[:)'4ON'#'C?;"Y#\!>T@I;7S-M
M85L1\[LW-PBXB27NB1=]X16WP2L^H%YQ(]4K3G )A,5Q25B9L.+O#'ZY^$?0
MV,*L+$1E)T"2P&OC&@-B"A%"Y^\P YB>!)K" 8V JR%  J*%FV^F3G[JVI5G
MG';WR7$&P+EB:IG<3BCZX/7XYONY=VY_;QS?Q\V1ED,NUW/$P<(*F'8]KC?L
M'\7AE_J/!_+W4'?=W! @B^M?ZTK"_W#V/7L/+]B3>BS$W>9&  .]#8Y'9).Z
MYP4#.EX(76.H,S&VEBR+TM2S"1U+DL*7?8<L)KY,I8C\:1U["S%N"W(!G$,#
MH>211PV6%FB9>LNT4!-38TH S2=$<@76F_92*,'HAX![,Q<4UH2P'%70W?P
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MD%(.WH9BH:36TL-)F8-_C3F=#4O%T>J<#,M&4S3LI^46]E-B4;\RBI9"W*T
M[4HF_ K*$MT*N<RM68%;80I5C@<#S>X?]?<MO1TCS_SDR9/K3W/&"A];[U.M
MSYD$F$L]Y J\"M,(Z:Y7*M2+VJ&QTWVYA#3%NY _(6E%M5J8+S=Q<V-./3R9
M'G-I:#]7]#EK9N.\5'E;_F)4"][7S[[U<JERSKA>;D&]@EIO)#4NG<+I<IE[
MNQAE+>!PF$99S<\WK?;/N^Z)\[+Y79KC8:F4559+C6J^_@=9_\/&=O.G.N3B
M<=C+Q^.0/Z^,)AB_'._",@FU6)OJ5'B!-4R)Q5FT!ZSQT+:"CO'O?__?UI9R
M8!I6YQ_E3.\9'\EB?P+#;L,BVD?:'NH?I:AL;?%:S(YY-[TO%8[48)VI8C"H
MPK;F:S.9K7EDPNFG-*(B&$HJ[4MI+TPKTV.]*F7 <9!]5* ZX!^EZ>HML_V1
M6,8#@X*5&+\$@)HFO_4W?PW^%-83\EK"__Y- )T$<]?0"=<SR'4@BP\19S+A
M/1L01\ 9KZI,A((,/( J!9Q$S2NZN,^R2S/K$WO:3=8^).>4!Y>>:BV>%PSH
M[Z9V78ZT?\_U0]?CQM7>P\/7+]_N>]KRZV5SKR!%E@@P<2SR,O4B;H'[#+UI
M3L>PT%T5>%0F&T0&@#*"V@MVDE<Z\,\N])K'VFYPAQ&^8?HCIOEP_YGI]_&M
ML#LS;WJPQ9H>;&[H(9@S*F9/T'1Y";<KUEEY_WI\[O]L!A???P=[C4R=E9LQ
MR$G-_\E?]V6$4$_\:CLL1R"H![Z3I>ER'7@Z>].E;1WAU?G[,#^O+IA%+")]
M!>T^P9):Z\Z>J:,<SDWO=JL+KC(3CD*XHN(2-KCL\2GY\9VE1!_$R Z)&0&D
M#@B@#AF<S@F8L,-.9W@=G 6ND6Q\>JY/3%KX(#4Z\=_'Q,@;! /N-/'W?AWV
M/_UN=.IAB[$4Q"S-)Y+UR!GM3'+,Z\@IYPF=,;MRJR@9E@#A=_]JV]74U,2_
ME*VDJ/,SH ;]0::&OM5N#VJ53P>MTHNB!OF4^5!#:;N1U#Y.5@?^6I>!4<OC
M>+G49"Y.XQ,.Y"P<S^V/=CVO^>/HKOT\:7S2!;PDCE?8KJ;2>!+'RR7_=>G4
M$.5XA9^G1^6]<MD)K!=%#?ES/&U;FPP _!6W@%8V:3-M+NSD)_E@)^7.L0A*
M+&+$/5^.FTNX+HG@.)2^"R#EJ&7VQXWNX?[5M]UZF"V9@):5WK#D S^MCEFK
M;J>F%ZQ4Q\R9&J(\][C@?;X=?#T_MU\0,>3/<&N-[9P9[G-D>$M3,;.2^$)*
M9N7RMV4<UKS3/_ISI/&5J9B$X:5F%20QO.="#5&&Y__:;1KV^2?ON_:"J&$)
M'*^Z/=G^[>E4S(6\F@*O, E%>0]S2;P/SY?][N716'D:_<'8%"U]MDT69GOG
M'5J[E4:S:/8FKY>,AL4&TTQG?4L90#,38)#.7Q1W)39G!F*,SP./,5O\J%L]
M//W3JYXTEH;'5*;U5'@D&G\E!8^O1L>;&"R_7.)<2*.KFC_;;N63-SJZ?3QQ
MSJM?/1V3*<S!8R;\?VN!QAB/Z=N_N@W]ASDREX;&->0QA?299.OBN&/Y"M7X
M& /X?$JH72"N8]Z9'</N*"-('$L=.K&$D:KSS, (QU4LW8NWQP"2S6LS/O*-
M^YH;?#[J)-R**' SYR]PR%17.F4E*U"FN7:B^7:Y1%*2K)K4<12)Z1MS3UA9
M&V)?NLT^G=CC8F)\_/.F5?ZR<_'MXE43^X3P>B:D/O<XE@J40O9V[,K@S^^?
MC;=Q+.M[,$RF->UAX(>9J]'<VCN>2\S2:EW(DH6:<MW6Z5WYW_^I%[7:1T_Q
MR"ZQ1,7V%2DE=AM&@</:CMQ30KQ%5'#?A+[6PZ!E$:W/Z7;)9F'&(CP=:P@
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M7T_M2_EZ//ISHWTN51N'T-AP>NT+JHX2W".5+\Q5O=KBEVQ,>K&REAEICU0
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M30(.VGV*2 &:,<]XKN7<TWV"'?8?K;Q=+BA#\AO<MN*X5(V&)^\<BU"?0BL
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M]E6D&AHM29O4#PF <$M&V,8SND70TRC 1HK3(A>=%@BS5AK\+VSFM+P>;7L
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M0V0.TOP+&*VYQ=($\+,H&KH0))WX;%,:S3OM>TKJYR!RF/0]<@Y#"BB"ETO
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MV]9X/R[88LQ\Q:XZT-9EB^P%6D0(4<\H$0^B%;<;B8M$B%%GY#A!7>+R<!=
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M"#4)?:ZB#IP\"[$"(\K9TVZ_0.>#!=^GT7PN88VQPDI.-+C!G(E+J6ID(5G
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M&93V]**X/7_2P)=QB7'*_8OU0*M$3/4<$)Q"Q9'5E4=E8AY!HEM_"=)&CKC
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MBHLP R_92^$H8#\A_%A4X[URN<#C<%Y+/U_#L<.WX='@OB,[P)9>O_V=SB,
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ME<PM?#M5<G@,K<=P]9J5-&(,V.M5+A:U&0#0_3W0;/RJB&&P&6"E8RL^([R
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M0X %FG?V-<UN$)(O+"ML^9=O8K-]%#/XN[Y@6*7V&]W+[0V%G=PM*0_"BIH
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MA=H'=M4VJI!Z/KF(2YW)U9G?YRUX[Z@'/>WK01^V'O2TKP?MZT&?F7I#8/Q
M!XU%QK<L)%N2Q2&F92/3Y\[3BHN\6K2"K&N85\-!"Q'4&ERVP@:CL=QP($D2
M6#BK%IN-]CYFB-I"H]2<]>C@]K@JC7NB2]C*[-?G<N7=!+Z12%K_1&H2ZH[C
MJ4FLK6DS,GLP-_&0[3SMIS^W)B2>P+=A:W4#;!CS89UXPV%SUC,FA@BND^K@
M9\J5(&:0QX983OV8GKXAL6](?(AEFI3UAL &/.Y\8ED?G><H#VX,]&13$$Q
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M"?5<+;(<X]0Z-?7;X>@$J./"^S@+P",=C9MQK!LL2LNS:S!4J?BL*E S?)S
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MAX$+S*079HF)UFM6#_OUN1*VB(L2; .4/+6]#0=(''D\Q2M)EI:^K. C2FO
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M7I;2EPRL$ML 1(4@F ;N*NBWPX=K31.U6!;W1<#B@;SFX$.7U&=9SO*LFLZ
M>DO##*U>4FF,:!CXY JT^D8)WB"8*-UDP8,,T9R;5;!M;-9H(@_&A<.+]"8X
MPC+XBAP'NUBJ@ +JAID$3@,K8K79%R.W81<[]7,8]C5L6V,V>"W\&!<SNR4+
M9T&[<GIXNU'.AH,;,B4)1@+[C?23$*>5\1LF5<+K;&%#X_80P99@7&&#W$Z%
M%B@?R/,V$W=VMV]BX(8<%03[/TP,DF<>J_(&T3P(K$$:[)H,1TWD3@->\^]S
M9)FXM(7@1.S?@-$76<+,7NL<QW?%./*@Q=D9OZ?=8/8>[$#&=JEAW%!O?38!
M$8(SSBDH+[PFF(0MF$%B#"IGDUZZX8"8G1H:4^IU0T84F!-8YK5IR&\K/8TQ
MHQ!.J(R+"4$ZPR5UQ26DR3!5\+0$YZLB*W+#)HM;7 GV2<I@>;?MTKX=FQB-
M$2!-9PRM0NUY&N\*VZ'<KKV"?%20=7M) -MRW%-LA@>"G;F%@+H5S"86O:]I
M=H.?EIX#6S,8$T*.BJ\-A*SY&ALJK6,CHR6F!]&<RKAPMHSM?BC5LUS/I-P?
M#MZ#K>.5RP4+.M_=2(N$X-U>EB;+-=="4 AP."4Q%?5'4Q=UP.1,DAU^A7TZ
M"5I'</X?5K\=;\+!V,'&AJPJ/$2@T@1(Y,4=%,%T2O@E)(P9N%95X%^(^J*Y
MG(%M0P(E@,MP7A7<X/_"K9"J7M+OG,O )CZTY6Y=LF@I9]6!AQ6=AP>O]!6/
MXZ"@7XU>"<'H90T'E M#_<E46BSG"Y!]Q,I$\/%<;A5,!+0^(VXSY4_3^O6L
M8;MPF5Z:Q[AX6JG9R%5J;&"7#-JBI&-;J=Y7C;#;FZ-SAL,'"6'PXQCO2I.X
M:/]6/6S'Y< G. 1D;I*.A3>+W*_W9AHJC<02"J;AK2[2%'T%ODJS6KE_4T^?
M6'I3G-XL@&/(LR!AINA%T,X"+X>W9'-0#I&O^6M/ $^2]A@9!"TC-<%B"I@/
MA(")O9JI<BAG\JPH]A@R);.KG+,PR><^8_WH:PDXJ(N@5"E%NTIJSDS!.DJI
MW]L=6K< )LKK+]%Q-7P<,5>]6,I:0IJXA'=89\A!ZP[8QJ@LU\=JJJ'+@@Q/
MOZ;1J*$4.V0;XM5M08;[C&*V2!%7>U*5V-_:.&[]0/$&EZN]+:K*YB.X41JJ
MK+&&)F(=2@FVJREL'J!9:RY>I==QGJ46""<P(X&Q_IM7+I_OS<2=W.UGTZEN
MHP<K6A4QH@$4;5U#W81>LB;W4G@KJ7%Q:$1>Y][?WESZ6D)HB.<"&#@)<J]F
M_>AO@8J1,,5:*- 64;#F&\)K?$[@FF9]7(&.BEASJQ[UL$NB0'W+M>WLAM0Q
M&.::H)1^<H&2/&KR9:1Q%V!EA98F^GBH^<+*(T<9^&C*:W0,YR,IMFK*"[*\
M;BW3#> CS<M0J //-] C>6&Z*\LU./7N1(Q34"I'A(U,YR-6[)+\9(310L45
M3]!;0$<;3*,LG9)%Z8XLQV7QX?%#2V /@N*PW:LV5( 5ZCX^DQ*+3E+'K6R/
M"S.^W.FS1F3%UQ_^<?5F;W3AXS_ OP$7!D<= T&AKU.@(=A\%UH-2VF_!>_>
M&</&#D !EX-3728U,N?/KR!;K8LJNI-%4!%*Y5U$4Z7FR*2H*"Z*2C%=(L@'
MNA0UZH0#5#F:I!62DBK(];NF(XIH4AR/>;'XDG"*/A%^I\JRX VA#DL0O]%O
M^5=$,70>.OW5R&:)*>1U.3]-1 Y*L2')I6675A3D(UEJ1Y!R./A0:50+RA/K
M5!]>%L("=/%Q:V)%EG<LE@]=$$]JWE('?( Q% 4*;(KBHM @%GX-. 89#=<H
M=A@-R: O.1 U(*>+<*:B*E'.G)Y][S-\AV \TU;QJAXU0E@P?%5$](KQ#O <
MLDA3A;4UD)[(@B6$1V[M1'N61GRT@H$KK!=M@;%!204[+K0([IG>:B%"#(:0
M9/ 1+B3S+3H+NMR@(N)<2UN'P)IP2'>NC]W?6<#@L?B9,>R23$GV!4PD \PM
MQ@1"VQ"U@R&:E;@0\+II'LP+.<E\7GN!3X"\*:Z/[#,6O*M?ZQ7VAI-E;YD]
M]50#IY/>X6POQXIB(6 ")!-7 /EK*QE?1^'!OP3*5BRE*>^#+^F,GX/$_$V%
MI(X"*JNII@7%D4D&2*&"?+QPL(@99*=+@3%$<#L?D$EMK(31''\7]L8<R9N;
MJ2!!!\6%&-,;&:M436)F$@>&4R!^QL!:%E)Z$23C+(QA86/:,\@'# ODA <)
M)[SZ^PBW!@^H?Z$J;\ NG5%V )U;D @.C)&[50O' ;<(W%NB[P8+EL7[I)"U
M]2"_Q-N9T/PDIH4"PTE%R0&QX<"1 KZ#RK0@Q.V.O,TN9^N A;1X:.WOCE*0
MB[X4Y&%+02[Z4I"^%&2[M/6CVR:(,!:P2D48PX(T@D CV!$49EQ 1E%.254'
M*QP^W[1_T7.+!2B3# ="%*M\?\ILU7-E!M+!&;&ED<A6F@RM=Z)VX5@/QAO_
M!L\ )_(K&LIMGVC?^_L"U:4#4$AA% D#4=UCASJ7K!J<AFB_/8H6<T2>C&CQ
M+SD'7LA\AYQJ;.BD"/F2F^04SE  H0.7<@WZF,0$'2:%'QCW"M=L<O<"8T4Q
M" *)V_>^T$KU^P(](M5$79V5Z1X?68TD3VW^AP))MP"=<KR=[]MB3\9S&Q#C
MH)#)3M#E:++B^^JR*NJHV8$I/C5+P<F/L']L3*P9'D$)BQQ7$I8QY- ,)[?,
M*XU.)N,8+06;-^8J453(JJM@Q38T-1%V $F!M2*E-P&/>(PJMQ8DNS.XDJ52
MW:0[JU='5L2TPX]/,P&LC*)<SKKLIH/;,%'XI?O>?V8WBA(7-@$F_OLW(=0F
M46 21SED*4$$SCS9XVQ\8 8.]=H'0V&\(*%B8F,ZDZ^)!JSL+ 9?Q!DX+LP;
ME_7T!IKL$G-<9'!:DH:7PR/G814SM\]SE1@$29+I\A]C0VL&1Q/93(1@OY_M
MWZ!#,M6-;".=.X0RK#V<41D R0'V1NX0F[7T$H?T0.X*^>4F2N:([BI= 6"J
M QY3=#,X&VG->':+'+#;J2J=6+8$@:XFNDC : "G,F!UNLLJ!Q/X<EH5W7#)
M6"TS(L>L4#8BR'&ZA*==*R#U "NH8K.:%2"Y!@=WW>5( ,?%.B<'3B[7B9O4
M*NTS?A G:PG\F2;?7E-] J5NL8I@GL&]X2;<O_*3<]Z&1%X1(U'E*?(M7T@/
M7-@#%_; A3^^OVR\,> *@_+6P*L[DA$3ZO;)N?*T._F 4D1*9YW,X2:+:0CO
MO@_\N?:9]E+BD;O$I>3R7LR)H@ +E;1'AD9OT(10U"7=8EV JS[.LX"&\Z$?
MED:<S$.S$$RRGM-[3N\Y?>LXG:(!5$_'_G]0VL&@3M+%HWH-'"90<+2$(53Q
M'Z$1$>PH;+:0FR!/&=_=AHC&V3<<I"9_Z05'+SAZP;$-CD1KN*Z)#?+('N6V
MJ@71'#R-HE2][N]9N&?A+6%A-T!JLE"K Z1ND-FI66STG9CO;PC1G!7EGHU#
MZ*"G.^BL%QR]X.@%QV,(#LPZ;BHZ.C-!Z$!$>7!#&8FB*G""DZ_;WQJS-;5Y
M@-&%^0)S*:X+L2'69$IU!S6'1*P1DFJ8RO,^O7W_F?(@THP_SR)R:.C3W#)G
MVC/QL[V\Z>5-+V^VP5 I*G ;@'5[ANP9LF?(1V!(VPFT838QF&.A)H(Z5%@>
MLJBXV*H--+G9<]?_OQ\+8'FP#_2Q%H)EWP6R81<(S0ZUI3%-J,=QG"VP?R@(
M"31"&G-G\7160R+:X4K_K;K_']J??2]2X!)0/4:6OIK:AE#=NLK85P:V M.7
M4M[%$\ 9 L#[V"ZZ,A!6*J"BK'E<, (/]PHBP)"WP+H^JL5RMX#E:P1,185R
MV+W-9:S4\8?)U@)K)ZEDE,;#VF2(S,(=#NK#<+D^N!M=@0J8=9ED1QT'-]@0
M0H^%$:OW)S,<!56F5FD0(NX0BESLPXE,-Q1_ZEL<DB/X2I?IV7T:W!1GXGLG
MQEJ6-]$S>'8YS;+7H"E4EF*^\XIJ%&6'"QRO2T_'+DWN(,0'%KJ(-#:CW=VF
M2_JC"F=IEF13TV:%:W [>;O *; Z=ZRH^*76;QGU#8H[N5O25 QQ2;$,^+1#
MTP[,9">TF &/H%)Z"_U0[W.L5U\$U">+.C&,J:]@O*26=<T]PX$.PBQYO'2C
M4U8:%%-5QXF0PNP4CHM[ O6GJ!& ]U+[@'!D#?E,L%[VO;<$Q6,+7AU=?D>Q
MF>^"4,C7/$&@,&V@AE&I'YSZN%FTX],3A$SP%D%>2OF[Z7\PXX-"1-)!8Y4Q
MI]6_JX!0'N/YN,H+BC#K0OLXC_;P6<#ZP9*TA$U'3_$QC!S#?Q11Q&T9[_$L
M" X)7L+_B*/AP'1!\R&FL R$7\2JVWP:I (W:A)H?]__O,^5TWP-!0ABO$OG
MY11Z;WQ58X7PUZ@+P>(&H<OM D%8(#)J!B4( 6Y.";EVFN)F<]! \)<Z,!)<
M>!5J(*&"5++])I:--\]/&NXEEC\<5,6*DFP!PG3/NY$7D$]@-T7@-&G0.HS^
MTC!(@28: F&A+IG)4B!!G&O'&F8'MWS,CTL8OC:*T;45]Z: _X0(.'$U<0FA
MV:U+)RA;OU%2$46LDF'U_CJD.!SH DQ#]P0ZHMG!U_:"Z&/Z6QW-13/2C=X5
MWUNOE79SMU<@?"U87#QQ@3AJ,#ZW0) 0OJ+&VW"2>F[M#S&DT4Z.!9>-$X$>
M1.21&G0=VW-8!Y#<(&($-2J8.1<WB#3;E5%84F\""V2/!<J<D#?,S#<TS1!S
MD Q_A"%)<9M@G,XY%X&]B5K;U1;N&[%MNOH9%P9.K YR0\:XK&62<T_O<M][
MC3H^)K[3/52%JJ4K<;\L2'SN7"&P%MLD3U;"TO9Y,)B-M).U+JU^["RI.B<G
M=&!K> 9:@Q?2#>GQ7!AEJ\3"P\=1_@D*%KQ;56-:C3=#=B99>41R+4_: L-R
MRQT2E) ()>,U8E^24$^:RJ7!2;MY,@#2JF)":>E#,CO!..3WM$D&7@@+R)<D
M[^!/ 9B8.;J_:&92[7>A:@1((BA8Q&BYI]DU!XP]AJJRL$C:^Y>F.0F@,.$R
M@!("A%"X@'%:3/VY_HIT,AK$/:I5*4OJ8R1"YI?:OF/W];K?>1[\"_TRQ,[C
M?E_$BJL= "]&F,: GN/VX\P$%)8N9Y$]#X;BTEO%?71&58JV9\&9=;>[M5!!
M#LHK3N'>RTIKW/<N\I:S$VXIKL:P,@T>-25,U=QJ")]#'[J7WKZ)#5ZK+<G1
M<M9 )K*-;0T'A"G7F/T:N:8&>T 5!N 8;*ONQW"+9Y+LN2=9!(FB3G ROC_/
M81.*[K.&XVT.;XX0;.0ADK&L060ZY"$Y=VA9H#M+(3MVY):&WH! 5<(&$M 3
M!\P([)6ZT>."X=2<[@@BPQ6-FDR>N+!)%E8%0YGIIX$'[6QY)64PDA@\@G%]
MT>6X1@QN[N!7"6,LP\K(RUBV;PA(A#?E8#!+^,Y#$1.'Q+$=GW%P[@@$?55(
M45IB#<N.BPS#(?O@$2/U% S7$(2,I^EZOG66(52 3F%CNX[U%"MJ<"9T8$.U
M')3C5M6TY$9IC55F[Q\XY[4CG&3Z",/D3:J<,>UJ"(%Z(I5MAK=.EQYI8*<6
MNR%%W)#FO49\ LED$9>FW0;O5L:J>'KRL=YZ2UCZ!F$\P? -@>:5,\9Y&6=L
MX!&9IXICWDOV#OE Y)XPOBRW(GSI,2W0/U(NC]$(>..@P-BZ8)?#M>$.0P?"
M3@MCNA)C#OC4%I#[\FMX2!.D#L/-&%TKM/',P>@5L5=!Z-"4YD9_:P=/0?6P
M8BQOP:4K%>-N:7*EKG(E@&,40NJ8-M:ZSAHXJD#H$U%\54NK]:Z5SCC(ZRB&
M92>LK1Y%8W)BM\ C!WS$@HG!C1<8\D!9P 3F8\ D-O\ E@!V8>1'='@*N!@X
M.(DAU (1O5NPD[MM[O,6G+"C@QXG[$%QPHX.>IRP)XH3MA.B"9:XWAC6A]^)
MFR,2Z(".'# ES.M#M5!)UBPFUKUQJ#I<'H$CLM8(VZQV=$*DYFR""JH0/TCR
M5F98W(R22HTXO(NOK/'0!19(?Q'AJSB?5 /3I2$U@M+B1.W1]%NAUWG<5CR.
M)6?#RW1=:<EZ@W*'K\KCP&1>%C'8#BFW;( I"(X:17U,TF>NRAGB':.!:B=7
M2!E7>R4:8,9YLCP6OT*6IT%O[30',9DURP@O)R/G,;]>#4>,)UZ1P<M7AKFR
M. ^K>4%;?,!(Y4_DA!_&TP\?831,W)P0X#I]DF0H.K,,<;T(1@=JF#7!02(R
M;B>XD 4,!?H&[IZPPUHY1Q/&,&[:G/*QY$O/JQ2%B,W:3VK@ZSIW]O"QRQ]S
M3[NC, A>TH+<WXO:##(]>O'HS2(FXI3D<[X>F%]<\FB!YCPS)-XI*K$:R/&Z
M9-M1:; .U6)R;;(J]N*<B8#S:^;":A.=:J;97A3),*OTZ\!J#"Q73_S)VZ@:
MJM*X\3>N"J0AD?"Y24QF&T/(W<;14N31V@@G,%T$<)<Y \3]Y\'W5 &" SEP
M#(L9EV&J^TP=P</!DVV=SNBAQYSE?G]_P+-O!9! TH80(C4 5PJ0\D 9GF4D
M@Q]9KFJ#LZ.A]Y&K^7MF[)GQ23$CA:$WXD,["":C_+Q;0E;3JCZ7F@=H#)6U
M2#6YF3US]LS9,^>MRW2R*)LK2\HO4BZ1D7$D2=>KRYXC>X[\8>H2G4B@,CLW
M5T]?[$"XY,J/)44Z36R '?9FS'61JR+,XTW;W 6P6S^[Y_>>WWM^?U!^-V-3
M3#1*UZ35H&,$YJIGP)X!>P9\-/^4\[].Z-R-A^L>J5JCDXPD[6Z9>K6Q$=ZS
M=\_>/7L_)'MC/U:0*-V-:'NG.,_C @:T(6*>//=][YHQK]1<-:7='S*!_PF'
M70T'GVP#[55:@H" .ZF"!)$N%@H%,$8'_VJ'PO99\!]98O%/JCZF[G9",G0N
M:*$O2 KU(Z=KG5L9Z@W4]->/$WA%;FJ9$A5$74E7QL# <<F!C"2FTHI"O\LT
M<NNJ>W28DXR=9S=7S- ;NO^<.Y!;T[_[ZHJ?G5!&,L.2MQI&#E?(P[>PGW8/
MH6.DSKU=6K_T/1!4W*Z*O;<\_=$E2ZYEV/<NDT0_F$T[PE*PXL5VR+K5&#;,
M4A5Z./V*^O=;N(&'U=?IVF(#U&D;A_^M1]S<J424S1/#Y]C6(=E/ZB@F@I>:
M.L?NK;4[K"HMW 7J>D0^J2_ZT3G^35PL*JI---U701X7V/!1WBB5XM1#W2[+
MY(2U/+F:!GG$H%!= MQ%S394&&"Q#*%2_-CBE=XWZ7V3W?9-BA#X#F6YR&^:
M,:JPS3;B:K\V#SJ]L/5APGL:?X9!&_I 8<^M/;?>MDRIP=T\3TY@BM^H9Q/T
M)/L3M49,W0J287B0>G(G:%RJU8X3>C6;+,.*!FJW"&BB#1:\.@K<?H82"EJ
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M$C$8%\&2L[AYMD2H5TSG%E5N@/HY3N72;X9I9"W]N@B>VT.<K_BR04Y+D_W
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M!0EKV).C%[U0ES"/:-O+#A)5,!B;89O+2>,TPA@KT'-!W\XI89R,U.""ZW.
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MQ.C<.<1'%YYJ%E[MI8B#Y)5=#\Q5'(L2("VTF.AG_R!5>]44Q+3:T1LIN_^
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MO:/4&I9:PSY6:]@MN$$(-YM. B([OIHB;#IACNQ2:[W8:!XVHX[.N]2<GJQ
ML@+7\M,<:00F&!B?F32^RC^;^WNO\3BR*3VP-)RF.4R2B/S9-&GFD2TE?DJ9
MDN*X44C>#1WIR=@D8Y.,S2T;&U/;:(# V-C$/4 .*M5(>]8NT&W'3*0"%C39
MLU?_]\7S!X^^MZ&L]=&WY2IMS;0UT]:\U6A TPCV_!PGF32SL#72.^=DESOR
MUKN>JXTNK[0*P'W+([V F_H6D;N LU^2#<DT)-.03,.G"Q$.>^K:5!@5DQD<
MOS2U69>$@#QF(,W07UDSL%$L(OL/H'CX G?]1QGS35H&SU/+X.VV#)ZGEL'[
MU3*8SO)TEG\99_E=)/V96R)DD3^:B=J7TNTUQGA%C"_E_9,A2(;@(QH";$$Z
M\9G[#IMQ!K-R( D?M8Y[W4O4"XY4L_C XD)<+V@<[ $%"P)\=QV@U<>,!>I^
M!%CT;;S!&/Q5";*C(_J?P08@A!?6!E8/1OS@2HCB)D*T.Z5)J\Y<$=(PF<-D
M#I,YO'N_R#$Y8L,:Y8X:R)PQHMP1 QR-A[#7D-[(<7>LOP.U$L E<V1P "+:
MSY 2C5'\#I!^I'T>J#_&)'[N9'>2W;E]N^,;9*A!1:*?B 7OPURBXU.\ 2ZX
MTH8<[F3:,AU>2TULKD_&-WJ3(TF<D,X-#,LQB</[;AH=?J1\8;]IF^%BP[WU
M^6Z?/0<V+]<>J9_SS@Z]I?1M^(DC@=?.'O+T<W3%VY4!S5V0E:[MSTTD0S$"
M ',#518L!W35KQ+_[#T )1,C<>X:'5R/ZKIA#LR>"!WXG5)31&>8(Q;$*VOS
MP"XM(GQ +QPU$3*/APJ=:<085(HZ_J AJLX2#;_4O%>TU&XUU%M#Y>4"!H6:
M@SL91]GYJR^B2U.+50<4.8#F%0M]SZ]H[D4LPL5/G-@=1ZL- L>A+D4L?(WV
MMKKG)%>^"N1:=%-0$:SL5D/7N8Y+UPD;;@?T!6%2FLS4Z'N3D%NS9M@8NY;X
M1-F2TM,+;9%$M%$_9]3,:^R**:65D$8>1*AX:;08GM.OG_H>YT_1T9$VW.R&
MJ['B92W+UN.67/149*'-SN9,=KDFWJ9@M]K+5-*,Q 2[3G&:,[5!GU+#LH7:
MM[A LH;V\'LVMUWGH.R"\Q'N\UUKB$"WSM&H*<Z -?@%BEO:O]SY%FC7^L1=
MLKZ&'+8SEUN$4FQXJ"O4_%YVTH2O&MJTO(,GTYM7D0]C]UNQ(Q$3^ZA,HA7U
M39^>> /'(%)[W:6=B$N[^4S>HJ-JELV&C8E6L&FCO?^]H;=%>(CP[CKTT%P,
M9<'MK>&)B_EE3%S)5&&!06&2OD7 PV5?'[Y'SVU?7UYVK!"U,=4.7ZL,9ED.
MX]XN4C0BV[7@C/'8D* WFOXA/[(+S[6GK>P'=KWD .):N^T8#?SS$HD/47K9
MU<)!\;CK/LR,J9. W!LIU-C7S;S@=F X$Z@]5ZF-W3EUP^7KUFRR>W?&,MD0
MLV-P,M,*>-^>89PW63%E-? \!SXD.LO^MBDKX[8.D2.H'+*-"#;AJNQ 6@ J
M;_)@87U=1GL1\N2+P0A_Z]S@D.%AQO\5[W8QZ_IR\,9K-Z"?9U((<;U</*@*
MCRK9E'/KO6_X9S:!VI3(4X?;#\Q9]A5I0[Z_**'QW-1%S7^ANU_E_%@K.ZZ)
M^29J+GOF$(<YX0'9 ?J[#0U@=WG[ZYX+62>LD2*\?LG'D'U2O)_)1-]EP^GG
MO,D^XU#UE9)J,-U+R#<\UTQZN"A5LE\05F2RHC&=@%?S>L(D=X#V>+:[]3TW
MQBZ,BD$IQ+WK3?%I5M;%D./(.4Q4*/7 !@(GHG8V-P EYYVL)5 U509G#E.>
M0)&A E/S]:PT<V,/=%8HX"1OR_XGN\%9HW0$TTLIB8^N]VZD(*)DMGJ8X"CN
M,L\-%!$MN& D/(;S&Z8X]TSM!2JA@^6717AK%F'9-J$+<8B-@1EVAKIOR\39
M<L^>Y&F<2F3RHTN*0G,;4EZ,"O(H?7%@ 7J,B)P,Q&HQ@93X;3L**0KB_Z!$
M$9+:+?$QA52G1!2[('^JZ2)BNI#+(.;5N@'2:3'#OA;+Z$P,D=W+IR>J>02.
M?>Z<.E"X/'!8D3L(1H81H&'H.W8#]>'R&5H^[$5BHI:M6 CK6KE=DN0+7&/&
MKE("0SA>H^]V>263:$UH. 0,K&NV1"#5T;K@?5L&O+ <$X*V9$/<)Z<G(RH>
M)@T>2P5.*A2?\:;X<K:W,H#JZ]J"J3PX0#21&:QD;ZJ5R'5FT<^O:SD( +'!
M@1@:"%Y(X:$UXQO$!7CL!.%,<PQS?OSN=!EM/N>IS+91>Z939;D.=;1F3LG(
MRC'[B@]<PR29TM"3G2M7%# :O4DG(G*#_L%>Y?2$G0ZDB%AU37B3>5ZF,N*8
M>E6O"M[3M>IP!Q^EK#DI7TM^B)8*32V&^!5,#J=2 VVQJ??1,==-3[9"%Y?S
MV<#[9HHYJCYK]YUH+)%.ZT]='LWI5\PN$[X^2228(F6C/EEX25R&IR=,9JC+
MXX#W3\??]-4MXHC1'2#6V6A&3G<H@\B;QJZ+>C!S&<^0HWY^<P;. P02.N8\
M\!(*P6#LQSGOWO+@SCJPJY"-H1O8G4E&9:@I1;XJ=[F((G-+ML-^)WZ[^W=J
MHIC+[!?7T&:HQP4G:G_#-1T98.'M"D.L*E^:"O^URU?O\@OZS].3SOXVOZ"
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MFD9"C#6]3T]B4>]Q2T8N+5#2Z3HB1<R7;9,7"BB&.%35H/'6$];G1;[KI3]
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M0]NRR,X?GC]FKP ]88B,]+X\1DZ!MLWO( 4A?$E-S#IVCOI-QZ0?9]D;;^
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MRB$-2R#)%ZU+3G'3GJA$2[)!XHKE2WL?6N6C7-(,0?X,&,C#FG(_- FQ:.\
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M!L]5YMX@63.2<5RP#RS4U&[A1G=UR7GU2$3WJ]^T.'$"7OT+G2D4%(K 3BY
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MG"].8/O>8DH(L=3%6.-!P0F<=QJ3YI@LUA"88?K71G(:-6UH1C, T-UY.:_
M_XA(Y>.;<7!W[0TU$T+B8N2ZI3#PKJWMT>(!)>L33L4#PLTDQ06E8IS9/%X5
M%O##ECQK+* V+TBTDXJOPB2R,XZ5JD$E:4TB($!30.W>8\U:2EEUO.6" KH7
MEP%XR'"/ X_-2V_VXFV'0ARL3Z)/T;3]VGIOC<3'*"2VQM4EP&0G5R7ANTOW
M24QM%W^%)I6>)?BU8IPX-#P].7_LOD42J0>_:=^)OUY\S]?/WL[\A'=X/=A-
M3)VHJZ9EI9FY6]E5$MSK+/N)RG\!U>;TZLR'8/>\L2^NP&L9**+^2W-%O1B<
M,N**T;A#G&4K9^RP-9U-5XJLM:^6K39Y11@[3J\S1J%R,XW7S?"&J]%"T#3Y
M!?0F"R;]0).[,I&06UDP=D_RPH1?U2N7]653.2'6WZF&):FR=<XCMZYLYUK(
MI-2PAN*E4HIP>ZC+<9]EO[ETMXICM7 HM#L#6ENR!KGD[1KT/X6"QQUY@(G\
M+!BN#U?_(/G9QWA[GP7Y&2S],9QG:EBIM,&5O1D;["HY,1$.G0.YT/Z+Z4AD
MIFF'IAUZW3"/EKIQ 1?EC\WOI900QOLU\$9UMT(\KHC%!QGL3<">#] #8>&.
M4! $K$YITZ=-GS;][1[+XHD'$(J-J0IVXBD50S!]))0IC^(#A;05TU9,6_':
MK4BQZK&;D3L6:#,B6O;AO!.QXR89RIQVFLLQUV1R, K*@APS#N2@+DTM4$&6
MU=.$%NO*KM6='WPJ:-R[R*,0:@WB0F7TV+$"?'M/3YJ(R9/E29;G(UL>K8=H
M<</GFHN!0W4SRD$SKXY]'&LJFD&J'F(5$D/YO4@*0EK>1W"=64&2PO'H$"43
M"(F48*>WUWM \.=AR_+A!Z&VZY+XD_2BR,QR+7#A"AE.<1S0Y=,3+QPE2X<)
MH.<R0D"P!\R@#,5MT:VF>&\[ 35EQ.7/566GM2T[ZJ+@;+OP_JTV#8'<:/S4
M!H<FEOD:BZ*>RKIN+G.7@)Y>11'ST\L$V*EH-#R5CEV6 (173/,\_VT]71V_
MTGR%58Y\3V_H")$Q^8RS)AP71?G:Z0,LF%);"X90^8L4T,J%S?5>!H)+YH3>
M$P<#3.:A/GK=U'/\%/:;_6Z@E4/Y>^HW(1J#ID%CDR^ A:M4IC(AL^[5DT2F
M1,M) ,>KDDU5LNH]S,JX0+/0JD]WT[(/VA&!J2;(5+8WN;WRTIB:JS<*O+=#
MV,:>)M>C4(5[[4MM;ZE&2@T0V2N""!C8#?[2VU<+U_L8<D;G82.(-+^Z/BH>
MQ;30A=WDVJJHPD0/H2V/0:E?3\J8^0W$%V(::,?0\1J9!F>+9:=P!5CL@+ _
M=/F6NBKXV;OHFO3?O]4P"V^ [3S+?K8387X70KP7UL'/F1U[4]9Y)HH'_"!A
M:3 H4 ($[*8$&.-LV11[.[74+*DVG0'",!D!S-=K@M(KI*KU -H2>R<[Z O[
MQC>E<&7(*@DNLCA01?5D]]&S!O3;\9Q2K-/O=]P1R[/KVCP'.[HJ>_1=MK5;
M8F._NZ;F1WO\X8#DPP?T_ROP:&*VA!+VK:M; D8C==MWM9W*49N?]B22&0:I
M@B-ZT>X9QL,(]+KCU2:@8Z+ZNZJYC"L';A$>(%J$F:M)>\*1V5O3*1\4_B/H
MS9I#/#^H4;-Z6,-9\ FT<&5B:O=E-T'!$"/QUTO"BCI- +Z[K')Z6],",$ '
M\J2!R-7[ZTU8*SI=2\-4E8 @C%$.X?9M9C#^]CI7FX8/7X%\8'ZYC&Z 3;:>
M%G7<,8I> G6 \T]/0F006JJ"I+B[LU:WQRBA,[MAB640&\N4TN'JGI_W/[L1
MK;V[D%J*10B^]-Z= R+.UH4-)2#XW/@]\\YPTSIOV^8JQG<%KS6=^??T25Y:
MTT66ELW7E#<CCYL16O/ U6SMM[;V'[+&=FU)'0IMKR>4'KR9-RT-CF4LW]F#
MCW;2Z0DK+*DSP?9OI_[(@KM=!*;3&CK5RCK7+G*RVQKR:OLX>O\!9'$-K[))
MU@:4L!PK&3(KG<N$X[";&J8FVG+C=)PUC[6V*H"+J]7!(7XARE>RIW[F%L&]
MV;:KB^-8Y&PH+F@6W5AR)(GFA%E,[>="3O.8+V7"%C>#3%2<6U%:IZS7YL2!
M&MD89T8>XAYN/RIW"];\T:(^ Y0.TM--583GX6MA^TOP6+$C9<T8FS;GH5&>
MJW648L%!%G+(3!*;,Z='R1"V''V>"_+U!%&*Q5^8P"56NZXRD?0 ,F=,(\PY
MEQ']E:=5\&78U+9RGY_DITL*2\IUX(O-KQQ*&N2=1S.BXUK=$?X8*0Z13LDE
MCE"RC$'X@\E8;(U=8_4%Y>;]8EZ ) "N15B61_.?_"%8@II<N"H[,WN/V;(\
MNUKAY;556U)#J[)=#=M+[@H<38A00F/=,_N@PU*#580,XMC=:8)""&:'4):!
M2>!$4-H2]^I)D"\((5RY;@GEFJ&$T<"91UC#DJ&A]BMV36W*W21FH(40!PT>
M;1^O,2T?N<*U\VJMJ6XE*IJX'?->;XXV@K/L#1W.[HICY395;0,HQCZ4#'=M
MG9#"[CU*=#$D&WQU+N#0K &''>PGXU!Q!SBB.A3GA]H]/$7JL\%&R#&+]-^D
M%:&G\P;^R.D)S,+0.7*9./R8;W.(/0+9EQ3:%A@NG_E\:W0.#^U<I.$M%AJ'
M9WP-K[4UC73^7%*9$BF!+44C*KD7]-]KXW+(E*NMJ\S&X<B*V._#.(BS9WP[
MGXO50=/<T&*0[@SR/BB-7H)C!&E.<C8V3=NC(Y7<3GS?3Q)"V.C(+SAX5G;^
MQ?0D\4CZ( ,46>Q 6,_G@Q2E%42:DS=]7(M+,K3'/,GM-V6])0]8^MS%#MD0
MO"_1PXV<:ABRD+T2QYF3/+3TXG:0\OKJ F=RK!N.R,L)XJ'UF@(RGX0)Q$.Y
M8< .SJY^VL0:]QAIT%9]). +QO*1J</IKK<'3N\@&Q>\J#$S$;<X==FPB[N;
MG&R&.WY4B=Z%0PWUR_DXB&J(]8!B +=Z,*L1.%0FQ#X!CS*14*M J:)0(@?R
MCW1!O14^)9J.NB/1#KBY\QLFB-"5<FF2^%]DR[(9'W:DA92OS,"&UK[7H>M;
M[<)B;P:[#W$O$4Y)WE;#4#SB0H-%WFPY4V4'MB#.(7A*N&MKBSA:J,5)DCXC
M>B6-U4,"E"A_@EJO9F6BX<AA&>6#0J'>95-(H6 F9P^F:?^B3D]HEO*NLT-W
M"*EMX&'EI(G;@:AIF5."G"CY%.X<)LO##C?Q(Z71:41F^"7L\SNW6#=@CGCR
M,#%'W"ISQ).'B3DB,4?<%PMPJPR9XM^N@4>CG()B92-=:4=-?+W;Z]C91KQ)
MVK/MT$T(JC@D]+ZY9+A%KSQ(>3&B2%468J?&9;Y1@1]S0X9-P#.0+-=+[F1V
M[5!TC.^370YDTK.?/ H8)>'Q#?3!@^0W.$#K!YK^,-*TN]QG%] 1X4Q@F#3,
MV:,,(0N1T^8JV2@E,%6NW@IID")T.99[3NTP!1>\RA6('$>Q+A=+0D<P*NE*
M/F,$RKB*;DU+2[0- 81H:G8A638P8H+K[0Q41C_A=)(]@=K:[#M9A*<G:T-.
MCL-<N[6+$(K2O\PGH$NY<)FTL^PI=&RQC-8CKP?CU5SP<"#P/^#+(7,%"!_7
M*7@F.PG_(@Y,KR 8)Y\T\ ,#F) 8>K'#9P%61KO+MV4'BE?KDE/:BU^4W3]K
M3D# +?;,=,V8]6#LN<=QJ+J4M;G@!#.1::P<(4/B/+[KT'G"-P,<C=@=7<:$
M_*F:C@%"V0'F"X0*86@7+)O%%*8P8WM7+K,1:'!6'NN0*%CN?I&35GA+2!K*
M) 6+("SLLH"P ^\@*D72@$DAW0(A0-8#8D//A:J%T=$FY,!P16&BU"XISTJ)
M?\(3RZ'H:Q,N9A\=SQ&0*%ZWPB1=[0/6E4!N@T]S-=B 9U<DHD.E_.*R[)I6
MU,I!A6DN2 W,6L&:$KZ4 @;RP3Y^$]E3@*XN6B/*#%I),=M=U>R-&?_4X;P6
M..F#O2CPWP<"#[!#<5<-?):((EQHPR\DD1\< [@CT[\T67 @A$/E^B2X2@2\
M0%? SS=Y(9X%:+DG<[WP;]M!JP\8"Y_[8<3TE..<]8;#<06U6E^?!755 )O[
M(X/2'(3 Q[AM>ZA%RNL?1K)A[<A6AH]U>O*S=93L/;9@5/' 1"?)$#\EW4%&
M[=;&(EZ%4,V@\]1QM2X$<#%:C@N%IMEWA'5('@)*8JK&( X/N0-".1IH/+#@
M7&=M E'OB$ZSO&9E3E5!,<@Q\P#VS) J(%=4H'EVD*S:4F4EIV+U-2_ET.N0
MFP>.[2S*WK?TO>_%,\_9W*V<"^I(SZ:B1QY_2:^,8O35QKC\^FZS[Y!@I,F@
ML*=M:N+B-:NA#<14"*AD7TJ\@B)/C(3I>(<RC3"A?+.BV8HAQ-^GOAC#CL9Q
M /&SFKRMY\]S:#@)^#7:! Z:0 3K+K<W<MREZ,4E$DY4&SG*&4-\P(DX9!%.
M3YZ27(D[7ERGBX=@EPR$K_9"_XNZI.NHR;P&.((D[2ZQ+ZS<X@3@/@[?>(F-
M%->:427<FF(O8'.MIP?1';DX=.[ AA%U/+B0("*PHCS2H'J""K7SJ,XK&#W%
MBQ(5=:1Z0MN\%*7TTY, B#Z73K?KD8.7?+[ CI46FZ_W^7B']R)EZ-GEEW@C
M1*\H1#!Y^'?HX;]B S=A^OPSI-BQOG[UL@EDL@EI]*,$9\G?_I2AV,],P TO
M:BSP]9<7KY\^]<<&6\SR,N?^F(#T?>\%-8!GT&2!BC^F..JN3<E3(@=L0X0.
MSG9UR0-ZRHW]_R3E1?^7_/=-7JU=5;=B[5VHOW*AU!1Z-MC_8H[[.!BWUWG]
MEQ<+A91CK6%M$9T?=4KR0M/(1+U,2M:.HP'Z'-]^@'/=$)UF3XM3[FN#>WO(
MV4EMMG!#)<L0##7/*"-W_O '30;9.$;U2/')HQ_8L:$VT.!*2.JU!YCUN<S,
M6X/KV+)G[*S91Y]37_3/#.TORLTZC)27GM&1S4Z$O(M1?K0DYY>^2?_FN7)C
M#I44D+REK"A<12Y/L]]X>D(*QQ<#Z38@4F55HE $(9(5T#KNS49M5X&^8?B%
M+J;SF6*:LF8MN61]!=PD2.L%R"S3LJH@TL:R5#%W6*X8-N()T:/U&1[1HXU4
MG2.28U;A\5. F)L%I[R$G/]XLBI",\IO.;26$K+(NY/L<*3YHU3&-,I5)%=T
M>K+FD&X1@G-<MC,61A K;.>*74IJ 9P/".DYJ/(=AKO!\^'E4$<FMXE#(M 5
M/-C[U<R&=#X'.M3D8$+M2@-_ZCRFG+ZH(,7%]D6TL-Q5_6"XS\K(+%(*0@OZ
MHV45A\?&[4)!$3NM:@9>PK^E1HU>I/OPWA;3]7K](E\@Q#UF!WO[XKFQU9#0
M0XWLR&%[;>VQPW@#TF,?T,;6---A62/HZ@FW!-4Y"+RC76=D+Z5<_$F2Y9_E
MH7W[SAAE.[V,2VW8GB".=&W*BDSRD%B[O>U:6FG+]=Y!_SG#).HS]OCU@C02
M#2+Z"V"R#+B998,7HT8@9=K%$HDJ43!0J=2=;2\8+#B0\892X%X%S27 %#&8
M"]XGN8KW@?7<U_N$( IF8^%;PH!&UW_!;'_0:LN<9K;2!8A'5+9A3XU+\CIA
M*<]/XSP!OK1<>%/N(MX[EKS5/,S2LUS+A9W!)KP]B=2KJ=7.^%K4ILS9Z<E8
M9'#VR;"1Y5R7 JOLY&@?^]T;.6Y"45XY_5E-6*U,80_*CM6G5GX@\)[KBP:=
M,DU-23=-1$4C"<U^WO>F#M/56Z^0U9M\"_!=H)?IVR*1@JPS.Z?5_D%'[4(\
M&$HB\Y0(*0FI%-? EOH'Q;$%^H!5OBO[O-+T%>91R+NC7&ZB[D[T8(D>[$:(
M[K*OCB3E_:\7FA-XTV"GOE&O\RF9?$HX0P>^-6O32HPC=".J;/?46I$'_UFN
MWBT)DDE)7^**.FX84H 5OYRO3V63T(I1Q:BQ(4Y+W3I[;O?I8""5Z* %D4RY
M$\]H.]1RD!TYFD,''94D\FXCW5CO2D2&%)C:\*76K F4>Z]LO(*'X'FC<LQ:
M]0B[XP:#IGH;HL'R:L_3W&65J"08#G\550/29F1E"UP,=O[(:=E9"[[)"1)6
M<;JO%3%$*CY248FC%HW-_>&.9,V!;C8;;^7'#>.PHJ(4:[OL)1#YW*3%_UU^
MB;RV'V7,-T%K/TIH[=M%:S]*:.W[A=9.G+')*?Q"G,)CU2)6Y65993_GE3WB
M!<0+7Q 'NC4NR[*(';20!ZC5"@O!>+0)SW]!BBQ'>D#K;(W1H-D^'XJA L?
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MZ4K7;D67)8RK<B>9NAM:1TY+S>H'9DG:RLA6<1)DW#4EX]'N$AV(M31>9NS
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M!]).3SL][?1;W>FH741[F60:4"A:43V'JP&\?8?.3'9R$-;*EO= A&/&0='
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MIVU9\S2K9NHD@.%(5&O;VF'J,A0&3#F>Z 8\T_#>@- [M_\?4$L! A0#%
M  @ F8IJ5>-Z!;8R#0  Q(   !$              ( !     &-E;&,M,C R
M,C Y,S N>'-D4$L! A0#%     @ F8IJ54D(3]-Y#@  \K$  !4
M     ( !80T  &-E;&,M,C R,C Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( )F*
M:E7DZ>^CP1P  ,'8 0 5              "  0T<  !C96QC+3(P,C(P.3,P
M7V1E9BYX;6Q02P$"% ,4    " "9BFI5&IJM(Z5.  #$9P0 %0
M    @ $!.0  8V5L8RTR,#(R,#DS,%]L86(N>&UL4$L! A0#%     @ F8IJ
M50L_@?G0,   ?2T# !4              ( !V8<  &-E;&,M,C R,C Y,S!?
M<')E+GAM;%!+ 0(4 Q0    ( )F*:E4,W]G7+Q0  %CR   )
M  "  =RX  !E>#,M,2YH=&U02P$"% ,4    " "9BFI57(RYZ/L'  #+0P
M"@              @ $RS0  97@S,2TQ+FAT;5!+ 0(4 Q0    ( )F*:E6(
MXI+QC@<  -8O   *              "  575  !E>#,Q+3(N:'1M4$L! A0#
M%     @ F8IJ51QN(IE\!   #Q8   H              ( !"]T  &5X,S(M
M,2YH=&U02P$"% ,4    " "9BFI5<297O4T$  "-%@  "@
M@ &OX0  97@S,BTR+FAT;5!+ 0(4 Q0    ( )F*:E6>>9B> LT! #_G$  ,
M              "  23F  !F;W)M,3 M<2YH=&U02P4&      L "P"< @
&4+,"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
